IL323911A - Immunogenic compounds containing conjugated capsular sugar antigens and their uses - Google Patents
Immunogenic compounds containing conjugated capsular sugar antigens and their usesInfo
- Publication number
- IL323911A IL323911A IL323911A IL32391125A IL323911A IL 323911 A IL323911 A IL 323911A IL 323911 A IL323911 A IL 323911A IL 32391125 A IL32391125 A IL 32391125A IL 323911 A IL323911 A IL 323911A
- Authority
- IL
- Israel
- Prior art keywords
- serotype
- saccharide
- glycoconjugate
- another embodiment
- kda
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Description
1 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof Field of the Invention The present invention relates to the field of immunogenic compositions and vaccines, their 5manufacture, and the use of such compositions in medicine.More particularly, it relates to isolated Streptococcus pneumoniae serotype 21saccharides, glycoconjugates thereof, methods for making Streptococcus pneumoniae serotypeglycoconjugates and immunogenic composition comprising a Streptococcus pneumoniaeserotype 21 glycoconjugate. 10The invention also relates to analytical methods to analyze isolated S. pneumoniaeserotype 21 polysaccharide, reduced serotype 21 polysaccharide or Streptococcus pneumoniaeserotype 21 glycoconjugates.The Streptococcus pneumoniae serotype 21 saccharide and glycoconjugates of theinvention can be used as a vaccine. 15 Background of the Invention The approach to increasing immunogenicity of poorly immunogenic molecules byconjugating these molecules to "carrier" molecules has been utilized successfully for decades(see, e.g., Goebel et al. (1939) J. Exp. Med. 69: 53). For example, many immunogeniccompositions have been described in which purified capsular polymers have been conjugated to 20carrier proteins to create more effective immunogenic compositions by exploiting this "carriereffect." Schneerson et al. (1984) Infect. Immun. 45: 582-591). Conjugation has also been shownto bypass the poor antibody response usually observed in infants when immunized with a freepolysaccharide (Anderson et al. (1985) J. Pediatr. 107: 346; Insel et al. (1986) J. Exp. Med. 158:294). 25Conjugates have been successfully generated using various cross-linking or couplingreagents, such as homobifunctional, heterobifunctional, or zero-length crosslinkers. Manymethods are currently available for coupling immunogenic molecules, such as saccharides,proteins, and peptides, to peptide or protein carriers. Most methods create amine, amide,urethane, isothiourea, or disulfide bonds, or in some cases thioethers. A disadvantage to the use 30of cross-linking or coupling reagents which introduce reactive sites into the side chains of reactiveamino acid molecules on carrier and/or immunogenic molecules is that the reactive sites, if notneutralized, are free to react with any unwanted molecule either in vitro (thus potentially adverselyaffecting the functionality or stability of the conjugates) or in vivo (thus posing a potential risk ofadverse events in persons or animals immunized with the preparations). Such excess reactive 35sites can be reacted or "capped", so as to inactivate these sites, utilizing various known chemicalreactions, but these reactions may be otherwise disruptive to the functionality of the conjugates. 2Thus, there remains a need for new glycoconjugates appropriately capped and methodsto prepare said conjugates, such that the functionality is preserved, and the conjugate retains theability to elicit the desired immune response.Pneumococcal polysaccharides, in particular capsular polysaccharides, are importantimmunogens found on the surface of the bacteria. This has led to them being an important 5component in the design of pneumococcal vaccines. They have proved useful in eliciting immuneresponses especially when linked to carrier proteins.Thus, there is a need for antigens which are able to generate a robust immune responseto Streptococcus pneumoniae serotype 21.The present invention provides in particular Streptococcus pneumoniae serotype 21 10glycoconjugates.
Summary of the Invention To meet these and other needs, the present invention relates an isolated S. pneumoniaeserotype 21 saccharide with the following repeating unit: where n represents the number of repeating units. 20In an aspect the present invention pertains to an isolated S. pneumoniae serotype 21saccharide with the following repeating unit: (VIII),where n represents the number of repeating units, wherein the O-acetyl group at position 3 of β-D-Galf is present in about 50% to about 80% of the repeating units, the O-acetyl group at positionof β-D-Galf is present in about 20% to about 40% of the repeating units, wherein the O-acetyl 30group at position 5 of β-D-Galf is present in about 1% to about 10% of the repeating units.In certain embodiments, the isolated S. pneumoniae serotype 21 saccharide of theinvention has between 10 and 5,000 repeating units.In an aspect, the invention provides a glycoconjugate consisting of a saccharide having theabove disclosed repeating unit conjugated to a carrier protein. 35In an aspect the invention relates to mode of preparation of such conjugates. [→ 6)-α-D-Galp-(1 →3)- β-L-Rhap-(1 →4)- β-D-Glcp-(1 →3)- β-D-GlcpNAc-(1→ 3)-α-D- Galp-(1-PO4 →]n↑β-D-Galf 3,5,6OAc [→ 6)-α-D-Galp-(1 →3)- β-L-Rhap-(1 →4)- β-D-Glcp-(1 →3)- β-D-GlcpNAc-(1→ 3)-α-D- Galp-(1-PO4 →]n↑β-D-Galf 3,5,6OAc 3In an embodiment the invention relates to an immunogenic composition comprising a S.pneumoniae serotype 21 saccharide of the invention and/or a Streptococcus pneumoniaeserotype 21 glycoconjugate of the invention.The invention further pertains to analytical methods of S. pneumoniae serotype 21saccharides and conjugates. 5 Detailed description of the drawings Figure 1. Schematic of pneumococcal polysaccharide serotype 21 repeat unit organization. Figure 2. 1DH spectrum of serotype 21 polysaccharide (insert spectrum shows the expandedanomeric region). Inset table shows the normalized and expected peak area for the anomeric andmethyl protons. The anomeric and the methyl signals are annotated. 10 Figure 3 . The expanded anomeric region of proton decoupledH-C HSQC spectrum of serotypepolysaccharide. The coupling constantJCH for each of the sugars is annotated. Figure 4. Quantitation of O-acetylation migration. Bottom, middle and top panel shows theexpanded region of 1DH spectrum of serotype 21 at 0 hr, 9 hr and 15 hr, respectively. All peaksare annotated. The scheme above shows the migration of the O-acetyl from the 3 to 6 position of 15β-D-Galf sugar. Figure 5. Quantitation of O-acetylation migration. Bottom, middle and top panel shows theexpanded region of 1D 1H spectrum of serotype 21 at 0, 9 and 14 day(s), respectively. All peaksare annotated. The scheme above shows the migration of the O-acetyl from the 3 to 6 position ofβ-D-Galf sugar 20 Figure 6. Expanded anomeric and methyl region 1DH spectra of O-acetylated (bottom panel)and de-O-acetylated (top panel) serotype 21 polysaccharides. The anomeric and the methylsignals are annotated for both spectra. Shaded box denotes the resonances observed due to theO-acetylation of β-D-Galf residue and are absent in the de-O-acetylated serotype 21polysaccharide. 25 Figure 7. Chemical shift difference plots of O-acetylated and de-O-acetylated serotype 21polysaccharide (left panels). The impact of the deacetylation on the structure of serotype 21polysaccharide is shown by dark balls on the structure of serotype 21 polysaccharide. Arrowspoints to bars representing the deacetylation resonances.
Detailed description of the Invention 30The present invention is based, in part, on the identification of novel pneumococcalpolysaccharide structure(s) by using NMR spectroscopy. It is believed that the structure providedherein is the first identification or the first correct identification of S. pneumoniae serotype 21.The produced (and purified) polysaccharide was used to generate polysaccharide-proteinconjugate (glycoconjugates). S. pneumoniae serotype 21 has a unique polysaccharide structure, 35which results in unique consideration when designing conjugate production process. The S.pneumoniae serotype 21 glycoconjugates of the invention also have a unique structure anddesign. 4 1. Isolated Streptococcus pneumoniae serotype 21 saccharide of the invention As used herein, the term "isolated" in connection with a saccharide refers to isolation ofS. pneumoniae serotype specific capsular polysaccharide from purified polysaccharide usingpurification techniques known in the art, including the use of centrifugation, depth filtration,precipitation, ultrafiltration, treatment with activate carbon, diafiltration and/or column 5chromatography. Generally, an isolated polysaccharide refers to partial removal of proteins,nucleic acids and non-specific endogenous polysaccharide (C-polysaccharide). The isolatedpolysaccharide contains less than 10%, 8%, 6%, 4%, or 2% protein impurities and/or nucleicacids. The isolated polysaccharide contains less than 20% of C-polysaccharide with respect totype specific polysaccharides. 10The term "saccharide" throughout this specification may indicate polysaccharide oroligosaccharide and includes both. In preferred embodiments, the saccharide is a polysaccharide,in particular a S. pneumoniae serotype 21 capsular polysaccharide.The term "serotype 21 saccharide", "serotype 21 capsular saccharide", "S. pneumoniaeserotype 21 saccharide" throughout this specification refers to S. pneumoniae serotype 21 15capsular saccharide and may be used interchangeably herein.The structure of S. pneumoniae serotype 21 capsular polysaccharide is disclosed for the firsttime and is shown in Figure 1. The inventors found that the serotype 21 polysaccharide is ahexasaccharide: α-D-galactopyranose (A), β-L-rhamnose (B), β-D-Glucose (C), β-D-glucosamine(D), α-D-galactopyranose (E) and O-acetylated β-D-galactofuranose (F). 20The inventors have also found that the O-acetylation of β-D-galactofuranose (residue F)occurs at three different positions: at position 3, 5 and 6. Therefore, three types of repeat unitsconstitute the native serotype 21 polysaccharide, a repeat unit O-acetylated at the C3 position ofthe β-D-galactofuranose residue (which is the most abundant form of repeat unit in thepolysaccharide), a repeat unit O-acetylated at the C6 position of the β-D-galactofuranose residue 25(the intermediate abundant form of repeat unit in the polysaccharide), a repeat unit O-acetylatedat the C5 position of the β-D-galactofuranose residue (the less abundant form of repeat unit inthe polysaccharide).Accordingly, in one embodiment, the present invention provides an isolated S.pneumoniae serotype 21 saccharide with the following repeating unit: 30 where n represents the number of repeating units. [→ 6)-α-D-Galp-(1 →3)- β-L-Rhap-(1 →4)- β-D-Glcp-(1 →3)- β-D-GlcpNAc-(1→ 3)-α-D- Galp-(1-PO4 →]n↑β-D-Galf 3,5,6OAc 5As shown at figure 1, β-D-galactofuranose (residue F) of serotype 21 polysaccharide isO-acetylated at carbon 3, 5 and 6 position.The serotype 21 polysaccharide is therefore composed of three types of repeat units: arepeat unit O-acetylated at the C3 position of the β-D-Galf residue, a repeat unit O-acetylated atthe C5 position of the β-D-Galf residue and a repeat unit O-acetylated at the C6 position of the β- 5D-Galf residue.Accordingly, in one embodiment, the present invention provides an isolated S.pneumoniae serotype 21 saccharide with the following repeating unit: (VIII)where n represents the number of repeating units, wherein the O-acetyl group at position 3 of β-D-Galf is present in about 50% to about 80% of the repeating units, the O-acetyl group at position 15of β-D-Galf is present in about 20% to about 40% of the repeating units, wherein the O-acetylgroup at position 5 of β-D-Galf is present in about 1% to about 10% of the repeating units.Preferably, all repeating unit bears one O-acetyl group on the β-D-Galf residue.In one embodiment, the present invention provides an isolated S. pneumoniae serotypesaccharide with the repeating unit of formula (VIII), where n represents the number of repeating 20units, wherein the O-acetyl group at position 3 of β-D-Galf is present in about 60% of the repeatingunits, the O-acetyl group at position 6 of β-D-Galf is present in about 30% of the repeating units,wherein the O-acetyl group at position 5 of β-D-Galf is present in about 10% of the repeatingunits. Preferably, all repeating unit bears one O-acetyl group on the β-D-Galf residue.In one embodiment, the present invention provides an isolated S. pneumoniae serotype 25saccharide with the repeating unit of formula (VIII), where n represents the number of repeatingunits, wherein the O-acetyl group at position 3 of β-D-Galf is present in about 64% of the repeatingunits, the O-acetyl group at position 6 of β-D-Galf is present in about 30% of the repeating units,wherein the O-acetyl group at position 5 of β-D-Galf is present in about 6% of the repeating units.Preferably, all repeating unit bears one O-acetyl group on the β-D-Galf residue. 30Furthermore, migration of the O-Acetyl group from 3 position to 6 position of the β-D-Galfsugar has been observed (see Example 3).Therefore, in one embodiment, the present invention provides an isolated S. pneumoniaeserotype 21 saccharide with the repeating unit of formula (VIII), where n represents the numberof repeating units, wherein the O-acetyl group at position 3 of β-D-Galf is present in about 25% 35to about 60% of the repeating units, the O-acetyl group at position 6 of β-D-Galf is present inabout 30% to about 65% of the repeating units, wherein the O-acetyl group at position 5 of β-D- [→ 6)-α-D-Galp-(1 →3)- β-L-Rhap-(1 →4)- β-D-Glcp-(1 →3)- β-D-GlcpNAc-(1→ 3)-α-D- Galp-(1-PO4 →]n↑β-D-Galf 3,5,6OAc 6Galf is present in about 5% to about 15% of the repeating units. Preferably, all repeating unitbears one O-acetyl group on the β-D-Galf residue.In one embodiment, the present invention provides an isolated S. pneumoniae serotypesaccharide with the repeating unit of formula (VIII), where n represents the number of repeatingunits, wherein the O-acetyl group at position 3 of β-D-Galf is present in about 50% of the repeating 5units, the O-acetyl group at position 6 of β-D-Galf is present in about 40% of the repeating units,wherein the O-acetyl group at position 5 of β-D-Galf is present in about 10% of the repeatingunits. Preferably, all repeating unit bears one O-acetyl group on the β-D-Galf residue.In one embodiment, the present invention provides an isolated S. pneumoniae serotypesaccharide with the repeating unit of formula (VIII), where n represents the number of repeating 10units, wherein the O-acetyl group at position 3 of β-D-Galf is present in about 47% of the repeatingunits, the O-acetyl group at position 6 of β-D-Galf is present in about 42% of the repeating units,wherein the O-acetyl group at position 5 of β-D-Galf is present in about 11% of the repeatingunits. Preferably, all repeating unit bears one O-acetyl group on the β-D-Galf residue.In one embodiment, the present invention provides an isolated S. pneumoniae serotype 15saccharide with the repeating unit of formula (VIII), where n represents the number of repeatingunits, wherein the O-acetyl group at position 3 of β-D-Galf is present in about 30% of the repeatingunits, the O-acetyl group at position 6 of β-D-Galf is present in about 60% of the repeating units,wherein the O-acetyl group at position 5 of β-D-Galf is present in about 10% of the repeatingunits. Preferably, all repeating unit bears one O-acetyl group on the β-D-Galf residue. 20In one embodiment, the present invention provides an isolated S. pneumoniae serotypesaccharide with the repeating unit of formula (VIII), where n represents the number of repeatingunits, wherein the O-acetyl group at position 3 of β-D-Galf is present in about 31% of the repeatingunits, the O-acetyl group at position 6 of β-D-Galf is present in about 61% of the repeating units,wherein the O-acetyl group at position 5 of β-D-Galf is present in about 8% of the repeating units. 25Preferably, all repeating unit bears one O-acetyl group on the β-D-Galf residue.Furthermore, native S. pneumoniae serotype 21 saccharide can be deacetylated, forexample by treatment with a base (alkaline pH). As shown in the example section, native serotypepolysaccharide can be completely deacetylated after incubating with 0.25N NH4OH at roomtemperature for 24 hours. 30Accordingly, in one embodiment, the present invention provides an isolated S.pneumoniae serotype 21 saccharide with the following repeating unit: (IX) where n represents the number of repeating units. [→ 6)-α-D-Galp-(1 →3)- β-L-Rhap-(1 →4)- β-D-Glcp-(1 →3)- β-D-GlcpNAc-(1→ 3)-α-D- Galp-(1-PO4 →]n↑β-D-Galf 7The native S. pneumoniae serotype 21 saccharide may be partially deacetylated, forexample by gentle treatment with a base (alkaline pH).Accordingly, in one embodiment, the present invention provides an isolated S.pneumoniae serotype 21 saccharide with the repeating unit of formula (VIII), where n representsthe number of repeating units, and wherein the O-acetyl group at position 3, 5 or 6 of β-D-Galf is 5present in about 0% to about 95% of the repeating units.In one embodiment, the present invention provides an isolated S. pneumoniae serotypesaccharide with the repeating unit of formula (VIII), where n represents the number of repeatingunits, and wherein the O-acetyl group at position 3, 5 or 6 of β-D-Galf is present in about 10% toabout 90% of the repeating units. 10In one embodiment, the present invention provides an isolated S. pneumoniae serotypesaccharide with the repeating unit of formula (VIII), where n represents the number of repeatingunits, and wherein the O-acetyl group at position 3, 5 or 6 of β-D-Galf is present in about 30% toabout 60% of the repeating units.In certain embodiments, the isolated S. pneumoniae serotype 21 saccharide of the 15invention has between 10 and 5,000 repeating units. In certain aspects, the isolated saccharidehas between 50 and 4,500 repeating units. In certain aspects, the isolated saccharide hasbetween 100 and 4,500 repeating units. In certain aspects, the isolated saccharide has between150 and 2,000 repeating units.Isolated capsular saccharides from S. pneumoniae serotype 21 can be prepared by 20standard techniques known to those of ordinary skill in the art. Typically capsular polysaccharidesare produced by growing a S. pneumoniae serotype 21 strain in a medium (e.g., in a soy-basedmedium), the polysaccharides are then prepared from the bacteria culture. Serotype 21Streptococcus pneumoniae strains may be obtained from established culture collections (such asfor example the Streptococcal Reference Laboratory (Centers for Disease Control and 25Prevention, Atlanta, GA)) or clinical specimens.The population of the organism (S. pneumoniae serotype 21) is often scaled up from aseed vial to seed bottles and passaged through one or more seed fermentors of increasingvolume until production scale fermentation volumes are reached. At the end of the growth cyclethe cells are lysed and the lysate broth is then harvested for downstream (purification) processing 30(see for example WO 2006/110381 and WO 2008/118752, U.S. Patent App. Pub. Nos.2006/0228380, 2006/0228381, 2008/0102498 and US2008/0286838). The polysaccharides aretypically purified through centrifugation, precipitation, ultra-filtration, and/or columnchromatography (see for example WO 2006/110352, WO 2008/118752 and WO2020/170190).The isolated polysaccharide can be characterized by different parameters including, for 35example the weight average molecular weight (Mw). The molecular weight of the polysaccharidecan be measured by Size Exclusion Chromatography (SEC) combined with Multiangle Laser LightScattering detector (MALLS). 8In an embodiment, the isolated S. pneumoniae serotype 21 saccharide of the inventionhas a weight average molecular weight between 5 kDa and 5000 kDa. In an embodiment, theisolated S. pneumoniae serotype 21 saccharide has a weight average molecular weight betweenkDa and 2000 kDa.In an embodiment, the isolated S. pneumoniae serotype 21 polysaccharide has a weight 5average molecular weight between 50 kDa and 5000 kDa. In an embodiment, the isolated S.pneumoniae serotype 21 polysaccharide has a weight average molecular weight between 50 kDaand 2000 kDa. In an embodiment, the isolated S. pneumoniae serotype 21 polysaccharide has aweight average molecular weight between 50 kDa and 1000 kDa.In an embodiment, the isolated S. pneumoniae serotype 21 polysaccharide has a weight 10average molecular weight between 100 kDa and 5000 kDa. In an embodiment, the isolated S.pneumoniae serotype 21 polysaccharide has a weight average molecular weight between 100kDa and 2000 kDa. In an embodiment, the isolated S. pneumoniae serotype 21 polysaccharidehas a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, theisolated S. pneumoniae serotype 21 polysaccharide has a weight average molecular weight 15between 100 kDa and 500 kDa.In an embodiment, the isolated S. pneumoniae serotype 21 polysaccharide has a weightaverage molecular weight between 300 kDa and 5000 kDa. In an embodiment, the isolated S.pneumoniae serotype 21 polysaccharide has a weight average molecular weight between 300kDa and 2000 kDa. In an embodiment, the isolated S. pneumoniae serotype 21 polysaccharide 20has a weight average molecular weight between 300 kDa and 1000 kDa.In an embodiment, the isolated S. pneumoniae serotype 21 polysaccharide has a weightaverage molecular weight between 500 kDa and 3000 kDa. In an embodiment, the isolatedpolysaccharide has a weight average molecular weight between 500 kDa and 2000 kDa. In anembodiment, the isolated polysaccharide has a weight average molecular weight between 500 25kDa and 1000 kDa.Preferably, in order to generate glycoconjugates with advantageous filterabilitycharacteristics, immunogenicity and/or yields, sizing of the saccharide to a target molecularweight range is performed prior to the conjugation to a carrier protein.Advantageously, the size of the purified capsular S. pneumoniae serotype 21 saccharide 30is reduced while preserving critical features of the structure of the polysaccharide. Mechanical orchemical sizing maybe employed.In an embodiment, the size of the purified S. pneumoniae serotype 21 capsular saccharideis reduced by chemical hydrolysis. Chemical hydrolysis maybe conducted using a mild acid (e.g.,acetic acid, formic acid, propanoic acid). In an embodiment, chemical hydrolysis is conducted 35using formic acid. In an embodiment, chemical hydrolysis is conducted using propanoic acid. Ina preferred embodiment, chemical hydrolysis is conducted using acetic acid. Chemical hydrolysismay also be conducted using a diluted strong acid (such as diluted hydrochloric acid, diluted 9sulfuric acid, diluted phosphoric acid, diluted nitric acid or diluted perchloric acid). In anembodiment, chemical hydrolysis is conducted using diluted hydrochloric acid. In an embodiment,chemical hydrolysis is conducted using diluted sulfuric acid. In an embodiment, chemicalhydrolysis is conducted using diluted phosphoric acid. In an embodiment, chemical hydrolysis isconducted using diluted nitric acid. In an embodiment, chemical hydrolysis is conducted using 5diluted perchloric acid.The size of the purified S. pneumoniae serotype 21 capsular saccharide can also bereduced by mechanical homogenization. In an embodiment, the size of the purified capsularsaccharide is reduced by high pressure homogenization. High pressure homogenization achieveshigh shear rates by pumping the process stream through a flow path with sufficiently small 10dimensions. The shear rate is increased by using a larger applied homogenization pressure, andexposure time can be increased by recirculating the feed stream through the homogenizer.The high-pressure homogenization process can be appropriate for reducing the size ofthe purified capsular saccharide while preserving the structural features of the saccharide.In a preferred embodiment, the isolated S. pneumoniae serotype 21 capsular saccharide 15is sized to a weight average molecular weight between 10 kDa and 1000 kDa. In an embodiment,the isolated S. pneumoniae serotype 21 capsular saccharide is sized to a weight averagemolecular weight between 50 kDa and 500 kDa. In an embodiment, the isolated S. pneumoniaeserotype 21 capsular saccharide is sized to a weight average molecular weight between 50 kDaand 400 kDa. In an embodiment, the isolated S. pneumoniae serotype 21 capsular saccharide is 20sized to a weight average molecular weight between 50 kDa and 250 kDa.In an embodiment, the isolated S. pneumoniae serotype 21 capsular saccharide is sizedto a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, theisolated S. pneumoniae serotype 21 capsular saccharide is sized to a weight average molecularweight between 100 kDa and 500 kDa. In an embodiment, the isolated S. pneumoniae serotype 25capsular saccharide is sized to a weight average molecular weight between 100 kDa and 400kDa. In an embodiment, the isolated S. pneumoniae serotype 21 capsular saccharide is sized toa weight average molecular weight between 100 kDa and 250 kDa.In a preferred embodiment, the isolated S. pneumoniae serotype 21 capsular saccharideis sized to a weight average molecular weight between 150 kDa and 400 kDa. 30In an embodiment, the isolated S. pneumoniae serotype 21 capsular saccharide is sizedto a weight average molecular weight between 250 kDa and 1000 kDa. In an embodiment, theisolated S. pneumoniae serotype 21 capsular saccharide is sized to a weight average molecularweight between 250 kDa and 500 kDa. In an embodiment, the isolated S. pneumoniae serotypecapsular saccharide is sized to a weight average molecular weight between 250 kDa and 400 35kDa. In a preferred embodiment, the isolated S. pneumoniae serotype 21 capsular saccharide issized to a weight average molecular weight between 200 kDa and 800 kDa. 10In an embodiment, the isolated S. pneumoniae serotype 21 capsular saccharide capsularsaccharide is sized to a weight average molecular weight of about 250 kDa. In an embodiment,the isolated S. pneumoniae serotype 21 capsular saccharide is sized to a weight averagemolecular weight of about 300 kDa. In an embodiment, the isolated S. pneumoniae serotype 21capsular saccharide is sized to a weight average molecular weight of about 350 kDa. In an 5embodiment, the isolated S. pneumoniae serotype 21 capsular saccharide is sized to a weightaverage molecular weight of about 400 kDa. In an embodiment, the isolated S. pneumoniaeserotype 21 capsular saccharide is sized to a weight average molecular weight of about 450 kDa.In an embodiment, the isolated S. pneumoniae serotype 21 capsular saccharide is sized to aweight average molecular weight of about 500 kDa. In an embodiment, the isolated S. 10pneumoniae serotype 21 capsular saccharide is sized to a weight average molecular weight ofabout 550 kDa. In an embodiment, the isolated S. pneumoniae serotype 21 capsular saccharideis sized to a weight average molecular weight of about 600 kDa. In an embodiment, the isolatedS. pneumoniae serotype 21 capsular saccharide is sized to a weight average molecular weightof about 700 kDa. In an embodiment, the isolated S. pneumoniae serotype 21 capsular 15saccharide is sized to a weight average molecular weight of about 800 kDa. In an embodiment,the isolated S. pneumoniae serotype 21 capsular saccharide is sized to a weight averagemolecular weight of about 900 kDa. In an embodiment, the isolated S. pneumoniae serotype 21capsular saccharide is sized to a weight average molecular weight of about 1000 kDa.In an embodiment, the isolated capsular saccharide is not sized. 20The isolated capsular saccharide described above may be activated (e.g., chemicallyactivated) to make them capable of reacting and then incorporated into glycoconjugates, asfurther described herein. 2. Streptococcus pneumoniae serotype 21 glycoconjugates of the invention For the purpose of the invention the term ‘glycoconjugate' indicates a capsular saccharide 25conjugated to a carrier protein via covalent or non-covalent bonds. In an embodiment, thecapsular saccharide is conjugated to a carrier protein via non-covalent bonds (such as therhizavidin/biotin system, see e.g. WO2012155007, WO2020056202). Preferably, the capsularsaccharide is conjugated via covalent bonds. In one embodiment the capsular saccharide isconjugated directly to a carrier protein. In a second embodiment the capsular saccharide is 30conjugated to a carrier protein through a spacer/linker.The present invention provides glycoconjugates in which saccharides as provided for aboveare conjugated to a carrier protein. Therefore, in an embodiment, the invention provides aglycoconjugate comprising a saccharide having the above disclosed repeating unit conjugated toa carrier protein. 35In an embodiment, the invention provides a glycoconjugate consisting of a saccharide havingthe above disclosed repeating unit conjugated to a carrier protein. 112.1 Attributes of the Streptococcus pneumoniae serotype 21 glycoconjugates of the inventionThe isolated polysaccharide described above may be activated (e.g., chemically activated) tomake them capable of reacting (e.g. with a linker or directly with the carrier protein) and thenincorporated into glycoconjugates, as further described herein.Before activation, the size of the isolated polysaccharide can be reduced while preserving 5critical features of the structure of the polysaccharide. Mechanical or chemical sizing maybeemployed. In an embodiment, the size of the isolated polysaccharide is reduced by chemicalhydrolysis. The size of the isolated polysaccharide can also be reduced by mechanicalhomogenization. In an embodiment, the size of the isolated polysaccharide is reduced by highpressure homogenization. High pressure homogenization achieves high shear rates by pumping 10the process stream through a flow path with sufficiently small dimensions. The shear rate isincreased by using a larger applied homogenization pressure, and exposure time can beincreased by recirculating the feed stream through the homogenizer.The weight average molecular weight (Mw) of the saccharide before conjugation refers to theMw before the activation of the saccharide (i.e. after an eventual sizing step but before reacting 15the saccharide with an activating agent). In the context of the present invention the Mw of thesaccharide is not substantially modified by the activation step and the Mw of the saccharideincorporated in the conjugate is similar to the Mw of the saccharide as measured before activation.In an embodiment, the serotype 21 glycoconjugate of the present invention comprises aserotype 21 polysaccharide wherein the weight average molecular weight (Mw) of said 20polysaccharide before conjugation is between 50 kDa and 1,000 kDa.In an embodiment, the serotype 21 glycoconjugate of the present invention comprises aserotype 21 polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 100 kDa and 600 kDa.In an embodiment, the serotype 21 glycoconjugate of the present invention comprises a 25serotype 21 polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 100 kDa and 400 kDa.In an embodiment, the serotype 21 glycoconjugate of the present invention comprises aserotype 21 polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 150 kDa and 300 kDa. 30In some embodiments, the serotype 21 glycoconjugate of the invention has a weight averagemolecular weight (Mw) of between 250 kDa and 20,000 kDa.In other embodiments, the serotype 21 glycoconjugate has a weight average molecularweight (Mw) of between 500 kDa and 15,000 kDa.In other embodiments, the serotype 21 glycoconjugate has a weight average molecular 35weight (Mw) of between 500 kDa and 10,000 kDa.In still other embodiments, the serotype 21 glycoconjugate has a weight average molecularweight (Mw) of between 750 kDa and 7,500 kDa. 12In preferred embodiments, the serotype 21 glycoconjugate has a weight average molecularweight (Mw) of between 1,000 kDa and 5,000 kDa.In a preferred embodiment, the serotype 21 glycoconjugate of the invention prepared by clickchemistry has a weight average molecular weight (Mw) of between 750 kDa and 7,500 kDa andeven preferably of between 800 kDa and 7,000 kDa. In an embodiment, the carrier protein of said 5serotype 21 saccharide glycoconjugate is SCP.In a preferred embodiment, the serotype 21 glycoconjugate of the invention prepared by directreductive amination has a weight average molecular weight (Mw) of between 2,000 kDa and10,500 kDa. In an embodiment, the carrier protein of said serotype 21 saccharide glycoconjugateis CRM 197. 10In a preferred embodiment, the serotype 21 glycoconjugate of the invention prepared by clickchemistry, comprises a serotype 21 polysaccharide wherein the weight average molecular weight(Mw) of said polysaccharide before conjugation is between 150 kDa and 400 kDa and has aweight average molecular weight (Mw) of between 750 kDa and 7,500 kDa and even preferablyof between 800 kDa and 7,000 kDa. In an embodiment, the carrier protein of said serotype 21 15saccharide glycoconjugate is SCP.In a preferred embodiment, the serotype 21 glycoconjugate of the invention prepared by directreductive amination comprises a serotype 21 polysaccharide wherein the weight averagemolecular weight (Mw) of said polysaccharide before conjugation is between 100 kDa and 400kDa and has a weight average molecular weight (Mw) of between 500 kDa and 15,000 kDa and 20even preferably of between 2,000 kDa and 10,500 kDa. In an embodiment, the carrier protein ofsaid serotype 21 saccharide glycoconjugate is CRM 197.Serotype 21 polysaccharide is O-acetylated and the total amount of O-acetylation isapproximately one O-acetyl group per polysaccharide repeating unit. The degree of O-acetylationof the polysaccharide can be determined by any method known in the art, for example, by proton 25NMR or by ion-HPLC analysis (see for example Lemercinier et al. (1996) Carbohydrate Research296:83-96; Jones et al. (2002) J. Pharmaceutical and Biomedical Analysis 30:1233-1247; Hestrin,S. (1949) J. Biol. Chem. 180:249-261).In an embodiment, the serotype 21 glycoconjugate of the present invention comprises aserotype 21 saccharide comprising on average at least 0.5 O-acetyl group per saccharide 30repeating unit. In a preferred embodiment, the serotype 21 glycoconjugate of the presentinvention comprises a serotype 21 saccharide comprising on average at least 0.8 O-acetyl groupper saccharide repeating unit.In a preferred embodiment, the serotype 21 glycoconjugate of the present inventioncomprises a serotype 21 saccharide comprising on average between about 0.8 and about 1 O- 35acetyl group per saccharide repeating unit.In an embodiment, the ratio of O-acetyl group per saccharide repeating unit in theglycoconjugate to O-acetyl group per saccharide repeating unit in the isolated polysaccharide is 13at least 0.6. In a preferred embodiment, the ratio of O-acetyl group per saccharide repeating unitin the glycoconjugate to O-acetyl group per saccharide repeating unit in the isolatedpolysaccharide is at least 0.9.Another way to characterize the serotype 21 glycoconjugates of the invention is by thenumber of lysine residues in the carrier protein (e.g., CRM 197, SCP, DT or TT) that become 5conjugated to the saccharide which can be characterized as a range of conjugated lysines(degree of conjugation). The evidence for lysine modification of the carrier protein, due to covalentlinkages to the polysaccharides, can be obtained by amino acid analysis using routine methodsknown to those of skill in the art. Conjugation results in a reduction in the number of lysine residuesrecovered compared to the carrier protein starting material used to generate the conjugate 10materials. In a preferred embodiment, the degree of conjugation of the serotype 21glycoconjugate of the invention is between 2 and 15. In an embodiment, the degree of conjugationof the serotype 21 glycoconjugate of the invention is between 2 and 10. In an embodiment, thedegree of conjugation of the serotype 21 glycoconjugate of the invention is between 3 and 5. Inan embodiment, the degree of conjugation of the serotype 21 glycoconjugate of the invention is 15between 2 and 6. In an embodiment, the degree of conjugation of the serotype 21 glycoconjugateof the invention is between 4 and 10.The serotype 21 glycoconjugates of the invention may also be characterized by the ratio(weight/weight) of saccharide to carrier protein. In some embodiments, the ratio of serotype 21saccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 3.0. In other 20embodiments, the saccharide to carrier protein ratio (w/w) is between 0.5 and 2.0. In otherembodiments, the saccharide to carrier protein ratio (w/w) is between 0.5 and 1.5. In otherembodiments, the saccharide to carrier protein ratio (w/w) is between 0.8 and 1.2. In otherembodiments, the saccharide to carrier protein ratio (w/w) is between 0.5 and 1.0. In otherembodiments, the saccharide to carrier protein ratio (w/w) is between 1.0 and 1.5. In other 25embodiments, the saccharide to carrier protein ratio (w/w) is between 1.0 and 2.0. In furtherembodiments, the saccharide to carrier protein ratio (w/w) is between 0.8 and 1.2. In a preferredembodiment, the ratio of serotype 21 saccharide to carrier protein in the conjugate is between 0.7and 1.1. In some such embodiments, the carrier protein is CRM 197.In a preferred embodiment, for the serotype 21 glycoconjugate of the invention prepared by 30click chemistry, the ratio of serotype 21 saccharide to carrier protein in the glycoconjugate (w/w)is between 0.5 and 1.1. In an embodiment, the carrier protein of said serotype 21 saccharideglycoconjugate is SCP.In a preferred embodiment, for the serotype 21 glycoconjugate of the invention prepared bydirect reductive amination, the ratio of serotype 21 saccharide to carrier protein in the 35glycoconjugate (w/w) is between 0.5 and 1.3. In an embodiment, the carrier protein of saidserotype 21 saccharide glycoconjugate is CRM 197. 14In a preferred embodiment, the serotype 21 glycoconjugate of the invention prepared by clickchemistry, comprises a serotype 21 polysaccharide wherein the weight average molecular weight(Mw) of said polysaccharide before conjugation is between 150 kDa and 400 kDa and has aweight average molecular weight (Mw) of between 750 kDa and 7,500 kDa and even preferablyof between 800 kDa and 7,000 kDa and the ratio of serotype 21 saccharide to carrier protein in 5the glycoconjugate (w/w) is between 0.5 and 1.1. In an embodiment, the carrier protein of saidserotype 21 saccharide glycoconjugate is SCP.In a preferred embodiment, the serotype 21 glycoconjugate of the invention prepared by directreductive amination comprises a serotype 21 polysaccharide wherein the weight averagemolecular weight (Mw) of said polysaccharide before conjugation is between 100 kDa and 400 10kDa and has a weight average molecular weight (Mw) of between 500 kDa and 15,000 kDa andeven preferably of between 2,000 kDa and 10,500 kDa and the ratio of serotype 21 saccharideto carrier protein in the glycoconjugate (w/w) is between 0.5 and 1.3. In an embodiment, the carrierprotein of said serotype 21 saccharide glycoconjugate is CRM 197.The serotype 21 glycoconjugates and immunogenic compositions of the invention may 15contain free saccharide that is not conjugated to the carrier protein but is nevertheless present inthe glycoconjugate composition. The free saccharide may be noncovalently associated with (i.e.,noncovalently bound to, adsorbed to, or entrapped in or with) the glycoconjugate. In a preferredembodiment, the serotype 21 glycoconjugate comprises less than about 50% of free serotype 21saccharide compared to the total amount of serotype 21 saccharide. In a preferred embodiment, 20the serotype 21 glycoconjugate comprises less than about 25% of free serotype 21 saccharidecompared to the total amount of serotype 21 saccharide. In an even preferred embodiment, theserotype 21 glycoconjugate comprises less than about 20% of free serotype 21 saccharidecompared to the total amount of serotype 21 saccharide. In a yet preferred embodiment, theserotype 21 glycoconjugate comprises less than about 15% of free serotype 21 saccharide 25compared to the total amount of serotype 21 saccharide.In a preferred embodiment, the serotype 21 glycoconjugate of the invention prepared by clickchemistry, comprises a serotype 21 polysaccharide wherein the weight average molecular weight(Mw) of said polysaccharide before conjugation is between 150 kDa and 400 kDa and has aweight average molecular weight (Mw) of between 750 kDa and 7,500 kDa and even preferably 30of between 800 kDa and 7,000 kDa, wherein the ratio of serotype 21 saccharide to carrier proteinin the glycoconjugate (w/w) is between 0.5 and 1.1 and wherein the serotype 21 glycoconjugatecomprises less than about 25% of free serotype 21 saccharide compared to the total amount ofserotype 21 saccharide. In an embodiment, the carrier protein of said serotype 21 saccharideglycoconjugate is SCP. 35In a preferred embodiment, the serotype 21 glycoconjugate of the invention prepared by directreductive amination comprises a serotype 21 polysaccharide wherein the weight averagemolecular weight (Mw) of said polysaccharide before conjugation is between 100 kDa and 400 15kDa and has a weight average molecular weight (Mw) of between 500 kDa and 15,000 kDa andeven preferably of between 2,000 kDa and 10,500 kDa, wherein the ratio of serotype 21saccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 1.3 and wherein theserotype 21 glycoconjugate comprises less than about 25% of free serotype 21 saccharidecompared to the total amount of serotype 21 saccharide. In an embodiment, the carrier protein of 5said serotype 21 saccharide glycoconjugate is CRM 197.In a preferred embodiment, the serotype 21 glycoconjugate of the invention prepared by clickchemistry, comprises a serotype 21 polysaccharide wherein the weight average molecular weight(Mw) of said polysaccharide before conjugation is between 150 kDa and 400 kDa and has aweight average molecular weight (Mw) of between 750 kDa and 7,500 kDa and even preferably 10of between 800 kDa and 7,000 kDa, wherein the ratio of serotype 21 saccharide to carrier proteinin the glycoconjugate (w/w) is between 0.5 and 1.1, wherein the degree of conjugation of saidserotype 21 glycoconjugate is between 2 and 10 and wherein the serotype 21 glycoconjugatecomprises less than about 25% of free serotype 21 saccharide compared to the total amount ofserotype 21 saccharide. In an embodiment, the carrier protein of said serotype 21 saccharide 15glycoconjugate is SCP.In a preferred embodiment, the serotype 21 glycoconjugate of the invention prepared by directreductive amination comprises a serotype 21 polysaccharide wherein the weight averagemolecular weight (Mw) of said polysaccharide before conjugation is between 100 kDa and 400kDa and has a weight average molecular weight (Mw) of between 500 kDa and 15,000 kDa and 20even preferably of between 2,000 kDa and 10,500 kDa, wherein the ratio of serotype 21saccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 1.3, wherein thedegree of conjugation of said serotype 21 glycoconjugate is between 2 and 10 and wherein theserotype 21 glycoconjugate comprises less than about 25% of free serotype 21 saccharidecompared to the total amount of serotype 21 saccharide. In an embodiment, the carrier protein of 25said serotype 21 saccharide glycoconjugate is CRM 197.The serotype 21 glycoconjugates may also be characterized by their molecular sizedistribution (Kd). Size exclusion chromatography media (CL-4B) can be used to determine therelative molecular size distribution of the conjugate. Size Exclusion Chromatography (SEC) isused in gravity fed columns to profile the molecular size distribution of conjugates. Large 30molecules excluded from the pores in the media elute more quickly than small molecules.Fraction collectors are used to collect the column eluate. The fractions are tested colorimetricallyby saccharide assay. For the determination of Kd, columns are calibrated to establish the fractionat which molecules are fully excluded (V0), (Kd=0), and the fraction representing the maximumretention (Vi), (Kd=1). The fraction at which a specified sample attribute is reached (Ve), is related 35to Kd by the expression, Kd = (Ve - V0)/ (Vi - V0).In a preferred embodiment, at least 30% of the serotype 21 glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 40% of the glycoconjugate 16has a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, at least 60% of theserotype 21 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. In a preferredembodiment, between 50% and 80% of the serotype 21 glycoconjugate has a Kd below or equalto 0.3 in a CL-4B column. In a preferred embodiment, between 65% and 80% of the serotype 21glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. 5In a preferred embodiment, the serotype 21 glycoconjugate of the invention prepared by clickchemistry, comprises a serotype 21 polysaccharide wherein the weight average molecular weight(Mw) of said polysaccharide before conjugation is between 150 kDa and 400 kDa and has aweight average molecular weight (Mw) of between 750 kDa and 7,500 kDa and even preferablyof between 800 kDa and 7,000 kDa, wherein the ratio of serotype 21 saccharide to carrier protein 10in the glycoconjugate (w/w) is between 0.5 and 1.1, wherein the serotype 21 glycoconjugatecomprises less than about 25% of free serotype 21 saccharide compared to the total amount ofserotype 21 saccharide and wherein between 65% and 80% of the serotype 21 glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In an embodiment, the carrier protein of saidserotype 21 saccharide glycoconjugate is SCP. 15In a preferred embodiment, the serotype 21 glycoconjugate of the invention prepared by directreductive amination comprises a serotype 21 polysaccharide wherein the weight averagemolecular weight (Mw) of said polysaccharide before conjugation is between 100 kDa and 400kDa and has a weight average molecular weight (Mw) of between 500 kDa and 15,000 kDa andeven preferably of between 2,000 kDa and 10,500 kDa, wherein the ratio of serotype 21 20saccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 1.3, wherein theserotype 21 glycoconjugate comprises less than about 25% of free serotype 21 saccharidecompared to the total amount of serotype 21 saccharide and wherein between 65% and 80% ofthe serotype 21 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. In anembodiment, the carrier protein of said serotype 21 saccharide glycoconjugate is CRM 197. 25In a preferred embodiment, the serotype 21 glycoconjugate of the invention prepared by clickchemistry, comprises a serotype 21 polysaccharide wherein the weight average molecular weight(Mw) of said polysaccharide before conjugation is between 150 kDa and 400 kDa and has aweight average molecular weight (Mw) of between 750 kDa and 7,500 kDa and even preferablyof between 800 kDa and 7,000 kDa, wherein the ratio of serotype 21 saccharide to carrier protein 30in the glycoconjugate (w/w) is between 0.5 and 1.1, wherein the degree of conjugation of saidserotype 21 glycoconjugate is between 2 and 10, wherein the serotype 21 glycoconjugatecomprises less than about 25% of free serotype 21 saccharide compared to the total amount ofserotype 21 saccharide and wherein between 65% and 80% of the serotype 21 glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In an embodiment, the carrier protein of said 35serotype 21 saccharide glycoconjugate is SCP.In a preferred embodiment, the serotype 21 glycoconjugate of the invention prepared by directreductive amination comprises a serotype 21 polysaccharide wherein the weight average 17molecular weight (Mw) of said polysaccharide before conjugation is between 100 kDa and 400kDa and has a weight average molecular weight (Mw) of between 500 kDa and 15,000 kDa andeven preferably of between 2,000 kDa and 10,500 kDa, wherein the ratio of serotype 21saccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 1.3, wherein thedegree of conjugation of said serotype 21 glycoconjugate is between 2 and 10, wherein the 5serotype 21 glycoconjugate comprises less than about 25% of free serotype 21 saccharidecompared to the total amount of serotype 21 saccharide and wherein between 65% and 80% ofthe serotype 21 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. In anembodiment, the carrier protein of said serotype 21 saccharide glycoconjugate is CRM 197. 2.2 Mode of preparation of the Streptococcus pneumoniae serotype 21 glycoconjugates 10of the inventionThe serotype 21 glycoconjugate of the present invention can be prepared by any couplingtechnique known to those of ordinary skill in the art.In an embodiment, the serotype 21 saccharide is coupled to the carrier protein via non-covalent bonds (see e.g. WO2012155007, WO2020056202). 15In an embodiment, the serotype 21 saccharide is conjugated via covalent bonds. In oneembodiment the capsular saccharide is conjugated directly to a carrier protein. In a secondembodiment the capsular saccharide is conjugated to a carrier protein through a spacer/linker.ln an embodiment, the serotype 21 glycoconjugate of the present invention is conjugatedto the carrier protein via a linker, for instance a bifunctional linker. The linker is optionally 20heterobifunctional or homobifunctional, having for example a reactive amino group and a reactivecarboxylic acid group, two reactive amino groups or two reactive carboxylic acid groups. Thelinker has for example between 4 and 20, 4 and 12, 5 and 10 carbon atoms.A possible linker is adipic acid dihydrazide (ADH). Other linkers include B-propionamido(WO 00/10599), nitrophenyl-ethylamine (Gever et al (1979) Med. Microbiol. lmmunol. 165; 171- 25288), haloalkyl halides (US4057685), glycosidic linkages (US4673574, US4808700), hexanediamine and 6-aminocaproic acid (US4459286).ln an embodiment, the serotype 21 glycoconjugate of the present invention is conjugateddirectly to the carrier protein (without a linker).ln general the following types of chemical groups on a protein carrier can be used for 30coupling / conjugation:1) Amino group (for instance via lysine). ln one embodiment this group is linked to carboxyl groupson saccharides directly or to a carboxyl group on a linker with carbodiimide chemistry e.g. withEDAC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide). ln another embodiment this group islinked to hydroxyl groups activated with CDAP or CNBr on saccharides directly or to such groups 35on a linker; to saccharides or linkers having an aldehyde group; to saccharides or linkers havinga succinimide ester group. 182) Carboxyl (for instance via aspartic acid or glutamic acid). ln one embodiment this group islinked to amino groups on saccharides directly or to an amino group on a linker with carbodiimidechemistry e.g. with EDAC.3) Sulphydryl (for instance via cysteine). ln one embodiment this group is linked to a bromo orchloro acetylated saccharide or linker with maleimide chemistry. ln one embodiment this group is 5activated/modified with bis diazobenzidine.4) Hydroxyl group (for instance via tyrosine). ln one embodiment this group is activated/modifiedwith bis diazobenzidine.5) lmidazolyl group (for instance via histidine). ln one embodiment this group is activated/modifiedwith bis diazobenzidine. 106) Guanidyl group (for instance via arginine).7) lndolyl group (for instance via tryptophan).On the serotype 21 saccharide, in general the following groups can be used for a coupling:OH, COOH or NH2. Aldehyde groups can be generated after different treatments known in theart such as: periodate, acid hydrolysis, hydrogen peroxide, etc. 15ln an embodiment, the serotype 21 glycoconjugate of the present invention is preparedusing CDAP chemistry. In said embodiment, the serotype 21 saccharide is activated with 1-cyano-4-dimethylamino pyridinium tetrafluoroborate (CDAP) to form a cyanate ester. The activatedsaccharide can then be coupled directly or via a spacer (linker) group to an amino group on thecarrier protein. For example, the spacer could be cystamine or cysteamine to give a thiolated 20polysaccharide which can be coupled to the carrier via a thioether linkage obtained after reactionwith a maleimide-activated carrier protein (for example using N-[ γ-maleimidobutyrloxy]succinimide ester (GMBS)) or a haloacetylated carrier protein (for exampleusing iodoacetimide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl(4-iodoacetyl)aminobenzoate (SlAB), sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB), 25N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetamido]proprionate (SBAP)).In a preferred embodiment, the cyanate ester of the activated saccharide is coupled with hexanediamine or adipic acid dihydrazide (ADH) and the amino-derivatised saccharide is conjugated tothe carrier protein using carbodiimide (e.g., EDAC or EDC) chemistry via a carboxyl group on theprotein carrier. Such conjugates are described for example in WO 93/15760, WO 95/08348 and 30WO 96/129094.ln an embodiment, the serotype 21 glycoconjugate of the present invention is preparedusing carbodiimides, hydrazides, active esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S--NHS, EDC, TSTU. Many are described in International Patent ApplicationPublication No. WO 98/42721. Conjugation may involve a carbonyl linker which may be formed 35by reaction of a free hydroxyl group of the saccharide with CDI (see Bethell et al. (1979) 1. Biol.Chern. 254:2572-2574; Hearn et al. (1981) J. Chromatogr. 218:509-518) followed by reaction witha protein to form a carbamate linkage. This may involve reduction of the anomeric terminus to a 19primary hydroxyl group, optional protection/deprotection of the primary hydroxyl group, reactionof the primary hydroxyl group with CDI to form a CDI carbamate intermediate and coupling theCDI carbamate intermediate with an amino group on a protein.
Direct reductive aminationIn an embodiment, the serotype 21 glycoconjugate of the present invention is prepared by 5direct reductive amination (see e.g. US 4365170, US 4673574, WO2006/110381,WO2008/079653, WO2008/143709, WO2008/079732, WO2011/110531, WO2012/119972,WO2015110941, WO2015110940, WO2018/144439, WO2018/156491).According to the present invention, reductive amination involves two steps, (1) oxidation(activation) of the serotype 21 purified saccharide, (2) reduction of the activated saccharide and 10the carrier protein (e.g., CRM 197, TT or SCP) to form a glycoconjugate.As mentioned above, before oxidation, sizing of the serotype 21 saccharide to a target molecularweight (MW) range can be performed. Therefore, in an embodiment, the isolated polysaccharideis sized before oxidation.In an embodiment, the serotype 21 saccharide of the invention is conjugated to a carrier 15protein by a process comprising the step of:(a) reacting said serotype 21 saccharide with an oxidizing agent;(b) compounding the activated saccharide of step (a) with a carrier protein; and(c) reacting the compounded activated saccharide and carrier protein with a reducing agent toform a glycoconjugate. 20In an embodiment, the serotype 21 saccharide of the invention is conjugated to a carrierprotein by a process comprising the step of:(a) reacting said serotype 21 saccharide with an oxidizing agent;(a’) quenching the oxidation reaction by addition of a quenching agent;(b) compounding the activated saccharide of step (a’) with a carrier protein; and 25(c) reacting the compounded activated saccharide and carrier protein with a reducing agent toform a glycoconjugate.Following the oxidation step (a) the saccharide is said to be activated and is referred to as"activated saccharide".In an embodiment, the oxidizing agent is any oxidizing agent which oxidizes a terminal 30hydroxyl group to an aldehyde. In an embodiment, the oxidizing agent is periodate. For thepurpose of the present invention, the term "periodate" includes both periodate and periodic acid;the term also includes both metaperiodate (IO4-) and orthoperiodate (IO65-) and the various saltsof periodate (e.g., sodium periodate and potassium periodate).In an embodiment, the oxidizing agent is periodate in the presence of bivalent cations (see 35WO2008/143709).In an embodiment, the oxidizing agent is periodic acid. In an embodiment, the oxidizingagent is periodic acid in the presence of bivalent cations. In an embodiment, the oxidizing agent 20is periodic acid in the presence of Mg2+. In an embodiment, the oxidizing agent is periodic acid inthe presence of Ca2+. In an embodiment, the oxidizing agent is orthoperiodate.In a preferred embodiment, the oxidizing agent is sodium periodate. In an embodiment,the periodate used for the oxidation is metaperiodate. In an embodiment the periodate used forthe oxidation is sodium metaperiodate. 5When a polysaccharide reacts with periodate, periodate oxidises vicinal hydroxyl groups to formcarbonyl or aldehyde groups and causes cleavage of a C-C bond. For this reason, the term"reacting a polysaccharide with periodate" includes oxidation of vicinal hydroxyl groups byperiodate.In one embodiment step a) comprises reacting the polysaccharide with 0.01-2 molar 10equivalents of periodate. In one embodiment step a) comprises reacting the polysaccharide with0.1-1.0 molar equivalents of periodate. In one embodiment step a) comprises reacting thepolysaccharide with 0.1-0.5 molar equivalents of periodate.In an embodiment, the oxidizing agent is a mixture of a stable nitroxyl radical compoundwith an oxidant (see WO2014097099). 15In an aspect, said stable nitroxyl radical compound is a molecule bearing a TEMPO or aPROXYL (2,2,5,5-tetramethyl-1-pyrrolidinyloxy) moiety. Preferably said molecule has the abilityto selectively oxidize primary alcohol in the presence of an oxidant, to generate aldehyde groups,without affecting secondary hydroxyl groups. More preferably said molecule has the ability toselectively oxidize primary alcohol in the presence of an oxidant, to generate aldehyde groups, 20without over oxidation to carboxyl groups. In an aspect, said stable nitroxyl radical compound isTEMPO, 2,2,6,6-Tetramethyl-4-(methylsulfonyloxy)-1-piperidinooxy, 4-Phosphonooxy-TEMPO,4-Oxo-TEMPO, 4-Methoxy-TEMPO, 4-Isothiocyanato-TEMPO, 4-(2-Iodoacetamido)-TEMPOfree radical, 4-Hydroxy-TEMPO, 4-Cyano-TEMPO, 4-Carboxy-TEMPO, 4-(2-Bromoacetamido)-TEMPO or 4-Amino-TEMPO, 4-Acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl. Preferably said 25stable nitroxyl radical compound is TEMPO. In an aspect, said stable nitroxyl radical compoundis selected from the groups consisting of TEMPO, 2,2,6,6-Tetramethyl-4-(methylsulfonyloxy)-1-piperidinooxy, 4-Phosphonooxy-TEMPO, 4-Oxo-TEMPO, 4-Methoxy-TEMPO, 4-Isothiocyanato-TEMPO, 4-(2-Iodoacetamido)-TEMPO free radical, 4-Hydroxy-TEMPO, 4-Cyano-TEMPO, 4-Carboxy-TEMPO, 4-(2-Bromoacetamido)-TEMPO, 4-Amino-TEMPO, 4-Acetamido-2,2,6,6- 30tetramethylpiperidine 1-oxyl. Preferably said stable nitroxyl radical compound is TEMPO. In afurther aspect, said stable nitroxyl radical compound is 3 β-DOXYL-5 α-cholestane, 5-DOXYL-stearic acid, 16-DOXYL-stearic acid, Methyl 5-DOXYL-stearate, 3-(Aminomethyl)-PROXYL, 3-Carbamoyl-PROXYL, 3-Carbamoyl-2,2,5,5-tetramethyl-3-pyrrolin-1-oxyl, 3-Carboxy-PROXYL or3-Cyano-PROXYL. In a further aspect, said stable nitroxyl radical compound is selected from the 35groups consisting of 3 β-DOXYL-5 α-cholestane, 5-DOXYL-stearic acid, 16-DOXYL-stearic acid,Methyl 5-DOXYL-stearate, 3-(Aminomethyl)-PROXYL, 3-Carbamoyl-PROXYL, 3-Carbamoyl-2,2,5,5-tetramethyl-3-pyrrolin-1-oxyl, 3-Carboxy-PROXYL, 3-Cyano-PROXYL. 21In an aspect, the oxidant is a molecule bearing a N-halo moiety. Preferably said molecule has theability to selectively oxidize primary alcohol in the presence of a nitroxyl radical compound. In anaspect, said oxidant is N-Chlorosuccinimide, N-Bromosuccinimide, N-Iodosuccinimide,Dichloroisocyanuric acid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione, Dibromoisocyanuric acid,1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione, Diiodoisocyanuric acid or 1,3,5-triiodo-1,3,5- 5triazinane-2,4,6-trione. In an aspect, said oxidant is selected from the group consisting of N-Chlorosuccinimide, N-Bromosuccinimide, N-Iodosuccinimide, Dichloroisocyanuric acid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione, Dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione, Diiodoisocyanuric acid and 1,3,5-triiodo-1,3,5-triazinane-2,4,6-trione. Preferably saidoxidant is N-Chlorosuccinimide. 10In an aspect, said stable nitroxyl radical compound is 2,2,6,6-Tetramethyl-1-piperidinyloxy freeradical (TEMPO) and said oxidant is N-Chlorosuccinimide (NCS).In one embodiment, the quenching agent of step a’) is selected from vicinal diols, 1,2-aminoalcohols, amino acids, glutathione, sulfite, bisulfate, dithionite, metabisulfite, thiosulfate,phosphites, hypophosphites or phosphorous acid. 15In one embodiment, the quenching agent is a 1,2-aminoalcohols of formula (I): (I)wherein R is selected from H, methyl, ethyl, propyl or isopropyl.In one embodiment, the quenching agent is selected from sodium and potassium salts ofsulfite, bisulfate, dithionite, metabisulfite, thiosulfate, phosphites, hypophosphites or phosphorous 20acid.In one embodiment, the quenching agent is an amino acid. In such embodiments, saidamino acid may be selected from serine, threonine, cysteine, cystine, methionine, proline,hydroxyproline, tryptophan, tyrosine, and histidine.In one embodiment, the quenching agent is a sulfite such as bisulfate, dithionite, 25metabisulfite, thiosulfate.In one embodiment, the quenching agent is a compound comprising two vicinal hydroxylgroups (vicinal diols), i.e., two hydroxyl groups covalently linked to two adjacent carbon atoms.Preferably, the quenching agent is a compound of formula (II): OH O H RR (II) 30wherein R and R are each independently selected from H, methyl, ethyl, propyl or isopropyl.
N HOH R1 22In a preferred embodiment, the quenching agent is glycerol, ethylene glycol, propan-1,2-diol,butan-1,2-diol or butan-2,3-diol, or ascorbic acid. In an even preferred embodiment, thequenching agent is butan-2,3-diol.In a preferred embodiment the degree of oxidation (also named "degree of activation" inthe present document) of the activated serotype 21 saccharide is between 2 and 30. In an 5embodiment the degree of oxidation (DO) of the activated serotype 21 polysaccharide is betweenand 25.In a very preferred embodiment the degree of oxidation of the activated serotype 21saccharide is between 10 and 21.In one embodiment the activated saccharide and the carrier protein are lyophilised before 10step b).In an embodiment the initial input ratio (weight by weight) of activated serotype 21saccharide to carrier protein at step b) is between 4:1 and 0.1:1. In an embodiment the initial inputratio (weight by weight) of activated serotype 21 saccharide to carrier protein at step b) is between1.5:1 and 0.5:1. 15In an embodiment, the reduction reaction (c) is carried out in aqueous solvent. In anotherembodiment, the reduction reaction (c) is carried out in aprotic solvent.In an embodiment, the reduction reaction (c) is carried out in the presence of dimethylsulphoxide(DMSO) or dimethylformamide (DMF). In an embodiment, the reduction reaction (c) is carried outin the presence of dimethylformamide (DMF). In an embodiment, the reduction reaction (c) is 20carried out in the presence of dimethylsulphoxide (DMSO).In one embodiment the reduction reaction (c) is carried out in a solution consistingessentially of dimethylsulphoxide (DMSO) or dimethylformamide (DMF). In one embodiment thereduction reaction (c) is carried out in a solution consisting essentially of dimethylformamide(DMF). In one embodiment the reduction reaction (c) is carried out in a solution consisting 25essentially of dimethylsulphoxide (DMSO).In an embodiment, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide)or in DMF (dimethylformamide)) solvent. In an embodiment, the reduction reaction (c) is carriedout in DMSO (dimethylsulfoxide) solvent.In an embodiment, the reducing agent is sodium cyanoborohydride, sodium 30triacetoxyborohydride, sodium or zinc borohydride in the presence of Bronsted or Lewis acids,amine boranes such as pyridine borane, 2-Picoline Borane, 2,6-diborane-methanol,dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane(PEMB). In an embodiment, the reducing agent is sodium triacetoxyborohydride. In a preferredembodiment, the reducing agent is sodium cyanoborohydride. In an embodiment, the reducing 35agent is sodium cyanoborohydride in the present of nickel (see WO2018144439).In one embodiment between 0.2 and 20 molar equivalents of reducing agent is used atstep c). In one embodiment between 0.5 and 10 molar equivalents of reducing agent is used at 23step c). In one embodiment between 1.0 and 5 molar equivalents of reducing agent is used atstep c).At the end of the reduction reaction, there may be unreacted aldehyde groups remainingin the conjugates, these may be capped using a suitable capping agent. In one embodiment thiscapping agent is sodium borohydride (NaBH4). In an embodiment capping is achieved by mixing 5the product of step c) with 1 to 20 molar equivalents of sodium borohydride. In an embodimentcapping is achieved by mixing the product of step c) with 1 to 10 molar equivalents of sodiumborohydride. In an embodiment capping is achieved by mixing the product of step c) with 1 to 5molar equivalents of sodium borohydride.Following conjugation to the carrier protein, the glycoconjugate can be purified (enriched 10with respect to the amount of saccharide-protein conjugate) by a variety of techniques known tothe skilled person. These techniques include dialysis, concentration/diafiltration operations,tangential flow filtration precipitation/elution, column chromatography (DEAE or hydrophobicinteraction chromatography), and depth filtration. Therefore, in one embodiment the process forproducing the glycoconjugate of the present invention comprises the step of purifying the 15glycoconjugate after it is produced.
CDI and/or CDT chemistryIn an embodiment, the serotype 21 glycoconjugate of the present invention is prepared byCDI and/or CDT chemistry as disclosed in WO2022249107.CDI and/or CDT chemistry involves two steps, (1) reacting the serotype 21 saccharide 20with CDI and/or CDT in an aprotic solvent to produce an activated saccharide (activation), (2)reacting the activated saccharide with a carrier protein (e.g. CRM 197, TT or SCP) to form aglycoconjugate.In an embodiment, the activating agent of step (1) is 1,1’-carbonyldiimidazole (CDI). In anembodiment, the activating agent of step (1) is 1,1'-Carbonyl-di-(1,2,4-triazole) (CDT). 25As mentioned above, before activation with CDI and/or CDT, sizing of the serotype 21saccharide to a target molecular weight (MW) range can be performed.Therefore, in an embodiment, the serotype 21 saccharide is sized before activation with CDI. Inan embodiment, the isolated polysaccharide is sized before activation with CDT. In anembodiment, the serotype 21 saccharide is sized to any of the target molecular weight (MW) 30range defined above.Therefore, in an embodiment, the serotype 21 saccharide is conjugated to a carrier proteinby a process comprising the step of:(a) reacting said isolated polysaccharide with CDI and/or CDT in an aprotic solvent;(b) reacting the activated polysaccharide of step (a) with a carrier protein in an aprotic solvent to 35form a glycoconjugate.Following step (a) the polysaccharide is said to be activated and is referred to as "activatedpolysaccharide". 24In one embodiment step a) comprises reacting the serotype 21 saccharide with CDI.In one embodiment step a) comprises reacting the serotype 21 saccharide with an amountof CDI that is between 0.5-10 molar equivalent to the amount of serotype 21 saccharide presentin the reaction mixture.In one embodiment step a) comprises reacting the serotype 21 saccharide with CDT. 5In one embodiment step a) comprises reacting the serotype 21 saccharide with an amountof CDT hat is between 0.5-10 molar equivalent to the amount of serotype 21 saccharide presentin the reaction mixture.In an embodiment, the activating reaction a) is carried out in the presence ofdimethylsulphoxide (DMSO), dimethylformamide (DMF), dimethylacetamide, N-methyl-2- 10pyrrolidone or hexamethylphosphoramide (HMPA). In an embodiment, the activating reaction a)is carried out in the presence of dimethylsulphoxide (DMSO).In one embodiment the activating reaction a) is carried out in a solution consistingessentially of dimethylsulphoxide (DMSO) or dimethylformamide (DMF). In one embodiment theactivating reaction a) is carried out in a solution consisting essentially of dimethylsulphoxide 15(DMSO).In an embodiment, the conjugation reaction b) is carried out in the presence ofdimethylsulphoxide (DMSO), dimethylformamide (DMF), dimethylacetamide, N-methyl-2-pyrrolidone or hexamethylphosphoramide (HMPA).In an embodiment, the conjugation reaction b) is carried out in the presence of dimethylsulphoxide 20(DMSO).In one embodiment the conjugation reaction b) is carried out in a solution consistingessentially of dimethylsulphoxide (DMSO) or dimethylformamide (DMF). In one embodiment theconjugation reaction b) is carried out in a solution consisting essentially of dimethylsulphoxide(DMSO). 25In one embodiment, weak organic base can be added to the reaction mixture after theactivating reaction a) but before the conjugation reaction b). The weak organic base can be addedbefore or after the carrier protein is introduced the reaction mixture. Therefore, in oneembodiment, the weak organic base is added to the reaction mixture before the carrier protein isintroduced. In another embodiment, the weak organic base is added to the reaction mixture after 30the carrier protein is introduced. Weak organic base can be selected from alkanamines, imidazole,triazole, pyridine, histidine and guanidine. Alkanamines include alkyl primary amines such asmethyl amine, ethylamine, propylamine, isopropylamine; alkyl secondary amines such asdimethyl amine, diethylamine, dipropylamine, diisopropylamine; alkyl tertially amines such astrimethyl amine, triethylamine, tri-isopropylamine, di-N,N’-isopropylethylamine, et al. In an 35embodiment, the weak organic base is an alkanamine. In an embodiment, the weak organic baseis an imidazole. In an embodiment, the weak organic base is a triazole. In an embodiment, the 25weak organic base is pyridine. In an embodiment, the weak organic base is histidine. In anembodiment, the weak organic base is guanidine.In one embodiment following the conjugation reaction b) unconjugated reactive sites ofthe activated polysaccharide are hydrolyzed. In one embodiment unconjugated reactive sites arehydrolyzed by addition to the conjugation solution of an aqueous solution. In one embodiment 5unconjugated reactive sites are hydrolyzed by addition to the conjugation solution of an aqueousbuffered solution. In one embodiment unconjugated reactive sites are hydrolyzed by addition tothe conjugation solution of an aqueous buffered solution and adjustment of the pH to betweenabout 3.0 to about 10.0. In one embodiment unconjugated reactive sites are hydrolyzed byaddition to the conjugation solution of an aqueous buffered solution and adjustment of the pH to 10between about 7.0 to about 10.0. In one embodiment unconjugated reactive sites are hydrolyzedby addition to the conjugation solution of an aqueous buffered solution and adjustment of the pHto between about 3.0 to about 7.0. In one embodiment unconjugated reactive sites are hydrolyzedby addition to the conjugation solution of an aqueous buffered solution and adjustment of the pHto about 4.0. In one embodiment unconjugated reactive sites are hydrolyzed by addition to the 15conjugation solution of an aqueous buffered solution and adjustment of the pH to about 9.0. eTEC chemistryIn an embodiment, the serotype 21 glycoconjugate of the present invention is prepared byeTEC chemistry as disclosed WO2014027302.The eTEC spacer includes seven linear atoms (i.e., –C(O)NH(CH2)2SCH2C(O)- ) and 20provides stable thioether and amide bonds between the saccharide and carrier protein. Synthesisof the eTEC linked glycoconjugate involves reaction of an activated hydroxyl group of thesaccharide with the amino group of a thioalkylamine reagent, e.g., cystamine or cysteinamine ora salt thereof, forming a carbamate linkage to the saccharide to provide a thiolated saccharide.Generation of one or more free sulfhydryl groups is accomplished by reaction with a reducing 25agent to provide an activated thiolated saccharide. Reaction of the free sulfhydryl groups of theactivated thiolated saccharide with an activated carrier protein having one or more α-haloacetamide groups on amine containing residues generates a thioether bond to form theconjugate, wherein the carrier protein is attached to the eTEC spacer through an amide bond.Therefore, in an embodiment, the serotype 21 glycoconjugate of the present invention 30comprises a serotype 21 saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer.In an embodiment, the serotype 21 glycoconjugate of the present invention comprises aserotype 21 saccharide conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, wherein the saccharide is covalently linked to the 35eTEC spacer through a carbamate linkage, and wherein the carrier protein is covalently linked tothe eTEC spacer through an amide linkage. 26The eTEC linked glycoconjugates of the invention may be represented by the generalformula (III): (III), where (saccharide)represents the serotype 21 saccharide.Formula (III) is a schematic representation of glycoconjugates of the invention. It should 5not be understood that only one linkage is present between the saccharide and the carrier protein.Rather, an individual carrier protein (CP) molecule may be linked to more than one serotype 21saccharide molecule and an individual saccharide molecule can be linked to more than oneindividual carrier protein (CP) molecule. Additionally, a majority of the saccharide repeating unitremains unmodified and covalent linkages between the carrier protein and the saccharide is for a 10minority of the saccharide repeat units.
Click chemistryIn an embodiment, the serotype 21 glycoconjugate of the present invention is prepared byclick chemistry (see e.g. PCT/IB2023/050202).Therefore, in an embodiment, the serotype 21 glycoconjugate of the present invention 15comprises a serotype 21 saccharide covalently conjugated to a carrier protein (CP) through aspacer and having the general formula (IV): (IV),wherein X is selected from the group consisting of CH2(CH2) n’, (CH 2CH 2O)mCH2CH 2,NHCO(CH2)n’, NHCO(CH2CH2O) mCH2CH2, OCH 2(CH2) n’ and O(CH 2CH2O)mCH2CH 2; where n’ is 20selected from 1 to 10 and m is selected from 1 to 4,wherein X' is selected from the group consisting of CH2O(CH 2) n’’CH 2C=O,CH2O(CH 2CH2O)m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is selected from 0to 4,wherein the structure in square backet represents a repeat unit of the serotype 21 saccharide and 25wherein n represents the number of repeating units.In a particular aspect, the invention is directed to a serotype 21 glycoconjugate comprisinga serotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is CH2(CH2) n’, where n’ is 2 and wherein X' isCH2O(CH 2)n’’CH 2C=O where n’’ is 1. 30 27In a particular aspect, the invention pertains to a serotype 21 glycoconjugate comprisinga serotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (V), (V)wherein the structure in square backet represents a repeat unit of the serotype 21 saccharide and 5wherein n represents the number of repeating units.Formulas (IV), (V) are schematic representations of glycoconjugates of the invention. Itshould not be understood that a linkage is present at every repeating unit of the saccharide (thestructure in square brackets). Rather, a majority of the saccharide repeating unit remainsunmodified and covalent linkages between the carrier protein and the saccharide is for a minority 10of the saccharide repeat units. Additionally, an individual carrier protein (CP) molecule may belinked to more than one saccharide molecule and an individual saccharide molecule can be linkedto more than one individual carrier protein (CP) molecule. The structure in square bracketsrepresents a repeat unit of the serotype 21 saccharide.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising a 15serotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is CH 2(CH2)n’, where n’ is selected from 1 to 10 andwherein X' is CH2O(CH 2) n’’CH2C=O where n’’ is selected from 0 to 10. In an embodiment, n’ isselected from 1 to 5 and n’’ is selected from 0 to 10. In an embodiment, n’ is selected from 1 to 5and n’’ is selected from 0 to 5. In an embodiment, n’ is selected from 1 to 3 and n’’ is selected 20from 0 to 3. In an embodiment, n’ is selected from 1 to 2 and n’’ is selected from 0 to 2. In aparticular embodiment, n’ is 1 and n’’ is 0. In another embodiment, n’ is 2 and n’’ is 0. In yetanother embodiment, n’ is 3 and n’’ is 0. In yet a further embodiment, n’ is 4 and n" is 0. In yet afurther embodiment, n’ is 5 and n" is 0. In yet a further embodiment, n’ is 6 and n" is 0. In aparticular embodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yet 25another embodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet afurther embodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In aparticular embodiment, n’ is 1 and n’’ is 2. In another embodiment, n’ is 2 and n’’ is 2. In yetanother embodiment, n’ is 3 and n’’ is 2. In yet a further embodiment, n’ is 4 and n" is 2. In yet afurther embodiment, n’ is 5 and n" is 2. In yet a further embodiment, n’ is 6 and n" is 2. In a 30particular embodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yetanother embodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet afurther embodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In a 28particular embodiment, n’ is 1 and n’’ is 4. In another embodiment, n’ is 2 and n’’ is 4. In yetanother embodiment, n’ is 3 and n’’ is 4. In yet a further embodiment, n’ is 4 and n" is 4. In yet afurther embodiment, n’ is 5 and n" is 4. In yet a further embodiment, n’ is 6 and n" is 4. In aparticular embodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yetanother embodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet a 5further embodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In aparticular embodiment, n’ is 1 and n’’ is 6. In another embodiment, n’ is 2 and n’’ is 6. In yetanother embodiment, n’ is 3 and n’’ is 6. In yet a further embodiment, n’ is 4 and n" is 6. In yet afurther embodiment, n’ is 5 and n" is 6. In yet a further embodiment, n’ is 6 and n" is 6.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising a 10serotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is CH 2(CH2)n’, where n’ is selected from 1 to 10 andwherein CH2O(CH 2CH2O) m’(CH2)n’’CH 2C=O, where n’’ is selected from 0 to 10 and m’ is selectedfrom 0 to 4.In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selected from 0 15to 10. In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, n’ is selected from 1 to 3, m’ is selected from 0 to 2 and n’’ isselected from 0 to 3. In an embodiment, n’ is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 0. In another embodiment, n’ is 1, m’ is 1 and 20n’’ is 0. In another embodiment, n’ is 1, m’ is 2 and n’’ is 0. In another embodiment, n’ is 1, m’ is 3and n’’ is 0.In another embodiment, n’ is 2, m’ is 0 and n’’ is 0. In another embodiment, n’ is 2, m’ is 1 and n’’is 0. In another embodiment, n’ is 2, m’ is 2 and n’’ is 0. In another embodiment, n’ is 2, m’ is 3and n’’ is 0. 25In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 0. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 0.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 4, m’ isand n" is 0. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 0. In yet a further embodiment, 30n’ is 4, m’ is 3 and n" is 0.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 5, m’ isand n" is 0.In yet a further embodiment, n’ is 5, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 0.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 1 35and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 1. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 1. 29In another embodiment, n’ is 2, m’ is 0 and n’’ is 1. In another embodiment, n’ is 2, m’ is 1 and n’’is 1. In another embodiment, n’ is 2, m’ is 2 and n’’ is 1. In another embodiment, n’ is 2, m’ is 3and n’’ is 1.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 1. In yet another embodiment, n’ 5is 3, m’ is 3 and n’’ is 1.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 4, m’ isand n" is 1. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 1.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 5, m’ is 10and n" is 1. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 2. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 2. 15In another embodiment, n’ is 2, m’ is 0 and n’’ is 2. In another embodiment, n’ is 2, m’ is 1 and n’’is 2. In another embodiment, n’ is 2, m’ is 2 and n’’ is 2. In another embodiment, n’ is 2, m’ is 3and n’’ is 2.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 2. In yet another embodiment, n’ 20is 3, m’ is 3 and n’’ is 2.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 4, m’ isand n" is 2. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 2. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 2.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 5, m’ is 25and n" is 2. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 2. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 2.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 3. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 3. 30In another embodiment, n’ is 2, m’ is 0 and n’’ is 3. In another embodiment, n’ is 2, m’ is 1 and n’’is 3. In another embodiment, n’ is 2, m’ is 2 and n’’ is 3. In another embodiment, n’ is 2, m’ is 3and n’’ is 3.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 3. In yet another embodiment, n’ 35is 3, m’ is 3 and n’’ is 3. 30In yet a further embodiment, n’ is 4, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 4, m’ isand n" is 3. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 3. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 3.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 5, m’ is and n" is 3. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 3. In yet a further embodiment, 5n’ is 5, m’ is 3 and n" is 3.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 4. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 4.In another embodiment, n’ is 2, m’ is 0 and n’’ is 4. In another embodiment, n’ is 2, m’ is 1 and 10n’’ is 4. In another embodiment, n’ is 2, m’ is 2 and n’’ is 4. In another embodiment, n’ is 2, m’ is and n’’ is 4.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 4. In yet another embodiment, n’ is 3, m’ is and n’’ is 4. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 4. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 4. 15In yet a further embodiment, n’ is 4, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 4, m’ is and n" is 4. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 4.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 5, m’ is and n" is 4. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 4. In yet a further embodiment, 20n’ is 5, m’ is 3 and n" is 4.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 5. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 5.In another embodiment, n’ is 2, m’ is 0 and n’’ is 5. In another embodiment, n’ is 2, m’ is 1 and 25n’’ is 5. In another embodiment, n’ is 2, m’ is 2 and n’’ is 5. In another embodiment, n’ is 2, m’ is and n’’ is 5.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 5. In yet another embodiment, n’ is 3, m’ is and n’’ is 5. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 5. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 5. 30In yet a further embodiment, n’ is 4, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 4, m’ is and n" is 5. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 5.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 5, m’ is and n" is 5. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 5. In yet a further embodiment, 35n’ is 5, m’ is 3 and n" is 5.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer and 31having the general formula (IV), wherein X is (CH 2CH2O)mCH2CH2, where m is selected from 1 toand wherein X' is CH 2O(CH 2) n’’CH 2C=O, where n’’ is selected from 0 to 10. In an embodiment,m is selected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment, m is selected from 1to 3 and n’’ is selected from 0 to 5. In an embodiment, m is selected from 1 to 2 and n’’ is selectedfrom 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selected from 0 to 2. In a 5particular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’ is 0. In yetanother embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is 0. In aparticular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. In yetanother embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In aparticular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yet 10another embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In aparticular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yetanother embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In aparticular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yetanother embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In a 15particular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yetanother embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In aparticular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yetanother embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising a 20serotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is (CH 2CH2O)mCH2CH2, where m is selected from 1 toand wherein X' is CH2O(CH 2CH2O) m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’is selected from 0 to 4.In an embodiment, m is selected from 1 to 3, m’ is selected from 0 to 4 and n’’ is selected from 0 25to 10. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 and n’’ isselected from 0 to 3. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, m is 1, m’ is 0 and n’’ is 0. In another embodiment, m is 1, m’ is 1 and 30n’’ is 0. In another embodiment, m is 1, m’ is 2 and n’’ is 0. In another embodiment, m is 1, m’ isand n’’ is 0.In another embodiment, m is 2, m’ is 0 and n’’ is 0. In another embodiment, m is 2, m’ is 1 and n’’is 0. In another embodiment, m is 2, m’ is 2 and n’’ is 0. In another embodiment, m is 2, m’ is 3and n’’ is 0. 35In yet another embodiment, m is 3, m’ is 0 and n’’ is 0. In yet another embodiment, m is 3, m’ is 1and n’’ is 0. In yet another embodiment, m is 3, m’ is 2 and n’’ is 0. In yet another embodiment, mis 3, m’ is 3 and n’’ is 0. 32In yet a further embodiment, m is 4, m’ is 0 and n" is 0. In yet a further embodiment, m is 4, m’ isand n" is 0. In yet a further embodiment, m is 4, m’ is 2 and n" is 0. In yet a further embodiment,m is 4, m’ is 3 and n" is 0.In a particular embodiment, m is 1, m’ is 0 and n’’ is 1. In a particular embodiment, m is 1, m’ is 1and n’’ is 1. In a particular embodiment, m is 1, m’ is 2 and n’’ is 1. In a particular embodiment, m 5is 1, m’ is 3 and n’’ is 1.In another embodiment, m is 2, m’ is 0 and n’’ is 1. In another embodiment, m is 2, m’ is 1 and n’’is 1. In another embodiment, m is 2, m’ is 2 and n’’ is 1. In another embodiment, m is 2, m’ is 3and n’’ is 1.In yet another embodiment, m is 3, m’ is 0 and n’’ is 1. In yet another embodiment, m is 3, m’ is 1 10and n’’ is 1. In yet another embodiment, m is 3, m’ is 2 and n’’ is 1. In yet another embodiment, mis 3, m’ is 3 and n’’ is 1.In yet a further embodiment, m is 4, m’ is 0 and n" is 1. In yet a further embodiment, m is 4, m’ isand n" is 1. In yet a further embodiment, m is 4, m’ is 2 and n" is 1. In yet a further embodiment,m is 4, m’ is 3 and n" is 1. 15In a particular embodiment, m is 1, m’ is 0 and n’’ is 2. In a particular embodiment, m is 1, m’ is 1and n’’ is 2. In a particular embodiment, m is 1, m’ is 2 and n’’ is 2. In a particular embodiment, mis 1, m’ is 3 and n’’ is 2.In another embodiment, m is 2, m’ is 0 and n’’ is 2. In another embodiment, m is 2, m’ is 1 and n’’is 2. In another embodiment, m is 2, m’ is 2 and n’’ is 2. In another embodiment, m is 2, m’ is 3 20and n’’ is 2.In yet another embodiment, m is 3, m’ is 0 and n’’ is 2. In yet another embodiment, m is 3, m’ is 1and n’’ is 2. In yet another embodiment, m is 3, m’ is 2 and n’’ is 2. In yet another embodiment, mis 3, m’ is 3 and n’’ is 2.In yet a further embodiment, m is 4, m’ is 0 and n" is 2. In yet a further embodiment, m is 4, m’ is 25and n" is 2. In yet a further embodiment, m is 4, m’ is 2 and n" is 2. In yet a further embodiment,m is 4, m’ is 3 and n" is 2.In a particular embodiment, m is 1, m’ is 0 and n’’ is 3. In a particular embodiment, m is 1, m’ is 1and n’’ is 3. In a particular embodiment, m is 1, m’ is 2 and n’’ is 3. In a particular embodiment, mis 1, m’ is 3 and n’’ is 3. 30In another embodiment, m is 2, m’ is 0 and n’’ is 3. In another embodiment, m is 2, m’ is 1 and n’’is 3. In another embodiment, m is 2, m’ is 2 and n’’ is 3. In another embodiment, m is 2, m’ is 3and n’’ is 3.In yet another embodiment, m is 3, m’ is 0 and n’’ is 3. In yet another embodiment, m is 3, m’ is 1and n’’ is 3. In yet another embodiment, m is 3, m’ is 2 and n’’ is 3. In yet another embodiment, m 35is 3, m’ is 3 and n’’ is 3. 33In yet a further embodiment, m is 4, m’ is 0 and n" is 3. In yet a further embodiment, m is 4, m’ isand n" is 3. In yet a further embodiment, m is 4, m’ is 2 and n" is 3. In yet a further embodiment,m is 4, m’ is 3 and n" is 3.In a particular embodiment, m is 1, m’ is 0 and n’’ is 4. In a particular embodiment, m is 1, m’ is and n’’ is 4. In a particular embodiment, m is 1, m’ is 2 and n’’ is 4. In a particular embodiment, 5m is 1, m’ is 3 and n’’ is 4.In another embodiment, m is 2, m’ is 0 and n’’ is 4. In another embodiment, m is 2, m’ is 1 andn’’ is 4. In another embodiment, m is 2, m’ is 2 and n’’ is 4. In another embodiment, m is 2, m’ isand n’’ is 4.In yet another embodiment, m is 3, m’ is 0 and n’’ is 4. In yet another embodiment, m is 3, m’ is 10 and n’’ is 4. In yet another embodiment, m is 3, m’ is 2 and n’’ is 4. In yet another embodiment,m is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, m is 4, m’ is 0 and n" is 4. In yet a further embodiment, m is 4, m’ is and n" is 4. In yet a further embodiment, m is 4, m’ is 2 and n" is 4. In yet a further embodiment,m is 4, m’ is 3 and n" is 4. 15In a particular embodiment, m is 1, m’ is 0 and n’’ is 5. In a particular embodiment, m is 1, m’ is and n’’ is 5. In a particular embodiment, m is 1, m’ is 2 and n’’ is 5. In a particular embodiment,m is 1, m’ is 3 and n’’ is 5.In another embodiment, m is 2, m’ is 0 and n’’ is 5. In another embodiment, m is 2, m’ is 1 andn’’ is 5. In another embodiment, m is 2, m’ is 2 and n’’ is 5. In another embodiment, m is 2, m’ is 20 and n’’ is 5.In yet another embodiment, m is 3, m’ is 0 and n’’ is 5. In yet another embodiment, m is 3, m’ is and n’’ is 5. In yet another embodiment, m is 3, m’ is 2 and n’’ is 5. In yet another embodiment,m is 3, m’ is 3 and n’’ is 5.In yet a further embodiment, m is 4, m’ is 0 and n" is 5. In yet a further embodiment, m is 4, m’ is 25 and n" is 5. In yet a further embodiment, m is 4, m’ is 2 and n" is 5. In yet a further embodiment,m is 4, m’ is 3 and n" is 5.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is NHCO(CH 2) n’, where n’ is selected from 1 to 10 and 30wherein X' is CH2O(CH 2)n’’CH2C=O, where n’’ is selected from 0 to 10. In an embodiment, n’ isselected from 1 to 5 and n’’ is selected from 0 to 10. In an embodiment, n’ is selected from 1 to 5and n’’ is selected from 0 to 5. In an embodiment, n’ is selected from 1 to 3 and n’’ is selectedfrom 0 to 3. In an embodiment, n’ is selected from 1 to 2 and n’’ is selected from 0 to 2. In aparticular embodiment, n’ is 1 and n’’ is 0. In another embodiment, n’ is 2 and n’’ is 0. In yet 35another embodiment, n’ is 3 and n’’ is 0. In yet a further embodiment, n’ is 4 and n" is 0. In yet afurther embodiment, n’ is 5 and n" is 0. In yet a further embodiment, n’ is 6 and n" is 0. In aparticular embodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yet 34another embodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet afurther embodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In aparticular embodiment, n’ is 1 and n’’ is 2. In another embodiment, n’ is 2 and n’’ is 2. In yetanother embodiment, n’ is 3 and n’’ is 2. In yet a further embodiment, n’ is 4 and n" is 2. In yet afurther embodiment, n’ is 5 and n" is 2. In yet a further embodiment, n’ is 6 and n" is 2. In a 5particular embodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yetanother embodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet afurther embodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In aparticular embodiment, n’ is 1 and n’’ is 4. In another embodiment, n’ is 2 and n’’ is 4. In yetanother embodiment, n’ is 3 and n’’ is 4. In yet a further embodiment, n’ is 4 and n" is 4. In yet a 10further embodiment, n’ is 5 and n" is 4. In yet a further embodiment, n’ is 6 and n" is 4. In aparticular embodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yetanother embodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet afurther embodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In aparticular embodiment, n’ is 1 and n’’ is 6. In another embodiment, n’ is 2 and n’’ is 6. In yet 15another embodiment, n’ is 3 and n’’ is 6. In yet a further embodiment, n’ is 4 and n" is 6. In yet afurther embodiment, n’ is 5 and n" is 6. In yet a further embodiment, n’ is 6 and n" is 6.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is NHCO(CH 2) n’, where n’ is selected from 1 to 10 and 20wherein X' is CH2O(CH 2CH2O) m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ isselected from 0 to 4.In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selected from 0to 10. In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, n’ is selected from 1 to 3, m’ is selected from 0 to 2 and n’’ is 25selected from 0 to 3. In an embodiment, n’ is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 0. In another embodiment, n’ is 1, m’ is 1 andn’’ is 0. In another embodiment, n’ is 1, m’ is 2 and n’’ is 0. In another embodiment, n’ is 1, m’ is 3and n’’ is 0. 30In another embodiment, n’ is 2, m’ is 0 and n’’ is 0. In another embodiment, n’ is 2, m’ is 1 and n’’is 0. In another embodiment, n’ is 2, m’ is 2 and n’’ is 0. In another embodiment, n’ is 2, m’ is 3and n’’ is 0.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 0. In yet another embodiment, n’ 35is 3, m’ is 3 and n’’ is 0. 35In yet a further embodiment, n’ is 4, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 4, m’ isand n" is 0. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 0.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 5, m’ isand n" is 0.In yet a further embodiment, n’ is 5, m’ is 2 and n" is 0. In yet a further embodiment, 5n’ is 5, m’ is 3 and n" is 0.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 1. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 1.In another embodiment, n’ is 2, m’ is 0 and n’’ is 1. In another embodiment, n’ is 2, m’ is 1 and n’’ 10is 1. In another embodiment, n’ is 2, m’ is 2 and n’’ is 1. In another embodiment, n’ is 2, m’ is 3and n’’ is 1.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 1. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 1. 15In yet a further embodiment, n’ is 4, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 4, m’ isand n" is 1. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 1.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 5, m’ isand n" is 1. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 1. In yet a further embodiment, 20n’ is 5, m’ is 3 and n" is 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 2. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 2.In another embodiment, n’ is 2, m’ is 0 and n’’ is 2. In another embodiment, n’ is 2, m’ is 1 and n’’ 25is 2. In another embodiment, n’ is 2, m’ is 2 and n’’ is 2. In another embodiment, n’ is 2, m’ is 3and n’’ is 2.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 2. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 2. 30In yet a further embodiment, n’ is 4, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 4, m’ isand n" is 2. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 2. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 2.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 5, m’ isand n" is 2. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 2. In yet a further embodiment, 35n’ is 5, m’ is 3 and n" is 2. 36In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 3. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 3.In another embodiment, n’ is 2, m’ is 0 and n’’ is 3. In another embodiment, n’ is 2, m’ is 1 and n’’is 3. In another embodiment, n’ is 2, m’ is 2 and n’’ is 3. In another embodiment, n’ is 2, m’ is 3 5and n’’ is 3.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 3. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 3.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 4, m’ is 10and n" is 3. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 3. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 3.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 5, m’ is and n" is 3. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 3. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 3. 15In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 4. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 4.In another embodiment, n’ is 2, m’ is 0 and n’’ is 4. In another embodiment, n’ is 2, m’ is 1 andn’’ is 4. In another embodiment, n’ is 2, m’ is 2 and n’’ is 4. In another embodiment, n’ is 2, m’ is 20 and n’’ is 4.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 4. In yet another embodiment, n’ is 3, m’ is and n’’ is 4. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 4. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 4, m’ is 25 and n" is 4. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 4.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 5, m’ is and n" is 4. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 4. 30In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 5. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 5.In another embodiment, n’ is 2, m’ is 0 and n’’ is 5. In another embodiment, n’ is 2, m’ is 1 andn’’ is 5. In another embodiment, n’ is 2, m’ is 2 and n’’ is 5. In another embodiment, n’ is 2, m’ is 35 and n’’ is 5. 37In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 5. In yet another embodiment, n’ is 3, m’ is and n’’ is 5. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 5. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 5.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 4, m’ is and n" is 5. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 5. In yet a further embodiment, 5n’ is 4, m’ is 3 and n" is 5.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 5, m’ is and n" is 5. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 5.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising a 10serotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is NHCO(CH 2CH2O)mCH2CH2, where m is selectedfrom 1 to 4 and wherein X' is CH2O(CH 2)n’’CH2C=O, where n’’ is selected from 0 to 10. In anembodiment, m is selected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment, m isselected from 1 to 3 and n’’ is selected from 0 to 5. In an embodiment, m is selected from 1 to 2 15and n’’ is selected from 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selectedfrom 0 to 2. In a particular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’is 0. In yet another embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is0. In a particular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. Inyet another embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In a 20particular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yetanother embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In aparticular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yetanother embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In aparticular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yet 25another embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In aparticular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yetanother embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In aparticular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yetanother embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6. 30In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is NHCO(CH 2CH2O)mCH2CH2, where m is selectedfrom 1 to 4 and wherein X' is CH2O(CH 2CH2O) m’(CH2)n’’CH2C=O, where n’’ is selected from 0 toand m’ is selected from 0 to 4. 35In an embodiment, m is selected from 1 to 3, m’ is selected from 0 to 4 and n’’ is selected from 0to 10. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 and n’’ is 38selected from 0 to 3. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, m is 1, m’ is 0 and n’’ is 0. In another embodiment, m is 1, m’ is 1 andn’’ is 0. In another embodiment, m is 1, m’ is 2 and n’’ is 0. In another embodiment, m is 1, m’ isand n’’ is 0. 5In another embodiment, m is 2, m’ is 0 and n’’ is 0. In another embodiment, m is 2, m’ is 1 and n’’is 0. In another embodiment, m is 2, m’ is 2 and n’’ is 0. In another embodiment, m is 2, m’ is 3and n’’ is 0.In yet another embodiment, m is 3, m’ is 0 and n’’ is 0. In yet another embodiment, m is 3, m’ is 1and n’’ is 0. In yet another embodiment, m is 3, m’ is 2 and n’’ is 0. In yet another embodiment, m 10is 3, m’ is 3 and n’’ is 0.In yet a further embodiment, m is 4, m’ is 0 and n" is 0. In yet a further embodiment, m is 4, m’ isand n" is 0. In yet a further embodiment, m is 4, m’ is 2 and n" is 0. In yet a further embodiment,m is 4, m’ is 3 and n" is 0.In a particular embodiment, m is 1, m’ is 0 and n’’ is 1. In a particular embodiment, m is 1, m’ is 1 15and n’’ is 1. In a particular embodiment, m is 1, m’ is 2 and n’’ is 1. In a particular embodiment, mis 1, m’ is 3 and n’’ is 1.In another embodiment, m is 2, m’ is 0 and n’’ is 1. In another embodiment, m is 2, m’ is 1 and n’’is 1. In another embodiment, m is 2, m’ is 2 and n’’ is 1. In another embodiment, m is 2, m’ is 3and n’’ is 1. 20In yet another embodiment, m is 3, m’ is 0 and n’’ is 1. In yet another embodiment, m is 3, m’ is 1and n’’ is 1. In yet another embodiment, m is 3, m’ is 2 and n’’ is 1. In yet another embodiment, mis 3, m’ is 3 and n’’ is 1.In yet a further embodiment, m is 4, m’ is 0 and n" is 1. In yet a further embodiment, m is 4, m’ isand n" is 1. In yet a further embodiment, m is 4, m’ is 2 and n" is 1. In yet a further embodiment, 25m is 4, m’ is 3 and n" is 1.In a particular embodiment, m is 1, m’ is 0 and n’’ is 2. In a particular embodiment, m is 1, m’ is 1and n’’ is 2. In a particular embodiment, m is 1, m’ is 2 and n’’ is 2. In a particular embodiment, mis 1, m’ is 3 and n’’ is 2.In another embodiment, m is 2, m’ is 0 and n’’ is 2. In another embodiment, m is 2, m’ is 1 and n’’ 30is 2. In another embodiment, m is 2, m’ is 2 and n’’ is 2. In another embodiment, m is 2, m’ is 3and n’’ is 2.In yet another embodiment, m is 3, m’ is 0 and n’’ is 2. In yet another embodiment, m is 3, m’ is 1and n’’ is 2. In yet another embodiment, m is 3, m’ is 2 and n’’ is 2. In yet another embodiment, mis 3, m’ is 3 and n’’ is 2. 35In yet a further embodiment, m is 4, m’ is 0 and n" is 2. In yet a further embodiment, m is 4, m’ isand n" is 2. In yet a further embodiment, m is 4, m’ is 2 and n" is 2. In yet a further embodiment,m is 4, m’ is 3 and n" is 2. 39In a particular embodiment, m is 1, m’ is 0 and n’’ is 3. In a particular embodiment, m is 1, m’ is 1and n’’ is 3. In a particular embodiment, m is 1, m’ is 2 and n’’ is 3. In a particular embodiment, mis 1, m’ is 3 and n’’ is 3.In another embodiment, m is 2, m’ is 0 and n’’ is 3. In another embodiment, m is 2, m’ is 1 and n’’is 3. In another embodiment, m is 2, m’ is 2 and n’’ is 3. In another embodiment, m is 2, m’ is 3 5and n’’ is 3.In yet another embodiment, m is 3, m’ is 0 and n’’ is 3. In yet another embodiment, m is 3, m’ is 1and n’’ is 3. In yet another embodiment, m is 3, m’ is 2 and n’’ is 3. In yet another embodiment, mis 3, m’ is 3 and n’’ is 3.In yet a further embodiment, m is 4, m’ is 0 and n" is 3. In yet a further embodiment, m is 4, m’ is 10and n" is 3. In yet a further embodiment, m is 4, m’ is 2 and n" is 3. In yet a further embodiment,m is 4, m’ is 3 and n" is 3.In a particular embodiment, m is 1, m’ is 0 and n’’ is 4. In a particular embodiment, m is 1, m’ is and n’’ is 4. In a particular embodiment, m is 1, m’ is 2 and n’’ is 4. In a particular embodiment,m is 1, m’ is 3 and n’’ is 4. 15In another embodiment, m is 2, m’ is 0 and n’’ is 4. In another embodiment, m is 2, m’ is 1 andn’’ is 4. In another embodiment, m is 2, m’ is 2 and n’’ is 4. In another embodiment, m is 2, m’ isand n’’ is 4.In yet another embodiment, m is 3, m’ is 0 and n’’ is 4. In yet another embodiment, m is 3, m’ is and n’’ is 4. In yet another embodiment, m is 3, m’ is 2 and n’’ is 4. In yet another embodiment, 20m is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, m is 4, m’ is 0 and n" is 4. In yet a further embodiment, m is 4, m’ is and n" is 4. In yet a further embodiment, m is 4, m’ is 2 and n" is 4. In yet a further embodiment,m is 4, m’ is 3 and n" is 4.In a particular embodiment, m is 1, m’ is 0 and n’’ is 5. In a particular embodiment, m is 1, m’ is 25 and n’’ is 5. In a particular embodiment, m is 1, m’ is 2 and n’’ is 5. In a particular embodiment,m is 1, m’ is 3 and n’’ is 5.In another embodiment, m is 2, m’ is 0 and n’’ is 5. In another embodiment, m is 2, m’ is 1 andn’’ is 5. In another embodiment, m is 2, m’ is 2 and n’’ is 5. In another embodiment, m is 2, m’ is and n’’ is 5. 30In yet another embodiment, m is 3, m’ is 0 and n’’ is 5. In yet another embodiment, m is 3, m’ is and n’’ is 5. In yet another embodiment, m is 3, m’ is 2 and n’’ is 5. In yet another embodiment,m is 3, m’ is 3 and n’’ is 5.In yet a further embodiment, m is 4, m’ is 0 and n" is 5. In yet a further embodiment, m is 4, m’ is and n" is 5. In yet a further embodiment, m is 4, m’ is 2 and n" is 5. In yet a further embodiment, 35m is 4, m’ is 3 and n" is 5.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer and 40having the general formula (IV), wherein X is OCH 2(CH2)n’, where n’ is selected from 1 to 10 andwherein X' is CH2O(CH 2) n’’CH 2C=O, where n’’ is selected from 0 to 10.In an embodiment, n’ is selected from 1 to 5 and n’’ is selected from 0 to 10. In an embodiment,n’ is selected from 1 to 5 and n’’ is selected from 0 to 5. In an embodiment, n’ is selected from 1to 3 and n’’ is selected from 0 to 3. In an embodiment, n’ is selected from 1 to 2 and n’’ is selected 5from 0 to 2. In a particular embodiment, n’ is 1 and n’’ is 0. In another embodiment, n’ is 2 and n’’is 0. In yet another embodiment, n’ is 3 and n’’ is 0. In yet a further embodiment, n’ is 4 and n" is0. In yet a further embodiment, n’ is 5 and n" is 0. In yet a further embodiment, n’ is 6 and n" is 0.In a particular embodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yetanother embodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet a 10further embodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In aparticular embodiment, n’ is 1 and n’’ is 2. In another embodiment, n’ is 2 and n’’ is 2. In yetanother embodiment, n’ is 3 and n’’ is 2. In yet a further embodiment, n’ is 4 and n" is 2. In yet afurther embodiment, n’ is 5 and n" is 2. In yet a further embodiment, n’ is 6 and n" is 2. In aparticular embodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yet 15another embodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet afurther embodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In aparticular embodiment, n’ is 1 and n’’ is 4. In another embodiment, n’ is 2 and n’’ is 4. In yetanother embodiment, n’ is 3 and n’’ is 4. In yet a further embodiment, n’ is 4 and n" is 4. In yet afurther embodiment, n’ is 5 and n" is 4. In yet a further embodiment, n’ is 6 and n" is 4. In a 20particular embodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yetanother embodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet afurther embodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In aparticular embodiment, n’ is 1 and n’’ is 6. In another embodiment, n’ is 2 and n’’ is 6. In yetanother embodiment, n’ is 3 and n’’ is 6. In yet a further embodiment, n’ is 4 and n" is 6. In yet a 25further embodiment, n’ is 5 and n" is 6. In yet a further embodiment, n’ is 6 and n" is 6.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is OCH 2(CH2)n’, where n’ is selected from 1 to 10 andwherein X' is CH2O(CH 2CH2O) m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is 30selected from 0 to 4.In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selected from 0to 10. In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, n’ is selected from 1 to 3, m’ is selected from 0 to 2 and n’’ isselected from 0 to 3. In an embodiment, n’ is selected from 1 to 2, m’ is selected from 0 to 2 and 35n’’ is selected from 0 to 1. 41In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 0. In another embodiment, n’ is 1, m’ is 1 andn’’ is 0. In another embodiment, n’ is 1, m’ is 2 and n’’ is 0. In another embodiment, n’ is 1, m’ is 3and n’’ is 0.In another embodiment, n’ is 2, m’ is 0 and n’’ is 0. In another embodiment, n’ is 2, m’ is 1 and n’’is 0. In another embodiment, n’ is 2, m’ is 2 and n’’ is 0. In another embodiment, n’ is 2, m’ is 3 5and n’’ is 0.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 0. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 0.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 4, m’ is 10and n" is 0. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 0.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 5, m’ isand n" is 0.In yet a further embodiment, n’ is 5, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 0. 15In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 1. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 1.In another embodiment, n’ is 2, m’ is 0 and n’’ is 1. In another embodiment, n’ is 2, m’ is 1 and n’’is 1. In another embodiment, n’ is 2, m’ is 2 and n’’ is 1. In another embodiment, n’ is 2, m’ is 3 20and n’’ is 1.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 1. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 1.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 4, m’ is 25and n" is 1. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 1.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 5, m’ isand n" is 1. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 1. 30In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 2. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 2.In another embodiment, n’ is 2, m’ is 0 and n’’ is 2. In another embodiment, n’ is 2, m’ is 1 and n’’is 2. In another embodiment, n’ is 2, m’ is 2 and n’’ is 2. In another embodiment, n’ is 2, m’ is 3 35and n’’ is 2. 42In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 2. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 2.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 4, m’ isand n" is 2. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 2. In yet a further embodiment, 5n’ is 4, m’ is 3 and n" is 2.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 5, m’ isand n" is 2. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 2. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 2.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 1 10and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 3. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 3.In another embodiment, n’ is 2, m’ is 0 and n’’ is 3. In another embodiment, n’ is 2, m’ is 1 and n’’is 3. In another embodiment, n’ is 2, m’ is 2 and n’’ is 3. In another embodiment, n’ is 2, m’ is 3and n’’ is 3. 15In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 3. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 3.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 4, m’ isand n" is 3. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 3. In yet a further embodiment, 20n’ is 4, m’ is 3 and n" is 3.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 5, m’ is and n" is 3. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 3. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 3.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 1 25and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 4. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 4.In another embodiment, n’ is 2, m’ is 0 and n’’ is 4. In another embodiment, n’ is 2, m’ is 1 andn’’ is 4. In another embodiment, n’ is 2, m’ is 2 and n’’ is 4. In another embodiment, n’ is 2, m’ is and n’’ is 4. 30In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 4. In yet another embodiment, n’ is 3, m’ is and n’’ is 4. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 4. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 4, m’ is and n" is 4. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 4. In yet a further embodiment, 35n’ is 4, m’ is 3 and n" is 4. 43In yet a further embodiment, n’ is 5, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 5, m’ is and n" is 4. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 4.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 5. In a particular embodiment, n’ 5is 1, m’ is 3 and n’’ is 5.In another embodiment, n’ is 2, m’ is 0 and n’’ is 5. In another embodiment, n’ is 2, m’ is 1 andn’’ is 5. In another embodiment, n’ is 2, m’ is 2 and n’’ is 5. In another embodiment, n’ is 2, m’ is and n’’ is 5.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 5. In yet another embodiment, n’ is 3, m’ is 10 and n’’ is 5. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 5. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 5.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 4, m’ is and n" is 5. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 5. 15In yet a further embodiment, n’ is 5, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 5, m’ is and n" is 5. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 5.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer and 20having the general formula (IV), wherein X is O(CH2CH2O)mCH2CH2, where m is selected from 1to 4 and wherein X' is CH2O(CH 2)n’’CH2C=O, where n’’ is selected from 0 to 10.In an embodiment, m is selected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment,m is selected from 1 to 3 and n’’ is selected from 0 to 5. In an embodiment, m is selected from 1to 2 and n’’ is selected from 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selected 25from 0 to 2. In a particular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’is 0. In yet another embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is0. In a particular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. Inyet another embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In aparticular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yet 30another embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In aparticular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yetanother embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In aparticular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yetanother embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In a 35particular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yetanother embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In a 44particular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yetanother embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is O(CH2CH2O)mCH2CH2, where m is selected from 1 5to 4 and wherein X' is CH2O(CH 2CH2O) m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 andm’ is selected from 0 to 4.In an embodiment, m is selected from 1 to 3, m’ is selected from 0 to 4 and n’’ is selected from 0to 10. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 and n’’ is 10selected from 0 to 3. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, m is 1, m’ is 0 and n’’ is 0. In another embodiment, m is 1, m’ is 1 andn’’ is 0. In another embodiment, m is 1, m’ is 2 and n’’ is 0. In another embodiment, m is 1, m’ isand n’’ is 0. 15In another embodiment, m is 2, m’ is 0 and n’’ is 0. In another embodiment, m is 2, m’ is 1 and n’’is 0. In another embodiment, m is 2, m’ is 2 and n’’ is 0. In another embodiment, m is 2, m’ is 3and n’’ is 0.In yet another embodiment, m is 3, m’ is 0 and n’’ is 0. In yet another embodiment, m is 3, m’ is 1and n’’ is 0. In yet another embodiment, m is 3, m’ is 2 and n’’ is 0. In yet another embodiment, m 20is 3, m’ is 3 and n’’ is 0.In yet a further embodiment, m is 4, m’ is 0 and n" is 0. In yet a further embodiment, m is 4, m’ isand n" is 0. In yet a further embodiment, m is 4, m’ is 2 and n" is 0. In yet a further embodiment,m is 4, m’ is 3 and n" is 0.In a particular embodiment, m is 1, m’ is 0 and n’’ is 1. In a particular embodiment, m is 1, m’ is 1 25and n’’ is 1. In a particular embodiment, m is 1, m’ is 2 and n’’ is 1. In a particular embodiment, mis 1, m’ is 3 and n’’ is 1.In another embodiment, m is 2, m’ is 0 and n’’ is 1. In another embodiment, m is 2, m’ is 1 and n’’is 1. In another embodiment, m is 2, m’ is 2 and n’’ is 1. In another embodiment, m is 2, m’ is 3and n’’ is 1. 30In yet another embodiment, m is 3, m’ is 0 and n’’ is 1. In yet another embodiment, m is 3, m’ is 1and n’’ is 1. In yet another embodiment, m is 3, m’ is 2 and n’’ is 1. In yet another embodiment, mis 3, m’ is 3 and n’’ is 1.In yet a further embodiment, m is 4, m’ is 0 and n" is 1. In yet a further embodiment, m is 4, m’ isand n" is 1. In yet a further embodiment, m is 4, m’ is 2 and n" is 1. In yet a further embodiment, 35m is 4, m’ is 3 and n" is 1. 45In a particular embodiment, m is 1, m’ is 0 and n’’ is 2. In a particular embodiment, m is 1, m’ is 1and n’’ is 2. In a particular embodiment, m is 1, m’ is 2 and n’’ is 2. In a particular embodiment, mis 1, m’ is 3 and n’’ is 2.In another embodiment, m is 2, m’ is 0 and n’’ is 2. In another embodiment, m is 2, m’ is 1 and n’’is 2. In another embodiment, m is 2, m’ is 2 and n’’ is 2. In another embodiment, m is 2, m’ is 3 5and n’’ is 2.In yet another embodiment, m is 3, m’ is 0 and n’’ is 2. In yet another embodiment, m is 3, m’ is 1and n’’ is 2. In yet another embodiment, m is 3, m’ is 2 and n’’ is 2. In yet another embodiment, mis 3, m’ is 3 and n’’ is 2.In yet a further embodiment, m is 4, m’ is 0 and n" is 2. In yet a further embodiment, m is 4, m’ is 10and n" is 2. In yet a further embodiment, m is 4, m’ is 2 and n" is 2. In yet a further embodiment,m is 4, m’ is 3 and n" is 2.In a particular embodiment, m is 1, m’ is 0 and n’’ is 3. In a particular embodiment, m is 1, m’ is 1and n’’ is 3. In a particular embodiment, m is 1, m’ is 2 and n’’ is 3. In a particular embodiment, mis 1, m’ is 3 and n’’ is 3. 15In another embodiment, m is 2, m’ is 0 and n’’ is 3. In another embodiment, m is 2, m’ is 1 and n’’is 3. In another embodiment, m is 2, m’ is 2 and n’’ is 3. In another embodiment, m is 2, m’ is 3and n’’ is 3.In yet another embodiment, m is 3, m’ is 0 and n’’ is 3. In yet another embodiment, m is 3, m’ is 1and n’’ is 3. In yet another embodiment, m is 3, m’ is 2 and n’’ is 3. In yet another embodiment, m 20is 3, m’ is 3 and n’’ is 3.In yet a further embodiment, m is 4, m’ is 0 and n" is 3. In yet a further embodiment, m is 4, m’ isand n" is 3. In yet a further embodiment, m is 4, m’ is 2 and n" is 3. In yet a further embodiment,m is 4, m’ is 3 and n" is 3.In a particular embodiment, m is 1, m’ is 0 and n’’ is 4. In a particular embodiment, m is 1, m’ is 25 and n’’ is 4. In a particular embodiment, m is 1, m’ is 2 and n’’ is 4. In a particular embodiment,m is 1, m’ is 3 and n’’ is 4.In another embodiment, m is 2, m’ is 0 and n’’ is 4. In another embodiment, m is 2, m’ is 1 andn’’ is 4. In another embodiment, m is 2, m’ is 2 and n’’ is 4. In another embodiment, m is 2, m’ isand n’’ is 4. 30In yet another embodiment, m is 3, m’ is 0 and n’’ is 4. In yet another embodiment, m is 3, m’ is and n’’ is 4. In yet another embodiment, m is 3, m’ is 2 and n’’ is 4. In yet another embodiment,m is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, m is 4, m’ is 0 and n" is 4. In yet a further embodiment, m is 4, m’ is and n" is 4. In yet a further embodiment, m is 4, m’ is 2 and n" is 4. In yet a further embodiment, 35m is 4, m’ is 3 and n" is 4. 46In a particular embodiment, m is 1, m’ is 0 and n’’ is 5. In a particular embodiment, m is 1, m’ is and n’’ is 5. In a particular embodiment, m is 1, m’ is 2 and n’’ is 5. In a particular embodiment,m is 1, m’ is 3 and n’’ is 5.In another embodiment, m is 2, m’ is 0 and n’’ is 5. In another embodiment, m is 2, m’ is 1 andn’’ is 5. In another embodiment, m is 2, m’ is 2 and n’’ is 5. In another embodiment, m is 2, m’ is 5 and n’’ is 5.In yet another embodiment, m is 3, m’ is 0 and n’’ is 5. In yet another embodiment, m is 3, m’ is and n’’ is 5. In yet another embodiment, m is 3, m’ is 2 and n’’ is 5. In yet another embodiment,m is 3, m’ is 3 and n’’ is 5.In yet a further embodiment, m is 4, m’ is 0 and n" is 5. In yet a further embodiment, m is 4, m’ is 10 and n" is 5. In yet a further embodiment, m is 4, m’ is 2 and n" is 5. In yet a further embodiment,m is 4, m’ is 3 and n" is 5.In a very preferred embodiment of the present invention, the serotype 21 glycoconjugateof the present invention are prepared using click chemistry. The invention also relates to a methodof making serotype 21 glycoconjugate, as disclosed herein above. 15In an embodiment, click chemistry may comprise three steps, (a) reacting an isolatedserotype 21 saccharide with a carbonic acid derivative and an azido linker in an aprotic solventto produce an activated azido saccharide (activation of the saccharide), (b) reacting a carrierprotein with an agent bearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group wherethe NHS moiety reacts with the amino groups to form an amide linkage thereby obtaining an 20alkyne functionalized carrier protein (activation of the carrier protein), (c) reacting the activatedazido saccharide of step (a) with the activated alkyne-carrier protein of step (b) by Cu+1 mediatedazide-alkyne cycloaddition reaction to form a glycoconjugate.Following step (a) the saccharide is said to be activated and is referred to herein as"activated saccharide" or "activated azido saccharide". 25Following step (b) the carrier is said to be activated and is referred to as "activated carrier".As mentioned above, before the activation (a), sizing of the saccharide to a targetmolecular weight (MW) range may be performed. Therefore, in an embodiment, the isolatedserotype 21 saccharide is sized before activation with a carbonic acid derivative and an azidolinker. In an embodiment, the isolated serotype 21 saccharide is sized to any of the target 30molecular weight (MW) range defined above. In an embodiment, the isolated serotype 21saccharide is not sized before activation with a carbonic acid derivative and an azido linker.In an embodiment, said carbonic acid derivative is selected from the group consisting of1,1’-carbonyldiimidazole (CDI), 1,1’-carbonyl-di-(1,2,4-triazole) (CDT), N,N′-Disuccinimidylcarbonate (DSC) and N-hydroxysuccinimidyl chloroformate. 35In an embodiment, said carbonic acid derivative is 1,1’-carbonyldiimidazole (CDI). Inanother embodiment, said carbonic acid derivative is 1,1'-Carbonyl-di-(1,2,4-triazole) (CDT). In 47another embodiment, said carbonic acid derivative is N,N′-Disuccinimidyl carbonate (DSC). In yeta further embodiment, said carbonic acid derivative is N-hydroxysuccinimidyl chloroformate.In an embodiment, said carbonic acid derivative is 1,1’-carbonyldiimidazole (CDI) or 1,1'-Carbonyl-di-(1,2,4-triazole) (CDT). In an embodiment, said carbonic acid derivative is 1,1’-carbonyldiimidazole (CDI). Preferably, said carbonic acid derivative N,N ′-Disuccinimidyl 5carbonate (DSC).In an embodiment, said azido linker is a compound of formula (X), (X)wherein X is selected from the group consisting of CH2(CH2) n, (CH 2CH2O)mCH 2CH2, NHCO(CH2)n,NHCO(CH2CH2O)mCH 2CH2, OCH 2(CH 2)n and O(CH2CH2O)mCH2CH2; where n is selected from 1 10to 10 and m is selected from 1 to 4.In an embodiment, said azido linker is a compound of formula (X), wherein X is CH2(CH2)n,and n is selected from 1 to 10. In an embodiment, n is selected from 1 to 5. In an embodiment, nis selected from 1 to 4. In an embodiment, n is selected from 1 to 3. In an embodiment, n isselected from 1 to 2. In a particular embodiment, n is 1. In another embodiment, n is 2. In yet 15another embodiment, n is 3. In yet a further embodiment, n is 4. In yet a further embodiment, n is5. In yet a further embodiment, n is 6. In yet a further embodiment, n is 7. In yet a furtherembodiment, n is 8. In yet a further embodiment, n is 9. In yet a further embodiment, n is 10.In an embodiment, said azido linker is a compound of formula (X), wherein X is(CH2CH2O)mCH 2CH2, wherein m is selected from 1 to 4. In an embodiment, m is selected from 1 20to 3. In an embodiment, m is selected from 1 to 2. In a particular embodiment, m is 1. In anotherembodiment, m is 2. In yet another embodiment, m is 3. In yet a further embodiment, m is 4.In an embodiment, said azido linker is a compound of formula (X), wherein X isNHCO(CH2)n, and n is selected from 1 to 10. In an embodiment, n is selected from 1 to 5. In anembodiment, n is selected from 1 to 4. In an embodiment, n is selected from 1 to 3. In an 25embodiment, n is selected from 1 to 2. In a particular embodiment, n is 1. In another embodiment,n is 2. In yet another embodiment, n is 3. In yet a further embodiment, n is 4. In yet a furtherembodiment, n is 5. In yet a further embodiment, n is 6. In yet a further embodiment, n is 7. In yeta further embodiment, n is 8. In yet a further embodiment, n is 9. In yet a further embodiment, nis 10. 30In an embodiment, said azido linker is a compound of formula (X), wherein X isNHCO(CH2CH2O)mCH 2CH2, where m is selected from 1 to 4. In an embodiment, m is selectedfrom 1 to 3. In an embodiment, m is selected from 1 to 2. In a particular embodiment, m is 1. Inanother embodiment, m is 2. In yet another embodiment, m is 3. In yet a further embodiment, mis 4. 35In an embodiment, said azido linker is a compound of formula (X), wherein X isOCH 2(CH2)n, and n is selected from 1 to 10. In an embodiment, n is selected from 1 to 5. In an 48embodiment, n is selected from 1 to 4. In an embodiment, n is selected from 1 to 3. In anembodiment, n is selected from 1 to 2. In a particular embodiment, n is 1. In another embodiment,n is 2. In yet another embodiment, n is 3. In yet a further embodiment, n is 4. In yet a furtherembodiment, n is 5. In yet a further embodiment, n is 6. In yet a further embodiment, n is 7. In yeta further embodiment, n is 8. In yet a further embodiment, n is 9. In yet a further embodiment, n 5is 10.In an embodiment, said azido linker is a compound of formula (X), wherein X isO(CH 2CH2O)mCH2CH2, where m is selected from 1 to 4. In an embodiment, m is selected from 1to 3. In an embodiment, m is selected from 1 to 2. In a particular embodiment, m is 1. In anotherembodiment, m is 2. In yet another embodiment, m is 3. In yet a further embodiment, m is 4. 10In an embodiment, said azido linker is a compound of formula (XI), (XI)In a preferred embodiment, said azido linker is 3-azido-propylamine.In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and analkyne group is an agent bearing an N-Hydroxysuccinimide (NHS) moiety and a terminal alkyne. 15In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and analkyne group is an agent bearing an N-Hydroxysuccinimide (NHS) moiety and a cycloalkyne.In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and analkyne group is a compound of formula (XII), (XII)where X is selected from the group consisting of CH2O(CH 2)nCH 2C=O andCH2O(CH 2CH2O)m(CH2)nCH2C=O, where n is selected from 0 to 10 and m is selected from 0 to 254.In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and analkyne group is a compound of formula (XII), wherein X is CH2O(CH 2)nCH2C=O, where n isselected from 0 to 10. In an embodiment, n is selected from 0 to 5. In an embodiment, n isselected from 0 to 4. In an embodiment, n is selected from 0 to 3. In an embodiment, n is 30selected from 0 to 2. In a particular embodiment, n is 0. In a particular embodiment, n is 1. Inanother embodiment, n is 2. In yet another embodiment, n is 3. In yet a further embodiment, n is4. In yet a further embodiment, n is 5. In yet a further embodiment, n is 6. In yet a furtherembodiment, n is 7. In yet a further embodiment, n is 8. In yet a further embodiment, n is 9. Inyet a further embodiment, n is 10. 35In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and analkyne group is a compound of formula (XII), wherein X is CH2O(CH 2CH2O)m(CH2)nCH 2C=O, X 49where n is selected from 0 to 10 and m is selected from 0 to 4. In an embodiment, n is selectedfrom 0 to 5. In an embodiment, n is selected from 0 to 4. In an embodiment, n is selected from 0to 3. In an embodiment, n is selected from 0 to 2. In a particular embodiment, n is 0. In a particularembodiment, n is 1. In another embodiment, n is 2. In yet another embodiment, n is 3. In yet afurther embodiment, n is 4. In yet a further embodiment, n is 5. In yet a further embodiment, n is 56. In yet a further embodiment, n is 7. In yet a further embodiment, n is 8. In yet a furtherembodiment, n is 9. In yet a further embodiment, n is 10. In an embodiment, m is selected from 0to 3. In an embodiment, m is selected from 0 to 2. In a particular embodiment, m is 1. In a particularembodiment, m is 1. In another embodiment, m is 2. In yet another embodiment, m is 3. In yet afurther embodiment, m is 4. 10In an embodiment, n is selected from 0 to 5 and m is selected from 0 to 3. In an embodiment, nis selected from 0 to 5 and m is selected from 0 to 2.In an embodiment, n is selected from 0 to 4 and m is selected from 0 to 3. In an embodiment, nis selected from 0 to 4 and m is selected from 0 to 2.In an embodiment, n is selected from 0 to 3 and m is selected from 0 to 3. In an embodiment, n 15is selected from 0 to 3 and m is selected from 0 to 2.In an embodiment, n is selected from 0 to 2 and m is selected from 0 to 3. In an embodiment, nis selected from 0 to 2 and m is selected from 0 to 2.In an embodiment, n is selected from 0 to 1 and m is selected from 0 to 3. In an embodiment, nis selected from 0 to 1 and m is selected from 0 to 2. 20In an embodiment, n is 0 and m is 0. In an embodiment, n is 1 and m is 0. In an embodiment, nis 2 and m is 0. In an embodiment, n is 3 and m is 0. In an embodiment, n is 4 and m is 0. In anembodiment, n is 5 and m is 0. In an embodiment, n is 6 and m is 0. In an embodiment, n is 7and m is 0. In an embodiment, n is 8 and m is 0. In an embodiment, n is 9 and m is 0. In anembodiment, n is 10 and m is 0. 25In an embodiment, n is 0 and m is 1. In an embodiment, n is 1 and m is 1. In an embodiment, nis 2 and m is 1. In an embodiment, n is 3 and m is 1. In an embodiment, n is 4 and m is 1. In anembodiment, n is 5 and m is 1. In an embodiment, n is 6 and m is 1. In an embodiment, n is 7and m is 1. In an embodiment, n is 8 and m is 1. In an embodiment, n is 9 and m is 1. In anembodiment, n is 10 and m is 1. 30In an embodiment, n is 0 and m is 2. In an embodiment, n is 1 and m is 2. In an embodiment, nis 2 and m is 2. In an embodiment, n is 3 and m is 2. In an embodiment, n is 4 and m is 2. In anembodiment, n is 5 and m is 2. In an embodiment, n is 6 and m is 2. In an embodiment, n is 7and m is 2. In an embodiment, n is 8 and m is 2. In an embodiment, n is 9 and m is 2. In anembodiment, n is 10 and m is 2. 35In an embodiment, n is 0 and m is 3. In an embodiment, n is 1 and m is 3. In an embodiment, nis 2 and m is 3. In an embodiment, n is 3 and m is 3. In an embodiment, n is 4 and m is 3. In anembodiment, n is 5 and m is 3. In an embodiment, n is 6 and m is 3. In an embodiment, n is 7 50and m is 3. In an embodiment, n is 8 and m is 3. In an embodiment, n is 9 and m is 3. In anembodiment, n is 10 and m is 3.In an embodiment, n is 0 and m is 4. In an embodiment, n is 1 and m is 4. In an embodiment, nis 2 and m is 4. In an embodiment, n is 3 and m is 4. In an embodiment, n is 4 and m is 4. In anembodiment, n is 5 and m is 4. In an embodiment, n is 6 and m is 4. In an embodiment, n is 7 5and m is 4. In an embodiment, n is 8 and m is 4. In an embodiment, n is 9 and m is 4. In anembodiment, n is 10 and m is 4.In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and analkyne group is a compound of formula (XIII): (XIII) 10In an embodiment, step a) comprises reacting the saccharide with a carbonic acidderivative followed by reacting the carbonic acid derivative-activated saccharide with an azidolinker in an aprotic solvent to produce an activated azido saccharide.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 0.01-10 molar equivalent to the amount of saccharide present in 15the reaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 0.1-10 molar equivalent to the amount of saccharide present in thereaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonic 20acid derivative that is between 0.5-5 molar equivalent to the amount of saccharide present in thereaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 1-5 molar equivalent to the amount of saccharide present in thereaction mixture. 25In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 2-5 molar equivalent to the amount of saccharide present in thereaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 5-10 molar equivalent to the amount of saccharide present in the 30reaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 0.1-5 molar equivalent to the amount of saccharide present in thereaction mixture. 51In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 0.5-2 molar equivalent to the amount of saccharide present in thereaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 0.01 molar equivalent to the amount of saccharide present in the reaction 5mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 0.1 molar equivalent to the amount of saccharide present in the reactionmixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonic 10acid derivative of about 0.2 molar equivalent to the amount of saccharide present in the reactionmixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 0.5 molar equivalent to the amount of saccharide present in the reactionmixture. 15In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 1 molar equivalent to the amount of saccharide present in the reactionmixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 2 molar equivalent to the amount of saccharide present in the reaction 20mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 5 molar equivalent to the amount of saccharide present in the reactionmixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonic 25acid derivative of about 10 molar equivalent to the amount of saccharide present in the reactionmixture.In an embodiment, at step a) the isolated saccharide is reacted with a carbonic acidderivative in an aprotic solvent.In one embodiment the isolated saccharide is reacted with a carbonic acid derivative in a 30solution consisting essentially of dimethylsulphoxide (DMSO) or dimethylformamide (DMF). Inone embodiment the isolated saccharide is reacted with a carbonic acid derivative in a solutionconsisting essentially of dimethylformamide (DMF). In one embodiment the isolated saccharideis reacted with a carbonic acid derivative in a solution consisting essentially of dimethylsulphoxide(DMSO). 35In an embodiment, the isolated saccharide is reacted with a carbonic acid derivative in asolution consisting essentially of dimethylacetamide. In an embodiment, the isolated saccharideis reacted with a carbonic acid derivative in a solution consisting essentially of N-methyl-2- 52pyrrolidone. In an embodiment, the isolated saccharide is reacted with a carbonic acid derivativein a solution consisting essentially of hexamethylphosphoramide (HMPA).In a preferred embodiment the isolated saccharide is reacted with a carbonic acidderivative in a solution consisting essentially of dimethylsulphoxide (DMSO).In one embodiment the isolated saccharide is reacted with a carbonic acid derivative in 5dimethylsulphoxide (DMSO) or dimethylformamide (DMF). In one embodiment the isolatedsaccharide is reacted with a carbonic acid derivative in dimethylformamide (DMF). In oneembodiment the isolated saccharide is reacted with a carbonic acid derivative indimethylsulphoxide (DMSO).In an embodiment, the isolated saccharide is reacted with a carbonic acid derivative in 10dimethylacetamide. In an embodiment, the isolated saccharide is reacted with a carbonic acidderivative in N-methyl-2-pyrrolidone. In an embodiment, the isolated saccharide is reacted witha carbonic acid derivative in hexamethylphosphoramide (HMPA).In a preferred embodiment the isolated saccharide is reacted with CDI indimethylsulphoxide (DMSO). In an embodiment the isolated saccharide is reacted with CDI in 15anhydrous DMSO.It has been surprisingly found that reacting the isolated saccharide with CDI in anenvironment with a moisture level of about 0.1% to 1% (v/v) allows to avoid side reactions.Therefore, in one embodiment the isolated saccharide is reacted with CDI in an aprotic solventcomprising 0.1% to 1% (v/v) water. In one embodiment the isolated saccharide is reacted with 20CDI in an aprotic solvent comprising 0.1% to 0.5% (v/v) water. In one embodiment the isolatedsaccharide is reacted with CDI in an aprotic solvent comprising 0.1% to 0.2% (v/v) water.In one embodiment the isolated saccharide is reacted with CDI in an aprotic solventcomprising about 0.1% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in an aprotic solvent comprising about 0.2% (v/v) water. In one embodiment the isolated 25saccharide is reacted with CDI in an aprotic solvent comprising about 0.3% (v/v) water. In oneembodiment the isolated saccharide is reacted with CDI in an aprotic solvent comprising about0.4% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in an aproticsolvent comprising about 0.5% (v/v) water. In one embodiment the isolated saccharide is reactedwith CDI in an aprotic solvent comprising about 0.6% (v/v) water. In one embodiment the isolated 30saccharide is reacted with CDI in an aprotic solvent comprising about 0.7% (v/v) water. In oneembodiment the isolated saccharide is reacted with CDI in an aprotic solvent comprising about0.8% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in an aproticsolvent comprising about 0.9% (v/v) water.In one embodiment the isolated saccharide is reacted with CDI in DMSO comprising 0.1% 35to 1% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in DMSOcomprising 0.1% to 0.5% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in DMSO comprising 0.1% to 0.2% (v/v) water. 53In one embodiment the isolated saccharide is reacted with CDI in DMSO comprising about0.1% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in DMSOcomprising about 0.2% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in DMSO comprising about 0.3% (v/v) water. In one embodiment the isolated saccharide isreacted with CDI in DMSO comprising about 0.4% (v/v) water. In one embodiment the isolated 5saccharide is reacted with CDI in DMSO comprising about 0.5% (v/v) water. In one embodimentthe isolated saccharide is reacted with CDI in DMSO comprising about 0.6% (v/v) water. In oneembodiment the isolated saccharide is reacted with CDI in DMSO comprising about 0.7% (v/v)water. In one embodiment the isolated saccharide is reacted with CDI in DMSO comprising about0.8% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in DMSO 10comprising about 0.9% (v/v) water.In one embodiment the free carbonic acid derivative is then quenched by the addition ofwater before the addition of the azido linker. Water can inactivate free CDI.Therefore, in an embodiment, carbonic acid derivative activation is followed by the addition ofwater. In an embodiment, water is added to bring the total water content in the mixture to between 15about 1% to about 10% (v/v). In an embodiment, water is added to bring the total water contentin the mixture to between about 1% to about 5% (v/v). In an embodiment, water is added to bringthe total water content in the mixture to about 1 % (v/v). In an embodiment, water is added tobring the total water content in the mixture to about 2% (v/v). In an embodiment, water is addedto bring the total water content in the mixture to about 5% (v/v). 20Once the saccharide has been reacted with carbonic acid derivative and following aneventual quenching of carbonic acid derivative with water, the carbonic acid derivative-activatedsaccharide is reacted with an azido linker.In one embodiment step a) further comprises reacting the carbonic acid derivative-activated saccharide with an amount of azido linker that is between 0.01-10 molar equivalent to 25the amount of polysaccharide Repeat Unit of the activated saccharide (molar equivalent of RU).In one embodiment step a) further comprises reacting the carbonic acid derivative-activated saccharide with an amount of azido linker that is between 0.1-5 molar equivalent to theamount of polysaccharide repeat unit of the activated saccharide.In one embodiment step a) further comprises reacting the carbonic acid derivative- 30activated saccharide with an amount of azido linker that is between 0.5-2 molar equivalent to theamount of polysaccharide repeat unit of the activated saccharide.In one embodiment step a) further comprises reacting the carbonic acid derivative-activated saccharide with an amount of azido linker that is between 1-5 molar equivalent to theamount of polysaccharide repeat unit of the activated saccharide. 35In the above embodiments, said carbonic acid derivative may be CDI. In anotherembodiment, said carbonic acid derivative is CDT. In a preferred embodiment, said carbonic acidderivative is DSC (N,N′-Disuccinimidyl carbonate). 54In one embodiment the degree of activation of the activated saccharide following step a)is between 1.0 to 100%. The degree of activation of the azido saccharide being defined as thepercentage of Repeating Unit linked to an azido linker.In one embodiment the degree of activation of the activated saccharide following step a)is between 5 to 70%. In another embodiment the degree of activation of the activated saccharide 5following step a) is between 5 to 50%.In a preferred embodiment the degree of activation of the activated saccharide followingstep a) is between 15 to 50%.In another embodiment the degree of activation of the activated saccharide following stepa) is between 10 to 40%. 10In another embodiment the degree of activation of the activated saccharide following stepa) is between 5 to 15%.In another embodiment the degree of activation of the activated saccharide following stepa) is between 15 to 35%.In a preferred embodiment the degree of activation of the activated saccharide following 15step a) is between 15 to 50%.In a very preferred embodiment the degree of activation of the activated saccharidefollowing step a) is between 10 to 40%.In an embodiment the degree of activation of the activated saccharide following step a) isabout 25%. 20In an embodiment the degree of activation of the activated saccharide following step a) isabout 30%.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is 0.1-10 molarequivalents to the lysines on the carrier. 25In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is 0.5-10 molarequivalents to the lysines on the carrier.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is 1-5 molar equivalents 30to the lysines on the carrier.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is 2-5 molar equivalentsto the lysines on the carrier.In one embodiment step b) comprises reacting the carrier protein with an amount of agent 35bearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is 5-10 molarequivalents to the lysines on the carrier. 55In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is 1-5 molar equivalentsto the lysines on the carrier.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is about 10 molar 5equivalents to the lysines on the carrier.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is about 5 molarequivalents to the lysines on the carrier.In one embodiment step b) comprises reacting the carrier protein with an amount of agent 10bearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is about 2 molarequivalents to the lysines on the carrier.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is about 1 molarequivalent to the lysines on the carrier. 15In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is about 0.5 molarequivalents to the lysines on the carrier.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is about 0.1 molar 20equivalents to the lysines on the carrier.In one embodiment the degree of activation of the activated carrier following step b) isbetween 1 and 50. The degree of activation of the activated carrier being defined as the numberof lysine residues in the carrier protein that become linked to the agent bearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group . 25In an embodiment, the carrier protein is CRM 197, which contains 39 lysine residues. In saidembodiment the degree of activation of the activated carrier following step b) may be between 1to 30. In another embodiment the degree of activation of the activated carrier (CRM 197) followingstep b) is between 5 to 20. In another embodiment the degree of activation of the activated carrier(CRM 197) following step b) is between 9 to 18. In another embodiment the degree of activation of 30the activated carrier (CRM 197) following step b) is between 8 to 11. In another embodiment thedegree of activation of the activated carrier (CRM 197) following step b) is between 15 to 20. Inanother embodiment the degree of activation of the activated carrier (CRM 197) following step b) isabout 5. In another embodiment the degree of activation of the activated carrier (CRM 197) followingstep b) is about 6. In another embodiment the degree of activation of the activated carrier 35(CRM 197) following step b) is about 7. In another embodiment the degree of activation of theactivated carrier (CRM 197) following step b) is about 8. In another embodiment the degree ofactivation of the activated carrier (CRM 197) following step b) is about 9. In another embodiment 56the degree of activation of the activated carrier (CRM 197) following step b) is about 10. In anotherembodiment the degree of activation of the activated carrier (CRM 197) following step b) is about11. In another embodiment the degree of activation of the activated carrier (CRM 197) followingstep b) is about 12. In another embodiment the degree of activation of the activated carrier(CRM 197) following step b) is about 13. In another embodiment the degree of activation of the 5activated carrier (CRM 197) following step b) is about 14. In another embodiment the degree ofactivation of the activated carrier (CRM 197) following step b) is about 15. In another embodimentthe degree of activation of the activated carrier (CRM 197) following step b) is about 16. In anotherembodiment the degree of activation of the activated carrier (CRM 197) following step b) is about17. In another embodiment the degree of activation of the activated carrier (CRM 197) following 10step b) is about 18. In another embodiment the degree of activation of the activated carrier(CRM 197) following step b) is about 19. In another embodiment the degree of activation of theactivated carrier (CRM 197) following step b) is about 20. In another embodiment the degree ofactivation of the activated carrier (CRM 197) following step b) is about 21. In another embodimentthe degree of activation of the activated carrier (CRM 197) following step b) is about 22. In another 15embodiment the degree of activation of the activated carrier (CRM 197) following step b) is about23. In another embodiment the degree of activation of the activated carrier (CRM 197) followingstep b) is about 24. In another embodiment the degree of activation of the activated carrier(CRM 197) following step b) is about 25.In an embodiment, the carrier protein is SCP or a fragment thereof. In said embodiment 20the degree of activation of the activated carrier following step b) may be between 1 to 50. Inanother embodiment the degree of activation of the activated carrier (SCP) following step b) isbetween 5 to 50. In another embodiment the degree of activation of the activated carrier (SCP)following step b) is between 7 to 45. In another embodiment the degree of activation of theactivated carrier (SCP) following step b) is between 5 to 25. In another embodiment the degree 25of activation of the activated carrier (SCP) following step b) is between 10 to 25. In anotherembodiment the degree of activation of the activated carrier (SCP) following step b) is betweento 22. In another embodiment the degree of activation of the activated carrier (SCP) followingstep b) is about 5. In another embodiment the degree of activation of the activated carrier (SCP)following step b) is about 7. In another embodiment the degree of activation of the activated carrier 30(SCP) following step b) is about 10. In another embodiment the degree of activation of theactivated carrier (SCP) following step b) is about 13. In another embodiment the degree ofactivation of the activated carrier (SCP) following step b) is about 15. In another embodiment thedegree of activation of the activated carrier (SCP) following step b) is about 20. In anotherembodiment the degree of activation of the activated carrier (SCP) following step b) is about 26. 35In another embodiment the degree of activation of the activated carrier (SCP) following step b) isabout 30. In another embodiment the degree of activation of the activated carrier (SCP) followingstep b) is about 35. In another embodiment the degree of activation of the activated carrier (SCP) 57following step b) is about 37. In another embodiment the degree of activation of the activatedcarrier (SCP) following step b) is about 40. In another embodiment the degree of activation of theactivated carrier (SCP) following step b) is about 45. In another embodiment the degree ofactivation of the activated carrier (SCP) following step b) is about 50.In an embodiment, the carrier protein is TT or a fragment thereof. In said embodiment the 5degree of activation of the activated carrier following step b) may be between 1 to 30. In anotherembodiment the degree of activation of the activated carrier (TT) following step b) is between 5to 25. In another embodiment the degree of activation of the activated carrier (TT) following stepb) is between 7 to 25. In another embodiment the degree of activation of the activated carrier (TT)following step b) is between 10 to 20. In another embodiment the degree of activation of the 10activated carrier (TT) following step b) is about 5. In another embodiment the degree of activationof the activated carrier (TT) following step b) is about 7. In another embodiment the degree ofactivation of the activated carrier (TT) following step b) is about 10. In another embodiment thedegree of activation of the activated carrier (TT) following step b) is about 12. In anotherembodiment the degree of activation of the activated carrier (TT) following step b) is about 15. In 15another embodiment the degree of activation of the activated carrier (TT) following step b) is about20. In another embodiment the degree of activation of the activated carrier (TT) following step b)is about 25. In another embodiment the degree of activation of the activated carrier (TT) followingstep b) is about 30.In an embodiment, the conjugation reaction c) is carried out in aqueous buffer. In an 20embodiment, the conjugation reaction c) is carried out in aqueous buffer in the presence of copper(I) as catalyst. In an embodiment, the conjugation reaction c) is carried out in aqueous buffer inthe presence an oxidant and of copper (I) as catalyst. In a preferred embodiment, the conjugationreaction c) is carried out in aqueous buffer in the presence of copper (I) as catalyst and ascorbateas oxidant. In an embodiment, THPTA (tris(3-hydroxypropyltriazolylmethyl)amine) and 25aminoguanidine may be further added to protect the protein from side reactions. Therefore, in apreferred embodiment, the conjugation reaction c) is carried out in aqueous buffer in the presenceof copper (I) as catalyst and ascorbate as oxidant, wherein the reaction mixture further comprisesTHPTA (tris(3-hydroxypropyltriazolylmethyl)amine) and aminoguanidine.In an embodiment the initial input ratio (weight by weight) of activated azido saccharide to 30activated alkyne-carrier at step c) is between 0.1 and 3. In an embodiment the initial input ratio(weight by weight) of activated azido saccharide to activated alkyne-carrier at step c) is between0.5 and 2. In an embodiment the initial input ratio (weight by weight) of activated azido saccharideto activated alkyne-carrier at step c) is between 0.6 and 1.5. In a preferred embodiment the initialinput ratio (weight by weight) of activated azido saccharide to activated alkyne-carrier at step c) 35is between 0.8 and 1. In an embodiment the initial input ratio (weight by weight) of activated azidosaccharide to activated alkyne-carrier at step c) is about 0.5. In an embodiment the initial inputratio (weight by weight) of activated azido saccharide to activated alkyne-carrier at step c) is about 580.6. In an embodiment the initial input ratio (weight by weight) of activated azido saccharide toactivated alkyne-carrier at step c) is about 0.7. In an embodiment the initial input ratio (weight byweight) of activated azido saccharide to activated alkyne-carrier at step c) is about 0.8. In anembodiment the initial input ratio (weight by weight) of activated azido saccharide to activatedalkyne-carrier at step c) is about 0.9. In an embodiment the initial input ratio (weight by weight) of 5activated azido saccharide to activated alkyne-carrier at step c) is about 1. In an embodiment theinitial input ratio (weight by weight) of activated azido saccharide to activated alkyne-carrier atstep c) is about 1.1. In an embodiment the initial input ratio (weight by weight) of activated azidosaccharide to activated alkyne-carrier at step c) is about 1.2. In an embodiment the initial inputratio (weight by weight) of activated azido saccharide to activated alkyne-carrier at step c) is about 101.3. In an embodiment the initial input ratio (weight by weight) of activated azido saccharide toactivated alkyne-carrier at step c) is about 1.4. In an embodiment the initial input ratio (weight byweight) of activated azido saccharide to activated alkyne-carrier at step c) is about 1.5. In anembodiment the initial input ratio (weight by weight) of activated azido saccharide to activatedalkyne-carrier at step c) is about 1.6. In an embodiment the initial input ratio (weight by weight) of 15activated azido saccharide to activated alkyne-carrier at step c) is about 1.7. In an embodimentthe initial input ratio (weight by weight) of activated azido saccharide to activated alkyne-carrierat step c) is about 1.8. In an embodiment the initial input ratio (weight by weight) of activated azidosaccharide to activated alkyne-carrier at step c) is about 1.9. In an embodiment the initial inputratio (weight by weight) of activated azido saccharide to activated alkyne-carrier at step c) is about 202.Following the click conjugation reaction, there may remain unreacted azido groups in theconjugates, these may be capped using a suitable azido group capping agent. Therefore, in anembodiment, following step c), unreacted azido groups in the conjugates, are capped using asuitable azido group capping agent. In one embodiment this azido group capping agent is an 25agent bearing an alkyne group. In one embodiment this azido group capping agent is an agentbearing a terminal alkyne. In one embodiment this azido group capping agent is an agent bearinga cycloalkyne.In an embodiment, said azido group capping agent is a compound of formula (XIV), (XIV), 30wherein X is (CH2)n wherein n is selected from 1 to 15.In one embodiment this azido group capping agent is propargyl alcohol.Therefore, in an embodiment, following step (c) the process further comprises a step ofcapping the unreacted azido groups remained in the conjugates with an azido group cappingagent. 35 59In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.05 to 20 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.1 to 15 molar equivalents to the amount of polysaccharide 5repeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.5 to 10 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amount 10of capping agent that is between 0.5 to 5 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.5 to 2 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide. 15In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.5 to 1 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 1 to 2 molar equivalents to the amount of polysaccharide repeat 20unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.75 to 1.5 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amount 25of capping agent that is about 1 molar equivalent to the amount of polysaccharide repeat unit ofthe activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is about 1.5 molar equivalent to the amount of polysaccharide repeat unitof the activated saccharide. 30In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is about 0.5 molar equivalent to the amount of polysaccharide repeat unitof the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is about 2 molar equivalents to the amount of polysaccharide repeat unit of 35the activated saccharide. 60Following the click conjugation reaction, unreacted alkyne groups may remain present inthe conjugates, these may be capped using a suitable alkyne group capping agent. In oneembodiment this alkyne group capping agent is an agent bearing an azido group.In an embodiment, said alkyne group capping agent is a compound of formula (XV), (XV), 5wherein X is (CH2)n wherein n is selected from 1 to 15.In one embodiment this alkyne group capping agent is 3-azido-1-propanol.Therefore, in an embodiment, following step (c) the process further comprises a step ofcapping the unreacted alkyne groups remained in the conjugates with an alkyne group cappingagent. 10In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.05 to 20 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.1 to 15 molar equivalents to the amount of 15polysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.5 to 10 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with an 20amount of capping agent that is between 0.5 to 5 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.5 to 2 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide. 25In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.5 to 1 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 1 to 5 molar equivalents to the amount of polysaccharide 30repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 1 to 2 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with an 35amount of capping agent that is between 1.5 to 2.5 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide. 61In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 0.5 molar equivalent to the amount of polysaccharide repeatunit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 1 molar equivalent to the amount of polysaccharide repeat 5unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 1.5 molar equivalent to the amount of polysaccharide repeatunit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with an 10amount of capping agent that about 2 molar equivalents to the amount of polysaccharide repeatunit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 2.5 molar equivalents to the amount of polysaccharide repeatunit of the activated saccharide. 15In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 5 molar equivalents to the amount of polysaccharide repeatunit of the activated saccharide.Following conjugation to the carrier protein, the glycoconjugate can be purified (enrichedwith respect to the amount of saccharide-protein conjugate) by a variety of techniques known to 20the skilled person. These techniques include dialysis, concentration/diafiltration operations,tangential flow filtration precipitation/elution, column chromatography (DEAE or hydrophobicinteraction chromatography), and depth filtration. Therefore, in one embodiment the process forproducing the glycoconjugate of the present invention comprises the step of purifying theglycoconjugate after it is produced. 25In an aspect, the invention provides a serotype 21 glycoconjugate produced according toany of the methods disclosed herein.
Alternative click chemistryIn an embodiment of the present invention, the serotype 21 glycoconjugate of the presentinvention is prepared by alternative click chemistry as disclosed e.g. in application No. 30PCT/IB2024/051122 (filed on February 07, 2024).Therefore, in an embodiment, the serotype 21 glycoconjugate of the present inventioncomprises a serotype 21 saccharide covalently conjugated to a carrier protein (CP) through aspacer and having the general formula (XVI): n OONH ONN NX' O HN CP X (XVI),wherein X is selected from the group consisting of CH2(CH2) n’, (CH 2CH 2O)mCH2CH 2,NHCO(CH2)n’, NHCO(CH2CH2O) mCH2CH2, OCH 2(CH2) n’ and O(CH 2CH2O)mCH2CH 2; where n’ isselected from 0 to 10 and m is selected from 1 to 4,wherein X' is selected from the group consisting of CH2(CH2)n", CH2O(CH 2)n’’CH2, 5CH2O(CH 2CH2O)m’(CH2)n’’CH2, where n’’ is selected from 0 to 10 and m’ is selected from 0 to 4and wherein the structure in square backet represents a repeat unit of the serotype 21 saccharideand wherein n represents the number of repeating units.In a particular aspect, the invention is directed to a serotype 21 glycoconjugate comprisinga serotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer and 10having the general formula (XVI), wherein X is CH2(CH2) n’, where n’ is 0 and wherein X' isCH2(CH2) n" where n’’ is 0.In a particular aspect, the invention pertains to a serotype 21 glycoconjugate comprisinga serotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XVII), 15 (XVII),wherein the structure in square backet represents a repeat unit of the serotype 21 saccharide andwherein n represents the number of repeating units.Formulas (XVI) and (XVII) are schematic representations of glycoconjugates of theinvention. It should not be understood that a linkage is present at every repeating unit of the 20saccharide (the structure in square brackets). Rather, a majority of the saccharide repeating unitremains unmodified and covalent linkages between the carrier protein and the saccharide is for aminority of the saccharide repeat units. Additionally, an individual carrier protein (CP) molecule 63may be linked to more than one saccharide molecule and an individual saccharide molecule canbe linked to more than one individual carrier protein (CP) molecule. The structure in squarebrackets represents a repeat unit of the serotype 21 saccharide.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer and 5having the general formula (XVI), wherein X is CH 2(CH2)n’, where n’ is selected from 0 to 10 andwherein X' is CH2(CH2) n" where n’’ is selected from 0 to 10. In an embodiment, n’ is selected fromto 5 and n’’ is selected from 0 to 10. In an embodiment, n’ is selected from 0 to 5 and n’’ isselected from 0 to 5. In an embodiment, n’ is selected from 0 to 3 and n’’ is selected from 0 to 3.In an embodiment, n’ is selected from 0 to 2 and n’’ is selected from 0 to 2. In a particular 10embodiment, n’ is 0 and n’’ is 0. In a particular embodiment, n’ is 1 and n’’ is 0. In anotherembodiment, n’ is 2 and n’’ is 0. In yet another embodiment, n’ is 3 and n’’ is 0. In yet a furtherembodiment, n’ is 4 and n" is 0. In yet a further embodiment, n’ is 5 and n" is 0. In yet a furtherembodiment, n’ is 6 and n" is 0. In a particular embodiment, n’ is à and n’’ is 1. In a particularembodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yet another 15embodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet a furtherembodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In a particularembodiment, n’ is 0 and n’’ is 2. In a particular embodiment, n’ is 1 and n’’ is 2. In anotherembodiment, n’ is 2 and n’’ is 2. In yet another embodiment, n’ is 3 and n’’ is 2. In yet a furtherembodiment, n’ is 4 and n" is 2. In yet a further embodiment, n’ is 5 and n" is 2. In yet a further 20embodiment, n’ is 6 and n" is 2. In a particular embodiment, n’ is 0 and n’’ is 3. In a particularembodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yet anotherembodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet a furtherembodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In a particularembodiment, n’ is 0 and n’’ is 4. In a particular embodiment, n’ is 1 and n’’ is 4. In another 25embodiment, n’ is 2 and n’’ is 4. In yet another embodiment, n’ is 3 and n’’ is 4. In yet a furtherembodiment, n’ is 4 and n" is 4. In yet a further embodiment, n’ is 5 and n" is 4. In yet a furtherembodiment, n’ is 6 and n" is 4. In a particular embodiment, n’ is 0 and n’’ is 5. In a particularembodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yet anotherembodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet a further 30embodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In a particularembodiment, n’ is 0 and n’’ is 6. In a particular embodiment, n’ is 1 and n’’ is 6. In anotherembodiment, n’ is 2 and n’’ is 6. In yet another embodiment, n’ is 3 and n’’ is 6. In yet a furtherembodiment, n’ is 4 and n" is 6. In yet a further embodiment, n’ is 5 and n" is 6. In yet a furtherembodiment, n’ is 6 and n" is 6. 35In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XVI), wherein X is CH 2(CH2)n’, where n’ is selected from 0 to 10 and 64wherein X' is CH2O(CH 2) n’’CH2 where n’’ is selected from 0 to 10. In an embodiment, n’ is selectedfrom 0 to 5 and n’’ is selected from 0 to 10. In an embodiment, n’ is selected from 0 to 5 and n’’ isselected from 0 to 5. In an embodiment, n’ is selected from 0 to 3 and n’’ is selected from 0 to 3.In an embodiment, n’ is selected from 0 to 2 and n’’ is selected from 0 to 2. In a particularembodiment, n’ is 0 and n’’ is 0. In a particular embodiment, n’ is 1 and n’’ is 0. In another 5embodiment, n’ is 2 and n’’ is 0. In yet another embodiment, n’ is 3 and n’’ is 0. In yet a furtherembodiment, n’ is 4 and n" is 0. In yet a further embodiment, n’ is 5 and n" is 0. In yet a furtherembodiment, n’ is 6 and n" is 0. In a particular embodiment, n’ is à and n’’ is 1. In a particularembodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yet anotherembodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet a further 10embodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In a particularembodiment, n’ is 0 and n’’ is 2. In a particular embodiment, n’ is 1 and n’’ is 2. In anotherembodiment, n’ is 2 and n’’ is 2. In yet another embodiment, n’ is 3 and n’’ is 2. In yet a furtherembodiment, n’ is 4 and n" is 2. In yet a further embodiment, n’ is 5 and n" is 2. In yet a furtherembodiment, n’ is 6 and n" is 2. In a particular embodiment, n’ is 0 and n’’ is 3. In a particular 15embodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yet anotherembodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet a furtherembodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In a particularembodiment, n’ is 0 and n’’ is 4. In a particular embodiment, n’ is 1 and n’’ is 4. In anotherembodiment, n’ is 2 and n’’ is 4. In yet another embodiment, n’ is 3 and n’’ is 4. In yet a further 20embodiment, n’ is 4 and n" is 4. In yet a further embodiment, n’ is 5 and n" is 4. In yet a furtherembodiment, n’ is 6 and n" is 4. In a particular embodiment, n’ is 0 and n’’ is 5. In a particularembodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yet anotherembodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet a furtherembodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In a particular 25embodiment, n’ is 0 and n’’ is 6. In a particular embodiment, n’ is 1 and n’’ is 6. In anotherembodiment, n’ is 2 and n’’ is 6. In yet another embodiment, n’ is 3 and n’’ is 6. In yet a furtherembodiment, n’ is 4 and n" is 6. In yet a further embodiment, n’ is 5 and n" is 6. In yet a furtherembodiment, n’ is 6 and n" is 6.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising a 30serotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XVI), wherein X is CH 2(CH2)n’, where n’ is selected from 0 to 10 andwherein X' is CH2O(CH 2CH2O) m’(CH2)n’’CH2, where n’’ is selected from 0 to 10 and m’ is selectedfrom 0 to 4.In an embodiment, n’ is selected from 0 to 5, m’ is selected from 0 to 4 and n’’ is selected from 0 35to 10. In an embodiment, n’ is selected from 0 to 5, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, n’ is selected from 0 to 3, m’ is selected from 0 to 2 and n’’ isselected from 0 to 3. In an embodiment, n’ is selected from 0 to 2, m’ is selected from 0 to 2 and 65n’’ is selected from 0 to 1. In an embodiment, n’ is selected from 0 to 1, m’ is selected from 0 to 1and n’’ is selected from 0 to 1.In a particular embodiment, n’ is 0, m’ is 0 and n’’ is 0. In another embodiment, n’ is 0, m’ is 1 andn’’ is 0. In another embodiment, n’ is 0, m’ is 2 and n’’ is 0. In another embodiment, n’ is 1, m’ is 3and n’’ is 0. 5In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 0. In another embodiment, n’ is 1, m’ is 1 andn’’ is 0. In another embodiment, n’ is 1, m’ is 2 and n’’ is 0. In another embodiment, n’ is 1, m’ is 3and n’’ is 0.In another embodiment, n’ is 2, m’ is 0 and n’’ is 0. In another embodiment, n’ is 2, m’ is 1 and n’’is 0. In another embodiment, n’ is 2, m’ is 2 and n’’ is 0. In another embodiment, n’ is 2, m’ is 3 10and n’’ is 0.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 0. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 0.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 4, m’ is 15and n" is 0. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 0.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 5, m’ isand n" is 0.In yet a further embodiment, n’ is 5, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 0. 20In a particular embodiment, n’ is 0, m’ is 0 and n’’ is 1. In a particular embodiment, n’ is 0, m’ is 1and n’’ is 1. In a particular embodiment, n’ is 0, m’ is 2 and n’’ is 1. In a particular embodiment, n’is 0, m’ is 3 and n’’ is 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 1. In a particular embodiment, n’ 25is 1, m’ is 3 and n’’ is 1.In another embodiment, n’ is 2, m’ is 0 and n’’ is 1. In another embodiment, n’ is 2, m’ is 1 and n’’is 1. In another embodiment, n’ is 2, m’ is 2 and n’’ is 1. In another embodiment, n’ is 2, m’ is 3and n’’ is 1.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 1 30and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 1. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 1.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 4, m’ isand n" is 1. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 1. 35In yet a further embodiment, n’ is 5, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 5, m’ isand n" is 1. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 1. 66In a particular embodiment, n’ is 0, m’ is 0 and n’’ is 2. In a particular embodiment, n’ is 0, m’ is 1and n’’ is 2. In a particular embodiment, n’ is 0, m’ is 2 and n’’ is 2. In a particular embodiment, n’is 0, m’ is 3 and n’’ is 2.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 2. In a particular embodiment, n’ 5is 1, m’ is 3 and n’’ is 2.In another embodiment, n’ is 2, m’ is 0 and n’’ is 2. In another embodiment, n’ is 2, m’ is 1 and n’’is 2. In another embodiment, n’ is 2, m’ is 2 and n’’ is 2. In another embodiment, n’ is 2, m’ is 3and n’’ is 2.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 1 10and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 2. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 2.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 4, m’ isand n" is 2. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 2. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 2. 15In yet a further embodiment, n’ is 5, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 5, m’ isand n" is 2. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 2. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 2.In a particular embodiment, n’ is 0, m’ is 0 and n’’ is 3. In a particular embodiment, n’ is 0, m’ is 1and n’’ is 3. In a particular embodiment, n’ is 0, m’ is 2 and n’’ is 3. In a particular embodiment, n’ 20is 0, m’ is 3 and n’’ is 3.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 3. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 3.In another embodiment, n’ is 2, m’ is 0 and n’’ is 3. In another embodiment, n’ is 2, m’ is 1 and n’’ 25is 3. In another embodiment, n’ is 2, m’ is 2 and n’’ is 3. In another embodiment, n’ is 2, m’ is 3and n’’ is 3.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 3. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 3. 30In yet a further embodiment, n’ is 4, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 4, m’ isand n" is 3. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 3. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 3.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 5, m’ isand n" is 3. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 3. In yet a further embodiment, 35n’ is 5, m’ is 3 and n" is 3. 67In a particular embodiment, n’ is 0, m’ is 0 and n’’ is 4. In a particular embodiment, n’ is 0, m’ is 1and n’’ is 4. In a particular embodiment, n’ is 0, m’ is 2 and n’’ is 4. In a particular embodiment, n’is 0, m’ is 3 and n’’ is 4.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 4. In a particular embodiment, n’ 5is 1, m’ is 3 and n’’ is 4.In another embodiment, n’ is 2, m’ is 0 and n’’ is 4. In another embodiment, n’ is 2, m’ is 1 andn’’ is 4. In another embodiment, n’ is 2, m’ is 2 and n’’ is 4. In another embodiment, n’ is 2, m’ is and n’’ is 4.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 4. In yet another embodiment, n’ is 3, m’ is 10 and n’’ is 4. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 4. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 4, m’ is and n" is 4. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 4. 15In yet a further embodiment, n’ is 5, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 5, m’ isand n" is 4. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 4.In a particular embodiment, n’ is 0, m’ is 0 and n’’ is 5. In a particular embodiment, n’ is 0, m’ is 1and n’’ is 5. In a particular embodiment, n’ is 0, m’ is 2 and n’’ is 5. In a particular embodiment, n’ 20is 0, m’ is 3 and n’’ is 5.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 5. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 5.In another embodiment, n’ is 2, m’ is 0 and n’’ is 5. In another embodiment, n’ is 2, m’ is 1 and n’’ 25is 5. In another embodiment, n’ is 2, m’ is 2 and n’’ is 5. In another embodiment, n’ is 2, m’ is 3and n’’ is 5.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 5. In yet another embodiment, n’ is 3, m’ is and n’’ is 5. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 5. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 5. 30In yet a further embodiment, n’ is 4, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 4, m’ is and n" is 5. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 5.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 5, m’ isand n" is 5. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 5. In yet a further embodiment, 35n’ is 5, m’ is 3 and n" is 5.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer and 68having the general formula (XVI), wherein X is (CH2CH2O)mCH2CH2, where m is selected from 1to 4 and wherein X' is CH2(CH2) n", where n’’ is selected from 0 to 10. In an embodiment, m isselected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment, m is selected from 1 to 3and n’’ is selected from 0 to 5. In an embodiment, m is selected from 1 to 2 and n’’ is selectedfrom 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selected from 0 to 2. In a 5particular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’ is 0. In yetanother embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is 0. In aparticular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. In yetanother embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In aparticular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yet 10another embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In aparticular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yetanother embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In aparticular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yetanother embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In a 15particular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yetanother embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In aparticular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yetanother embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising a 20serotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XVI), wherein X is (CH2CH2O)mCH2CH2, where m is selected from 1to 4 and wherein X' is CH2O(CH 2) n’’CH2, where n’’ is selected from 0 to 10. In an embodiment, mis selected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment, m is selected from 1 toand n’’ is selected from 0 to 5. In an embodiment, m is selected from 1 to 2 and n’’ is selected 25from 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selected from 0 to 2. In aparticular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’ is 0. In yetanother embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is 0. In aparticular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. In yetanother embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In a 30particular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yetanother embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In aparticular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yetanother embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In aparticular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yet 35another embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In aparticular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yetanother embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In a 69particular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yetanother embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XVI), wherein X is (CH2CH2O)mCH2CH2, where m is selected from 1 5to 4 and wherein X' is CH2O(CH 2CH2O) m’(CH2) n’’CH2, where n’’ is selected from 0 to 10 and m’ isselected from 0 to 4.In an embodiment, m is selected from 1 to 3, m’ is selected from 0 to 4 and n’’ is selected from 0to 10. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 and n’’ is 10selected from 0 to 3. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, m is 1, m’ is 0 and n’’ is 0. In another embodiment, m is 1, m’ is 1 andn’’ is 0. In another embodiment, m is 1, m’ is 2 and n’’ is 0. In another embodiment, m is 1, m’ isand n’’ is 0. 15In another embodiment, m is 2, m’ is 0 and n’’ is 0. In another embodiment, m is 2, m’ is 1 and n’’is 0. In another embodiment, m is 2, m’ is 2 and n’’ is 0. In another embodiment, m is 2, m’ is 3and n’’ is 0.In yet another embodiment, m is 3, m’ is 0 and n’’ is 0. In yet another embodiment, m is 3, m’ is 1and n’’ is 0. In yet another embodiment, m is 3, m’ is 2 and n’’ is 0. In yet another embodiment, m 20is 3, m’ is 3 and n’’ is 0.In yet a further embodiment, m is 4, m’ is 0 and n" is 0. In yet a further embodiment, m is 4, m’ isand n" is 0. In yet a further embodiment, m is 4, m’ is 2 and n" is 0. In yet a further embodiment,m is 4, m’ is 3 and n" is 0.In a particular embodiment, m is 1, m’ is 0 and n’’ is 1. In a particular embodiment, m is 1, m’ is 1 25and n’’ is 1. In a particular embodiment, m is 1, m’ is 2 and n’’ is 1. In a particular embodiment, mis 1, m’ is 3 and n’’ is 1.In another embodiment, m is 2, m’ is 0 and n’’ is 1. In another embodiment, m is 2, m’ is 1 and n’’is 1. In another embodiment, m is 2, m’ is 2 and n’’ is 1. In another embodiment, m is 2, m’ is 3and n’’ is 1. 30In yet another embodiment, m is 3, m’ is 0 and n’’ is 1. In yet another embodiment, m is 3, m’ is 1and n’’ is 1. In yet another embodiment, m is 3, m’ is 2 and n’’ is 1. In yet another embodiment, mis 3, m’ is 3 and n’’ is 1.In yet a further embodiment, m is 4, m’ is 0 and n" is 1. In yet a further embodiment, m is 4, m’ isand n" is 1. In yet a further embodiment, m is 4, m’ is 2 and n" is 1. In yet a further embodiment, 35m is 4, m’ is 3 and n" is 1. 70In a particular embodiment, m is 1, m’ is 0 and n’’ is 2. In a particular embodiment, m is 1, m’ is 1and n’’ is 2. In a particular embodiment, m is 1, m’ is 2 and n’’ is 2. In a particular embodiment, mis 1, m’ is 3 and n’’ is 2.In another embodiment, m is 2, m’ is 0 and n’’ is 2. In another embodiment, m is 2, m’ is 1 and n’’is 2. In another embodiment, m is 2, m’ is 2 and n’’ is 2. In another embodiment, m is 2, m’ is 3 5and n’’ is 2.In yet another embodiment, m is 3, m’ is 0 and n’’ is 2. In yet another embodiment, m is 3, m’ is 1and n’’ is 2. In yet another embodiment, m is 3, m’ is 2 and n’’ is 2. In yet another embodiment, mis 3, m’ is 3 and n’’ is 2.In yet a further embodiment, m is 4, m’ is 0 and n" is 2. In yet a further embodiment, m is 4, m’ is 10and n" is 2. In yet a further embodiment, m is 4, m’ is 2 and n" is 2. In yet a further embodiment,m is 4, m’ is 3 and n" is 2.In a particular embodiment, m is 1, m’ is 0 and n’’ is 3. In a particular embodiment, m is 1, m’ is 1and n’’ is 3. In a particular embodiment, m is 1, m’ is 2 and n’’ is 3. In a particular embodiment, mis 1, m’ is 3 and n’’ is 3. 15In another embodiment, m is 2, m’ is 0 and n’’ is 3. In another embodiment, m is 2, m’ is 1 and n’’is 3. In another embodiment, m is 2, m’ is 2 and n’’ is 3. In another embodiment, m is 2, m’ is 3and n’’ is 3.In yet another embodiment, m is 3, m’ is 0 and n’’ is 3. In yet another embodiment, m is 3, m’ is 1and n’’ is 3. In yet another embodiment, m is 3, m’ is 2 and n’’ is 3. In yet another embodiment, m 20is 3, m’ is 3 and n’’ is 3.In yet a further embodiment, m is 4, m’ is 0 and n" is 3. In yet a further embodiment, m is 4, m’ isand n" is 3. In yet a further embodiment, m is 4, m’ is 2 and n" is 3. In yet a further embodiment,m is 4, m’ is 3 and n" is 3.In a particular embodiment, m is 1, m’ is 0 and n’’ is 4. In a particular embodiment, m is 1, m’ is 1 25and n’’ is 4. In a particular embodiment, m is 1, m’ is 2 and n’’ is 4. In a particular embodiment, mis 1, m’ is 3 and n’’ is 4.In another embodiment, m is 2, m’ is 0 and n’’ is 4. In another embodiment, m is 2, m’ is 1 and n’’is 4. In another embodiment, m is 2, m’ is 2 and n’’ is 4. In another embodiment, m is 2, m’ is 3and n’’ is 4. 30In yet another embodiment, m is 3, m’ is 0 and n’’ is 4. In yet another embodiment, m is 3, m’ is 1and n’’ is 4. In yet another embodiment, m is 3, m’ is 2 and n’’ is 4. In yet another embodiment, mis 3, m’ is 3 and n’’ is 4.In yet a further embodiment, m is 4, m’ is 0 and n" is 4. In yet a further embodiment, m is 4, m’ isand n" is 4. In yet a further embodiment, m is 4, m’ is 2 and n" is 4. In yet a further embodiment, 35m is 4, m’ is 3 and n" is 4. 71In a particular embodiment, m is 1, m’ is 0 and n’’ is 5. In a particular embodiment, m is 1, m’ is 1and n’’ is 5. In a particular embodiment, m is 1, m’ is 2 and n’’ is 5. In a particular embodiment, mis 1, m’ is 3 and n’’ is 5.In another embodiment, m is 2, m’ is 0 and n’’ is 5. In another embodiment, m is 2, m’ is 1 and n’’is 5. In another embodiment, m is 2, m’ is 2 and n’’ is 5. In another embodiment, m is 2, m’ is 3 5and n’’ is 5.In yet another embodiment, m is 3, m’ is 0 and n’’ is 5. In yet another embodiment, m is 3, m’ is 1and n’’ is 5. In yet another embodiment, m is 3, m’ is 2 and n’’ is 5. In yet another embodiment, mis 3, m’ is 3 and n’’ is 5.In yet a further embodiment, m is 4, m’ is 0 and n" is 5. In yet a further embodiment, m is 4, m’ is 10and n" is 5. In yet a further embodiment, m is 4, m’ is 2 and n" is 5. In yet a further embodiment,m is 4, m’ is 3 and n" is 5.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XVI), wherein X is NHCO(CH2) n’, where n’ is selected from 1 to 10 15and wherein X' is CH2(CH2) n", where n’’ is selected from 0 to 10. In an embodiment, n’ is selectedfrom 1 to 5 and n’’ is selected from 0 to 10. In an embodiment, n’ is selected from 1 to 5 and n’’ isselected from 0 to 5. In an embodiment, n’ is selected from 1 to 3 and n’’ is selected from 0 to 3.In an embodiment, n’ is selected from 1 to 2 and n’’ is selected from 0 to 2. In a particularembodiment, n’ is 1 and n’’ is 0. In another embodiment, n’ is 2 and n’’ is 0. In yet another 20embodiment, n’ is 3 and n’’ is 0. In yet a further embodiment, n’ is 4 and n" is 0. In yet a furtherembodiment, n’ is 5 and n" is 0. In yet a further embodiment, n’ is 6 and n" is 0. In a particularembodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yet anotherembodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet a furtherembodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In a particular 25embodiment, n’ is 1 and n’’ is 2. In another embodiment, n’ is 2 and n’’ is 2. In yet anotherembodiment, n’ is 3 and n’’ is 2. In yet a further embodiment, n’ is 4 and n" is 2. In yet a furtherembodiment, n’ is 5 and n" is 2. In yet a further embodiment, n’ is 6 and n" is 2. In a particularembodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yet anotherembodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet a further 30embodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In a particularembodiment, n’ is 1 and n’’ is 4. In another embodiment, n’ is 2 and n’’ is 4. In yet anotherembodiment, n’ is 3 and n’’ is 4. In yet a further embodiment, n’ is 4 and n" is 4. In yet a furtherembodiment, n’ is 5 and n" is 4. In yet a further embodiment, n’ is 6 and n" is 4. In a particularembodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yet another 35embodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet a furtherembodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In a particularembodiment, n’ is 1 and n’’ is 6. In another embodiment, n’ is 2 and n’’ is 6. In yet another 72embodiment, n’ is 3 and n’’ is 6. In yet a further embodiment, n’ is 4 and n" is 6. In yet a furtherembodiment, n’ is 5 and n" is 6. In yet a further embodiment, n’ is 6 and n" is 6.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XVI), wherein X is NHCO(CH2) n’, where n’ is selected from 1 to 10 5and wherein X' is CH2O(CH 2) n’’CH2, where n’’ is selected from 0 to 10. In an embodiment, n’ isselected from 1 to 5 and n’’ is selected from 0 to 10. In an embodiment, n’ is selected from 1 to 5and n’’ is selected from 0 to 5. In an embodiment, n’ is selected from 1 to 3 and n’’ is selectedfrom 0 to 3. In an embodiment, n’ is selected from 1 to 2 and n’’ is selected from 0 to 2. In aparticular embodiment, n’ is 1 and n’’ is 0. In another embodiment, n’ is 2 and n’’ is 0. In yet 10another embodiment, n’ is 3 and n’’ is 0. In yet a further embodiment, n’ is 4 and n" is 0. In yet afurther embodiment, n’ is 5 and n" is 0. In yet a further embodiment, n’ is 6 and n" is 0. In aparticular embodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yetanother embodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet afurther embodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In a 15particular embodiment, n’ is 1 and n’’ is 2. In another embodiment, n’ is 2 and n’’ is 2. In yetanother embodiment, n’ is 3 and n’’ is 2. In yet a further embodiment, n’ is 4 and n" is 2. In yet afurther embodiment, n’ is 5 and n" is 2. In yet a further embodiment, n’ is 6 and n" is 2. In aparticular embodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yetanother embodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet a 20further embodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In aparticular embodiment, n’ is 1 and n’’ is 4. In another embodiment, n’ is 2 and n’’ is 4. In yetanother embodiment, n’ is 3 and n’’ is 4. In yet a further embodiment, n’ is 4 and n" is 4. In yet afurther embodiment, n’ is 5 and n" is 4. In yet a further embodiment, n’ is 6 and n" is 4. In aparticular embodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yet 25another embodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet afurther embodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In aparticular embodiment, n’ is 1 and n’’ is 6. In another embodiment, n’ is 2 and n’’ is 6. In yetanother embodiment, n’ is 3 and n’’ is 6. In yet a further embodiment, n’ is 4 and n" is 6. In yet afurther embodiment, n’ is 5 and n" is 6. In yet a further embodiment, n’ is 6 and n" is 6. 30In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XVI), wherein X is NHCO(CH2) n’, where n’ is selected from 1 to 10and wherein X' is CH2O(CH 2CH2O) m’(CH2)n’’CH2, where n’’ is selected from 0 to 10 and m’ isselected from 0 to 4. 35In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selected from 0to 10. In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, n’ is selected from 1 to 3, m’ is selected from 0 to 2 and n’’ is 73selected from 0 to 3. In an embodiment, n’ is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 0. In another embodiment, n’ is 1, m’ is 1 andn’’ is 0. In another embodiment, n’ is 1, m’ is 2 and n’’ is 0. In another embodiment, n’ is 1, m’ is 3and n’’ is 0. 5In another embodiment, n’ is 2, m’ is 0 and n’’ is 0. In another embodiment, n’ is 2, m’ is 1 and n’’is 0. In another embodiment, n’ is 2, m’ is 2 and n’’ is 0. In another embodiment, n’ is 2, m’ is 3and n’’ is 0.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 0. In yet another embodiment, n’ 10is 3, m’ is 3 and n’’ is 0.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 4, m’ isand n" is 0. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 0.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 5, m’ is 15and n" is 0.In yet a further embodiment, n’ is 5, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 0.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 1. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 1. 20In another embodiment, n’ is 2, m’ is 0 and n’’ is 1. In another embodiment, n’ is 2, m’ is 1 and n’’is 1. In another embodiment, n’ is 2, m’ is 2 and n’’ is 1. In another embodiment, n’ is 2, m’ is 3and n’’ is 1.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 1. In yet another embodiment, n’ 25is 3, m’ is 3 and n’’ is 1.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 4, m’ isand n" is 1. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 1.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 5, m’ is 30and n" is 1. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 2. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 2. 35In another embodiment, n’ is 2, m’ is 0 and n’’ is 2. In another embodiment, n’ is 2, m’ is 1 and n’’is 2. In another embodiment, n’ is 2, m’ is 2 and n’’ is 2. In another embodiment, n’ is 2, m’ is 3and n’’ is 2. 74In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 2. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 2.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 4, m’ isand n" is 2. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 2. In yet a further embodiment, 5n’ is 4, m’ is 3 and n" is 2.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 5, m’ isand n" is 2. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 2. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 2.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 1 10and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 3. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 3.In another embodiment, n’ is 2, m’ is 0 and n’’ is 3. In another embodiment, n’ is 2, m’ is 1 and n’’is 3. In another embodiment, n’ is 2, m’ is 2 and n’’ is 3. In another embodiment, n’ is 2, m’ is 3and n’’ is 3. 15In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 3. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 3.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 4, m’ isand n" is 3. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 3. In yet a further embodiment, 20n’ is 4, m’ is 3 and n" is 3.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 5, m’ is and n" is 3. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 3. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 3.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 1 25and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 4. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 4.In another embodiment, n’ is 2, m’ is 0 and n’’ is 4. In another embodiment, n’ is 2, m’ is 1 andn’’ is 4. In another embodiment, n’ is 2, m’ is 2 and n’’ is 4. In another embodiment, n’ is 2, m’ is and n’’ is 4. 30In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 4. In yet another embodiment, n’ is 3, m’ is and n’’ is 4. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 4. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 4, m’ is and n" is 4. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 4. In yet a further embodiment, 35n’ is 4, m’ is 3 and n" is 4. 75In yet a further embodiment, n’ is 5, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 5, m’ is and n" is 4. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 4.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 5. In a particular embodiment, n’ 5is 1, m’ is 3 and n’’ is 5.In another embodiment, n’ is 2, m’ is 0 and n’’ is 5. In another embodiment, n’ is 2, m’ is 1 andn’’ is 5. In another embodiment, n’ is 2, m’ is 2 and n’’ is 5. In another embodiment, n’ is 2, m’ is and n’’ is 5.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 5. In yet another embodiment, n’ is 3, m’ is 10 and n’’ is 5. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 5. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 5.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 4, m’ is and n" is 5. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 5. 15In yet a further embodiment, n’ is 5, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 5, m’ is and n" is 5. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 5.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer and 20having the general formula (XVI), wherein X is NHCO(CH 2CH2O)mCH 2CH2, where m is selectedfrom 1 to 4 and wherein X' is CH2(CH2) n", where n’’ is selected from 0 to 10. In an embodiment, mis selected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment, m is selected from 1 toand n’’ is selected from 0 to 5. In an embodiment, m is selected from 1 to 2 and n’’ is selectedfrom 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selected from 0 to 2. In a 25particular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’ is 0. In yetanother embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is 0. In aparticular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. In yetanother embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In aparticular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yet 30another embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In aparticular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yetanother embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In aparticular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yetanother embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In a 35particular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yetanother embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In a 76particular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yetanother embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XVI), wherein X is NHCO(CH 2CH2O)mCH 2CH2, where m is selected 5from 1 to 4 and wherein X' is CH2O(CH 2) n’’CH 2, where n’’ is selected from 0 to 10. In anembodiment, m is selected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment, m isselected from 1 to 3 and n’’ is selected from 0 to 5. In an embodiment, m is selected from 1 to 2and n’’ is selected from 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selectedfrom 0 to 2. In a particular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’ 10is 0. In yet another embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is0. In a particular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. Inyet another embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In aparticular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yetanother embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In a 15particular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yetanother embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In aparticular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yetanother embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In aparticular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yet 20another embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In aparticular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yetanother embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer and 25having the general formula (XVI), wherein X is NHCO(CH 2CH2O)mCH 2CH2, where m is selectedfrom 1 to 4 and wherein X' is CH2O(CH 2CH2O) m’(CH2)n’’CH2, where n’’ is selected from 0 to 10and m’ is selected from 0 to 4.In an embodiment, m is selected from 1 to 3, m’ is selected from 0 to 4 and n’’ is selected from 0to 10. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 4 and n’’ is selected 30from 0 to 5. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 and n’’ isselected from 0 to 3. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, m is 1, m’ is 0 and n’’ is 0. In another embodiment, m is 1, m’ is 1 andn’’ is 0. In another embodiment, m is 1, m’ is 2 and n’’ is 0. In another embodiment, m is 1, m’ is 35and n’’ is 0. 77In another embodiment, m is 2, m’ is 0 and n’’ is 0. In another embodiment, m is 2, m’ is 1 and n’’is 0. In another embodiment, m is 2, m’ is 2 and n’’ is 0. In another embodiment, m is 2, m’ is 3and n’’ is 0.In yet another embodiment, m is 3, m’ is 0 and n’’ is 0. In yet another embodiment, m is 3, m’ is 1and n’’ is 0. In yet another embodiment, m is 3, m’ is 2 and n’’ is 0. In yet another embodiment, m 5is 3, m’ is 3 and n’’ is 0.In yet a further embodiment, m is 4, m’ is 0 and n" is 0. In yet a further embodiment, m is 4, m’ isand n" is 0. In yet a further embodiment, m is 4, m’ is 2 and n" is 0. In yet a further embodiment,m is 4, m’ is 3 and n" is 0.In a particular embodiment, m is 1, m’ is 0 and n’’ is 1. In a particular embodiment, m is 1, m’ is 1 10and n’’ is 1. In a particular embodiment, m is 1, m’ is 2 and n’’ is 1. In a particular embodiment, mis 1, m’ is 3 and n’’ is 1.In another embodiment, m is 2, m’ is 0 and n’’ is 1. In another embodiment, m is 2, m’ is 1 and n’’is 1. In another embodiment, m is 2, m’ is 2 and n’’ is 1. In another embodiment, m is 2, m’ is 3and n’’ is 1. 15In yet another embodiment, m is 3, m’ is 0 and n’’ is 1. In yet another embodiment, m is 3, m’ is 1and n’’ is 1. In yet another embodiment, m is 3, m’ is 2 and n’’ is 1. In yet another embodiment, mis 3, m’ is 3 and n’’ is 1.In yet a further embodiment, m is 4, m’ is 0 and n" is 1. In yet a further embodiment, m is 4, m’ isand n" is 1. In yet a further embodiment, m is 4, m’ is 2 and n" is 1. In yet a further embodiment, 20m is 4, m’ is 3 and n" is 1.In a particular embodiment, m is 1, m’ is 0 and n’’ is 2. In a particular embodiment, m is 1, m’ is 1and n’’ is 2. In a particular embodiment, m is 1, m’ is 2 and n’’ is 2. In a particular embodiment, mis 1, m’ is 3 and n’’ is 2.In another embodiment, m is 2, m’ is 0 and n’’ is 2. In another embodiment, m is 2, m’ is 1 and n’’ 25is 2. In another embodiment, m is 2, m’ is 2 and n’’ is 2. In another embodiment, m is 2, m’ is 3and n’’ is 2.In yet another embodiment, m is 3, m’ is 0 and n’’ is 2. In yet another embodiment, m is 3, m’ is 1and n’’ is 2. In yet another embodiment, m is 3, m’ is 2 and n’’ is 2. In yet another embodiment, mis 3, m’ is 3 and n’’ is 2. 30In yet a further embodiment, m is 4, m’ is 0 and n" is 2. In yet a further embodiment, m is 4, m’ isand n" is 2. In yet a further embodiment, m is 4, m’ is 2 and n" is 2. In yet a further embodiment,m is 4, m’ is 3 and n" is 2.In a particular embodiment, m is 1, m’ is 0 and n’’ is 3. In a particular embodiment, m is 1, m’ is 1and n’’ is 3. In a particular embodiment, m is 1, m’ is 2 and n’’ is 3. In a particular embodiment, m 35is 1, m’ is 3 and n’’ is 3. 78In another embodiment, m is 2, m’ is 0 and n’’ is 3. In another embodiment, m is 2, m’ is 1 and n’’is 3. In another embodiment, m is 2, m’ is 2 and n’’ is 3. In another embodiment, m is 2, m’ is 3and n’’ is 3.In yet another embodiment, m is 3, m’ is 0 and n’’ is 3. In yet another embodiment, m is 3, m’ is 1and n’’ is 3. In yet another embodiment, m is 3, m’ is 2 and n’’ is 3. In yet another embodiment, m 5is 3, m’ is 3 and n’’ is 3.In yet a further embodiment, m is 4, m’ is 0 and n" is 3. In yet a further embodiment, m is 4, m’ isand n" is 3. In yet a further embodiment, m is 4, m’ is 2 and n" is 3. In yet a further embodiment,m is 4, m’ is 3 and n" is 3.In a particular embodiment, m is 1, m’ is 0 and n’’ is 4. In a particular embodiment, m is 1, m’ is 10 and n’’ is 4. In a particular embodiment, m is 1, m’ is 2 and n’’ is 4. In a particular embodiment,m is 1, m’ is 3 and n’’ is 4.In another embodiment, m is 2, m’ is 0 and n’’ is 4. In another embodiment, m is 2, m’ is 1 andn’’ is 4. In another embodiment, m is 2, m’ is 2 and n’’ is 4. In another embodiment, m is 2, m’ isand n’’ is 4. 15In yet another embodiment, m is 3, m’ is 0 and n’’ is 4. In yet another embodiment, m is 3, m’ is and n’’ is 4. In yet another embodiment, m is 3, m’ is 2 and n’’ is 4. In yet another embodiment,m is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, m is 4, m’ is 0 and n" is 4. In yet a further embodiment, m is 4, m’ is and n" is 4. In yet a further embodiment, m is 4, m’ is 2 and n" is 4. In yet a further embodiment, 20m is 4, m’ is 3 and n" is 4.In a particular embodiment, m is 1, m’ is 0 and n’’ is 5. In a particular embodiment, m is 1, m’ is and n’’ is 5. In a particular embodiment, m is 1, m’ is 2 and n’’ is 5. In a particular embodiment,m is 1, m’ is 3 and n’’ is 5.In another embodiment, m is 2, m’ is 0 and n’’ is 5. In another embodiment, m is 2, m’ is 1 and 25n’’ is 5. In another embodiment, m is 2, m’ is 2 and n’’ is 5. In another embodiment, m is 2, m’ is and n’’ is 5.In yet another embodiment, m is 3, m’ is 0 and n’’ is 5. In yet another embodiment, m is 3, m’ is and n’’ is 5. In yet another embodiment, m is 3, m’ is 2 and n’’ is 5. In yet another embodiment,m is 3, m’ is 3 and n’’ is 5. 30In yet a further embodiment, m is 4, m’ is 0 and n" is 5. In yet a further embodiment, m is 4, m’ is and n" is 5. In yet a further embodiment, m is 4, m’ is 2 and n" is 5. In yet a further embodiment,m is 4, m’ is 3 and n" is 5.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer and 35having the general formula (XVI), wherein X is OCH2(CH2)n’, where n’ is selected from 1 to 10 andwherein X' is CH2(CH2) n", where n’’ is selected from 0 to 10. 79In an embodiment, n’ is selected from 1 to 5 and n’’ is selected from 0 to 10. In an embodiment,n’ is selected from 1 to 5 and n’’ is selected from 0 to 5. In an embodiment, n’ is selected from 1to 3 and n’’ is selected from 0 to 3. In an embodiment, n’ is selected from 1 to 2 and n’’ is selectedfrom 0 to 2. In a particular embodiment, n’ is 1 and n’’ is 0. In another embodiment, n’ is 2 and n’’is 0. In yet another embodiment, n’ is 3 and n’’ is 0. In yet a further embodiment, n’ is 4 and n" is 50. In yet a further embodiment, n’ is 5 and n" is 0. In yet a further embodiment, n’ is 6 and n" is 0.In a particular embodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yetanother embodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet afurther embodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In aparticular embodiment, n’ is 1 and n’’ is 2. In another embodiment, n’ is 2 and n’’ is 2. In yet 10another embodiment, n’ is 3 and n’’ is 2. In yet a further embodiment, n’ is 4 and n" is 2. In yet afurther embodiment, n’ is 5 and n" is 2. In yet a further embodiment, n’ is 6 and n" is 2. In aparticular embodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yetanother embodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet afurther embodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In a 15particular embodiment, n’ is 1 and n’’ is 4. In another embodiment, n’ is 2 and n’’ is 4. In yetanother embodiment, n’ is 3 and n’’ is 4. In yet a further embodiment, n’ is 4 and n" is 4. In yet afurther embodiment, n’ is 5 and n" is 4. In yet a further embodiment, n’ is 6 and n" is 4. In aparticular embodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yetanother embodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet a 20further embodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In aparticular embodiment, n’ is 1 and n’’ is 6. In another embodiment, n’ is 2 and n’’ is 6. In yetanother embodiment, n’ is 3 and n’’ is 6. In yet a further embodiment, n’ is 4 and n" is 6. In yet afurther embodiment, n’ is 5 and n" is 6. In yet a further embodiment, n’ is 6 and n" is 6.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising a 25serotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XVI), wherein X is OCH2(CH2)n’, where n’ is selected from 1 to 10 andwherein X' is CH2O(CH 2) n’’CH 2, where n’’ is selected from 0 to 10.In an embodiment, n’ is selected from 1 to 5 and n’’ is selected from 0 to 10. In an embodiment,n’ is selected from 1 to 5 and n’’ is selected from 0 to 5. In an embodiment, n’ is selected from 1 30to 3 and n’’ is selected from 0 to 3. In an embodiment, n’ is selected from 1 to 2 and n’’ is selectedfrom 0 to 2. In a particular embodiment, n’ is 1 and n’’ is 0. In another embodiment, n’ is 2 and n’’is 0. In yet another embodiment, n’ is 3 and n’’ is 0. In yet a further embodiment, n’ is 4 and n" is0. In yet a further embodiment, n’ is 5 and n" is 0. In yet a further embodiment, n’ is 6 and n" is 0.In a particular embodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yet 35another embodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet afurther embodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In aparticular embodiment, n’ is 1 and n’’ is 2. In another embodiment, n’ is 2 and n’’ is 2. In yet 80another embodiment, n’ is 3 and n’’ is 2. In yet a further embodiment, n’ is 4 and n" is 2. In yet afurther embodiment, n’ is 5 and n" is 2. In yet a further embodiment, n’ is 6 and n" is 2. In aparticular embodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yetanother embodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet afurther embodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In a 5particular embodiment, n’ is 1 and n’’ is 4. In another embodiment, n’ is 2 and n’’ is 4. In yetanother embodiment, n’ is 3 and n’’ is 4. In yet a further embodiment, n’ is 4 and n" is 4. In yet afurther embodiment, n’ is 5 and n" is 4. In yet a further embodiment, n’ is 6 and n" is 4. In aparticular embodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yetanother embodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet a 10further embodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In aparticular embodiment, n’ is 1 and n’’ is 6. In another embodiment, n’ is 2 and n’’ is 6. In yetanother embodiment, n’ is 3 and n’’ is 6. In yet a further embodiment, n’ is 4 and n" is 6. In yet afurther embodiment, n’ is 5 and n" is 6. In yet a further embodiment, n’ is 6 and n" is 6.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising a 15serotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XVI), wherein X is OCH2(CH2)n’, where n’ is selected from 1 to 10 andwherein X' is CH2O(CH 2CH2O) m’(CH2)n’’CH2, where n’’ is selected from 0 to 10 and m’ is selectedfrom 0 to 4.In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selected from 0 20to 10. In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, n’ is selected from 1 to 3, m’ is selected from 0 to 2 and n’’ isselected from 0 to 3. In an embodiment, n’ is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 0. In another embodiment, n’ is 1, m’ is 1 and 25n’’ is 0. In another embodiment, n’ is 1, m’ is 2 and n’’ is 0. In another embodiment, n’ is 1, m’ is 3and n’’ is 0.In another embodiment, n’ is 2, m’ is 0 and n’’ is 0. In another embodiment, n’ is 2, m’ is 1 and n’’is 0. In another embodiment, n’ is 2, m’ is 2 and n’’ is 0. In another embodiment, n’ is 2, m’ is 3and n’’ is 0. 30In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 0. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 0.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 4, m’ isand n" is 0. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 0. In yet a further embodiment, 35n’ is 4, m’ is 3 and n" is 0. 81In yet a further embodiment, n’ is 5, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 5, m’ isand n" is 0.In yet a further embodiment, n’ is 5, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 0.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 1. In a particular embodiment, n’ 5is 1, m’ is 3 and n’’ is 1.In another embodiment, n’ is 2, m’ is 0 and n’’ is 1. In another embodiment, n’ is 2, m’ is 1 and n’’is 1. In another embodiment, n’ is 2, m’ is 2 and n’’ is 1. In another embodiment, n’ is 2, m’ is 3and n’’ is 1.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 1 10and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 1. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 1.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 4, m’ isand n" is 1. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 1. 15In yet a further embodiment, n’ is 5, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 5, m’ isand n" is 1. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 2. In a particular embodiment, n’ 20is 1, m’ is 3 and n’’ is 2.In another embodiment, n’ is 2, m’ is 0 and n’’ is 2. In another embodiment, n’ is 2, m’ is 1 and n’’is 2. In another embodiment, n’ is 2, m’ is 2 and n’’ is 2. In another embodiment, n’ is 2, m’ is 3and n’’ is 2.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 1 25and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 2. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 2.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 4, m’ isand n" is 2. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 2. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 2. 30In yet a further embodiment, n’ is 5, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 5, m’ isand n" is 2. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 2. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 2.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 3. In a particular embodiment, n’ 35is 1, m’ is 3 and n’’ is 3. 82In another embodiment, n’ is 2, m’ is 0 and n’’ is 3. In another embodiment, n’ is 2, m’ is 1 and n’’is 3. In another embodiment, n’ is 2, m’ is 2 and n’’ is 3. In another embodiment, n’ is 2, m’ is 3and n’’ is 3.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 3. In yet another embodiment, n’ 5is 3, m’ is 3 and n’’ is 3.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 4, m’ isand n" is 3. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 3. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 3.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 5, m’ is 10 and n" is 3. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 3. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 3.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 4. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 4. 15In another embodiment, n’ is 2, m’ is 0 and n’’ is 4. In another embodiment, n’ is 2, m’ is 1 andn’’ is 4. In another embodiment, n’ is 2, m’ is 2 and n’’ is 4. In another embodiment, n’ is 2, m’ is and n’’ is 4.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 4. In yet another embodiment, n’ is 3, m’ is and n’’ is 4. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 4. In yet another embodiment, 20n’ is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 4, m’ is and n" is 4. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 4.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 5, m’ is 25 and n" is 4. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 4.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 5. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 5. 30In another embodiment, n’ is 2, m’ is 0 and n’’ is 5. In another embodiment, n’ is 2, m’ is 1 andn’’ is 5. In another embodiment, n’ is 2, m’ is 2 and n’’ is 5. In another embodiment, n’ is 2, m’ is and n’’ is 5.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 5. In yet another embodiment, n’ is 3, m’ is and n’’ is 5. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 5. In yet another embodiment, 35n’ is 3, m’ is 3 and n’’ is 5. 83In yet a further embodiment, n’ is 4, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 4, m’ is and n" is 5. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 5.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 5, m’ is and n" is 5. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 5. In yet a further embodiment, 5n’ is 5, m’ is 3 and n" is 5.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XVI), wherein X is O(CH2CH2O)mCH2CH2, where m is selected fromto 4 and wherein X' is CH2(CH2) n", where n’’ is selected from 0 to 10. 10In an embodiment, m is selected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment,m is selected from 1 to 3 and n’’ is selected from 0 to 5. In an embodiment, m is selected from 1to 2 and n’’ is selected from 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selectedfrom 0 to 2. In a particular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’is 0. In yet another embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is 150. In a particular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. Inyet another embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In aparticular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yetanother embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In aparticular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yet 20another embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In aparticular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yetanother embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In aparticular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yetanother embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In a 25particular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yetanother embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6.In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XVI), wherein X is O(CH2CH2O)mCH2CH2, where m is selected from 30to 4 and wherein X' is CH2O(CH 2) n’’CH2, where n’’ is selected from 0 to 10.In an embodiment, m is selected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment,m is selected from 1 to 3 and n’’ is selected from 0 to 5. In an embodiment, m is selected from 1to 2 and n’’ is selected from 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selectedfrom 0 to 2. In a particular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’ 35is 0. In yet another embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is0. In a particular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. Inyet another embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In a 84particular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yetanother embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In aparticular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yetanother embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In aparticular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yet 5another embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In aparticular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yetanother embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In aparticular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yetanother embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6. 10In an embodiment, the invention provides a serotype 21 glycoconjugate comprising aserotype 21 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XVI), wherein X is O(CH2CH2O)mCH2CH2, where m is selected fromto 4 and wherein X' is CH2O(CH 2CH2O) m’(CH 2)n’’CH2, where n’’ is selected from 0 to 10 and m’is selected from 0 to 4. 15In an embodiment, m is selected from 1 to 3, m’ is selected from 0 to 4 and n’’ is selected from 0to 10. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 and n’’ isselected from 0 to 3. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1. 20In a particular embodiment, m is 1, m’ is 0 and n’’ is 0. In another embodiment, m is 1, m’ is 1 andn’’ is 0. In another embodiment, m is 1, m’ is 2 and n’’ is 0. In another embodiment, m is 1, m’ isand n’’ is 0.In another embodiment, m is 2, m’ is 0 and n’’ is 0. In another embodiment, m is 2, m’ is 1 and n’’is 0. In another embodiment, m is 2, m’ is 2 and n’’ is 0. In another embodiment, m is 2, m’ is 3 25and n’’ is 0.In yet another embodiment, m is 3, m’ is 0 and n’’ is 0. In yet another embodiment, m is 3, m’ is 1and n’’ is 0. In yet another embodiment, m is 3, m’ is 2 and n’’ is 0. In yet another embodiment, mis 3, m’ is 3 and n’’ is 0.In yet a further embodiment, m is 4, m’ is 0 and n" is 0. In yet a further embodiment, m is 4, m’ is 30and n" is 0. In yet a further embodiment, m is 4, m’ is 2 and n" is 0. In yet a further embodiment,m is 4, m’ is 3 and n" is 0.In a particular embodiment, m is 1, m’ is 0 and n’’ is 1. In a particular embodiment, m is 1, m’ is 1and n’’ is 1. In a particular embodiment, m is 1, m’ is 2 and n’’ is 1. In a particular embodiment, mis 1, m’ is 3 and n’’ is 1. 35In another embodiment, m is 2, m’ is 0 and n’’ is 1. In another embodiment, m is 2, m’ is 1 and n’’is 1. In another embodiment, m is 2, m’ is 2 and n’’ is 1. In another embodiment, m is 2, m’ is 3and n’’ is 1. 85In yet another embodiment, m is 3, m’ is 0 and n’’ is 1. In yet another embodiment, m is 3, m’ is 1and n’’ is 1. In yet another embodiment, m is 3, m’ is 2 and n’’ is 1. In yet another embodiment, mis 3, m’ is 3 and n’’ is 1.In yet a further embodiment, m is 4, m’ is 0 and n" is 1. In yet a further embodiment, m is 4, m’ isand n" is 1. In yet a further embodiment, m is 4, m’ is 2 and n" is 1. In yet a further embodiment, 5m is 4, m’ is 3 and n" is 1.In a particular embodiment, m is 1, m’ is 0 and n’’ is 2. In a particular embodiment, m is 1, m’ is 1and n’’ is 2. In a particular embodiment, m is 1, m’ is 2 and n’’ is 2. In a particular embodiment, mis 1, m’ is 3 and n’’ is 2.In another embodiment, m is 2, m’ is 0 and n’’ is 2. In another embodiment, m is 2, m’ is 1 and n’’ 10is 2. In another embodiment, m is 2, m’ is 2 and n’’ is 2. In another embodiment, m is 2, m’ is 3and n’’ is 2.In yet another embodiment, m is 3, m’ is 0 and n’’ is 2. In yet another embodiment, m is 3, m’ is 1and n’’ is 2. In yet another embodiment, m is 3, m’ is 2 and n’’ is 2. In yet another embodiment, mis 3, m’ is 3 and n’’ is 2. 15In yet a further embodiment, m is 4, m’ is 0 and n" is 2. In yet a further embodiment, m is 4, m’ isand n" is 2. In yet a further embodiment, m is 4, m’ is 2 and n" is 2. In yet a further embodiment,m is 4, m’ is 3 and n" is 2.In a particular embodiment, m is 1, m’ is 0 and n’’ is 3. In a particular embodiment, m is 1, m’ is 1and n’’ is 3. In a particular embodiment, m is 1, m’ is 2 and n’’ is 3. In a particular embodiment, m 20is 1, m’ is 3 and n’’ is 3.In another embodiment, m is 2, m’ is 0 and n’’ is 3. In another embodiment, m is 2, m’ is 1 and n’’is 3. In another embodiment, m is 2, m’ is 2 and n’’ is 3. In another embodiment, m is 2, m’ is 3and n’’ is 3.In yet another embodiment, m is 3, m’ is 0 and n’’ is 3. In yet another embodiment, m is 3, m’ is 1 25and n’’ is 3. In yet another embodiment, m is 3, m’ is 2 and n’’ is 3. In yet another embodiment, mis 3, m’ is 3 and n’’ is 3.In yet a further embodiment, m is 4, m’ is 0 and n" is 3. In yet a further embodiment, m is 4, m’ isand n" is 3. In yet a further embodiment, m is 4, m’ is 2 and n" is 3. In yet a further embodiment,m is 4, m’ is 3 and n" is 3. 30In a particular embodiment, m is 1, m’ is 0 and n’’ is 4. In a particular embodiment, m is 1, m’ is and n’’ is 4. In a particular embodiment, m is 1, m’ is 2 and n’’ is 4. In a particular embodiment,m is 1, m’ is 3 and n’’ is 4.In another embodiment, m is 2, m’ is 0 and n’’ is 4. In another embodiment, m is 2, m’ is 1 andn’’ is 4. In another embodiment, m is 2, m’ is 2 and n’’ is 4. In another embodiment, m is 2, m’ is 35and n’’ is 4. 86In yet another embodiment, m is 3, m’ is 0 and n’’ is 4. In yet another embodiment, m is 3, m’ is and n’’ is 4. In yet another embodiment, m is 3, m’ is 2 and n’’ is 4. In yet another embodiment,m is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, m is 4, m’ is 0 and n" is 4. In yet a further embodiment, m is 4, m’ is and n" is 4. In yet a further embodiment, m is 4, m’ is 2 and n" is 4. In yet a further embodiment, 5m is 4, m’ is 3 and n" is 4.In a particular embodiment, m is 1, m’ is 0 and n’’ is 5. In a particular embodiment, m is 1, m’ is and n’’ is 5. In a particular embodiment, m is 1, m’ is 2 and n’’ is 5. In a particular embodiment,m is 1, m’ is 3 and n’’ is 5.In another embodiment, m is 2, m’ is 0 and n’’ is 5. In another embodiment, m is 2, m’ is 1 and 10n’’ is 5. In another embodiment, m is 2, m’ is 2 and n’’ is 5. In another embodiment, m is 2, m’ is and n’’ is 5.In yet another embodiment, m is 3, m’ is 0 and n’’ is 5. In yet another embodiment, m is 3, m’ is and n’’ is 5. In yet another embodiment, m is 3, m’ is 2 and n’’ is 5. In yet another embodiment,m is 3, m’ is 3 and n’’ is 5. 15In yet a further embodiment, m is 4, m’ is 0 and n" is 5. In yet a further embodiment, m is 4, m’ is and n" is 5. In yet a further embodiment, m is 4, m’ is 2 and n" is 5. In yet a further embodiment,m is 4, m’ is 3 and n" is 5.In an embodiment of the present invention, the serotype 21 glycoconjugate of the presentinvention are prepared using the alternative click chemistry of the present section. The invention 20also relates to a method of making serotype 21 glycoconjugate, as disclosed herein above.In an embodiment, click chemistry may comprise three steps, (a) reacting an isolatedserotype 21 saccharide with a carbonic acid derivative and an alkyne linker in an aprotic solventto produce an activated alkynyl saccharide (activation of the saccharide), (b) reacting a carrierprotein with an agent bearing an N-Hydroxysuccinimide (NHS) moiety and an azido group where 25the NHS moiety reacts with the amino groups to form an amide linkage thereby obtaining an azidofunctionalized carrier protein (activation of the carrier protein), (c) reacting the activated alkynylsaccharide of step (a) with the activated azido-carrier protein of step (b) by Cu+1 mediated azide-alkyne cycloaddition reaction to form a glycoconjugate.Following step (a) the saccharide is said to be activated and is referred to herein as 30"activated saccharide" or "activated alkynyl saccharide".Following step (b) the carrier is said to be activated and is referred to as "activated carrier"or "activated azido-carrier".As mentioned above, before the activation (a), sizing of the serotype 21 saccharide to atarget molecular weight (MW) range may be performed. Therefore, in an embodiment, the isolated 35serotype 21 saccharide is sized before activation with a carbonic acid derivative and an alkynelinker. In an embodiment, the isolated serotype 21 saccharide is sized to any of the target 87molecular weight (MW) range defined above. In an embodiment, the isolated serotype 21saccharide is not sized before activation with a carbonic acid derivative and an alkyne linker.In an embodiment, said carbonic acid derivative is selected from the group consisting of1,1’-carbonyldiimidazole (CDI), 1,1’-carbonyl-di-(1,2,4-triazole) (CDT), disuccinimidyl carbonate(DSC) and N-hydroxysuccinimidyl chloroformate. 5In an embodiment, said carbonic acid derivative is 1,1’-carbonyldiimidazole (CDI). Inanother embodiment, said carbonic acid derivative is 1,1'-Carbonyl-di-(1,2,4-triazole) (CDT). Inanother embodiment, said carbonic acid derivative is disuccinimidyl carbonate (DSC). In yet afurther embodiment, said carbonic acid derivative is N-hydroxysuccinimidyl chloroformate.In an embodiment, said carbonic acid derivative is 1,1’-carbonyldiimidazole (CDI) or 1,1'- 10Carbonyl-di-(1,2,4-triazole) (CDT). In an embodiment, said carbonic acid derivative is 1,1’-carbonyldiimidazole (CDI). In an embodiment, said carbonic acid derivative is 1,1'-Carbonyl-di-(1,2,4-triazole) (CDT). Preferably, said carbonic acid derivative N,N′-Disuccinimidyl carbonate(DSC).In an embodiment, said alkyne linker is a compound of formula (XVIII), 15 (XVIII),wherein X is selected from the group consisting of CH2, CH2(CH2)n, (CH2CH2O)mCH 2CH2,NHCO(CH2)n, NHCO(CH2CH2O)mCH2CH2, OCH 2(CH2)n and O(CH2CH2O)mCH2CH2; where n isselected from 1 to 10 and m is selected from 1 to 4. 20In an embodiment, said alkyne linker is a compound of formula (XVIII), wherein X is CH2.In an embodiment, said alkyne linker is a compound of formula (XVIII), wherein X isCH2(CH2) n, and n is selected from 1 to 10. In an embodiment, n is selected from 1 to 5. In anembodiment, n is selected from 1 to 4. In an embodiment, n is selected from 1 to 3. In anembodiment, n is selected from 1 to 2. In a particular embodiment, n is 1. In another embodiment, 25n is 2. In yet another embodiment, n is 3. In yet a further embodiment, n is 4. In yet a furtherembodiment, n is 5. In yet a further embodiment, n is 6. In yet a further embodiment, n is 7. In yeta further embodiment, n is 8. In yet a further embodiment, n is 9. In yet a further embodiment, nis 10.In an embodiment, said alkyne linker is a compound of formula (XVIII), wherein X is 30(CH2CH2O)mCH 2CH2, wherein m is selected from 1 to 4. In an embodiment, m is selected from 1to 3. In an embodiment, m is selected from 1 to 2. In a particular embodiment, m is 1. In anotherembodiment, m is 2. In yet another embodiment, m is 3. In yet a further embodiment, m is 4.In an embodiment, said alkyne linker is a compound of formula (XVIII), wherein X isNHCO(CH2)n, and n is selected from 1 to 10. In an embodiment, n is selected from 1 to 5. In an 35embodiment, n is selected from 1 to 4. In an embodiment, n is selected from 1 to 3. In anembodiment, n is selected from 1 to 2. In a particular embodiment, n is 1. In another embodiment,n is 2. In yet another embodiment, n is 3. In yet a further embodiment, n is 4. In yet a further HN X 88embodiment, n is 5. In yet a further embodiment, n is 6. In yet a further embodiment, n is 7. In yeta further embodiment, n is 8. In yet a further embodiment, n is 9. In yet a further embodiment, nis 10.In an embodiment, said alkyne linker is a compound of formula (XVIII), wherein X isNHCO(CH2CH2O)mCH 2CH2, where m is selected from 1 to 4. In an embodiment, m is selected 5from 1 to 3. In an embodiment, m is selected from 1 to 2. In a particular embodiment, m is 1. Inanother embodiment, m is 2. In yet another embodiment, m is 3. In yet a further embodiment, mis 4.In an embodiment, said alkyne linker is a compound of formula (XVIII), wherein X isOCH 2(CH2)n, and n is selected from 1 to 10. In an embodiment, n is selected from 1 to 5. In an 10embodiment, n is selected from 1 to 4. In an embodiment, n is selected from 1 to 3. In anembodiment, n is selected from 1 to 2. In a particular embodiment, n is 1. In another embodiment,n is 2. In yet another embodiment, n is 3. In yet a further embodiment, n is 4. In yet a furtherembodiment, n is 5. In yet a further embodiment, n is 6. In yet a further embodiment, n is 7. In yeta further embodiment, n is 8. In yet a further embodiment, n is 9. In yet a further embodiment, n 15is 10.In an embodiment, said alkyne linker is a compound of formula (XVIII), wherein X isO(CH 2CH2O)mCH2CH2, where m is selected from 1 to 4. In an embodiment, m is selected from 1to 3. In an embodiment, m is selected from 1 to 2. In a particular embodiment, m is 1. In anotherembodiment, m is 2. In yet another embodiment, m is 3. In yet a further embodiment, m is 4. 20In an embodiment, said alkyne linker is a compound of formula (XIX), (XIX).Hence in a preferred embodiment, said alkyne linker is propargylamine. In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and an 25azido group is a compound of formula (XX), (XX),where X is selected from the group consisting of (CH 2)nCH2C=O and (CH2CH2O)mCH2CH2=O 30where n is selected from 0 to 10 and m is selected from 0 to 4.In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and anazido group is a compound of formula (XX), wherein X is (CH2)nCH2C=O, where n is selectedfrom 0 to 10. In an embodiment, n is selected from 0 to 5. In an embodiment, n is selected fromto 4. In an embodiment, n is selected from 0 to 3. In an embodiment, n is selected from 0 to 352. In a particular embodiment, n is 0. In a particular embodiment, n is 1. In another embodiment,n is 2. In yet another embodiment, n is 3. In yet a further embodiment, n is 4. In yet a furtherembodiment, n is 5. In yet a further embodiment, n is 6. In yet a further embodiment, n is 7. In HN X N3 89yet a further embodiment, n is 8. In yet a further embodiment, n is 9. In yet a furtherembodiment, n is 10.In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and anazido group is a compound of formula (XX), wherein X is (CH 2CH2O)mCH2CH2=O, where m isselected from 0 to 4. In an embodiment, m is selected from 0 to 3. In an embodiment, m is selected 5from 0 to 2. In an embodiment, m is selected from 0 to 1. In a particular embodiment, m is 0. In aparticular embodiment, m is 1. In another embodiment, m is 2. In yet another embodiment, m is3. In yet a further embodiment, m is 4.In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and anazido group is a compound of formula (XXI): 10 (XXI),Hence in an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety andan azido group is (2,5-Dioxopyrrolidin-1-yl) 2-azidoacetate.In an embodiment, step a) comprises reacting the saccharide with a carbonic acidderivative followed by reacting the carbonic acid derivative-activated saccharide with an alkyne 15linker in an aprotic solvent to produce an activated alkynyl saccharide.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 0.01-10 molar equivalent to the amount of saccharide present inthe reaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonic 20acid derivative that is between 0.1-10 molar equivalent to the amount of saccharide present in thereaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 0.5-5 molar equivalent to the amount of saccharide present in thereaction mixture. 25In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 1-5 molar equivalent to the amount of saccharide present in thereaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 2-5 molar equivalent to the amount of saccharide present in the 30reaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 5-10 molar equivalent to the amount of saccharide present in thereaction mixture. 90In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 0.1-5 molar equivalent to the amount of saccharide present in thereaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 0.5-2 molar equivalent to the amount of saccharide present in the 5reaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 0.01 molar equivalent to the amount of saccharide present in the reactionmixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonic 10acid derivative of about 0.1 molar equivalent to the amount of saccharide present in the reactionmixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 0.2 molar equivalent to the amount of saccharide present in the reactionmixture. 15In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 0.5 molar equivalent to the amount of saccharide present in the reactionmixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 1 molar equivalent to the amount of saccharide present in the reaction 20mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 2 molar equivalents to the amount of saccharide present in the reactionmixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonic 25acid derivative of about 5 molar equivalents to the amount of saccharide present in the reactionmixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 10 molar equivalents to the amount of saccharide present in the reactionmixture. 30In an embodiment, at step a) the isolated saccharide is reacted with a carbonic acidderivative in an aprotic solvent.In one embodiment the isolated saccharide is reacted with a carbonic acid derivative in asolution comprising dimethylsulphoxide (DMSO) or dimethylformamide (DMF). In oneembodiment the isolated saccharide is reacted with a carbonic acid derivative in a solution 35comprising dimethylformamide (DMF). In one embodiment the isolated saccharide is reacted witha carbonic acid derivative in a solution comprising dimethylsulphoxide (DMSO). 91In a preferred embodiment the isolated saccharide is reacted with a carbonic acidderivative in a solution comprising dimethylsulphoxide (DMSO).In one embodiment the isolated saccharide is reacted with a carbonic acid derivative in asolution consisting essentially of dimethylsulphoxide (DMSO) or dimethylformamide (DMF). Inone embodiment the isolated saccharide is reacted with a carbonic acid derivative in a solution 5consisting essentially of dimethylformamide (DMF). In one embodiment the isolated saccharideis reacted with a carbonic acid derivative in a solution consisting essentially of dimethylsulphoxide(DMSO).In an embodiment, the isolated saccharide is reacted with a carbonic acid derivative in asolution consisting essentially of dimethylacetamide. In an embodiment, the isolated saccharide 10is reacted with a carbonic acid derivative in a solution consisting essentially of N-methyl-2-pyrrolidone. In an embodiment, the isolated saccharide is reacted with a carbonic acid derivativein a solution consisting essentially of hexamethylphosphoramide (HMPA).In a preferred embodiment the isolated saccharide is reacted with a carbonic acidderivative in a solution consisting essentially of dimethylsulphoxide (DMSO). 15In one embodiment the isolated saccharide is reacted with a carbonic acid derivative indimethylsulphoxide (DMSO) or dimethylformamide (DMF). In one embodiment the isolatedsaccharide is reacted with a carbonic acid derivative in dimethylformamide (DMF). In oneembodiment the isolated saccharide is reacted with a carbonic acid derivative indimethylsulphoxide (DMSO). 20In an embodiment, the isolated saccharide is reacted with a carbonic acid derivative indimethylacetamide. In an embodiment, the isolated saccharide is reacted with a carbonic acidderivative in N-methyl-2-pyrrolidone. In an embodiment, the isolated saccharide is reacted witha carbonic acid derivative in hexamethylphosphoramide (HMPA).In a preferred embodiment the isolated saccharide is reacted with CDI in 25dimethylsulphoxide (DMSO). In an embodiment the isolated saccharide is reacted with CDI inanhydrous DMSO.It has been surprisingly found that reacting the isolated saccharide with CDI in anenvironment with a moisture level of about 0.1% to 1% (v/v) allows to avoid side reactions.Therefore, in one embodiment the isolated saccharide is reacted with CDI in an aprotic solvent 30comprising 0.1% to 1% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in an aprotic solvent comprising 0.1% to 0.8% (v/v) water. In one embodiment the isolatedsaccharide is reacted with CDI in an aprotic solvent comprising 0.1% to 0.5% (v/v) water. In oneembodiment the isolated saccharide is reacted with CDI in an aprotic solvent comprising 0.1% to0.4% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in an aprotic 35solvent comprising 0.1% to 0.3% (v/v) water. In one embodiment the isolated saccharide isreacted with CDI in an aprotic solvent comprising 0.1% to 0.2% (v/v) water. 92In one embodiment the isolated saccharide is reacted with CDI in an aprotic solventcomprising 0.2% to 1% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in an aprotic solvent comprising 0.2% to 0.8% (v/v) water. In one embodiment the isolatedsaccharide is reacted with CDI in an aprotic solvent comprising 0.2% to 0.5% (v/v) water. In oneembodiment the isolated saccharide is reacted with CDI in an aprotic solvent comprising 0.2% to 50.4% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in an aproticsolvent comprising 0.2% to 0.3% (v/v) water.In one embodiment the isolated saccharide is reacted with CDI in an aprotic solventcomprising 0.3% to 0.8% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in an aprotic solvent comprising 0.3% to 0.5% (v/v) water. In one embodiment the isolated 10saccharide is reacted with CDI in an aprotic solvent comprising 0.3% to 0.4% (v/v) water.Preferably, in one embodiment the isolated saccharide is reacted with CDI in an aproticsolvent comprising 0.1% to 0.5% (v/v) water.In one embodiment the isolated saccharide is reacted with CDI in an aprotic solventcomprising about 0.1% (v/v) water. In one embodiment the isolated saccharide is reacted with 15CDI in an aprotic solvent comprising about 0.2% (v/v) water. In one embodiment the isolatedsaccharide is reacted with CDI in an aprotic solvent comprising about 0.3% (v/v) water. In oneembodiment the isolated saccharide is reacted with CDI in an aprotic solvent comprising about0.4% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in an aproticsolvent comprising about 0.5% (v/v) water. In one embodiment the isolated saccharide is reacted 20with CDI in an aprotic solvent comprising about 0.6% (v/v) water. In one embodiment the isolatedsaccharide is reacted with CDI in an aprotic solvent comprising about 0.7% (v/v) water. In oneembodiment the isolated saccharide is reacted with CDI in an aprotic solvent comprising about0.8% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in an aproticsolvent comprising about 0.9% (v/v) water. 25In one embodiment the isolated saccharide is reacted with CDI in DMSO comprising 0.1%to 1% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in DMSOcomprising 0.1% to 0.8% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in DMSO comprising 0.1% to 0.5% (v/v) water. In one embodiment the isolated saccharideis reacted with CDI in DMSO comprising 0.1% to 0.4% (v/v) water. In one embodiment the isolated 30saccharide is reacted with CDI in DMSO comprising 0.1% to 0.3% (v/v) water. In one embodimentthe isolated saccharide is reacted with CDI in DMSO comprising 0.1% to 0.2% (v/v) water.In one embodiment the isolated saccharide is reacted with CDI in DMSO comprising 0.2%to 1% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in DMSOcomprising 0.2% to 0.8% (v/v) water. In one embodiment the isolated saccharide is reacted with 35CDI in DMSO comprising 0.2% to 0.5% (v/v) water. In one embodiment the isolated saccharideis reacted with CDI in DMSO comprising 0.2% to 0.4% (v/v) water. In one embodiment the isolatedsaccharide is reacted with CDI in DMSO comprising 0.2% to 0.3% (v/v) water. 93In one embodiment the isolated saccharide is reacted with CDI in DMSO comprising 0.3%to 0.8% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in DMSOcomprising 0.3% to 0.5% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in DMSO comprising 0.3% to 0.4% (v/v) water.Preferably, in one embodiment the isolated saccharide is reacted with CDI in DMSO 5comprising 0.1% to 0.5% (v/v) water.In one embodiment the isolated saccharide is reacted with CDI in DMSO comprising about0.1% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in DMSOcomprising about 0.2% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in DMSO comprising about 0.3% (v/v) water. In one embodiment the isolated saccharide is 10reacted with CDI in DMSO comprising about 0.4% (v/v) water. In one embodiment the isolatedsaccharide is reacted with CDI in DMSO comprising about 0.5% (v/v) water. In one embodimentthe isolated saccharide is reacted with CDI in DMSO comprising about 0.6% (v/v) water. In oneembodiment the isolated saccharide is reacted with CDI in DMSO comprising about 0.7% (v/v)water. In one embodiment the isolated saccharide is reacted with CDI in DMSO comprising about 150.8% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in DMSOcomprising about 0.9% (v/v) water.In one embodiment the free carbonic acid derivative is then quenched by the addition ofwater before the addition of the alkyne linker. Water can inactivate free CDI.Therefore, in an embodiment, carbonic acid derivative activation is followed by the addition of 20water. In an embodiment, water is added to bring the total water content in the mixture to betweenabout 1% to about 10% (v/v). In an embodiment, water is added to bring the total water contentin the mixture to between about 1% to about 5% (v/v). In an embodiment, water is added to bringthe total water content in the mixture to about 1 % (v/v). In an embodiment, water is added tobring the total water content in the mixture to about 2% (v/v). In an embodiment, water is added 25to bring the total water content in the mixture to about 5% (v/v).Once the saccharide has been reacted with carbonic acid derivative and following aneventual quenching of carbonic acid derivative with water, the carbonic acid derivative-activatedsaccharide is reacted with an alkyne linker.In one embodiment step a) further comprises reacting the carbonic acid derivative- 30activated saccharide with an amount of alkyne linker that is between 0.01-10 molar equivalent tothe amount of polysaccharide Repeat Unit of the activated saccharide (molar equivalent of RU).In one embodiment step a) further comprises reacting the carbonic acid derivative-activated saccharide with an amount of alkyne linker that is between 0.1-5 molar equivalent to theamount of polysaccharide repeat unit of the activated saccharide. 35In one embodiment step a) further comprises reacting the carbonic acid derivative-activated saccharide with an amount of alkyne linker that is between 0.1-5 molar equivalent to theamount of polysaccharide repeat unit of the activated saccharide. 94In one embodiment step a) further comprises reacting the carbonic acid derivative-activated saccharide with an amount of alkyne linker that is between 0.5-2 molar equivalent to theamount of polysaccharide repeat unit of the activated saccharide.In one embodiment step a) further comprises reacting the carbonic acid derivative-activated saccharide with an amount of alkyne linker that is between 1-5 molar equivalent to the 5amount of polysaccharide repeat unit of the activated saccharide.In the above embodiments, said carbonic acid derivative is CDI. In another embodiment,said carbonic acid derivative is CDT. In the above embodiments, said carbonic acid derivative ispreferably DSC.In one embodiment the degree of activation of the activated saccharide following step a) 10is between 0.5 to 50%. The degree of activation of the alkynyl saccharide being defined as thepercentage of Repeating Unit linked to an alkyne linker.In one embodiment the degree of activation of the activated saccharide following step a)is between 1 to 30%. In another embodiment the degree of activation of the activated saccharidefollowing step a) is between 2 to 25%. In another embodiment the degree of activation of the 15activated saccharide following step a) is between 3 to 20%.In another embodiment the degree of activation of the activated saccharide following stepa) is between 3 to 15%. In another embodiment the degree of activation of the activatedsaccharide following step a) is between 4 to 15%. In an embodiment the degree of activation ofthe activated saccharide following step a) is between 1 to 6%. 20In an embodiment the degree of activation of the activated saccharide following step a) isbetween 3 to 6%. In an embodiment the degree of activation of the activated saccharide followingstep a) is between 10 to 15%. In a preferred embodiment the degree of activation of the activatedsaccharide following step a) is between 15 to 50%.In an embodiment the degree of activation of the activated saccharide following step a) is 25about 1%. In an embodiment the degree of activation of the activated saccharide following stepa) is about 2%. In an embodiment the degree of activation of the activated saccharide followingstep a) is about 3%. In an embodiment the degree of activation of the activated saccharidefollowing step a) is about 4%. In an embodiment the degree of activation of the activatedsaccharide following step a) is about 5%. In an embodiment the degree of activation of the 30activated saccharide following step a) is about 6%. In an embodiment the degree of activation ofthe activated saccharide following step a) is about 7%. In an embodiment the degree of activationof the activated saccharide following step a) is about 8%. In an embodiment the degree ofactivation of the activated saccharide following step a) is about 9%. In an embodiment the degreeof activation of the activated saccharide following step a) is about 10%. In an embodiment the 35degree of activation of the activated saccharide following step a) is about 11%. In an embodimentthe degree of activation of the activated saccharide following step a) is about 12%. In anembodiment the degree of activation of the activated saccharide following step a) is about 13%. 95In an embodiment the degree of activation of the activated saccharide following step a) is about14%. In an embodiment the degree of activation of the activated saccharide following step a) isabout 15%. In an embodiment the degree of activation of the activated saccharide following stepa) is about 16%. In an embodiment the degree of activation of the activated saccharide followingstep a) is about 17%. In an embodiment the degree of activation of the activated saccharide 5following step a) is about 18%. In an embodiment the degree of activation of the activatedsaccharide following step a) is about 19%. In an embodiment the degree of activation of theactivated saccharide following step a) is about 20%.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is 0.1-10 molar 10equivalents to the lysines on the carrier protein.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is 0.5-10 molarequivalents to the lysines on the carrier protein.In one embodiment step b) comprises reacting the carrier protein with an amount of agent 15bearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is 1-5 molar equivalentsto the lysines on the carrier protein.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is 2-5 molar equivalentsto the lysines on the carrier protein. 20In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is about 10 molarequivalents to the lysines on the carrier protein.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is about 7.5 molar 25equivalents to the lysines on the carrier protein.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is about 5 molarequivalents to the lysines on the carrier protein.In one embodiment step b) comprises reacting the carrier protein with an amount of agent 30bearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is about 2 molarequivalents to the lysines on the carrier protein.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is about 1 molarequivalent to the lysines on the carrier protein. 35In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is about 0.5 molarequivalents to the lysines on the carrier protein. 96In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is about 0.1 molarequivalents to the lysines on the carrier protein.In one embodiment the degree of activation of the activated carrier following step b) isbetween 1 and 50. The degree of activation of the activated carrier being defined as the number 5of lysine residues in the carrier protein that become linked to the agent bearing an N-Hydroxysuccinimide (NHS) moiety and an azido group.In an embodiment, the carrier protein is CRM 197, which contains 39 lysine residues. In saidembodiment the degree of activation of the activated carrier following step b) may be between 1to 30. In another embodiment the degree of activation of the activated carrier (CRM 197) following 10step b) is between 5 to 20. In another embodiment the degree of activation of the activated carrier(CRM 197) following step b) is between 9 to 18. In another embodiment the degree of activation ofthe activated carrier (CRM 197) following step b) is between 8 to 11. In another embodiment thedegree of activation of the activated carrier (CRM 197) following step b) is between 15 to 20. Inanother embodiment the degree of activation of the activated carrier (CRM 197) following step b) is 15about 5. In another embodiment the degree of activation of the activated carrier (CRM 197) followingstep b) is about 6. In another embodiment the degree of activation of the activated carrier(CRM 197) following step b) is about 7. In another embodiment the degree of activation of theactivated carrier (CRM 197) following step b) is about 8. In another embodiment the degree ofactivation of the activated carrier (CRM 197) following step b) is about 9. In another embodiment 20the degree of activation of the activated carrier (CRM 197) following step b) is about 10. In anotherembodiment the degree of activation of the activated carrier (CRM 197) following step b) is about11. In another embodiment the degree of activation of the activated carrier (CRM 197) followingstep b) is about 12. In another embodiment the degree of activation of the activated carrier(CRM 197) following step b) is about 13. In another embodiment the degree of activation of the 25activated carrier (CRM 197) following step b) is about 14. In another embodiment the degree ofactivation of the activated carrier (CRM 197) following step b) is about 15. In another embodimentthe degree of activation of the activated carrier (CRM 197) following step b) is about 16. In anotherembodiment the degree of activation of the activated carrier (CRM 197) following step b) is about17. In another embodiment the degree of activation of the activated carrier (CRM 197) following 30step b) is about 18. In another embodiment the degree of activation of the activated carrier(CRM 197) following step b) is about 19. In another embodiment the degree of activation of theactivated carrier (CRM 197) following step b) is about 20. In another embodiment the degree ofactivation of the activated carrier (CRM 197) following step b) is about 21. In another embodimentthe degree of activation of the activated carrier (CRM 197) following step b) is about 22. In another 35embodiment the degree of activation of the activated carrier (CRM 197) following step b) is about23. In another embodiment the degree of activation of the activated carrier (CRM 197) following 97step b) is about 24. In another embodiment the degree of activation of the activated carrier(CRM 197) following step b) is about 25.In an embodiment, the carrier protein is SCP or a fragment thereof. In said embodimentthe degree of activation of the activated carrier following step b) may be between 1 to 50. Inanother embodiment the degree of activation of the activated carrier (SCP) following step b) is 5between 5 to 50. In another embodiment the degree of activation of the activated carrier (SCP)following step b) is between 7 to 45. In another embodiment the degree of activation of theactivated carrier (SCP) following step b) is between 5 to 15. In another embodiment the degreeof activation of the activated carrier (SCP) following step b) is between 20 to 30. In anotherembodiment the degree of activation of the activated carrier (SCP) following step b) is between 10to 50. In another embodiment the degree of activation of the activated carrier (SCP) followingstep b) is between 30 to 40. In another embodiment the degree of activation of the activatedcarrier (SCP) following step b) is between 10 to 40. In a preferred embodiment the degree ofactivation of the activated carrier (SCP) following step b) is between 15 to 25. In anotherembodiment the degree of activation of the activated carrier (SCP) following step b) is about 5. In 15another embodiment the degree of activation of the activated carrier (SCP) following step b) isabout 7. In another embodiment the degree of activation of the activated carrier (SCP) followingstep b) is about 10. In another embodiment the degree of activation of the activated carrier (SCP)following step b) is about 13. In another embodiment the degree of activation of the activatedcarrier (SCP) following step b) is about 15. In another embodiment the degree of activation of the 20activated carrier (SCP) following step b) is about 20. In another embodiment the degree ofactivation of the activated carrier (SCP) following step b) is about 26. In another embodiment thedegree of activation of the activated carrier (SCP) following step b) is about 30. In anotherembodiment the degree of activation of the activated carrier (SCP) following step b) is about 35.In another embodiment the degree of activation of the activated carrier (SCP) following step b) is 25about 37. In another embodiment the degree of activation of the activated carrier (SCP) followingstep b) is about 40. In another embodiment the degree of activation of the activated carrier (SCP)following step b) is about 45. In another embodiment the degree of activation of the activatedcarrier (SCP) following step b) is about 50.In an embodiment, the carrier protein is TT or a fragment thereof. In said embodiment the 30degree of activation of the activated carrier following step b) may be between 1 to 30. In anotherembodiment the degree of activation of the activated carrier (TT) following step b) is between 5to 25. In another embodiment the degree of activation of the activated carrier (TT) following stepb) is between 7 to 25. In another embodiment the degree of activation of the activated carrier (TT)following step b) is between 10 to 20. In another embodiment the degree of activation of the 35activated carrier (TT) following step b) is about 5. In another embodiment the degree of activationof the activated carrier (TT) following step b) is about 7. In another embodiment the degree ofactivation of the activated carrier (TT) following step b) is about 10. In another embodiment the 98degree of activation of the activated carrier (TT) following step b) is about 12. In anotherembodiment the degree of activation of the activated carrier (TT) following step b) is about 15. Inanother embodiment the degree of activation of the activated carrier (TT) following step b) is about20. In another embodiment the degree of activation of the activated carrier (TT) following step b)is about 25. In another embodiment the degree of activation of the activated carrier (TT) following 5step b) is about 30.In an embodiment, the conjugation reaction c) is carried out in aqueous buffer. In anembodiment, the conjugation reaction c) is carried out in aqueous buffer in the presence of copper(I) as catalyst. In an embodiment, the conjugation reaction c) is carried out in aqueous buffer inthe presence an oxidant and of copper (I) as catalyst. In a preferred embodiment, the conjugation 10reaction c) is carried out in aqueous buffer in the presence of copper (I) as catalyst and ascorbateas oxidant. In an embodiment, THPTA (tris(3-hydroxypropyltriazolylmethyl)amine) andaminoguanidine may be further added to protect the protein from side reactions. Therefore, in apreferred embodiment, the conjugation reaction c) is carried out in aqueous buffer in the presenceof copper (I) as catalyst and ascorbate as oxidant, wherein the reaction mixture further comprises 15THPTA (tris(3-hydroxypropyltriazolylmethyl)amine) and aminoguanidine.In an embodiment the initial input ratio (weight by weight) of activated alkynyl saccharideto activated azido-carrier at step c) is between 0.1 and 3. In an embodiment the initial input ratio(weight by weight) of activated alkynyl saccharide to activated azido-carrier at step c) is between0.5 and 2. In an embodiment the initial input ratio (weight by weight) of activated alkynyl 20saccharide to activated azido-carrier at step c) is between 0.6 and 1.5. In an embodiment theinitial input ratio (weight by weight) of activated alkynyl saccharide to activated azido-carrier atstep c) is between 0.8 and 1. In a preferred embodiment the initial input ratio (weight by weight)of activated alkynyl saccharide to activated azido-carrier at step c) is between 0.8 and 1.2 In anembodiment the initial input ratio (weight by weight) of activated alkynyl saccharide to activated 25azido-carrier at step c) is about 0.5. In an embodiment the initial input ratio (weight by weight) ofactivated alkynyl saccharide to activated azido-carrier at step c) is about 0.6. In an embodimentthe initial input ratio (weight by weight) of activated alkynyl saccharide to activated azido-carrierat step c) is about 0.7. In an embodiment the initial input ratio (weight by weight) of activatedalkynyl saccharide to activated azido-carrier at step c) is about 0.8. In an embodiment the initial 30input ratio (weight by weight) of activated alkynyl saccharide to activated azido-carrier at step c)is about 0.9. In an embodiment the initial input ratio (weight by weight) of activated alkynylsaccharide to activated azido-carrier at step c) is about 1. In an embodiment the initial input ratio(weight by weight) of activated alkynyl saccharide to activated azido-carrier at step c) is about1.1. In an embodiment the initial input ratio (weight by weight) of activated alkynyl saccharide to 35activated azido-carrier at step c) is about 1.2. In an embodiment the initial input ratio (weight byweight) of activated alkynyl saccharide to activated azido-carrier at step c) is about 1.3. In anembodiment the initial input ratio (weight by weight) of activated alkynyl saccharide to activated 99azido-carrier at step c) is about 1.4. In an embodiment the initial input ratio (weight by weight) ofactivated alkynyl saccharide to activated azido-carrier at step c) is about 1.5. In an embodimentthe initial input ratio (weight by weight) of activated alkynyl saccharide to activated azido-carrierat step c) is about 1.6. In an embodiment the initial input ratio (weight by weight) of activatedalkynyl saccharide to activated azido-carrier at step c) is about 1.7. In an embodiment the initial 5input ratio (weight by weight) of activated alkynyl saccharide to activated azido-carrier at step c)is about 1.8. In an embodiment the initial input ratio (weight by weight) of activated alkynylsaccharide to activated azido-carrier at step c) is about 1.9. In an embodiment the initial inputratio (weight by weight) of activated alkynyl saccharide to activated azido-carrier at step c) isabout 2. 10Following the click conjugation reaction, unreacted alkyne groups may remain present inthe conjugates, these may be capped using a suitable alkyne group capping agent. In oneembodiment this alkyne group capping agent is an agent bearing an azido group.In an embodiment, said alkyne group capping agent is a compound of formula (VI), (VI), 15wherein X is (CH2)n wherein n is selected from 1 to 15.In one embodiment this alkyne group capping agent is 3-azido-1-propanol.Therefore, in an embodiment, following step (c) the process further comprises a step ofcapping the unreacted alkyne groups remained in the conjugates with an alkyne group cappingagent. 20In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.05 to 20 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.1 to 15 molar equivalents to the amount of 25polysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.5 to 10 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with an 30amount of capping agent that is between 0.5 to 5 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.5 to 2 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide. 35 100In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.5 to 1 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 1 to 2 molar equivalents to the amount of polysaccharide 5repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 1.5 to 2.5 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with an 10amount of capping agent that about 0.5 molar equivalent to the amount of polysaccharide repeatunit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 1 molar equivalent to the amount of polysaccharide repeatunit of the activated saccharide. 15In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 1.5 molar equivalent to the amount of polysaccharide repeatunit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 2 molar equivalents to the amount of polysaccharide repeat 20unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 2.5 molar equivalents to the amount of polysaccharide repeatunit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with an 25amount of capping agent that about 5 molar equivalents to the amount of polysaccharide repeatunit of the activated saccharide.Following the click conjugation reaction, there may remain unreacted azido groups in theconjugates, these may be capped using a suitable azido group capping agent. Therefore, in anembodiment, following step c), unreacted azido groups in the conjugates, are capped using a 30suitable azido group capping agent. In one embodiment this azido group capping agent is anagent bearing an alkyne group. In one embodiment this azido group capping agent is an agentbearing a terminal alkyne. In one embodiment this azido group capping agent is an agent bearinga cycloalkyne.In an embodiment, said azido group capping agent is a compound of formula (VII), 35 (VII),wherein X is (CH2)n wherein n is selected from 1 to 15. 101In one embodiment this azido group capping agent is propargyl alcohol.Therefore, in an embodiment, following step (c) the process further comprises a step ofcapping the unreacted azido groups remained in the conjugates with an azido group cappingagent.In an embodiment the capping of the unreacted azido groups is performed with an amount 5of capping agent that is between 0.05 to 20 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.5 to 10 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide. 10In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.5 to 5 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.5 to 2 molar equivalents to the amount of polysaccharide 15repeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.5 to 1 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amount 20of capping agent that is between 1 to 2 molar equivalents to the amount of polysaccharide repeatunit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.75 to 1.5 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide. 25In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is about 1 molar equivalent to the amount of polysaccharide repeat unit ofthe activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is about 1.5 molar equivalent to the amount of polysaccharide repeat unit 30of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is about 0.5 molar equivalent to the amount of polysaccharide repeat unitof the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amount 35of capping agent that is about 2 molar equivalents to the amount of polysaccharide repeat unit ofthe activated saccharide. 102Following conjugation to the carrier protein, the serotype 21 glycoconjugate of theinvention can be purified (enriched with respect to the amount of saccharide-protein conjugate)by a variety of techniques known to the skilled person. These techniques include dialysis,concentration/diafiltration operations, tangential flow filtration precipitation/elution, columnchromatography (DEAE or hydrophobic interaction chromatography), and depth filtration. 5Therefore, in one embodiment the process for producing the glycoconjugate of the presentinvention comprises the step of purifying the glycoconjugate after it is produced.In an aspect, the invention provides a a serotype 21 glycoconjugate produced accordingto any of the methods disclosed herein. 2.3 Carrier Proteins 10A component of the glycoconjugate is a carrier protein to which the serotype 21 saccharideis conjugated. The terms "protein carrier" or "carrier protein" or "carrier" may be usedinterchangeably herein. Carrier proteins should be amenable to standard conjugationprocedures.In a preferred embodiment, the carrier protein of the serotype 21 saccharide 15glycoconjugate is selected in the group consisting of: DT (Diphtheria Toxoid), TT (Tetanus Toxoid)or fragment C of TT, CRM 197 (a nontoxic but antigenically identical variant of diphtheria toxin),other DT mutants (such as CRM 176, CRM 228, CRM45 (Uchida et al. (1973) J. Biol. Chem. 218:3838-3844), CRM 9, CRM 102, CRM 103 or CRM 107; and other mutations described by Nicholls and Youlein Genetically Engineered Toxins, Ed: Frankel, Maecel Dekker Inc. (1992); deletion or mutation 20of Glu-148 to Asp, Gln or Ser and/or Ala 158 to GIy and other mutations disclosed in U.S. PatentNos. 4,709,017 and 4,950,740; mutation of at least one or more residues Lys 516, Lys 526, Phe530 and/or Lys 534 and other mutations disclosed in U.S. Patent Nos. 5,917,017 and 6,455,673;or fragment disclosed in U.S. Patent No. 5,843,711, pneumococcal pneumolysin (ply) (Kuo et al.(1995) Infect lmmun 63:2706-2713) including ply detoxified in some fashion, for example dPLY- 25GMBS (WO 2004/081515, WO 2006/032499) or dPLY-formol, PhtX, including PhtA, PhtB, PhtD,PhtE (sequences of PhtA, PhtB, PhtD or PhtE are disclosed in WO 00/37105 and WO 00/39299)and fusions of Pht proteins, for example PhtDE fusions, PhtBE fusions, Pht A-E (WO 01/98334,WO 03/054007, WO 2009/000826), OMPC (meningococcal outer membrane protein), which isusually extracted from Neisseria meningitidis serogroup B (EP0372501), PorB (from N. 30meningitidis), PD (Haemophilus influenzae protein D; see, e.g., EP0594610 B), orimmunologically functional equivalents thereof, synthetic peptides (EP0378881, EP0427347),heat shock proteins (WO 93/17712, WO 94/03208), pertussis proteins (WO 98/58668,EP0471177), cytokines, lymphokines, growth factors or hormones (WO 91/01146), artificialproteins comprising multiple human CD4+ T cell epitopes from various pathogen derived antigens 35(Falugi et al. (2001) Eur J Immunol 31:3816-3824) such as N19 protein (Baraldoi et al. (2004)Infect lmmun 72:4884-4887) pneumococcal surface protein PspA (WO 02/091998), iron uptakeproteins (WO 01/72337), toxin A or B of Clostridium difficile (WO 00/61761), transferrin binding 103proteins, pneumococcal adhesion protein (PsaA), recombinant Pseudomonas aeruginosaexotoxin A (in particular non-toxic mutants thereof (such as exotoxin A bearing a substution atglutamic acid 553 (Douglas et al. (1987) J. Bacteriol. 169(11):4967-4971)). Other proteins, suchas ovalbumin, keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or purified proteinderivative of tuberculin (PPD) also can be used as carrier proteins. Other suitable carrier proteins 5include inactivated bacterial toxins such as cholera toxoid (e.g., as described in WO2004/083251), Escherichia coli LT, E. coli ST, and exotoxin A from P. aeruginosa. Anothersuitable carrier protein is a C5a peptidase from Streptococcus (SCP). Another suitable carrierprotein is rhizavidin [aa 45-179J-GGGGSSS-SP1500- AAA-SP0785] (CP1) (WO2020056202).Another suitable carrier protein is Rhavi-linker-PdT(G294P)-linker-SP0435 [aa 62-185] fusion 10protein (SPP2), see WO2023039223. WO2020/056202 and WO2023/039223 are incorporatedby reference. SPP2 is described in particular at sections [0245] to [250] of WO2023/039223.In a preferred embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is selected from the group consisting of TT, DT, DT mutants (suchas CRM 197), and a C5a peptidase from Streptococcus (SCP). 15In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate is DT(Diphtheria Toxoid). In another embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate is TT (Tetanus Toxoid).In another embodiment, the carrier protein of the serotype 21 saccharide glycoconjugateis PD (H. influenzae protein D; see, e.g., EP0594610 B). 20In a preferred embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate is CRM 197 or a C5a peptidase from Streptococcus (SCP).In another embodiment, the carrier protein of the serotype 21 saccharide glycoconjugateis rhizavidin [aa 45-179J-GGGGSSS-SP1500- AAA-SP0785] (CP1).In another embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate 25is Rhavi-linker-PdT(G294P)-linker-SP0435 [aa 62-185] fusion protein (SPP2). In an embodiment,said SPP2 has the amino acid sequence as set forth at SEQ ID NO: 19 of WO2023/039223.In a preferred embodiment, the serotype 21 saccharide is conjugated to CRM 197 protein.The CRM 197 protein is a nontoxic form of diphtheria toxin but is immunologically indistinguishablefrom the diphtheria toxin. CRM 197 is produced by Corynebacterium diphtheriae infected by the 30nontoxigenic phage β197tox-created by nitrosoguanidine mutagenesis of the toxigeniccorynephage beta (Uchida et al. (1971) Nature New Biology 233:8-11). The CRM 197 protein hasthe same molecular weight as the diphtheria toxin but differs therefrom by a single base change(guanine to adenine) in the structural gene. This single base change causes an amino acidsubstitution (glutamic acid for glycine) in the mature protein and eliminates the toxic properties of 35diphtheria toxin. The CRM 197 protein is a safe and effective T-cell dependent carrier forsaccharides. Further details about CRM 197 and production thereof can be found, e.g., in U.S.Patent No. 5,614,382. 104In an embodiment, the serotype 21 saccharide is conjugated to CRM 197 protein. In anembodiment, the serotype 21 saccharide is conjugated to CRM 197 protein or the A chain of CRM 197(see CN103495161). In an embodiment, the serotype 21 saccharide is conjugated the A chain ofCRM 197 obtained via expression by genetically recombinant E. coli (see CN103495161).In other preferred embodiments, the carrier protein of the serotype 21 saccharide glycoconjugate 5of the invention is SCP (Streptococcal C5a Peptidase).Two important species of β-hemolytic streptococci, Streptococcus pyogenes (group AStreptococcus, GAS) and Streptococcus agalactiae (group B Streptococcus, GBS), which causea variety of serious human infections that range from mild cases of pharyngitis and impetigo toserious invasive diseases such as necrotizing fasciitis (GAS) and neonatal 10sepsis (GBS) have developed a way to defeat this immune response. All human isolates of β-hemolytic streptococci, including GAS and GBS, produce a highly conserved cell-wall proteinSCP (Streptococcal C5a Peptidase) that specifically inactivates C5a. The scp genes from GASand GBS encode a polypeptide containing between 1,134 and 1,181 amino acids (Brown et al.,PNAS, 2005, vol. 102, no. 51 pages 18391–18396). The first 31 residues are the export signal 15presequence and are removed upon passing through the cytoplasmic membrane. The next 68residues serve as a pro-sequence and must be removed to produce active SCP. The next 10residues can be removed without loss of protease activity. At the other end, starting with Lys-1034, are four consecutive 17-residue motifs followed by a cell sorting and cell-wall attachmentsignal. This combined signal is composed of a 20-residue hydrophilic sequence containing an 20LPTTND sequence, a 17-residue hydrophobic sequence, and a short basic carboxyl terminus.SCP can be divided in domains (see figure 1B of Brown et al., PNAS, 2005, vol. 102, no. 51 pages18391–18396). These domains are the Pre/Pro domain (which comprises the export signalpresequence (commonly the first 31 residues) and the pro-sequence (commonly the next 68residues)), the protease domain (which is splitted in two part (protease part 1 commonly residues 2589–333/334 and protease domain part 2 and commonly residues 467/468–583/584), theprotease-associated domain (PA domain) (commonly residues 333/334–467/468), threefibronectin type III (Fn) domains (Fn1, commonly residues 583/584–712/713; Fn2, commonlyresidues 712/713–928/929/930; commonly Fn3, residues 929/930-1029/1030/1031) and a cellwall anchor domain (commonly redisues 1029/1030/1031 to the C-terminus). 30In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an SCP from GBS (SCPB). An exemple of SCPB is provided at SEQ. ID.NO: 3 ofWO97/26008. See also SEQ ID NO: 3 of WO00/34487.In another preferred embodiments, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is an SCP from GAS (SCPA). 35Examples of SCPA can be found at SEQ.ID.No.1 and SEQ.ID.No.2 of WO97/26008. See alsoSEQ ID NO: 1, 2 and 23 of WO00/34487. 105In a preferred embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is an enzymatically inactive SCP.In other preferred embodiments, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is an enzymatically inactive SCP from GBS (SCPB).In another preferred embodiments, the carrier protein of the serotype 21 saccharide 5glycoconjugate of the invention is an enzymatically inactive SCP from GAS (SCPA).In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is a fragment of an SCP. In an embodiment, the carrier protein of the serotype 21saccharide glycoconjugate of the invention is a fragment of an SCPA. Preferably, the carrierprotein of the serotype 21 saccharide glycoconjugate of the invention is a fragment of an SCPB. 10In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is a fragment of an SCP which comprises the protease domain, the protease-associateddomain (PA domain) and the three fibronectin type III (Fn) domains but does not comprise theexport signal presequence, the pro-sequence and the cell wall anchor domain.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of the 15invention is a fragment of an SCP which comprises the protease domain, the protease-associateddomain (PA domain) and the three fibronectin type III (Fn) domains but does not comprise theexport signal presequence, the pro-sequence and the cell wall anchor domain.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of an SCP which comprises the protease domain, 20the protease-associated domain (PA domain) and two of the three fibronectin type III (Fn)domains but does not comprise the export signal presequence, the pro-sequence and the cellwall anchor domain.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of an SCP. In an embodiment, said enzymatically 25inactive fragment of SCP comprises the protease domain, the protease-associated domain (PAdomain) and the three fibronectin type III (Fn) domains but does not comprise the export signalpresequence, the pro-sequence and the cell wall anchor domain.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of an SCPA. In an embodiment, said enzymatically 30inactive fragment of an SCPA comprises the protease domain, the protease-associated domain(PA domain) and the three fibronectin type III (Fn) domains but does not comprise the exportsignal presequence, the pro-sequence and the cell wall anchor domain.In a preferred embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCPB. Preferably, said 35enzymatically inactive fragment of SCPB comprises the protease domain, the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but does notcomprise the export signal presequence, the pro-sequence and the cell wall anchor domain. 106In an embodiment, the enzymatic activity of SCP is inactivated by replacing at least oneamino acid of the wild type sequence. In an embodiment, said replacement is selected from thegroup consisting of D130A, H193A, N295A and S512A. The numbers indicate the amino acidresidue position in the peptidase according to the numbering of SEQ ID NO: 1 of WO00/34487.Therefore, in an embodiment, the carrier protein of the serotype 21 saccharide 5glycoconjugate of the invention is an enzymatically inactive SCP where said inactivation isaccomplished by replacing at least one amino acid of the wild type sequence. Preferably, saidreplacement of at least one amino acid is in the protease domain. In an embodiment, saidreplacement of at least one amino acid is in part 1 of the protease domain. In an embodiment,said replacement of at least one amino acid is in part 2 of the protease domain. In an embodiment, 10said replacement is selected from the group consisting of D130A, H193A, N295A and S512A. Inan embodiment, said replacement is D130A. In another embodiment, said replacement is H193A.In another embodiment, said replacement is N295A. In yet another embodiment, saidreplacement is S512A.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of the 15invention is an enzymatically inactive SCPA where said inactivation is accomplished by replacingat least one amino acid of the wild type sequence. Preferably, said replacement of at least oneamino acid is in the protease domain. In an embodiment, said replacement of at least one aminoacid is in part 1 of the protease domain. In an embodiment, said replacement of at least one aminoacid is in part 2 of the protease domain. In an embodiment, said replacement is selected from the 20group consisting of D130A, H193A, N295A and S512A. In an embodiment, said replacement isD130A. In another embodiment, said replacement is H193A. In another embodiment, saidreplacement is N295A. In yet another embodiment, said replacement is S512A.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive SCPB where said inactivation is accomplished by replacing 25at least one amino acid of the wild type sequence. Preferably, said replacement of at least oneamino acid is in the protease domain. In an embodiment, said replacement of at least one aminoacid is in part 1 of the protease domain. In an embodiment, said replacement of at least one aminoacid is in part 2 of the protease domain. In an embodiment, said replacement is selected from thegroup consisting of D130A, H193A, N295A and S512A. In an embodiment, said replacement is 30D130A. In another embodiment, said replacement is H193A. In another embodiment, saidreplacement is N295A. In yet another embodiment, said replacement is S512A.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of an SCP where said inactivation is accomplishedby replacing at least one amino acid of the wild type sequence. Preferably, said replacement of 35at least one amino acid is in the protease domain. In an embodiment, said replacement of at leastone amino acid is in part 1 of the protease domain. In an embodiment, said replacement of atleast one amino acid is in part 2 of the protease domain. In an embodiment, said replacement is 107selected from the group consisting of D130A, H193A, N295A and S512A. In an embodiment, saidreplacement is D130A. In another embodiment, said replacement is H193A. In anotherembodiment, said replacement is N295A. In yet another embodiment, said replacement is S512A.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCP which comprises the protease domain, the 5protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but doesnot comprise the export signal presequence, the pro-sequence and the cell wall anchor domain,where said inactivation is accomplished by replacing at least one amino acid of the wild typesequence. Preferably, said replacement of at least one amino acid is in the protease domain. Inan embodiment, said replacement of at least one amino acid is in part 1 of the protease domain. 10In an embodiment, said replacement of at least one amino acid is in part 2 of the protease domain.In an embodiment, said replacement is selected from the group consisting of D130A, H193A,N295A and S512A. In an embodiment, said replacement is D130A. In another embodiment, saidreplacement is H193A. In another embodiment, said replacement is N295A. In yet anotherembodiment, said replacement is S512A. 15In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCPA which comprises the protease domain,the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains butdoes not comprise the export signal presequence, the pro-sequence and the cell wall anchordomain, where said inactivation is accomplished by replacing at least one amino acid of the wild 20type sequence. Preferably, said replacement of at least one amino acid is in the protease domain.In an embodiment, said replacement of at least one amino acid is in part 1 of the protease domain.In an embodiment, said replacement of at least one amino acid is in part 2 of the protease domain.In an embodiment, said replacement is selected from the group consisting of D130A, H193A,N295A and S512A. In an embodiment, said replacement is D130A. In another embodiment, said 25replacement is H193A. In another embodiment, said replacement is N295A. In yet anotherembodiment, said replacement is S512A.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCPB which comprises the protease domain,the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but 30does not comprise the export signal presequence, the pro-sequence and the cell wall anchordomain, where said inactivation is accomplished by replacing at least one amino acid of the wildtype sequence. Preferably, said replacement of at least one amino acid is in the protease domain.In an embodiment, said replacement of at least one amino acid is in part 1 of the protease domain.In an embodiment, said replacement of at least one amino acid is in part 2 of the protease domain. 35In an embodiment, said replacement is selected from the group consisting of D130A, H193A,N295A and S512A. In an embodiment, said replacement is D130A. In another embodiment, said 108replacement is H193A. In another embodiment, said replacement is N295A. In yet anotherembodiment, said replacement is S512A.In an embodiment, the enzymatic activity of SCP is inactivated by replacing at least twoamino acids of the wild type sequence. In an embodiment, said at least two amino acidsreplacements are selected from the group consisting of D130A, H193A, N295A and S512A. In an 5embodiment, said at least two amino acids replacements are D130A and H193A. In anembodiment, said at least two amino acids replacements are D130A and N295A. In anembodiment, said at least two amino acids replacements are D130A and S512A. In anembodiment, said at least two amino acids replacements are H193A and N295A. In anembodiment, said at least two amino acids replacements are H193A and S512A. In an 10embodiment, said at least two amino acids replacements are N295A and S512A.Therefore, in an embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is an enzymatically inactive SCP where said inactivation isaccomplished by replacing at least two amino acids of the wild type sequence. Preferably, saidreplacement of at least two amino acids is in the protease domain. In an embodiment, said 15replacement of at least two amino acid is in part 1 of the protease domain. In an embodiment,said replacement of at least two amino acid is in part 2 of the protease domain. In an embodiment,said at least two amino acids replacements are selected from the group consisting of D130A,H193A, N295A and S512A. In an embodiment, said at least two amino acids replacements areD130A and H193A. In an embodiment, said at least two amino acids replacements are D130A 20and N295A. Preferably, said at least two amino acids replacements are D130A and S512A. In anembodiment, said at least two amino acids replacements are H193A and N295A. In anembodiment, said at least two amino acids replacements are H193A and S512A. In anembodiment, said at least two amino acids replacements are N295A and S512A.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of the 25invention is an enzymatically inactive SCPA where said inactivation is accomplished by replacingat least two amino acids of the wild type sequence. Preferably, said replacement of at least twoamino acids is in the protease domain. In an embodiment, said replacement of at least two aminoacids is in part 1 of the protease domain. In an embodiment, said replacement of at least twoamino acid is in part 2 of the protease domain. In an embodiment, said at least two amino acids 30replacements are selected from the group consisting of D130A, H193A, N295A and S512A. In anembodiment, said at least two amino acids replacements are D130A and H193A. In anembodiment, said at least two amino acids replacements are D130A and N295A. Preferably, saidat least two amino acids replacements are D130A and S512A. In an embodiment, said at leasttwo amino acids replacements are H193A and N295A. In an embodiment, said at least two amino 35acids replacements are H193A and S512A. In an embodiment, said at least two amino acidsreplacements are N295A and S512A. 109In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive SCPB where said inactivation is accomplished by replacingat least two amino acids of the wild type sequence. Preferably, said replacement of at least twoamino acids is in the protease domain. In an embodiment, said replacement of at least two aminoacids is in part 1 of the protease domain. In an embodiment, said replacement of at least two 5amino acid is in part 2 of the protease domain. In an embodiment, said at least two amino acidsreplacements are selected from the group consisting of D130A, H193A, N295A and S512A. In anembodiment, said at least two amino acids replacements are D130A and H193A. In anembodiment, said at least two amino acids replacements are D130A and N295A. Preferably, saidat least two amino acids replacements are D130A and S512A. In an embodiment, said at least 10two amino acids replacements are H193A and N295A. In an embodiment, said at least two aminoacids replacements are H193A and S512A. In an embodiment, said at least two amino acidsreplacements are N295A and S512A.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of an SCP where said inactivation is accomplished 15by replacing at least two amino acids of the wild type sequence. Preferably, said replacement ofat least two amino acids is in the protease domain. In an embodiment, said replacement of atleast two amino acids is in part 1 of the protease domain. In an embodiment, said replacement ofat least two amino acid is in part 2 of the protease domain. In an embodiment, said at least twoamino acids replacements are selected from the group consisting of D130A, H193A, N295A and 20S512A. In an embodiment, said at least two amino acids replacements are D130A and H193A.In an embodiment, said at least two amino acids replacements are D130A and N295A. Preferably,said at least two amino acids replacements are D130A and S512A. In an embodiment, said atleast two amino acids replacements are H193A and N295A. In an embodiment, said at least twoamino acids replacements are H193A and S512A. In an embodiment, said at least two amino 25acids replacements are N295A and S512A.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCP which comprises the protease domain, theprotease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but doesnot comprise the export signal presequence, the pro-sequence and the cell wall anchor domain, 30where said inactivation is accomplished by replacing at least two amino acids of the wild typesequence. Preferably, said replacement of at least two amino acids is in the protease domain. Inan embodiment, said replacement of at least two amino acids is in part 1 of the protease domain.In an embodiment, said replacement of at least two amino acid is in part 2 of the protease domain.In an embodiment, said at least two amino acids replacements are selected from the group 35consisting of D130A, H193A, N295A and S512A. In an embodiment, said at least two amino acidsreplacements are D130A and H193A. In an embodiment, said at least two amino acidsreplacements are D130A and N295A. Preferably, said at least two amino acids replacements are 110D130A and S512A. In an embodiment, said at least two amino acids replacements are H193Aand N295A. In an embodiment, said at least two amino acids replacements are H193A andS512A. In an embodiment, said at least two amino acids replacements are N295A and S512A.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCPA which comprises the protease domain, 5the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains butdoes not comprise the export signal presequence, the pro-sequence and the cell wall anchordomain, where said inactivation is accomplished by replacing at least two amino acids of the wildtype sequence. Preferably, said replacement of at least two amino acids is in the proteasedomain. In an embodiment, said replacement of at least two amino acids is in part 1 of the 10protease domain. In an embodiment, said replacement of at least one amino acids is in part 2 ofthe protease domain. In an embodiment, said at least two amino acids replacements are selectedfrom the group consisting of D130A, H193A, N295A and S512A. In an embodiment, said at leasttwo amino acids replacements are D130A and H193A. In an embodiment, said at least two aminoacids replacements are D130A and N295A. Preferably, said at least two amino acids 15replacements are D130A and S512A. In an embodiment, said at least two amino acidsreplacements are H193A and N295A. In an embodiment, said at least two amino acidsreplacements are H193A and S512A. In an embodiment, said at least two amino acidsreplacements are N295A and S512A.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of the 20invention is an enzymatically inactive fragment of SCPB which comprises the protease domain,the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains butdoes not comprise the export signal presequence, the pro-sequence and the cell wall anchordomain, where said inactivation is accomplished by replacing at least two amino acids of the wildtype sequence. Preferably, said replacement of at least two amino acids is in the protease 25domain. In an embodiment, said replacement of at least two amino acids is in part 1 of theprotease domain. In an embodiment, said replacement of at least two amino acids is in part 2 ofthe protease domain. In an embodiment, said at least two amino acids replacements are selectedfrom the group consisting of D130A, H193A, N295A and S512A. In an embodiment, said at leasttwo amino acids replacements are D130A and H193A. In an embodiment, said at least two amino 30acids replacements are D130A and N295A. Preferably, said at least two amino acidsreplacements are D130A and S512A. In an embodiment, said at least two amino acidsreplacements are H193A and N295A. In an embodiment, said at least two amino acidsreplacements are H193A and S512A. In an embodiment, said at least two amino acidsreplacements are N295A and S512A. 35In an embodiment, the enzymatic activity of SCP is inactivated by replacing at least threeamino acids of the wild type sequence. In an embodiment, said at least three amino acidsreplacements are selected from the group consisting of D130A, H193A, N295A and S512A. In an 111embodiment, said at least three amino acids replacements are D130A, H193A and N295A. In anembodiment, said at least three amino acids replacements are D130A, H193A and S512A. In anembodiment, said at least three amino acids replacements are D130A, N295A and S512A. In anembodiment, said at least three amino acids replacements are H193A, N295A and S512A.Therefore, in an embodiment, the carrier protein of the serotype 21 saccharide 5glycoconjugate of the invention is an enzymatically inactive SCP where said inactivation isaccomplished by replacing at least three amino acids of the wild type sequence. Preferably, saidreplacement of at least three amino acids is in the protease domain. In an embodiment, saidreplacement of at least three amino acid is in part 1 of the protease domain. In an embodiment,said replacement of at least three amino acid is in part 2 of the protease domain. In an 10embodiment, said at least three amino acids replacements are selected from the group consistingof D130A, H193A, N295A and S512A. In an embodiment, said at least three amino acidsreplacements are D130A, H193A and N295A. In an embodiment, said at least three amino acidsreplacements are D130A, H193A and S512A. In an embodiment, said at least three amino acidsreplacements are D130A, N295A and S512A. In an embodiment, said at least three amino acids 15replacements are H193A, N295A and S512A.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive SCPA where said inactivation is accomplished by replacingat least three amino acids of the wild type sequence. Preferably, said replacement of at leastthree amino acids is in the protease domain. In an embodiment, said replacement of at least three 20amino acids is in part 1 of the protease domain. In an embodiment, said replacement of at leastthree amino acid is in part 2 of the protease domain. In an embodiment, said at least three aminoacids replacements are selected from the group consisting of D130A, H193A, N295A and S512A.In an embodiment, said at least three amino acids replacements are D130A, H193A and N295A.In an embodiment, said at least three amino acids replacements are D130A, H193A and S512A. 25In an embodiment, said at least three amino acids replacements are D130A, N295A and S512A.In an embodiment, said at least three amino acids replacements are H193A, N295A and S512A.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive SCPB where said inactivation is accomplished by replacingat least three amino acids of the wild type sequence. Preferably, said replacement of at least 30three amino acids is in the protease domain. In an embodiment, said replacement of at least threeamino acids is in part 1 of the protease domain. In an embodiment, said replacement of at leastthree amino acid is in part 2 of the protease domain. In an embodiment, said at least three aminoacids replacements are selected from the group consisting of D130A, H193A, N295A and S512A.In an embodiment, said at least three amino acids replacements are D130A, H193A and N295A. 35In an embodiment, said at least three amino acids replacements are D130A, H193A and S512A.In an embodiment, said at least three amino acids replacements are D130A, N295A and S512A.In an embodiment, said at least three amino acids replacements are H193A, N295A and S512A. 112In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of an SCP where said inactivation is accomplishedby replacing at least three amino acids of the wild type sequence. Preferably, said replacementof at least three amino acids is in the protease domain. In an embodiment, said replacement ofat least three amino acids is in part 1 of the protease domain. In an embodiment, said replacement 5of at least three amino acid is in part 2 of the protease domain. In an embodiment, said at leastthree amino acids replacements are selected from the group consisting of D130A, H193A, N295Aand S512A. In an embodiment, said at least three amino acids replacements are D130A, H193Aand N295A. In an embodiment, said at least three amino acids replacements are D130A, H193Aand S512A. In an embodiment, said at least three amino acids replacements are D130A, N295A 10and S512A. In an embodiment, said at least three amino acids replacements are H193A, N295Aand S512A.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCP which comprises the protease domain, theprotease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but does 15not comprise the export signal presequence, the pro-sequence and the cell wall anchor domain,where said inactivation is accomplished by replacing at least three amino acids of the wild typesequence. Preferably, said replacement of at least three amino acids is in the protease domain.In an embodiment, said replacement of at least three amino acids is in part 1 of the proteasedomain. In an embodiment, said replacement of at least three amino acid is in part 2 of the 20protease domain. In an embodiment, said at least three amino acids replacements are selectedfrom the group consisting of D130A, H193A, N295A and S512A. In an embodiment, said at leastthree amino acids replacements are D130A, H193A and N295A. In an embodiment, said at leastthree amino acids replacements are D130A, H193A and S512A. In an embodiment, said at leastthree amino acids replacements are D130A, N295A and S512A. In an embodiment, said at least 25three amino acids replacements are H193A, N295A and S512A.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCPA which comprises the protease domain,the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains butdoes not comprise the export signal presequence, the pro-sequence and the cell wall anchor 30domain, where said inactivation is accomplished by replacing at least three amino acids of thewild type sequence. Preferably, said replacement of at least three amino acids is in the proteasedomain. In an embodiment, said replacement of at least three amino acids is in part 1 of theprotease domain. In an embodiment, said replacement of at least three amino acids is in part 2of the protease domain. In an embodiment, said at least three amino acids replacements are 35selected from the group consisting of D130A, H193A, N295A and S512A. In an embodiment, saidat least three amino acids replacements are D130A, H193A and N295A. In an embodiment, saidat least three amino acids replacements are D130A, H193A and S512A. In an embodiment, said 113at least three amino acids replacements are D130A, N295A and S512A. In an embodiment, saidat least three amino acids replacements are H193A, N295A and S512A.In an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCPB which comprises the protease domain,the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but 5does not comprise the export signal presequence, the pro-sequence and the cell wall anchordomain, where said inactivation is accomplished by replacing at least three amino acids of thewild type sequence. Preferably, said replacement of at least three amino acids is in the proteasedomain. In an embodiment, said replacement of at least three amino acids is in part 1 of theprotease domain. In an embodiment, said replacement of at least three amino acids is in part 2 10of the protease domain. In an embodiment, said at least three amino acids replacements areselected from the group consisting of D130A, H193A, N295A and S512A. In an embodiment, saidat least three amino acids replacements are D130A, H193A and N295A. In an embodiment, saidat least three amino acids replacements are D130A, H193A and S512A. In an embodiment, saidat least three amino acids replacements are D130A, N295A and S512A. In an embodiment, said 15at least three amino acids replacements are H193A, N295A and S512A.In an embodiment, the enzymatic activity of SCP is inactivated by replacing at least fouramino acids of the wild type sequence. In an embodiment, said at least four amino acidsreplacements are D130A, H193A, N295A and S512A.Therefore, in an embodiment, the carrier protein of the serotype 21 saccharide 20glycoconjugate of the invention is an enzymatically inactive SCP where said inactivation isaccomplished by replacing at least four amino acids of the wild type sequence. Preferably, saidreplacement of at least four amino acids is in the protease domain. In an embodiment, saidreplacement of at least four amino acid is in part 1 of the protease domain. In an embodiment,said replacement of at least four amino acid is in part 2 of the protease domain. In an embodiment, 25said at least four amino acids replacements are D130A, H193A, N295A and S512AIn an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive SCPA where said inactivation is accomplished by replacingat least four amino acids of the wild type sequence. Preferably, said replacement of at least fouramino acids is in the protease domain. In an embodiment, said replacement of at least four amino 30acids is in part 1 of the protease domain. In an embodiment, said replacement of at least fouramino acid is in part 2 of the protease domain. In an embodiment, said at least four amino acidsreplacements are D130A, H193A, N295A and S512AIn an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive SCPB where said inactivation is accomplished by replacing 35at least four amino acids of the wild type sequence. Preferably, said replacement of at least fouramino acids is in the protease domain. In an embodiment, said replacement of at least four aminoacids is in part 1 of the protease domain. In an embodiment, said replacement of at least four 114amino acid is in part 2 of the protease domain. In an embodiment, said at least four amino acidsreplacements are D130A, H193A, N295A and S512AIn an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of an SCP where said inactivation is accomplishedby replacing at least four amino acids of the wild type sequence. Preferably, said replacement of 5at least four amino acids is in the protease domain. In an embodiment, said replacement of atleast four amino acids is in part 1 of the protease domain. In an embodiment, said replacementof at least four amino acid is in part 2 of the protease domain. In an embodiment, said at leastfour amino acids replacements are D130A, H193A, N295A and S512AIn an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of the 10invention is an enzymatically inactive fragment of SCP which comprises the protease domain, theprotease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but doesnot comprise the export signal presequence, the pro-sequence and the cell wall anchor domain,where said inactivation is accomplished by replacing at least four amino acids of the wild typesequence. Preferably, said replacement of at least four amino acids is in the protease domain. In 15an embodiment, said replacement of at least four amino acids is in part 1 of the protease domain.In an embodiment, said replacement of at least four amino acid is in part 2 of the protease domain.In an embodiment, said at least four amino acids replacements are D130A, H193A, N295A andS512AIn an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of the 20invention is an enzymatically inactive fragment of SCPA which comprises the protease domain,the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains butdoes not comprise the export signal presequence, the pro-sequence and the cell wall anchordomain, where said inactivation is accomplished by replacing at least four amino acids of the wildtype sequence. Preferably, said replacement of at least four amino acids is in the protease 25domain. In an embodiment, said replacement of at least four amino acids is in part 1 of theprotease domain. In an embodiment, said replacement of at least one amino acids is in part 2 ofthe protease domain. In an embodiment, said at least four amino acids replacements are D130A,H193A, N295A and S512AIn an embodiment, the carrier protein of the serotype 21 saccharide glycoconjugate of the 30invention is an enzymatically inactive fragment of SCPB which comprises the protease domain,the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains butdoes not comprise the export signal presequence, the pro-sequence and the cell wall anchordomain, where said inactivation is accomplished by replacing at least four amino acids of the wildtype sequence. Preferably, said replacement of at least four amino acids is in the protease 35domain. In an embodiment, said replacement of at least four amino acids is in part 1 of theprotease domain. In an embodiment, said replacement of at least four amino acids is in part 2 of 115the protease domain. In an embodiment, said at least four amino acids replacements are D130A,H193A, N295A and S512AIn a particular embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP which consists ofSEQ ID NO: 1. 5In a particular embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP which consists ofSEQ ID NO: 2.
SEQ ID NO: 1 : 10 MAKTADTPATSKATIRDLNDPSQVKTLQEKAGKGAGTVVAVIAAGFDKNH EAWRLTDKAKARYQSKEDLEKAKKEHGITYGEWVNDKVAYYHDYSKDGKT AVDQEHGTHVSGILSGNAPSETKEPYRLEGAMPEAQLLLMRVEIVNGLAD YARNYAQAIRDAINLGAKVINMSFGNAALAYANLPDETKKAFDYAKSKGV SIVTSAGNDSSFGGKTRLPLADHPDYGVVGTPAAADSTLTVASYSPDKQL 15 TETVTVKTADQQDKEMPVLSTNRFEPNKAYDYAYANRGTKEDDFKDVKGK IALIERGDIDFKDKIAKAKKAGAVGVLIYDNQDKGFPIELPNVDQMPAAF ISRKDGLLLKDNPQKTITFNATPKVLPTASGTKLSRFSSWGLTADGNIKP DIAAPGQDILSSVANNKYAKLSGTAMSAPLVAGIMGLLQEQYETQYPDMT PSERLDLAKKVLMSSATALYDEDEKAYFSPRQQGAGAVDAKKASAATMYV 20 TDKDNTSSKVHLNNVSDKFEVTVTVHNKSDKPQELYYQATVQTDKVDGKH FALAPKALYETSWQKITIPANSSKQVTVPIDASRFSKDLLAQMKNGYFLE GFVRFKQDPKKEELMSIPYIGFRGDFGNLSALEKPIYDSKDGSSYYHEAN SDAKDQLDGDGLQFYALKNNFTALTTESNPWTIIKAVKEGVENIEDIESS EITETIFAGTFAKQDDDSHYYIHRHANGKPYAAISPNGDGNRDYVQFQGT 25 FLRNAKNLVAEVLDKEGNVVWTSEVTEQVVKNYNNDLASTLGSTRFEKTR WDGKDKDGKVVANGTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATS ATFSTEDRRLTLASKPKTSQPVYRERIAYTYMDEDLPTTEYISPNEDGTF TLPEEAETMEGATVPLKMSDFTYVVEDMAGNITYTPVTKLLEGHSNKPEQSEQ ID NO: 1 is 950 amino acids long.
SEQ ID NO: 2 : AKTADTPATSKATIRDLNDPSQVKTLQEKAGKGAGTVVAVIAAGFDKNH EAWRLTDKAKARYQSKEDLEKAKKEHGITYGEWVNDKVAYYHDYSKDGKT 35 AVDQEHGTHVSGILSGNAPSETKEPYRLEGAMPEAQLLLMRVEIVNGLAD YARNYAQAIRDAINLGAKVINMSFGNAALAYANLPDETKKAFDYAKSKGV SIVTSAGNDSSFGGKTRLPLADHPDYGVVGTPAAADSTLTVASYSPDKQL 116 TETVTVKTADQQDKEMPVLSTNRFEPNKAYDYAYANRGTKEDDFKDVKGK IALIERGDIDFKDKIAKAKKAGAVGVLIYDNQDKGFPIELPNVDQMPAAF ISRKDGLLLKDNPQKTITFNATPKVLPTASGTKLSRFSSWGLTADGNIKP DIAAPGQDILSSVANNKYAKLSGTAMSAPLVAGIMGLLQEQYETQYPDMT PSERLDLAKKVLMSSATALYDEDEKAYFSPRQQGAGAVDAKKASAATMYV 5 TDKDNTSSKVHLNNVSDKFEVTVTVHNKSDKPQELYYQATVQTDKVDGKH FALAPKALYETSWQKITIPANSSKQVTVPIDASRFSKDLLAQMKNGYFLE GFVRFKQDPKKEELMSIPYIGFRGDFGNLSALEKPIYDSKDGSSYYHEAN SDAKDQLDGDGLQFYALKNNFTALTTESNPWTIIKAVKEGVENIEDIESS EITETIFAGTFAKQDDDSHYYIHRHANGKPYAAISPNGDGNRDYVQFQGT 10 FLRNAKNLVAEVLDKEGNVVWTSEVTEQVVKNYNNDLASTLGSTRFEKTR WDGKDKDGKVVANGTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATS ATFSTEDRRLTLASKPKTSQPVYRERIAYTYMDEDLPTTEYISPNEDGTF TLPEEAETMEGATVPLKMSDFTYVVEDMAGNITYTPVTKLLEGHSNKPEQSEQ ID NO: 2 is 949 amino acids long.
In a particular embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 90% identity with SEQ ID NO: 1. 20In a particular embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 95% identity with SEQ ID NO: 1.In a particular embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of a 25polypeptide having at least 99% identity with SEQ ID NO: 1.In a particular embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 99.5% identity with SEQ ID NO: 1.In a particular embodiment, the carrier protein of the serotype 21 saccharide 30glycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 99.8% identity with SEQ ID NO: 1.In a particular embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 99.85% identity with SEQ ID NO: 1. 35In a particular embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 90% identity with SEQ ID NO: 2. 117In a particular embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 95% identity with SEQ ID NO: 2.In a particular embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of a 5polypeptide having at least 99% identity with SEQ ID NO: 2.In a particular embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 99.5% identity with SEQ ID NO: 2.In a particular embodiment, the carrier protein of the serotype 21 saccharide 10glycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 99.8% identity with SEQ ID NO: 2.In a particular embodiment, the carrier protein of the serotype 21 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 99.85% identity with SEQ ID NO: 2. 15 3. Immunogenic compositions In an embodiment the invention relates to an immunogenic composition comprising a S.pneumoniae serotype 21 saccharide of the invention.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention. 20In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and comprising from 1to 45 different glycoconjugates.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and comprising from 1 25to 45 glycoconjugates from different serotypes of S. pneumoniae (1 to 45 pneumococcalconjugates).In one embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25different serotypes of S. pneumoniae. In one embodiment the immunogenic composition 30comprises glycoconjugates from 16 or 20 different serotypes of S. pneumoniae.In an embodiment the immunogenic composition is a 21, 22, 23, 24 or 25-valentpneumococcal conjugate composition.In an embodiment the immunogenic composition is a 21-valent pneumococcal conjugatecomposition. In an embodiment the immunogenic composition is a 22-valent pneumococcal 35conjugate composition. In an embodiment the immunogenic composition is a 23-valentpneumococcal conjugate composition. In an embodiment the immunogenic composition is a 24- 118valent pneumococcal conjugate composition. In an embodiment the immunogenic composition isa 25-valent pneumococcal conjugate composition.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and comprising from 26to 45 glycoconjugates from different serotypes of S. pneumoniae (26 to 45 pneumococcal 5conjugates). In one embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 ordifferent serotypes of S. pneumoniae.In one embodiment the immunogenic composition comprises glycoconjugates from 35 ordifferent serotypes of S. pneumoniae. In an embodiment the immunogenic composition is a 1035, 36, 37, 38, 39, 40, 41, 42, 43, 44 or 45-valent pneumococcal conjugate compositions. In anembodiment the immunogenic composition is a 40, 41, 42, 43, 44 or 45-valent pneumococcalconjugate compositions. In an embodiment the immunogenic composition is a 40-valentpneumococcal conjugate composition. In an embodiment the immunogenic composition is a 41-valent pneumococcal conjugate composition. In an embodiment the immunogenic composition is 15a 42-valent pneumococcal conjugate composition. In an embodiment the immunogeniccomposition is a 43-valent pneumococcal conjugate composition. In an embodiment theimmunogenic composition is a 44-valent pneumococcal conjugate composition. In anembodiment the immunogenic composition is a 45-valent pneumococcal conjugate composition.In an embodiment the invention relates to an immunogenic composition comprising a 20Streptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F.In an embodiment said immunogenic composition comprises in addition glycoconjugatesfrom S. pneumoniae serotypes 1, 5 and 7F.In an embodiment any of the immunogenic compositions above comprises in addition 25glycoconjugates from S. pneumoniae serotype 3.In an embodiment any of the immunogenic compositions above comprises in additionglycoconjugates from S. pneumoniae serotypes 6A and 19A.In an embodiment any of the immunogenic compositions above comprise in addition aglycoconjugates from S. pneumoniae serotype 22F and 33F. 30In an embodiment any of the immunogenic compositions above comprise in addition aglycoconjugates from S. pneumoniae serotypes 8, 10A, 11A, 12F and 15B.In an embodiment any of the immunogenic compositions above comprise in addition aglycoconjugates from S. pneumoniae serotype 2.In an embodiment any of the immunogenic compositions above comprise in addition a 35glycoconjugates from S. pneumoniae serotype 9N.In an embodiment any of the immunogenic compositions above comprise in addition aglycoconjugates from S. pneumoniae serotype 17F. 119In an embodiment any of the immunogenic compositions above comprise in addition aglycoconjugates from S. pneumoniae serotype 20.In an embodiment any of the immunogenic compositions above comprise in addition aglycoconjugates from S. pneumoniae serotype 15C.In an embodiment the invention relates to an immunogenic composition comprising a 5Streptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. In anembodiment the immunogenic composition is an 8-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprising 10glycoconjugates from S. pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. In anembodiment the immunogenic composition is an 11-valent pneumococcal conjugatecompositions.In an embodiment the invention relates to an immunogenic composition comprising a S.pneumoniae serotype 21 glycoconjugate of the invention and further comprising glycoconjugates 15from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. In anembodiment the immunogenic composition is a 14-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 2022F, 23F and 33F. In an embodiment the immunogenic composition is a 16-valent pneumococcalconjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 2515B, 18C, 19A, 19F, 22F, 23F and 33F. In an embodiment the immunogenic composition is a 21-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 3015C, 18C, 19A, 19F, 22F, 23F and 33F. In an embodiment the immunogenic composition is a 21-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 3514, 15B, 18C, 19A, 19F, 22F, 23F and 33F. In an embodiment the immunogenic composition isa 22-valent pneumococcal conjugate compositions. 120In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F,14, 15C, 18C, 19A, 19F, 22F, 23F and 33F. In an embodiment the immunogenic composition isa 22-valent pneumococcal conjugate compositions. 5In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A, 12F,14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. In an embodiment the immunogenic composition isa 22-valent pneumococcal conjugate compositions. 10In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A,12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. In an embodiment the immunogenic compositionis a 23-valent pneumococcal conjugate compositions. 15In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A,12F, 14, 15B, 17F, 18C, 19A, 19F, 22F, 23F and 33F. In an embodiment the immunogeniccomposition is a 24-valent pneumococcal conjugate compositions. 20In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A,12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. In an embodiment the immunogeniccomposition is a 25-valent pneumococcal conjugate compositions. 25In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23F and 33F. In an embodiment the immunogenic composition isa 22-valent pneumococcal conjugate compositions. 30In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23A, 23F and 33F. In an embodiment the immunogenic composition isa 22-valent pneumococcal conjugate compositions. 35In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 12115B, 18C, 19A, 19F, 22F, 23B, 23F and 33F. In an embodiment the immunogenic composition isa 22-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 515B, 18C, 19A, 19F, 22F, 23F, 24F and 33F. In an embodiment the immunogenic composition isa 22-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 1015B, 18C, 19A, 19F, 22F, 23F, 33F and 35B. In an embodiment the immunogenic composition isa 22-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 1515A, 15B, 18C, 19A, 19F, 22F, 23A, 23F and 33F. In an embodiment the immunogeniccomposition is a 23-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 2015A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B. In one embodiment, the S.pneumoniae saccharides are conjugated to CRM 197. In one embodiment, the S. pneumoniaesaccharides from serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A,19F, 22F, 23A, 23B, 23F, 24F, 33F, 35B and 21 are conjugated to CRM 197 and the S. pneumoniaesaccharide from serotype 3 is conjugated to SCP. In an embodiment the immunogenic 25composition is a 26-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingat least one glycoconjugate selected from the group consisting of glycoconjugates from S.pneumoniae serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 20, 22A, 23A, 23B, 24B, 24F, 27, 29, 3031, 33B, 34, 35B, 35F and 38.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingtwenty one glycoconjugates selected from the group consisting of glycoconjugates from S.pneumoniae serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 20, 22A, 23A, 23B, 24B, 24F, 27, 29, 3531, 33B, 34, 35B, 35F and 38. In an embodiment the immunogenic composition is a 22-valentpneumococcal conjugate compositions. 122In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 20, 22A, 23A, 23B, 24B, 24F,27, 29, 31, 33B, 34, 35B, 35F and 38. In an embodiment the immunogenic composition is a 23-valent pneumococcal conjugate compositions. 5In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingat least one glycoconjugate selected from the group consisting of glycoconjugates from S.pneumoniae serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 19A, 19F, 20, 22A, 23A, 23B, 24B, 24F,27, 29, 31, 33B, 34, 35B, 35F and 38. 10In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingtwenty two glycoconjugates selected from the group consisting of glycoconjugates from S.pneumoniae serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 19A, 19F, 20, 22A, 23A, 23B, 24B, 24F,27, 29, 31, 33B, 34, 35B, 35F and 38. In an embodiment the immunogenic composition is a 23- 15valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingtwenty three glycoconjugates selected from the group consisting of glycoconjugates from S.pneumoniae serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 19A, 19F, 20, 22A, 23A, 23B, 24B, 24F, 2027, 29, 31, 33B, 34, 35B, 35F and 38. In an embodiment the immunogenic composition is a 24-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 20, 22A, 23A, 23B, 24B, 24F, 2527, 29, 31, 33B, 34, 35B, 35F and 38. In an embodiment the immunogenic composition is a 23-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 21 glycoconjugate of the invention and further comprisingglycoconjugates from serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 19A, 19F, 20, 22A, 23A, 23B, 3024B, 24F, 27, 29, 31, 33B, 34, 35B, 35F and 38. In an embodiment the immunogenic compositionis a 25-valent pneumococcal conjugate compositions.
Compositions of the invention may include a small amount of free carrier. When a givencarrier protein is present in both free and conjugated form in a composition of the invention, the 35unconjugated form is preferably no more than 5% of the total amount of the carrier protein in thecomposition as a whole, and more preferably present at less than 2% by weight. 123 4 Adjuvant(s) In some embodiments, the immunogenic compositions disclosed herein may furthercomprise at least one, two or three adjuvants. In some embodiments, the immunogeniccompositions disclosed herein may further comprise at least one adjuvant.In some embodiments, the immunogenic compositions disclosed herein may further 5comprise one adjuvant.In some embodiments, the immunogenic compositions disclosed herein may furthercomprise two adjuvants.The term "adjuvant" refers to a compound or mixture that enhances the immune responseto an antigen. Antigens may act primarily as a delivery system, primarily as an immune modulator 10or have strong features of both. Suitable adjuvants include those suitable for use in mammals,including humans.Examples of known suitable delivery-system type adjuvants that can be used in humansinclude, but are not limited to, alum (e.g., aluminum phosphate, aluminum sulfate or aluminumhydroxide), calcium phosphate, liposomes, oil-in-water emulsions such as MF59 (4.3% w/v 15squalene, 0.5% w/v polysorbate 80 (Tween 80), 0.5% w/v sorbitan trioleate (Span 85)), water-in-oil emulsions such as Montanide, and poly(D,L-lactide-co-glycolide) (PLG) microparticles ornanoparticles.In an embodiment, the immunogenic compositions disclosed herein comprise aluminumsalts (alum) as adjuvant (e.g., aluminum phosphate, aluminum sulfate or aluminum hydroxide). 20In a preferred embodiment, the immunogenic compositions disclosed herein comprisealuminum phosphate or aluminum hydroxide as adjuvant. In an even preferred embodiment, theimmunogenic compositions disclosed herein comprise aluminum phosphate as adjuvant.Further exemplary adjuvants to enhance effectiveness of the immunogenic compositionsas disclosed herein include, but are not limited to: (1) oil-in-water emulsion formulations (with or 25without other specific immunostimulating agents such as muramyl peptides (see below) orbacterial cell wall components), such as for example (a) SAF, containing 10% Squalene, 0.4%Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP either microfluidized into a submicronemulsion or vortexed to generate a larger particle size emulsion, and (b) RIBI™ adjuvant system(RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or 30more bacterial cell wall components such as monophosphorylipid A (MPL), trehalose dimycolate(TDM), and cell wall skeleton (CWS), preferably MPL + CWS (DETOX™); (2) saponin adjuvants,such as QS21, STIMULON™ (Cambridge Bioscience, Worcester, MA), ABISCO® (Isconova,Sweden), or ISCOMATRIX® (Commonwealth Serum Laboratories, Australia), may be used orparticles generated therefrom such as ISCOMs (immunostimulating complexes), which ISCOMS 35may be devoid of additional detergent (e.g., WO 00/07621); (3) Complete Freund's Adjuvant(CFA) and Incomplete Freund's Adjuvant (IFA); (4) cytokines, such as interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 (e.g., WO 99/44636)), interferons (e.g., gamma interferon), 124macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.; (5)monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL) (see, e.g., GB-2220221,EP0689454), optionally in the substantial absence of alum when used with pneumococcalsaccharides (see, e.g., WO 00/56358); (6) combinations of 3dMPL with, for example, QS21 and/oroil-in-water emulsions (see, e.g., EP0835318, EP0735898, EP0761231); (7) a polyoxyethylene 5ether or a polyoxyethylene ester (see, e.g., WO 99/52549); (8) a polyoxyethylene sorbitan estersurfactant in combination with an octoxynol (e.g., WO 01/21207) or a polyoxyethylene alkyl etheror ester surfactant in combination with at least one additional non-ionic surfactant such as anoctoxynol (e.g., WO 01/21152); (9) a saponin and an immunostimulatory oligonucleotide (e.g., aCpG oligonucleotide) (e.g., WO 00/62800); (10) an immunostimulant and a particle of metal salt 10(see, e.g., WO 00/23105); (11) a saponin and an oil-in-water emulsion (e.g., WO 99/11241); (12)a saponin (e.g., QS21) + 3dMPL + IM2 (optionally + a sterol) (e.g., WO 98/57659); (13) othersubstances that act as immunostimulating agents to enhance the efficacy of the composition.Muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-25 acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutarninyl-L- 15alanine-2-(1'-2'-dipalmitoyl-sn-gIycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE), etc.In an embodiment of the present invention, the immunogenic compositions as disclosedherein comprise a CpG Oligonucleotide as adjuvant. A CpG oligonucleotide as used herein refersto an immunostimulatory CpG oligodeoxynucleotide (CpG ODN), and accordingly these termsare used interchangeably unless otherwise indicated. Immunostimulatory CpG 20oligodeoxynucleotides contain one or more immunostimulatory CpG motifs that are unmethylatedcytosine-guanine dinucleotides, optionally within certain preferred base contexts. The methylationstatus of the CpG immunostimulatory motif generally refers to the cytosine residue in thedinucleotide. An immunostimulatory oligonucleotide containing at least one unmethylated CpGdinucleotide is an oligonucleotide which contains a 5' unmethylated cytosine linked by a 25phosphate bond to a 3' guanine, and which activates the immune system through binding to Toll-like receptor 9 (TLR-9). In another embodiment the immunostimulatory oligonucleotide maycontain one or more methylated CpG dinucleotides, which will activate the immune systemthrough TLR9 but not as strongly as if the CpG motif(s) was/were unmethylated. CpGimmunostimulatory oligonucleotides may comprise one or more palindromes that in turn may 30encompass the CpG dinucleotide. CpG oligonucleotides have been described in a number ofissued patents, published patent applications, and other publications, including U.S. Patent Nos.6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068.In an embodiment of the present invention, the immunogenic compositions as disclosed hereincomprise any of the CpG Oligonucleotide described at page 3, line 22, to page 12, line 36, of WO 352010/125480.Different classes of CpG immunostimulatory oligonucleotides have been identified. Theseare referred to as A, B, C and P class, and are described in greater detail at page 3, line 22, to 125page 12, line 36, of WO 2010/125480. Methods of the invention embrace the use of these differentclasses of CpG immunostimulatory oligonucleotides.
Formulation The immunogenic compositions of the invention may be formulated in liquid form (i.e.,solutions or suspensions) or in a lyophilized form. In an embodiment, the immunogenic 5composition of the invention is formulated in a liquid form. In an embodiment, the immunogeniccomposition of the invention is formulated in a lyophilized form. Liquid formulations mayadvantageously be administered directly from their packaged form and are thus ideal for injectionwithout the need for reconstitution in aqueous medium as otherwise required for lyophilizedcompositions of the invention. 10Formulation of the immunogenic composition of the present disclosure can be accomplishedusing art-recognized methods. For instance, the individual polysaccharides and/or conjugates canbe formulated with a physiologically acceptable vehicle to prepare the composition. Examples ofsuch vehicles include, but are not limited to, water, buffered saline, polyols (e.g., glycerol,propylene glycol, liquid polyethylene glycol) and dextrose solutions. 15The present disclosure provides an immunogenic composition comprising any ofcombination of glycoconjugates disclosed herein and a pharmaceutically acceptable excipient,carrier, or diluent.In an embodiment, the immunogenic composition of the disclosure is in liquid form,preferably in aqueous liquid form. 20Immunogenic compositions of the disclosure may comprise one or more of a buffer, a salt,a divalent cation, a non-ionic detergent, a cryoprotectant such as a sugar, and an anti-oxidantsuch as a free radical scavenger or chelating agent, or any multiple combinations thereof.In an embodiment, the immunogenic compositions of the disclosure comprise a buffer. Inan embodiment, said buffer has a pKa of about 3.5 to about 7.5. In some embodiments, the buffer 25is phosphate, succinate, histidine or citrate. In some embodiments, the buffer is succinate. Insome embodiments, the buffer is histidine. In certain embodiments, the buffer is succinate at afinal concentration of 1 mM to 10 mM. In one particular embodiment, the final concentration of thesuccinate buffer is about 5 mM.In an embodiment, the immunogenic compositions of the disclosure comprise a salt. In 30some embodiments, the salt is selected from the groups consisting of magnesium chloride,potassium chloride, sodium chloride and a combination thereof. In one particular embodiment,the salt is sodium chloride. In one particular embodiment, the immunogenic compositions of theinvention comprise sodium chloride at 150 mM.In an embodiment, the immunogenic compositions of the disclosure comprise a surfactant. 35In an embodiment, the surfactant is selected from the group consisting of polysorbate 20(TWEENTM20), polysorbate 40 (TWEENTM40), polysorbate 60 (TWEEN™60), polysorbate 65(TWEEN™65), polysorbate 80 (TWEEN™80), polysorbate 85 (TWEEN™85), TRITON™ N-101, 126TRITON™ X-100, oxtoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptideoleate, polyoxyethylene-660 hydroxystearate (PEG-15, Solutol H 15), polyoxyethylene-35-ricinoleate (CREMOPHOR® EL), soy lecithin and a poloxamer.In one particular embodiment, the surfactant is polysorbate 80. In some said embodiment,the final concentration of polysorbate 80 in the formulation is at least 0.0001% to 10% polysorbate 5weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 80in the formulation is at least 0.001% to 1% polysorbate 80 weight to weight (w/w). In some saidembodiments, the final concentration of polysorbate 80 in the formulation is at least 0.01% to 1%polysorbate 80 weight to weight (w/w). In other embodiments, the final concentration ofpolysorbate 80 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 100.09% or 0.1% polysorbate 80 (w/w). In another embodiment, the final concentration of thepolysorbate 80 in the formulation is 0.02% polysorbate 80 (w/w). In another embodiment, the finalconcentration of the polysorbate 80 in the formulation is 0.01% polysorbate 80 (w/w). In anotherembodiment, the final concentration of the polysorbate 80 in the formulation is 0.03% polysorbate(w/w). In another embodiment, the final concentration of the polysorbate 80 in the formulation 15is 0.04% polysorbate 80 (w/w). In another embodiment, the final concentration of the polysorbatein the formulation is 0.05% polysorbate 80 (w/w). In another embodiment, the finalconcentration of the polysorbate 80 in the formulation is 1% polysorbate 80 (w/w).In one particular embodiment, the surfactant is polysorbate 20. In some said embodiment,the final concentration of polysorbate 20 in the formulation is at least 0.0001% to 10% polysorbate 20weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 20in the formulation is at least 0.001% to 1% polysorbate 20 weight to weight (w/w). In some saidembodiments, the final concentration of polysorbate 20 in the formulation is at least 0.01% to 1%polysorbate 20 weight to weight (w/w). In other embodiments, the final concentration ofpolysorbate 20 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 250.09% or 0.1% polysorbate 20 (w/w). In another embodiment, the final concentration of thepolysorbate 20 in the formulation is 0.02% polysorbate 20 (w/w). In another embodiment, the finalconcentration of the polysorbate 20 in the formulation is 0.01% polysorbate 20 (w/w). In anotherembodiment, the final concentration of the polysorbate 20 in the formulation is 0.03% polysorbate(w/w). In another embodiment, the final concentration of the polysorbate 20 in the formulation 30is 0.04% polysorbate 80 (w/w). In another embodiment, the final concentration of the polysorbatein the formulation is 0.05% polysorbate 20 (w/w). In another embodiment, the finalconcentration of the polysorbate 20 in the formulation is 1% polysorbate 20 (w/w).In one particular embodiment, the surfactant is polysorbate 40. In some said embodiment,the final concentration of polysorbate 40 in the formulation is at least 0.0001% to 10% polysorbate 35weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 40in the formulation is at least 0.001% to 1% polysorbate 40 weight to weight (w/w). In some saidembodiments, the final concentration of polysorbate 40 in the formulation is at least 0.01% to 1% 127polysorbate 40 weight to weight (w/w). In other embodiments, the final concentration ofpolysorbate 40 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%,0.09% or 0.1% polysorbate 40 (w/w). In another embodiment, the final concentration of thepolysorbate 40 in the formulation is 1% polysorbate 40 (w/w).In one particular embodiment, the surfactant is polysorbate 60. In some said embodiment, 5the final concentration of polysorbate 60 in the formulation is at least 0.0001% to 10% polysorbateweight to weight (w/w). In some said embodiments, the final concentration of polysorbate 60in the formulation is at least 0.001% to 1% polysorbate 60 weight to weight (w/w). In some saidembodiments, the final concentration of polysorbate 60 in the formulation is at least 0.01% to 1%polysorbate 60 weight to weight (w/w). In other embodiments, the final concentration of 10polysorbate 60 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%,0.09% or 0.1% polysorbate 60 (w/w). In another embodiment, the final concentration of thepolysorbate 60 in the formulation is 1% polysorbate 60 (w/w).In one particular embodiment, the surfactant is polysorbate 65. In some said embodiment,the final concentration of polysorbate 65 in the formulation is at least 0.0001% to 10% polysorbate 15weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 65in the formulation is at least 0.001% to 1% polysorbate 65 weight to weight (w/w). In some saidembodiments, the final concentration of polysorbate 65 in the formulation is at least 0.01% to 1%polysorbate 65 weight to weight (w/w). In other embodiments, the final concentration ofpolysorbate 65 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 200.09% or 0.1% polysorbate 65 (w/w). In another embodiment, the final concentration of thepolysorbate 65 in the formulation is 1% polysorbate 65 (w/w).In one particular embodiment, the surfactant is polysorbate 85. In some said embodiment,the final concentration of polysorbate 85 in the formulation is at least 0.0001% to 10% polysorbateweight to weight (w/w). In some said embodiments, the final concentration of polysorbate 85 25in the formulation is at least 0.001% to 1% polysorbate 85 weight to weight (w/w). In some saidembodiments, the final concentration of polysorbate 85 in the formulation is at least 0.01% to 1%polysorbate 85 weight to weight (w/w). In other embodiments, the final concentration ofpolysorbate 85 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%,0.09% or 0.1% polysorbate 85 (w/w). In another embodiment, the final concentration of the 30polysorbate 85 in the formulation is 1% polysorbate 85 (w/w).In certain embodiments, the immunogenic composition of the disclosure has a pH of 5.5to 7.5, more preferably a pH of 5.6 to 7.0, even more preferably a pH of 5.8 to 6.0.In one embodiment, the present disclosure provides a container filled with any of theimmunogenic compositions disclosed herein. In one embodiment, the container is selected from 35the group consisting of a vial, a syringe, a flask, a fermentor, a bioreactor, a bag, a jar, anampoule, a cartridge and a disposable pen. In certain embodiments, the container is siliconized. 128In an embodiment, the container of the present disclosure is made of glass, metals (e.g.,steel, stainless steel, aluminium, etc.) and/or polymers (e.g., thermoplastics, elastomers,thermoplastic-elastomers). In an embodiment, the container of the present disclosure is made ofglass.In one embodiment, the present disclosure provides a syringe filled with any of the 5immunogenic compositions disclosed herein. In certain embodiments, the syringe is siliconizedand/or is made of glass.A typical dose of the immunogenic composition of the invention for injection has a volumeof 0.1 mL to 2 mL. In an embodiment, the immunogenic composition of the invention for injectionhas a volume of 0.2 mL to 1 mL, even more preferably a volume of about 0.5 mL. 10 6 Uses of the glycoconjugate and immunogenic compositions of the invention The glycoconjugates disclosed herein may be use as antigens. For example, they may bepart of a vaccine.Therefore, in an embodiment, the immunogenic compositions of the invention are for useas a medicament. 15In an embodiment, the immunogenic compositions of the invention are for use as avaccine.Therefore, in an embodiment, the immunogenic compositions described herein are for usein generating an immune response in a subject. In one aspect, the subject is a mammal, such asa human, non-human primate, cat, sheep, pig, horse, bovine or dog. Preferably, the subject is a 20human.The immunogenic compositions described herein may be used in therapeutic orprophylactic methods for preventing, treating or ameliorating a bacterial infection, disease orcondition in a subject. In particular, immunogenic compositions described herein may be used toprevent, treat or ameliorate a S. pneumoniae infection, disease or condition in a subject. 25Preferably, the immunogenic compositions described herein may be used to prevent, treat orameliorate S. pneumoniae infection, disease or condition by the serotypes contained in thecomposition in a subject.Thus, in one aspect, the disclosure provides a method of preventing, treating orameliorating an infection, disease or condition associated with S. pneumoniae serotype 21 in a 30subject, comprising administering to the subject an immunologically effective amount of animmunogenic composition of the disclosure.In some such embodiments, the infection, disease or condition is selected from the groupconsisting of pneumonia, sinusitis, otitis media, acute otitis media, meningitis, bacteraemia,sepsis, pleural empyema, conjunctivitis, osteomyelitis, septic arthritis, endocarditis, peritonitis, 35pericarditis, mastoiditis, cellulitis, soft tissue infection and brain abscess.In an embodiment, the disclosure provides a method of inducing an immune response toS. pneumoniae serotype 21 in a subject comprising administering to the subject an 129immunologically effective amount of an immunogenic composition of the invention. In one aspect,the subject is a mammal, such as a human, cat, sheep, pig, horse, bovine or dog. Preferably thesubject is a human.In an embodiment, the immunogenic compositions disclosed herein are for use as avaccine. In such embodiments the immunogenic compositions described herein may be used to 5prevent S. pneumoniae serotype 21 infection in a subject. Thus, in one aspect, the inventionprovides a method of preventing an infection by S. pneumoniae serotype 21 in a subjectcomprising administering to the subject an immunologically effective amount of an immunogeniccomposition of the disclosure. In some such embodiments, the infection is selected from the groupconsisting of pneumonia, sinusitis, otitis media, acute otitis media, meningitis, bacteraemia, 10sepsis, pleural empyema, conjunctivitis, osteomyelitis, septic arthritis, endocarditis, peritonitis,pericarditis, mastoiditis, cellulitis, soft tissue infection and brain abscess. In one aspect, thesubject is a mammal, such as a human, cat, sheep, pig, horse, bovine or dog. Preferably thesubject is a human.The immunogenic composition of the present disclosure can be used to protect or treat a 15human susceptible to a S. pneumoniae serotype 21 infection, by means of administering theimmunogenic composition via a systemic or mucosal route. In an embodiment, the immunogeniccomposition of the invention is administered by intramuscular, intraperitoneal, intradermal orsubcutaneous routes. . In an embodiment, the immunogenic composition of the invention isadministered by intramuscular, intraperitoneal, intradermal or subcutaneous injection. In an 20embodiment, the immunogenic composition of the invention is administered by intramuscular orsubcutaneous injection. In an embodiment, the immunogenic composition of the invention isadministered by intramuscular injection. In an embodiment, the immunogenic composition of theinvention is administered by subcutaneous injection. 7 Subject to be treated with the immunogenic compositions of the invention 25As disclosed herein, the immunogenic compositions described herein may be used invarious therapeutic or prophylactic methods for preventing, treating or ameliorating a bacterialinfection, disease or condition in a subject.In a preferred embodiment, said subject is a human. In a most preferred embodiment, saidsubject is a newborn (i.e., under three months of age), an infant (i.e., from 3 months to one year 30of age) or a toddler (i.e., from one year to four years of age). In an embodiment, the immunogeniccompositions disclosed herein are for use as a vaccine.In such embodiment, the subject to be vaccinated may be less than 1 year of age. Forexample, the subject to be vaccinated can be about 1, about 2, about 3, about 4, about 5, about6, about 7, about 8, about 9, about 10, about 11 or about 12 months of age. In an embodiment, 35the subject to be vaccinated is about 2, about 4 or about 6 months of age. In another embodiment,the subject to be vaccinated is less than 2 years of age. For example, the subject to be vaccinatedcan be about 12 to about 15 months of age. In some cases, as little as one dose of the 130immunogenic composition according to the invention is needed, but under some circumstances,a second, third or fourth dose may be given (see section 8 below).In an embodiment of the present invention, the subject to be vaccinated is a human adultyears of age or older, more preferably a human adult 55 years of age or older. In anembodiment, the subject to be vaccinated is a human adult 65 years of age or older, 70 years of 5age or older, 75 years of age or older or 80 years of age or older.In an embodiment the subject to be vaccinated is an immunocompromised individual, inparticular a human. An immunocompromised individual is generally defined as a person whoexhibits an attenuated or reduced ability to mount a normal humoral or cellular defense tochallenge by infectious agents. 10In an embodiment of the present invention, the immunocompromised subject to bevaccinated suffers from a disease or condition that impairs the immune system and results in anantibody response that is insufficient to protect against or treat pneumococcal disease.In an embodiment, said disease is a primary immunodeficiency disorder. Preferably, saidprimary immunodeficiency disorder is selected from the group consisting of: combined T- and B- 15cell immunodeficiencies, antibody deficiencies, well-defined syndromes, immune dysregulationdiseases, phagocyte disorders, innate immunity deficiencies, autoinflammatory disorders, andcomplement deficiencies. In an embodiment, said primary immunodeficiency disorder is selectedfrom the one disclosed on page 24, line 11, to page 25, line 19, of WO 2010/125480.In a particular embodiment of the present invention, the immunocompromised subject to 20be vaccinated suffers from a disease selected from the groups consisting of: HIV-infection,acquired immunodeficiency syndrome (AIDS), cancer, chronic heart or lung disorders, congestiveheart failure, diabetes mellitus, chronic liver disease, alcoholism, cirrhosis, spinal fluid leaks,cardiomyopathy, chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD),spleen dysfunction (such as sickle cell disease), lack of spleen function (asplenia), blood 25malignancy, leukemia, multiple myeloma, Hodgkin’s disease, lymphoma, kidney failure, nephroticsyndrome and asthma.In an embodiment of the present invention, the immunocompromised subject to be vaccinatedsuffers from malnutrition.In a particular embodiment of the present invention, the immunocompromised subject to 30be vaccinated is taking a drug or treatment that lowers the body’s resistance to infection. In anembodiment, said drug is selected from the one disclosed on page 26, line 33, to page 26, line 4,of WO 2010/125480.In a particular embodiment of the present invention, the immunocompromised subject tobe vaccinated is a smoker. 35In a particular embodiment of the present invention, the immunocompromised subject tobe vaccinated has a white blood cell count (leukocyte count) below 5 x 10 cells per liter, or belowx 10 cells per liter, or below 3 x 10 cells per liter, or below 2 x 10 cells per liter, or below 1 x 1319 cells per liter, or below 0.5 x 10 cells per liter, or below 0.3 x 10 cells per liter, or below 0.1x 10 cells per liter.White blood cell count (leukocyte count): The number of white blood cells (WBC) in theblood. The WBC is usually measured as part of the CBC (complete blood count). White bloodcells are the infection-fighting cells in the blood and are distinct from the red (oxygen-carrying) 5blood cells known as erythrocytes. There are different types of white blood cells, includingneutrophils (polymorphonuclear leukocytes; PMN), band cells (slightly immature neutrophils), T-type lymphocytes (T-cells), B-type lymphocytes (B-cells), monocytes, eosinophils, and basophils.All the types of white blood cells are reflected in the white blood cell count. The normal range forthe white blood cell count is usually between 4,300 and 10,800 cells per cubic millimeter of blood. 10This can also be referred to as the leukocyte count and can be expressed in international unitsas 4.3 - 10.8 x 10 cells per liter.In a particular embodiment of the present invention, the immunocompromised subject tobe vaccinated suffers from neutropenia. In a particular embodiment of the present invention, theimmunocompromised subject to be vaccinated has a neutrophil count below 2 x 10 cells per liter, 15or below 1 x 10 cells per liter, or below 0.5 x 10 cells per liter, or below 0.1 x 10 cells per liter,or below 0.05 x 10 cells per liter.A low white blood cell count or "neutropenia" is a condition characterized by abnormally low levelsof neutrophils in the circulating blood. Neutrophils are a specific kind of white blood cell that helpto prevent and fight infections. The most common reason that cancer patients experience 20neutropenia is as a side effect of chemotherapy. Chemotherapy-induced neutropenia increasesa patient’s risk of infection and disrupts cancer treatment.In a particular embodiment of the present invention, the immunocompromised subject tobe vaccinated has a CD4+ cell count below 500/mm, or CD4+ cell count below 300/mm, orCD4+ cell count below 200/mm, CD4+ cell count below 100/mm, CD4+ cell count below 2575/mm, or CD4+ cell count below 50/mm.CD4 cell tests are normally reported as the number of cells in mm. Normal CD4 counts arebetween 500 and 1,600, and CD8 counts are between 375 and 1,100. CD4 counts dropdramatically in people with HIV.In an embodiment of the invention, any of the immunocompromised subjects disclosed 30herein is a human male or a human female. 8 Regimen In some cases, as little as one dose of the immunogenic composition according to theinvention is needed, but under some circumstances, such as conditions of greater immunedeficiency, a second, third or fourth dose may be given. Following an initial vaccination, subjects 35can receive one or several booster immunizations adequately spaced. 132In an embodiment, the schedule of vaccination of the immunogenic composition accordingto the invention is a single dose. In a particular embodiment, said single dose schedule is forhealthy persons being at least 2 years of age.In an embodiment, the schedule of vaccination of the immunogenic composition accordingto the invention is a multiple dose schedule. In a particular embodiment, said multiple dose 5schedule consists of a series of 2 doses separated by an interval of about 1 month to about 2months. In a particular embodiment, said multiple dose schedule consists of a series of 2 dosesseparated by an interval of about 1 month, or a series of 2 doses separated by an interval of aboutmonths.In another embodiment, said multiple dose schedule consists of a series of 3 doses 10separated by an interval of about 1 month to about 2 months. In another embodiment, saidmultiple dose schedule consists of a series of 3 doses separated by an interval of about 1 month,or a series of 3 doses separated by an interval of about 2 months.In another embodiment, said multiple dose schedule consists of a series of 3 dosesseparated by an interval of about 1 month to about 2 months followed by a fourth dose about 10 15months to about 13 months after the first dose. In another embodiment, said multiple doseschedule consists of a series of 3 doses separated by an interval of about 1 month followed by afourth dose about 10 months to about 13 months after the first dose, or a series of 3 dosesseparated by an interval of about 2 months followed by a fourth dose about 10 months to aboutmonths after the first dose. 20In an embodiment, the multiple dose schedule consists of at least one dose (e.g., 1, 2 ordoses) in the first year of age followed by at least one toddler dose.In an embodiment, the multiple dose schedule consists of a series of 2 or 3 dosesseparated by an interval of about 1 month to about 2 months (for example 28-56 days betweendoses), starting at 2 months of age, and followed by a toddler dose at 12-18 months of age. In an 25embodiment, said multiple dose schedule consists of a series of 3 doses separated by an intervalof about 1 month to about 2 months (for example 28-56 days between doses), starting at 2 monthsof age, and followed by a toddler dose at 12-15 months of age. In another embodiment, saidmultiple dose schedule consists of a series of 2 doses separated by an interval of about 2 months,starting at 2 months of age, and followed by a toddler dose at 12-18 months of age. 30In an embodiment, the multiple dose schedule consists of a 4-dose series of vaccine at 2,4, 6, and 12-15 months of age.In an embodiment, a prime dose is given at day 0 and one or more boosts are given atintervals that range from about 2 to about 24 weeks, preferably with a dosing interval of 4-8 weeks.In an embodiment, a prime dose is given at day 0 and a boost is given about 3 months 35later. 133 9. Analytical methods Native serotype 21 polysaccharide is O-acetylated and the total amount of O-acetylationhas been found to be approximately one O-acetyl group per polysaccharide repeating unit. Thedegree of O-acetylation of the polysaccharide can be determined by any method known in theart, for example, by proton NMR or by ion-HPLC analysis (see for example Lemercinier et al. 5(1996) Carbohydrate Research 296:83-96; Jones et al. (2002) J. Pharmaceutical and BiomedicalAnalysis 30:1233-1247; Hestrin, S. (1949) J. Biol. Chem. 180:249-261).In an embodiment the invention relates to a method of detecting the presence of O-acetylgroups in an isolated S. pneumoniae serotype 21 polysaccharide, said method comprising thestep of: a) isolating an S. pneumoniae serotype 21 polysaccharide and b) detecting the presence 10of O-acetyl groups in said polysaccharide.In an embodiment the presence of O-acetyl groups is detected by NMR, MassSpectrometry (MS) or High-performance liquid chromatography (HPLC).In an embodiment the presence of O-acetyl groups is detected by NMR.In an embodiment the presence of O-acetyl groups is detected by Mass Spectrometry 15(MS).In a preferred embodiment the presence of O-acetyl groups is detected by High-performance liquid chromatography (HPLC).In an embodiment, the invention relates to a method of detecting the presence of O-acetylgroups in a reduced serotype 21 polysaccharide, said method comprising the step of: a) reacting 20an isolated S. pneumoniae serotype 21 polysaccharide with a reducing agent and b) detectingthe presence of O-acetyl groups in said reduced polysaccharide.In an embodiment the presence of O-acetyl groups is detected by NMR, MassSpectrometry (MS) or High-performance liquid chromatography (HPLC).In an embodiment the presence of O-acetyl groups is detected by NMR. 25In an embodiment the presence of O-acetyl groups is detected by Mass Spectrometry(MS).In a preferred embodiment the presence of O-acetyl groups is detected by High-performance liquid chromatography (HPLC).In an embodiment, said reducing agent is sodium borohydride (NaBH4). 30In an embodiment, said isolated S. pneumoniae serotype 21 polysaccharide has beenpreviously treated with an oxidizing agent. In an embodiment, the oxidizing agent is any oxidizingagent which oxidizes a terminal hydroxyl group to an aldehyde. In an embodiment, the oxidizingagent is periodate. In an embodiment, the oxidizing agent is orthoperiodate. In a preferredembodiment, the oxidizing agent is sodium periodate. In an embodiment, the oxidizing agent is 35metaperiodate. In a preferred embodiment the oxidizing agent is sodium metaperiodate.In an embodiment, said isolated S. pneumoniae serotype 21 polysaccharide has beenpreviously treated with a stable nitroxyl radical compound and an oxidant. In an aspect, said stable 134nitroxyl radical compound is a molecule bearing a TEMPO or a PROXYL (2,2,5,5-tetramethyl-1-pyrrolidinyloxy) moiety. Preferably said molecule has the ability to selectively oxidize primaryalcohol in the presence of an oxidant, to generate aldehyde groups, without affecting secondaryhydroxyl groups. More preferably said molecule has the ability to selectively oxidize primaryalcohol in the presence of an oxidant, to generate aldehyde groups, without over oxidation to 5carboxyl groups. In an aspect, said stable nitroxyl radical compound is TEMPO, 2,2,6,6-Tetramethyl-4-(methylsulfonyloxy)-1-piperidinooxy, 4-Phosphonooxy-TEMPO, 4-Oxo-TEMPO,4-Methoxy-TEMPO, 4-Isothiocyanato-TEMPO, 4-(2-Iodoacetamido)-TEMPO free radical, 4-Hydroxy-TEMPO, 4-Cyano-TEMPO, 4-Carboxy-TEMPO, 4-(2-Bromoacetamido)-TEMPO, 4-Amino-TEMPO or 4-Acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl. In an aspect, said stable 10nitroxyl radical compound is selected from the groups consisting of TEMPO, 2,2,6,6-Tetramethyl-4-(methylsulfonyloxy)-1-piperidinooxy, 4-Phosphonooxy-TEMPO, 4-Oxo-TEMPO, 4-Methoxy-TEMPO, 4-Isothiocyanato-TEMPO, 4-(2-Iodoacetamido)-TEMPO free radical, 4-Hydroxy-TEMPO, 4-Cyano-TEMPO, 4-Carboxy-TEMPO, 4-(2-Bromoacetamido)-TEMPO, 4-Amino-TEMPO, 4-Acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl. Preferably said stable nitroxyl radical 15compound is TEMPO. In a further aspect, said stable nitroxyl radical compound is 3 β-DOXYL-5 α-cholestane, 5-DOXYL-stearic acid, 16-DOXYL-stearic acid, Methyl 5-DOXYL-stearate, 3-(Aminomethyl)-PROXYL, 3-Carbamoyl-PROXYL, 3-Carbamoyl-2,2,5,5-tetramethyl-3-pyrrolin-1-oxyl, 3-Carboxy-PROXYL or 3-Cyano-PROXYL. In a further aspect, said stable nitroxyl radicalcompound is selected from the groups consisting of 3 β-DOXYL-5 α-cholestane, 5-DOXYL-stearic 20acid, 16-DOXYL-stearic acid, Methyl 5-DOXYL-stearate, 3-(Aminomethyl)-PROXYL, 3-Carbamoyl-PROXYL, 3-Carbamoyl-2,2,5,5-tetramethyl-3-pyrrolin-1-oxyl, 3-Carboxy-PROXYL, 3-Cyano-PROXYL. In an aspect, the oxidant is a molecule bearing a N-halo moiety. Preferably saidmolecule has the ability to selectively oxidize primary alcohol in the presence of a nitroxyl radicalcompound. In an aspect, said oxidant is N-Chlorosuccinimide, N-Bromosuccinimide, N- 25Iodosuccinimide, Dichloroisocyanuric acid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione,Dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione, Diiodoisocyanuric acid or1,3,5-triiodo-1,3,5-triazinane-2,4,6-trione. In an aspect, said oxidant is selected from the groupconsisting of N-Chlorosuccinimide, N-Bromosuccinimide, N-Iodosuccinimide, Dichloroisocyanuricacid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione, Dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5- 30triazinane-2,4,6-trione, Diiodoisocyanuric acid and 1,3,5-triiodo-1,3,5-triazinane-2,4,6-trione.Preferably said oxidant is N-Chlorosuccinimide.In an aspect, said stable nitroxyl radical compound is 2,2,6,6-Tetramethyl-1-piperidinyloxyfree radical (TEMPO) and said oxidant is N-Chlorosuccinimide (NCS).In an embodiment the invention relates to a method of detecting the presence of O-acetyl 35groups in S. pneumoniae serotype 21 glycoconjugate, said method comprising the step of: a)preparing a S. pneumoniae serotype 21 glycoconjugate and b) detecting the presence of O-acetylgroups in said glycoconjugate. 135In an embodiment the presence of O-acetyl groups is detected by NMR, MassSpectrometry (MS) or High-performance liquid chromatography (HPLC).In an embodiment the presence of O-acetyl groups is detected by NMR.In an embodiment the presence of O-acetyl groups is detected by Mass Spectrometry(MS). 5In a preferred embodiment the presence of O-acetyl groups is detected by High-performance liquid chromatography (HPLC).In an embodiment the invention relates to a method of measuring the degree of O-acetylation of an isolated S. pneumoniae serotype 21 polysaccharide, said method comprisingthe step of: a) isolating an S. pneumoniae serotype 21 polysaccharide and b) measuring the 10amount of O-acetyl groups in said polysaccharide.In an embodiment the amount of O-acetyl groups is measured by NMR, MassSpectrometry (MS) or High-performance liquid chromatography (HPLC).In an embodiment the amount of O-acetyl groups is measured by NMR.In an embodiment the amount of O-acetyl groups is measured by Mass Spectrometry 15(MS).In a preferred embodiment the amount of O-acetyl groups is measured by High-performance liquid chromatography (HPLC).In an embodiment the invention relates to a method of measuring the degree of O-acetylation of an isolated S. pneumoniae serotype 21 polysaccharide, said method comprising 20the step of: a) isolating an S. pneumoniae serotype 21 polysaccharide b) treating saidpolysaccharide with a base and c) measuring the amount of O-acetyl groups in saidpolysaccharide.In an embodiment the amount of O-acetyl groups is measured by NMR, MassSpectrometry (MS) or High-performance liquid chromatography (HPLC). 25In an embodiment the amount of O-acetyl groups is measured by NMR.In an embodiment the amount of O-acetyl groups is measured by Mass Spectrometry(MS).In a preferred embodiment the amount of O-acetyl groups is measured by High-performance liquid chromatography (HPLC). 30In an embodiment, the invention relates to a method of measuring the degree of O-acetylation in a reduced serotype 21 polysaccharide, said method comprising the step of: a)reacting an isolated S. pneumoniae serotype 21 polysaccharide with a reducing agent and b)measuring the amount of O-acetyl groups in said reduced polysaccharide.In an embodiment the amount of O-acetyl groups is measured by NMR, Mass 35Spectrometry (MS) or High-performance liquid chromatography (HPLC).In an embodiment the amount of O-acetyl groups is measured by NMR. 136In an embodiment the amount of O-acetyl groups is measured by Mass Spectrometry(MS).In a preferred embodiment the amount of O-acetyl groups is measured by High-performance liquid chromatography (HPLC).In an embodiment, said reducing agent is sodium borohydride (NaBH4). 5In an embodiment, said isolated S. pneumoniae serotype 21 polysaccharide has beenpreviously treated with an oxidizing agent. In an embodiment, the oxidizing agent is any oxidizingagent which oxidizes a terminal hydroxyl group to an aldehyde. In an embodiment, the oxidizingagent is periodate. In an embodiment, the oxidizing agent is orthoperiodate. In a preferredembodiment, the oxidizing agent is sodium periodate. In an embodiment, the oxidizing agent is 10metaperiodate. In a preferred embodiment the oxidizing agent is sodium metaperiodate.In an embodiment, said isolated S. pneumoniae serotype 21 polysaccharide has beenpreviously treated with a stable nitroxyl radical compound and an oxidant. In an aspect, said stablenitroxyl radical compound is a molecule bearing a TEMPO or a PROXYL (2,2,5,5-tetramethyl-1-pyrrolidinyloxy) moiety. Preferably said molecule has the ability to selectively oxidize primary 15alcohol in the presence of an oxidant, to generate aldehyde groups, without affecting secondaryhydroxyl groups. More preferably said molecule has the ability to selectively oxidize primaryalcohol in the presence of an oxidant, to generate aldehyde groups, without over oxidation tocarboxyl groups. In an aspect, said stable nitroxyl radical compound is TEMPO, 2,2,6,6-Tetramethyl-4-(methylsulfonyloxy)-1-piperidinooxy, 4-Phosphonooxy-TEMPO, 4-Oxo-TEMPO, 204-Methoxy-TEMPO, 4-Isothiocyanato-TEMPO, 4-(2-Iodoacetamido)-TEMPO free radical, 4-Hydroxy-TEMPO, 4-Cyano-TEMPO, 4-Carboxy-TEMPO, 4-(2-Bromoacetamido)-TEMPO, 4-Amino-TEMPO or 4-Acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl. In an aspect, said stablenitroxyl radical compound is selected from the groups consisting of TEMPO, 2,2,6,6-Tetramethyl-4-(methylsulfonyloxy)-1-piperidinooxy, 4-Phosphonooxy-TEMPO, 4-Oxo-TEMPO, 4-Methoxy- 25TEMPO, 4-Isothiocyanato-TEMPO, 4-(2-Iodoacetamido)-TEMPO free radical, 4-Hydroxy-TEMPO, 4-Cyano-TEMPO, 4-Carboxy-TEMPO, 4-(2-Bromoacetamido)-TEMPO, 4-Amino-TEMPO, 4-Acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl. Preferably said stable nitroxyl radicalcompound is TEMPO. In a further aspect, said stable nitroxyl radical compound is 3 β-DOXYL-5 α-cholestane, 5-DOXYL-stearic acid, 16-DOXYL-stearic acid, Methyl 5-DOXYL-stearate, 3- 30(Aminomethyl)-PROXYL, 3-Carbamoyl-PROXYL, 3-Carbamoyl-2,2,5,5-tetramethyl-3-pyrrolin-1-oxyl, 3-Carboxy-PROXYL or 3-Cyano-PROXYL. In a further aspect, said stable nitroxyl radicalcompound is selected from the groups consisting of 3 β-DOXYL-5 α-cholestane, 5-DOXYL-stearicacid, 16-DOXYL-stearic acid, Methyl 5-DOXYL-stearate, 3-(Aminomethyl)-PROXYL, 3-Carbamoyl-PROXYL, 3-Carbamoyl-2,2,5,5-tetramethyl-3-pyrrolin-1-oxyl, 3-Carboxy-PROXYL, 3- 35Cyano-PROXYL. In an aspect, the oxidant is a molecule bearing a N-halo moiety. Preferably saidmolecule has the ability to selectively oxidize primary alcohol in the presence of a nitroxyl radicalcompound. In an aspect, said oxidant is N-Chlorosuccinimide, N-Bromosuccinimide, N- 137Iodosuccinimide, Dichloroisocyanuric acid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione,Dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione, Diiodoisocyanuric acid or1,3,5-triiodo-1,3,5-triazinane-2,4,6-trione. In an aspect, said oxidant is selected from the groupconsisting of N-Chlorosuccinimide, N-Bromosuccinimide, N-Iodosuccinimide, Dichloroisocyanuricacid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione, Dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5- 5triazinane-2,4,6-trione, Diiodoisocyanuric acid and 1,3,5-triiodo-1,3,5-triazinane-2,4,6-trione.Preferably said oxidant is N-Chlorosuccinimide.In an aspect, said stable nitroxyl radical compound is 2,2,6,6-Tetramethyl-1-piperidinyloxyfree radical (TEMPO) and said oxidant is N-Chlorosuccinimide (NCS).In an embodiment the invention relates to a method of measuring the degree of O- 10acetylation in S. pneumoniae serotype 21 glycoconjugate, said method comprising the step of: a)preparing a S. pneumoniae serotype 21 glycoconjugate and b) measuring the amount of O-acetylgroups in said glycoconjugate.In an embodiment the amount of O-acetyl groups is measured by NMR, MassSpectrometry (MS) or High-performance liquid chromatography (HPLC). 15In an embodiment the amount of O-acetyl groups is measured by NMR.In an embodiment the amount of O-acetyl groups is measured by Mass Spectrometry(MS).In a preferred embodiment the amount of O-acetyl groups is measured by High-performance liquid chromatography (HPLC). 20 Particular embodiments of the invention are set forth in the following numbered paragraphs 1 to 324: 1. An isolated S. pneumoniae serotype 21 saccharide with the following repeating unit: where n represents the number of repeating units. 2. An isolated S. pneumoniae serotype 21 saccharide with the following repeating unit: (VIII) where n represents the number of repeating units, wherein the O-acetyl group at position 3 of β- 35D-Galf is present in about 50% to about 80% of the repeating units, the O-acetyl group at position [→ 6)-α-D-Galp-(1 →3)- β-L-Rhap-(1 →4)- β-D-Glcp-(1 →3)- β-D-GlcpNAc-(1→ 3)-α-D- Galp-(1-PO4 →]n↑β-D-Galf 3,5,6OAc [→ 6)-α-D-Galp-(1 →3)- β-L-Rhap-(1 →4)- β-D-Glcp-(1 →3)- β-D-GlcpNAc-(1→ 3)-α-D- Galp-(1-PO4 →]n↑β-D-Galf 3,5,6OAc 138of β-D-Galf is present in about 20% to about 40% of the repeating units, wherein the O-acetylgroup at position 5 of β-D-Galf is present in about 1% to about 10% of the repeating units. 3. The isolated S. pneumoniae serotype 21 saccharide of paragraph 2, wherein all the repeatingunit bears one O-acetyl group on the β-D-Galf residue. 4. An isolated S. pneumoniae serotype 21 saccharide with the repeating unit of formula (VIII), 5where n represents the number of repeating units, wherein the O-acetyl group at position 3 of β-D-Galf is present in about 60% of the repeating units, the O-acetyl group at position 6 of β-D-Galfis present in about 30% of the repeating units, wherein the O-acetyl group at position 5 of β-D-Galf is present in about 10% of the repeating units.
. The isolated S. pneumoniae serotype 21 saccharide of paragraph 4, wherein all the repeating 10unit bears one O-acetyl group on the β-D-Galf residue. 6. An isolated S. pneumoniae serotype 21 saccharide with the repeating unit of formula (VIII),where n represents the number of repeating units, wherein the O-acetyl group at position 3 of β-D-Galf is present in about 64% of the repeating units, the O-acetyl group at position 6 of β-D-Galfis present in about 30% of the repeating units, wherein the O-acetyl group at position 5 of β-D- 15Galf is present in about 6% of the repeating units. 7. The isolated S. pneumoniae serotype 21 saccharide of paragraph 6, wherein all the repeatingunit bears one O-acetyl group on the β-D-Galf residue. 8. An isolated S. pneumoniae serotype 21 saccharide with the repeating unit of formula (VIII),where n represents the number of repeating units, wherein the O-acetyl group at position 3 of β- 20D-Galf is present in about 25% to about 60% of the repeating units, the O-acetyl group at positionof β-D-Galf is present in about 30% to about 65% of the repeating units, wherein the O-acetylgroup at position 5 of β-D-Galf is present in about 5% to about 15% of the repeating units. 9. The isolated S. pneumoniae serotype 21 saccharide of paragraph 8, wherein all the repeatingunit bears one O-acetyl group on the β-D-Galf residue. 25 . An isolated S. pneumoniae serotype 21 saccharide with the repeating unit of formula (VIII),where n represents the number of repeating units, wherein the O-acetyl group at position 3 of β-D-Galf is present in about 50% of the repeating units, the O-acetyl group at position 6 of β-D-Galfis present in about 40% of the repeating units, wherein the O-acetyl group at position 5 of β-D-Galf is present in about 10% of the repeating units. 30 11. The isolated S. pneumoniae serotype 21 saccharide of paragraph 10, wherein all therepeating unit bears one O-acetyl group on the β-D-Galf residue. 12. An isolated S. pneumoniae serotype 21 saccharide with the repeating unit of formula (VIII),where n represents the number of repeating units, wherein the O-acetyl group at position 3 of β-D-Galf is present in about 47% of the repeating units, the O-acetyl group at position 6 of β-D-Galf 35 139is present in about 42% of the repeating units, wherein the O-acetyl group at position 5 of β-D-Galf is present in about 11% of the repeating units. 13. The isolated S. pneumoniae serotype 21 saccharide of paragraph 12, wherein all therepeating unit bears one O-acetyl group on the β-D-Galf residue. 14. An isolated S. pneumoniae serotype 21 saccharide with the repeating unit of formula (VIII), 5where n represents the number of repeating units, wherein the O-acetyl group at position 3 of β-D-Galf is present in about 30% of the repeating units, the O-acetyl group at position 6 of β-D-Galfis present in about 60% of the repeating units, wherein the O-acetyl group at position 5 of β-D-Galf is present in about 10% of the repeating units.
. The isolated S. pneumoniae serotype 21 saccharide of paragraph 14, wherein all the 10repeating unit bears one O-acetyl group on the β-D-Galf residue. 16. An isolated S. pneumoniae serotype 21 saccharide with the repeating unit of formula (VIII),where n represents the number of repeating units, wherein the O-acetyl group at position 3 of β-D-Galf is present in about 31% of the repeating units, the O-acetyl group at position 6 of β-D-Galfis present in about 61% of the repeating units, wherein the O-acetyl group at position 5 of β-D- 15Galf is present in about 8% of the repeating units. 17. The isolated S. pneumoniae serotype 21 saccharide of paragraph 16, wherein all therepeating unit bears one O-acetyl group on the β-D-Galf residue. 18. An isolated S. pneumoniae serotype 21 saccharide with the following repeating unit: (IX) where n represents the number of repeating units. 25 19. An isolated S. pneumoniae serotype 21 saccharide with the repeating unit of formula (VIII),where n represents the number of repeating units, and wherein the O-acetyl group at position 3,or 6 of β-D-Galf is present in about 0% to about 95% of the repeating units.
. An isolated S. pneumoniae serotype 21 saccharide with the repeating unit of formula (VIII),where n represents the number of repeating units, and wherein the O-acetyl group at position 3, 30or 6 of β-D-Galf is present in about 10% to about 90% of the repeating units. 21. An isolated isolated S. pneumoniae serotype 21 saccharide with the repeating unit of formula(VIII), where n represents the number of repeating units, and wherein the O-acetyl group atposition 3, 5 or 6 of β-D-Galf is present in about 30% to about 60% of the repeating units. [→ 6)-α-D-Galp-(1 →3)- β-L-Rhap-(1 →4)- β-D-Glcp-(1 →3)- β-D-GlcpNAc-(1→ 3)-α-D- Galp-(1-PO4 →]n↑β-D-Galf 14022. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 havingbetween 10 and 5,000 repeating units. 23. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 havingbetween 50 and 4,500 repeating units. 24. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 having 5between 100 and 4,500 repeating units.
. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 havingbetween 150 and 2,000 repeating units. 26. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 having aweight average molecular weight between 5 kDa and 5000 kDa. 10 27. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 having aweight average molecular weight between 5 kDa and 2000 kDa. 28. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 having aweight average molecular weight between 50 kDa and 5000 kDa. 29. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 having a 15weight average molecular weight between 50 kDa and 1000 kDa.
. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 having aweight average molecular weight between 100 kDa and 5000 kDa. 31. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 having aweight average molecular weight between 100 kDa and 1000 kDa. 20 32. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 having aweight average molecular weight between 100 kDa and 500 kDa. 33. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 having aweight average molecular weight between 300 kDa and 5000 kDa. 34. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 having a 25weight average molecular weight between 300 kDa and 1000 kDa.
. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 having aweight average molecular weight between 500 kDa and 3000 kDa. 36. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 having aweight average molecular weight between 500 kDa and 2000 kDa. 30 37. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 having aweight average molecular weight between 500 kDa and 1000 kDa. 14138. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 sized toa weight average molecular weight between 10 kDa and 1000 kDa. 39. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 sized toa weight average molecular weight between 50 kDa and 500 kDa. 40. The isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-21 sized to 5a weight average molecular weight between 100 kDa and 400 kDa. 41. A glycoconjugate comprising an isolated S. pneumoniae serotype 21 saccharide of any oneof paragraphs 1-40 conjugated to a carrier protein. 42. A glycoconjugate consisting of an isolated S. pneumoniae serotype 21 saccharide of any oneof paragraphs 1-40 conjugated to a carrier protein. 10 43. The serotype 21 glycoconjugate of paragraph 41 or 42 wherein said serotype 21glycoconjugate comprises a serotype 21 saccharide covalently conjugated to a carrier proteinthrough a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer. 44. The serotype 21 glycoconjugate of paragraph 41 or 42 wherein said serotype 21glycoconjugate is prepared by click chemistry. 15 45. The serotype 21 glycoconjugate of paragraph 41 or 42 wherein said serotype 21glycoconjugate is prepared by direct reductive amination. 45a. The serotype 21 glycoconjugate of paragraph 41 or 42 wherein said serotype 21glycoconjugate is prepared by CDI or CDT chemistry. 46. A serotype 21 glycoconjugate comprising a serotype 21 saccharide covalently conjugated to 20a carrier protein (CP) through a spacer and having the general formula (IV): (IV),wherein X is selected from the group consisting of CH2(CH2) n’, (CH 2CH 2O)mCH2CH 2,NHCO(CH2)n’, NHCO(CH2CH2O) mCH2CH2, OCH 2(CH2) n’ and O(CH 2CH2O)mCH2CH 2; where n’ isselected from 1 to 10 and m is selected from 1 to 4, 25wherein X' is selected from the group consisting of CH2O(CH 2) n’’CH 2C=O,CH2O(CH 2CH2O)m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is selected from 0to 4,wherein the structure in square backet represents a repeat unit of the serotype 21 saccharide andwherein n represents the number of repeating units. 30 14247. A serotype 21 glycoconjugate comprising a serotype 21 saccharide covalently conjugated toa carrier protein (CP) through a spacer and having the general formula (IV), wherein X isCH2(CH2) n’, where n’ is 2 and wherein X' is CH2O(CH 2)n’’CH2C=O where n’’ is 1. 48. A serotype 21 glycoconjugate comprising a serotype 21 saccharide covalently conjugated toa carrier protein (CP) through a spacer and having the general formula (V), 5 (V), wherein the structure in square backet represents a repeat unit of the serotype 21 saccharide andwherein n represents the number of repeating units. 49. A serotype 21 glycoconjugate comprising a serotype 21 saccharide covalently conjugated toa carrier protein (CP) through a spacer and having the general formula (XVI): 10 n OONH ONN NX' O HN CP X (XVI),wherein X is selected from the group consisting of CH2(CH2) n’, (CH 2CH 2O)mCH2CH 2,NHCO(CH2)n’, NHCO(CH2CH2O) mCH2CH2, OCH 2(CH2) n’ and O(CH 2CH2O)mCH2CH 2; where n’ isselected from 0 to 10 and m is selected from 1 to 4, wherein X' is selected from the group consisting of CH2(CH2)n", CH2O(CH 2)n’’CH2, 15CH2O(CH 2CH2O)m’(CH2)n’’CH2, where n’’ is selected from 0 to 10 and m’ is selected from 0 to 4and wherein the structure in square backet represents a repeat unit of the serotype 21 saccharideand wherein n represents the number of repeating units. 50. A serotype 21 glycoconjugate comprising a serotype 21 saccharide covalently conjugated toa carrier protein (CP) through a spacer and having the general formula (XVI), wherein X is 20CH2(CH2) n’, where n’ is 0 and wherein X' is CH2(CH2) n" where n’’ is 0. 51. A serotype 21 glycoconjugate comprising a serotype 21 saccharide covalently conjugated toa carrier protein (CP) through a spacer and having the general formula (XVII), 143 (XVII), wherein the structure in square backet represents a repeat unit of the serotype 21 saccharide andwherein n represents the number of repeating units. 52. The glycoconjugate of any one of paragraphs 46 to 51 wherein said a serotype 21 saccharideis an isolated S. pneumoniae serotype 21 saccharide of any one of paragraphs 1-40. 5 53. The glycoconjugate of any one of paragraphs 41 to 52 wherein the weight average molecularweight (Mw) of said S. pneumoniae serotype 21 saccharide before conjugation is between 50kDa and 1,000 kDa. 54. The glycoconjugate of any one of paragraphs 41 to 52 wherein the weight average molecularweight (Mw) of said S. pneumoniae serotype 21 saccharide before conjugation is between 100 10kDa and 600 kDa. 55. The glycoconjugate of any one of paragraphs 41 to 52 wherein the weight average molecularweight (Mw) of said S. pneumoniae serotype 21 saccharide before conjugation is between 100kDa and 400 kDa. 55a. The glycoconjugate of paragraph 45 wherein the weight average molecular weight (Mw) of 15said S. pneumoniae serotype 21 saccharide before conjugation is between 100 kDa and 400 kDa. 56. The glycoconjugate of any one of paragraphs 41 to 52 wherein the weight average molecularweight (Mw) of said S. pneumoniae serotype 21 saccharide before conjugation is between 150kDa and 300 kDa. 56a. The glycoconjugate of any one of paragraphs 41 to 52 wherein the weight average molecular 20weight (Mw) of said S. pneumoniae serotype 21 saccharide before conjugation is between 150kDa and 400 kDa. 56b. The glycoconjugate of paragraph 44 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and 400 kDa. 57. The glycoconjugate of any one of paragraphs 41 to 56b wherein said serotype 21 25glycoconjugate has a weight average molecular weight (Mw) of between 250 kDa and 20,000kDa. 14458. The glycoconjugate of any one of paragraphs 41 to 56b wherein said serotype 21glycoconjugate has a weight average molecular weight (Mw) of between 500 kDa and 15,000kDa. 59. The glycoconjugate of any one of paragraphs 41 to 56b wherein said serotype 21glycoconjugate has a weight average molecular weight (Mw) of between 500 kDa and 10,000 5kDa. 60. The glycoconjugate of any one of paragraphs 41 to 56b wherein said serotype 21glycoconjugate has a weight average molecular weight (Mw) of between 750 kDa and 7,500 kDa. 60a. The glycoconjugate of paragraph 44 wherein said serotype 21 glycoconjugate has a weightaverage molecular weight (Mw) of between 800 kDa and 7,000 kDa. 10 60b. The glycoconjugate of paragraph 44 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and 400 kDaand wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 800 kDa and 7,000 kDa. 60c. The glycoconjugate of paragraph 48 wherein the weight average molecular weight (Mw) of 15said S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and 400 kDaand wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 800 kDa and 7,000 kDa. 61. The glycoconjugate of any one of paragraphs 41 to 56b wherein said serotype 21glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDa and 5,000 20kDa. 61a. The glycoconjugate of paragraph 45 wherein said serotype 21 glycoconjugate has a weightaverage molecular weight (Mw) of between 2,000 kDa and 10,500 kDa. 61b. The glycoconjugate of paragraph 45 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 100 kDa and 400 kDa 25and wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 2000 kDa and 10,500 kDa. 62. The glycoconjugate of any one of paragraphs 41 to 61b wherein said conjugate comprises aserotype 21 saccharide comprising on average at least 0.5 O-acetyl group per sacchariderepeating unit. 30 63. The glycoconjugate of any one of paragraphs 41 to 61b wherein said conjugate comprises aserotype 21 saccharide comprising on average at least 0.8 O-acetyl group per sacchariderepeating unit. 14564. The glycoconjugate of any one of paragraphs 41 to 61b wherein said conjugate comprises aserotype 21 saccharide comprising on average between about 0.8 and about 1 O-acetyl groupper saccharide repeating unit. 65. The glycoconjugate of any one of paragraphs 41 to 61b wherein the ratio of O-acetyl groupper saccharide repeating unit in the glycoconjugate to O-acetyl group per saccharide repeating 5unit in the isolated polysaccharide is at least 0.6. 66. The glycoconjugate of any one of paragraphs 41 to 61b wherein the ratio of O-acetyl groupper saccharide repeating unit in the glycoconjugate to O-acetyl group per saccharide repeatingunit in the isolated polysaccharide is at least 0.9. 67. The glycoconjugate of any one of paragraphs 41 to 66 wherein the degree of conjugation of 10said serotype 21 glycoconjugate is between 2 and 15. 68. The glycoconjugate of any one of paragraphs 41 to 66 wherein the degree of conjugation ofsaid serotype 21 glycoconjugate is between 2 and 10. 69. The glycoconjugate of any one of paragraphs 41 to 66 wherein the degree of conjugation ofsaid serotype 21 glycoconjugate is between 3 and 5. 15 70. The glycoconjugate of any one of paragraphs 41 to 66 wherein the degree of conjugation ofsaid serotype 21 glycoconjugate is between 2 and 6. 71. The glycoconjugate of any one of paragraphs 41 to 66 wherein the degree of conjugation ofsaid serotype 21 glycoconjugate is between 4 and 10. 71a. The glycoconjugate of paragraph 44 wherein the weight average molecular weight (Mw) of 20said S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and 400 kDaand wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 800 kDa and 7,000 kDa and wherein the degree of conjugation of said serotype 21glycoconjugate is between 2 and 10. 71b. The glycoconjugate of paragraph 45 wherein the weight average molecular weight (Mw) of 25said S. pneumoniae serotype 21 saccharide before conjugation is between 100 kDa and 400 kDaand wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 2000 kDa and 10,500 kDa and wherein the degree of conjugation of said serotype 21glycoconjugate is between 2 and 10. 71c. The glycoconjugate of paragraph 48 wherein the weight average molecular weight (Mw) of 30said S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and 400 kDaand wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 800 kDa and 7,000 kDa and wherein the degree of conjugation of said serotype 21glycoconjugate is between 2 and 10. 14672. The glycoconjugate of any one of paragraphs 41 to 71c wherein the ratio of serotype 21saccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 3.0. 73. The glycoconjugate of any one of paragraphs 41 to 71c wherein the ratio of serotype 21saccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 2.0. 74. The glycoconjugate of any one of paragraphs 41 to 71c wherein the ratio of serotype 21 5saccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 1.5. 75. The glycoconjugate of any one of paragraphs 41 to 71c wherein the ratio of serotype 21saccharide to carrier protein in the glycoconjugate (w/w) is between 0.8 and 1.2. 76. The glycoconjugate of any one of paragraphs 41 to 71c wherein the ratio of serotype 21saccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 1.0. 10 77. The glycoconjugate of any one of paragraphs 41 to 71c wherein the ratio of serotype 21saccharide to carrier protein in the glycoconjugate (w/w) is between 1.0 and 1.5. 78. The glycoconjugate of any one of paragraphs 41 to 71c wherein the ratio of serotype 21saccharide to carrier protein in the glycoconjugate (w/w) is between 1.0 and 2.0. 79. The glycoconjugate of any one of paragraphs 41 to 71c wherein the ratio of serotype 21 15saccharide to carrier protein in the glycoconjugate (w/w) is between 0.8 and 1.2. 80. The glycoconjugate of any one of paragraphs 41 to 71c wherein the ratio of serotype 21saccharide to carrier protein in the glycoconjugate (w/w) is between 0.7 and 1.1. 80a. The glycoconjugate of paragraph 44 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and 400 kDa 20and wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 800 kDa and 7,000 kDa and the ratio of serotype 21 saccharide to carrier protein in theglycoconjugate (w/w) is between 0.5 and 1.1. 80b. The glycoconjugate of paragraph 45 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 100 kDa and 400 kDa 25and wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 2000 kDa and 10,500 kDa and the ratio of serotype 21 saccharide to carrier protein inthe glycoconjugate (w/w) is between 0.5 and 1.3. 80c. The glycoconjugate of paragraph 44 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and 400 kDa 30and wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 800 kDa and 7,000 kDa, wherein the degree of conjugation of said serotype 21glycoconjugate is between 2 and 10 and the ratio of serotype 21 saccharide to carrier protein inthe glycoconjugate (w/w) is between 0.5 and 1.1. 14780d. The glycoconjugate of paragraph 45 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 100 kDa and 400 kDaand wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 2000 kDa and 10,500 kDa, wherein the degree of conjugation of said serotype 21glycoconjugate is between 2 and 10 and the ratio of serotype 21 saccharide to carrier protein in 5the glycoconjugate (w/w) is between 0.5 and 1.3. 80e. The glycoconjugate of paragraph 44 wherein the ratio of serotype 21 saccharide to carrierprotein in the glycoconjugate (w/w) is between 0.5 and 1.1. 80f. The glycoconjugate of paragraph 45 wherein the ratio of serotype 21 saccharide to carrierprotein in the glycoconjugate (w/w) is between 0.5 and 1.3. 10 80g. The glycoconjugate of paragraph 48 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and 400 kDaand wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 800 kDa and 7,000 kDa and the ratio of serotype 21 saccharide to carrier protein in theglycoconjugate (w/w) is between 0.5 and 1.1. 15 80h. The glycoconjugate of paragraph 48 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and 400 kDaand wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 800 kDa and 7,000 kDa, wherein the degree of conjugation of said serotype 21glycoconjugate is between 2 and 10 and the ratio of serotype 21 saccharide to carrier protein in 20the glycoconjugate (w/w) is between 0.5 and 1.1. 81. The glycoconjugate of any one of paragraphs 41 to 80h wherein said serotype 21glycoconjugate comprises less than about 50% of free serotype 21 saccharide compared to thetotal amount of serotype 21 saccharide. 82. The glycoconjugate of any one of paragraphs 41 to 80h wherein said serotype 21 25glycoconjugate comprises less than about 25% of free serotype 21 saccharide compared to thetotal amount of serotype 21 saccharide. 82a. The glycoconjugate of paragraph 44 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and 400 kDaand wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) of 30between 800 kDa and 7,000 kDa, wherein the ratio of serotype 21 saccharide to carrier protein inthe glycoconjugate (w/w) is between 0.5 and 1.1 and wherein said serotype 21 glycoconjugatecomprises less than about 25% of free serotype 21 saccharide compared to the total amount ofserotype 21 saccharide. 82b. The glycoconjugate of paragraph 45 wherein the weight average molecular weight (Mw) of 35said S. pneumoniae serotype 21 saccharide before conjugation is between 100 kDa and 400 kDa 148and wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 2000 kDa and 10,500 kDa, wherein the ratio of serotype 21 saccharide to carrier proteinin the glycoconjugate (w/w) is between 0.5 and 1.3 and wherein said serotype 21 glycoconjugatecomprises less than about 25% of free serotype 21 saccharide compared to the total amount ofserotype 21 saccharide. 5 82c. The glycoconjugate of paragraph 44 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and 400 kDaand wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 800 kDa and 7,000 kDa, wherein the ratio of serotype 21 saccharide to carrier protein inthe glycoconjugate (w/w) is between 0.5 and 1.1, wherein the degree of conjugation of said 10serotype 21 glycoconjugate is between 2 and 10 and wherein said serotype 21 glycoconjugatecomprises less than about 25% of free serotype 21 saccharide compared to the total amount ofserotype 21 saccharide. 82d. The glycoconjugate of paragraph 45 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 100 kDa and 400 kDa 15and wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 2000 kDa and 10,500 kDa, wherein the ratio of serotype 21 saccharide to carrier proteinin the glycoconjugate (w/w) is between 0.5 and 1.3, wherein the degree of conjugation of saidserotype 21 glycoconjugate is between 2 and 10 and wherein said serotype 21 glycoconjugatecomprises less than about 25% of free serotype 21 saccharide compared to the total amount of 20serotype 21 saccharide. 82e. The glycoconjugate of paragraph 48 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and 400 kDaand wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 800 kDa and 7,000 kDa, wherein the ratio of serotype 21 saccharide to carrier protein in 25the glycoconjugate (w/w) is between 0.5 and 1.1 and wherein said serotype 21 glycoconjugatecomprises less than about 25% of free serotype 21 saccharide compared to the total amount ofserotype 21 saccharide. 82f. The glycoconjugate of paragraph 48 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and 400 kDa 30and wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 800 kDa and 7,000 kDa, wherein the ratio of serotype 21 saccharide to carrier protein inthe glycoconjugate (w/w) is between 0.5 and 1.1, wherein the degree of conjugation of saidserotype 21 glycoconjugate is between 2 and 10 and wherein said serotype 21 glycoconjugatecomprises less than about 25% of free serotype 21 saccharide compared to the total amount of 35serotype 21 saccharide. 14983. The glycoconjugate of any one of paragraphs 41 to 80h wherein said serotype 21glycoconjugate comprises less than about 20% of free serotype 21 saccharide compared to thetotal amount of serotype 21 saccharide. 84. The glycoconjugate of any one of paragraphs 41 to 80h wherein said serotype 21glycoconjugate comprises less than about 15% of free serotype 21 saccharide compared to the 5total amount of serotype 21 saccharide. 85. The glycoconjugate of any one of paragraphs 41 to 84 wherein at least 30% of the serotypeglycoconjugate has a K d below or equal to 0.3 in a CL-4B column. 86. The glycoconjugate of any one of paragraphs 41 to 84 wherein at least 40% of theglycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. 10 87. The glycoconjugate of any one of paragraphs 41 to 84 wherein at least 60% of the serotypeglycoconjugate has a K d below or equal to 0.3 in a CL-4B column. 88. The glycoconjugate of any one of paragraphs 41 to 84 wherein between 50% and 80% of theserotype 21 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. 89. The glycoconjugate of any one of paragraphs 41 to 84 wherein between 65% and 80% of the 15serotype 21 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. 89a. The glycoconjugate of paragraph 44 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and 400 kDaand wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 800 kDa and 7,000 kDa, wherein the ratio of serotype 21 saccharide to carrier protein in 20the glycoconjugate (w/w) is between 0.5 and 1.1, wherein said serotype 21 glycoconjugatecomprises less than about 25% of free serotype 21 saccharide compared to the total amount ofserotype 21 saccharide and wherein between 65% and 80% of the serotype 21 glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. 89b. The glycoconjugate of paragraph 45 wherein the weight average molecular weight (Mw) of 25said S. pneumoniae serotype 21 saccharide before conjugation is between 100 kDa and 400 kDaand wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 2000 kDa and 10,500 kDa, wherein the ratio of serotype 21 saccharide to carrier proteinin the glycoconjugate (w/w) is between 0.5 and 1.3, wherein said serotype 21 glycoconjugatecomprises less than about 25% of free serotype 21 saccharide compared to the total amount of 30serotype 21 saccharide and wherein between 65% and 80% of the serotype 21 glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. 89c. The glycoconjugate of paragraph 44 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and 400 kDaand wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) of 35 150between 800 kDa and 7,000 kDa, wherein the ratio of serotype 21 saccharide to carrier protein inthe glycoconjugate (w/w) is between 0.5 and 1.1, wherein the degree of conjugation of saidserotype 21 glycoconjugate is between 2 and 10, wherein said serotype 21 glycoconjugatecomprises less than about 25% of free serotype 21 saccharide compared to the total amount ofserotype 21 saccharide and wherein between 65% and 80% of the serotype 21 glycoconjugate 5has a Kd below or equal to 0.3 in a CL-4B column. 89d. The glycoconjugate of paragraph 45 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 100 kDa and 400 kDaand wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 2000 kDa and 10,500 kDa, wherein the ratio of serotype 21 saccharide to carrier protein 10in the glycoconjugate (w/w) is between 0.5 and 1.3, wherein the degree of conjugation of saidserotype 21 glycoconjugate is between 2 and 10, wherein said serotype 21 glycoconjugatecomprises less than about 25% of free serotype 21 saccharide compared to the total amount ofserotype 21 saccharide and wherein between 65% and 80% of the serotype 21 glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. 15 89e. The glycoconjugate of paragraph 48 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and 400 kDaand wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 800 kDa and 7,000 kDa, wherein the ratio of serotype 21 saccharide to carrier protein inthe glycoconjugate (w/w) is between 0.5 and 1.1, wherein said serotype 21 glycoconjugate 20comprises less than about 25% of free serotype 21 saccharide compared to the total amount ofserotype 21 saccharide and wherein between 65% and 80% of the serotype 21 glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. 89f. The glycoconjugate of paragraph 48 wherein the weight average molecular weight (Mw) ofsaid S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and 400 kDa 25and wherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) ofbetween 800 kDa and 7,000 kDa, wherein the ratio of serotype 21 saccharide to carrier protein inthe glycoconjugate (w/w) is between 0.5 and 1.1, wherein the degree of conjugation of saidserotype 21 glycoconjugate is between 2 and 10, wherein said serotype 21 glycoconjugatecomprises less than about 25% of free serotype 21 saccharide compared to the total amount of 30serotype 21 saccharide and wherein between 65% and 80% of the serotype 21 glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column 90. The glycoconjugate of any one of paragraphs 41 to 89f wherein the carrier protein of theserotype 21 saccharide glycoconjugate is selected in the group consisting of: TT, DT, DT mutantsand a C5a peptidase from Streptococcus (SCP). 35 15191. The glycoconjugate of any one of paragraphs 41 to 89f wherein the carrier protein of theserotype 21 saccharide glycoconjugate is rhizavidin [aa 45-179J-GGGGSSS-SP1500- AAA-SP0785] (CP1). 91a. The glycoconjugate of any one of paragraphs 41 to 89f wherein the carrier protein of theserotype 21 saccharide glycoconjugate is Rhavi-linker-PdT(G294P)-linker-SP0435 [aa 62-185] 5fusion protein (SPP2). 92. The glycoconjugate of any one of paragraphs 41 to 89f wherein the carrier protein of theserotype 21 saccharide glycoconjugate is DT. 93. The glycoconjugate of any one of paragraphs 41 to 89f wherein the carrier protein of theserotype 21 saccharide glycoconjugate is TT. 10 94. The glycoconjugate of any one of paragraphs 41 to 89f wherein the carrier protein of theserotype 21 saccharide glycoconjugate is PD. 95. The glycoconjugate of any one of paragraphs 41 to 89f wherein the carrier protein of theserotype 21 saccharide glycoconjugate is CRM 197 or a C5a peptidase from Streptococcus (SCP). 96. The glycoconjugate of any one of paragraphs 41 to 89f wherein the carrier protein of the 15serotype 21 saccharide glycoconjugate is CRM 197. 97. The glycoconjugate of any one of paragraphs 41 to 89f wherein the carrier protein of theserotype 21 saccharide glycoconjugate is SCP. 98. The glycoconjugate of any one of paragraphs 41 to 89f wherein the carrier protein of theserotype 21 saccharide glycoconjugate is an enzymatically inactive SCP. 20 99. The glycoconjugate of any one of paragraphs 41 to 89f wherein the carrier protein of theserotype 21 saccharide glycoconjugate is an enzymatically inactive SCP from GBS (SCPB). 100. The glycoconjugate of any one of paragraphs 41 to 89f wherein the carrier protein of theserotype 21 saccharide glycoconjugate is an enzymatically inactive SCP from GAS (SCPA). 101. The glycoconjugate of any one of paragraphs 41 to 89f wherein the carrier protein of the 25serotype 21 saccharide glycoconjugate is a fragment of an SCPB. 102. The glycoconjugate of any one of paragraphs 41 to 89f wherein the carrier protein of theserotype 21 saccharide glycoconjugate is an enzymatically inactive fragment of SCP whichconsists of SEQ ID NO: 1. 103. The glycoconjugate of any one of paragraphs 41 to 89f wherein the carrier protein of the 30serotype 21 saccharide glycoconjugate is an enzymatically inactive fragment of SCP whichconsists of SEQ ID NO: 2. 104. An immunogenic composition comprising a S. pneumoniae serotype 21 saccharideaccording to any one of paragraphs 1-40. 152105. An immunogenic composition comprising a S. pneumoniae serotype 21 saccharideglycoconjugate according to any one of paragraphs 41 to 103. 106. The immunogenic composition of paragraph 105 comprising from 1 to 45 differentglycoconjugates. 107. The immunogenic composition of paragraph 105 comprising from 1 to 45 glycoconjugates 5from different serotypes of S. pneumoniae. 108. The immunogenic composition of paragraph 105 comprising glycoconjugates from 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 different serotypes of S. pneumoniae. 109. The immunogenic composition of paragraph 105 comprising glycoconjugates from 16 or 20different serotypes of S. pneumoniae. 10 110. The immunogenic composition of paragraph 105 which is a 21, 22, 23, 24 or 25-valentpneumococcal conjugate composition. 111. The immunogenic composition of paragraph 105 which is a 21-valent pneumococcalconjugate composition. 112. The immunogenic composition of paragraph 105 which is a 22-valent pneumococcal 15conjugate composition. 113. The immunogenic composition of paragraph 105 which is a 23-valent pneumococcalconjugate composition. 114. The immunogenic composition of paragraph 105 which is a 24-valent pneumococcalconjugate composition. 20 115. The immunogenic composition of paragraph 105 which is a 25-valent pneumococcalconjugate composition. 116. The immunogenic composition of paragraph 105 comprising glycoconjugates from 26 to 45glycoconjugates from different serotypes of S. pneumoniae. 117. The immunogenic composition of paragraph 105 comprising glycoconjugates from 26, 27, 2528, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 or 45 different serotypes of S.pneumoniae. 118. The immunogenic composition of paragraph 105 comprising glycoconjugates from 35 or 45different serotypes of S. pneumoniae. 118a. The immunogenic composition of paragraph 105 which is a 35-valent pneumococcal 30conjugate composition 119. The immunogenic composition of paragraph 105 which is a 35, 36, 37, 38, 39, 40, 41, 42,43, 44 or 45-valent pneumococcal conjugate composition. 153120. The immunogenic composition of paragraph 105 which is a 40, 41, 42, 43, 44 or 45-valentpneumococcal conjugate composition. 121. The immunogenic composition of paragraph 105 which is a 40-valent pneumococcalconjugate composition. 122. The immunogenic composition of paragraph 105 which is a 41-valent pneumococcal 5conjugate composition. 123. The immunogenic composition of paragraph 105 which is a 42-valent pneumococcalconjugate composition. 124. The immunogenic composition of paragraph 105 which is a 43-valent pneumococcalconjugate composition. 10 125. The immunogenic composition of paragraph 105 which is a 44-valent pneumococcalconjugate composition. 126. The immunogenic composition of paragraph 105 which is a 45-valent pneumococcalconjugate composition. 127. The immunogenic composition of any one of paragraphs 105-126 further comprising 15glycoconjugates from S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. 128. The immunogenic composition of paragraph 127 further comprising glycoconjugates from S.pneumoniae serotypes 1, 5 and 7F. 129. The immunogenic composition of paragraph 128 further comprising a glycoconjugate fromS. pneumoniae serotype 3. 20 130. The immunogenic composition of paragraph 129 further comprising glycoconjugates from S.pneumoniae serotypes 6A and 19A. 131. The immunogenic composition of paragraph 130 further comprising glycoconjugates from S.pneumoniae serotype 22F and 33F. 132. The immunogenic composition of paragraph 1131 further comprising glycoconjugates from 25S. pneumoniae serotypes 8, 10A, 11A, 12F and 15B. 133. The immunogenic composition of paragraph 132 further comprising a glycoconjugate fromS. pneumoniae serotype 2. 134. The immunogenic composition of paragraph 133 further comprising a glycoconjugate fromS. pneumoniae serotype 9N. 30 135. The immunogenic composition of paragraph 134 further comprising a glycoconjugate fromS. pneumoniae serotype 17F. 154136. The immunogenic composition of paragraph 135 further comprising a glycoconjugate fromS. pneumoniae serotype 20. 137. The immunogenic composition of paragraph 136 further comprising a glycoconjugate fromS. pneumoniae serotype 2. 138. The immunogenic composition of paragraph 137 further comprising a glycoconjugate from 5S. pneumoniae serotype 15C. 139. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F and whereinsaid immunogenic composition is an 8-valent pneumococcal conjugate composition. 140. The immunogenic composition of any one of paragraphs 105-108 further comprising 10glycoconjugates from S. pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F andwherein said immunogenic composition is an 11-valent pneumococcal conjugate composition. 141. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and23F and wherein said immunogenic composition is a 14-valent pneumococcal conjugate 15composition. 142. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F,22F, 23F and 33F and wherein said immunogenic composition is a 16-valent pneumococcalconjugate composition. 20 143. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F and wherein said immunogenic composition is a 21-valentpneumococcal conjugate composition. 143. The immunogenic composition of any one of paragraphs 105-108 further comprising 25glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15C, 18C, 19A, 19F, 22F, 23F and 33F. 144. The immunogenic composition of paragraph 168 which is a 21-valent pneumococcalconjugate composition. 145. The immunogenic composition of any one of paragraphs 105-108 further comprising 30glycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F,14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. 146. The immunogenic composition of paragraph 145 which is a 22-valent pneumococcalconjugate composition. 155147. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F,14, 15C, 18C, 19A, 19F, 22F, 23F and 33F. 148. The immunogenic composition of paragraph 147 which is a 22-valent pneumococcalconjugate composition. 5 149. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A, 12F,14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. 150. The immunogenic composition of paragraph 149 which is a 22-valent pneumococcalconjugate composition. 10 151. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A,12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. 152. The immunogenic composition of paragraph 151 which is a 23-valent pneumococcalconjugate composition. 15 153. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A,12F, 14, 15B, 17F, 18C, 19A, 19F, 22F, 23F and 33F. 154. The immunogenic composition of paragraph 153 which is a 24-valent pneumococcalconjugate composition. 20 155. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A,12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. 156. The immunogenic composition of paragraph 155 which is a 25-valent pneumococcalconjugate composition. 25 157. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23F and 33F. 158. The immunogenic composition of paragraph 157 which is a 22-valent pneumococcalconjugate composition. 30 159. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23A, 23F and 33F. 156160. The immunogenic composition of paragraph 159 which is a 22-valent pneumococcalconjugate composition. 161. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23B, 23F and 33F. 5 162. The immunogenic composition of paragraph 186 which is a 22-valent pneumococcalconjugate composition. 163. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F, 24F and 33F. 10 164. The immunogenic composition of paragraph 163 which is a 22-valent pneumococcalconjugate composition. 165. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F, 33F and 35B. 15 166. The immunogenic composition of paragraph 165 which is a 22-valent pneumococcalconjugate composition. 167. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23F and 33F. 20 168. The immunogenic composition of paragraph 167 which is a 23-valent pneumococcalconjugate composition. 169. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B. 25 170. The immunogenic composition of paragraph 169 wherein the S. pneumoniae saccharidesare conjugated to CRM 197. 171. The immunogenic composition of paragraph 169 wherein the S. pneumoniae saccharidesfrom serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 21, 22F,23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197 and the S. pneumoniae saccharide 30serotype 3 is conjugated to SCP. 172. The immunogenic composition of paragraph 171 which is a 26-valent pneumococcalconjugate composition. 157173. The immunogenic composition of any one of paragraphs 105-108 further comprising at leastone glycoconjugate selected from the group consisting of glycoconjugates from S. pneumoniaeserotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 20, 22A, 23A, 23B, 24B, 24F, 27, 29, 31, 33B, 34,35B, 35F and 38. 174. The immunogenic composition of any one of paragraphs 105-108 further comprising twenty- 5one glycoconjugates selected from the group consisting of glycoconjugates from S. pneumoniaeserotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 20, 22A, 23A, 23B, 24B, 24F, 27, 29, 31, 33B, 34,35B, 35F and 38. 175. The immunogenic composition of paragraph 174 which is a 22-valent pneumococcalconjugate composition. 10 176. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 20, 22A, 23A, 23B, 24B, 24F,27, 29, 31, 33B, 34, 35B, 35F and 38. 177. The immunogenic composition of paragraph 176 which is a 23-valent pneumococcalconjugate composition. 15 178. The immunogenic composition of any one of paragraphs 105-108 further comprising at leastone glycoconjugate selected from the group consisting of glycoconjugates from S. pneumoniaeserotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 19A, 19F, 20, 22A, 23A, 23B, 24B, 24F, 27, 29, 31,33B, 34, 35B, 35F and 38. 179. The immunogenic composition of any one of paragraphs 105-108 further comprising twenty- 20two glycoconjugates selected from the group consisting of glycoconjugates from S. pneumoniaeserotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 19A, 19F, 20, 22A, 23A, 23B, 24B, 24F, 27, 29, 31,33B, 34, 35B, 35F and 38. 180. The immunogenic composition of paragraph 179 which is a 23-valent pneumococcalconjugate composition. 25 181. The immunogenic composition of any one of paragraphs 105-108 further comprising twenty-three glycoconjugates selected from the group consisting of glycoconjugates from S. pneumoniaeserotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 19A, 19F, 20, 22A, 23A, 23B, 24B, 24F, 27, 29, 31,33B, 34, 35B, 35F and 38. 182. The immunogenic composition of paragraph 181 which is a 24-valent pneumococcal 30conjugate composition. 183. The immunogenic composition of any one of paragraphs 105-150 further comprisingglycoconjugates from serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 20, 22A, 23A, 23B, 24B, 24F,27, 29, 31, 33B, 34, 35B, 35F and 38. 158184. The immunogenic composition of paragraph 183 which is a 23-valent pneumococcalconjugate composition. 185. The immunogenic composition of any one of paragraphs 105-108 further comprisingglycoconjugates from serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 19A, 19F, 20, 22A, 23A, 23B,24B, 24F, 27, 29, 31, 33B, 34, 35B, 35F and 38. 5 186. The immunogenic composition of paragraph 185 which is a 23-valent pneumococcalconjugate composition. 187. The immunogenic composition of any one of paragraphs 104-186 further comprising at leastone, two or three adjuvants. 188. The immunogenic composition of any one of paragraphs 104-186 further comprising one 10adjuvant. 189. The immunogenic composition of any one of paragraphs 104-186 further comprising twoadjuvants. 190. The immunogenic composition of any one of paragraphs 104-186 further comprisingaluminum salts (alum) as adjuvant. 15 191. The immunogenic composition of any one of paragraphs 104-186 further comprisingaluminum phosphate as adjuvant. 192. The immunogenic composition of any one of paragraphs 104-186 further comprising asaponin based adjuvant. 193. The immunogenic composition of any one of paragraphs 104-186 further comprising a QS21 20based adjuvant. 194. The immunogenic composition of any one of paragraphs 104-186 further comprising a CpGOligonucleotide as adjuvant. 195. The immunogenic composition of any one of paragraphs 104-194 for use as a vaccine. 196. The immunogenic composition of any one of paragraphs 104-194 for use in a method of 25preventing, treating or ameliorating an infection, disease or condition associated with S.pneumoniae serotype 21 in a subject. 197. The immunogenic composition of any one of paragraphs 104-194 for use in a method ofinducing an immune response to S. pneumoniae serotype 21 in a subject said method comprisingadministering to the subject an immunologically effective amount of said immunogenic 30composition. 198. The immunogenic composition of any one of paragraphs 104-194 for use in a method ofpreventing an infection by S. pneumoniae 21 in a subject said method comprising administeringto the subject an immunologically effective amount of said immunogenic composition. 159199. A method of detecting the presence of O-acetyl groups in an isolated S. pneumoniaeserotype 21 polysaccharide, said method comprising the step of: a) isolating an S. pneumoniaeserotype 21 polysaccharide and b) detecting the presence of O-acetyl groups in saidpolysaccharide. 200. The method of paragraph 199, wherein the presence of O-acetyl groups is detected by NMR, 5Mass Spectrometry (MS) or High-performance liquid chromatography (HPLC). 201. The method of paragraph 199, wherein the presence of O-acetyl groups is detected by NMR. 202. The method of paragraph 199, wherein the presence of O-acetyl groups is detected by MassSpectrometry (MS). 203. The method of paragraph 199, wherein the presence of O-acetyl groups is detected by High- 10performance liquid chromatography (HPLC). 204. The method of paragraph 199, wherein the presence of O-acetyl groups is detected by High-performance liquid chromatography (HPLC). 205. A method of detecting the presence of O-acetyl groups in a reduced serotype 21polysaccharide, said method comprising the step of: a) reacting an isolated S. pneumoniae 15serotype 21 polysaccharide with a reducing agent and b) detecting the presence of O-acetylgroups in said reduced polysaccharide. 206. The method of paragraph 205, wherein the presence of O-acetyl groups is detected by NMR,Mass Spectrometry (MS) or High-performance liquid chromatography (HPLC). 207. The method of paragraph 205, wherein the presence of O-acetyl groups is detected by NMR. 20 208. The method of paragraph 205, wherein the presence of O-acetyl groups is detected by MassSpectrometry (MS). 209. The method of paragraph 205, wherein the presence of O-acetyl groups is detected by High-performance liquid chromatography (HPLC). 210. The method of paragraph 205, wherein the presence of O-acetyl groups is detected by High- 25performance liquid chromatography (HPLC). 211. The method of any one of paragraphs 205 to 210, wherein said reducing agent is sodiumborohydride (NaBH4). 212. The method of any one of paragraphs 205 to 211, wherein said isolated S. pneumoniaeserotype 21 polysaccharide has been previously treated with an oxidizing agent. 30 213. The method of paragraph 212, wherein said oxidizing agent is any oxidizing agent whichoxidizes a terminal hydroxyl group to an aldehyde. 214. The method of paragraph 212, wherein said oxidizing agent is periodate. 160215. The method of paragraph 212, wherein said oxidizing agent is sodium metaperiodate. 216. The method of any one of paragraphs 205 to 211, wherein said isolated S. pneumoniaeserotype 21 polysaccharide has been previously treated with a stable nitroxyl radical compoundand an oxidant. 217. The method of paragraph 216, wherein said stable nitroxyl radical compound is a molecule 5bearing a TEMPO or a PROXYL (2,2,5,5-tetramethyl-1-pyrrolidinyloxy) moiety. 218. The method of paragraph 216 or 217, wherein said oxidant is a molecule bearing a N-halomoiety. 219. The method of paragraph 216 or 217, wherein said oxidant is N-Chlorosuccinimide, N-Bromosuccinimide, N-Iodosuccinimide, Dichloroisocyanuric acid, 1,3,5-trichloro-1,3,5-triazinane- 102,4,6-trione, Dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione,Diiodoisocyanuric acid or 1,3,5-triiodo-1,3,5-triazinane-2,4,6-trione. In an aspect, said oxidant isselected from the group consisting of N-Chlorosuccinimide, N-Bromosuccinimide, N-Iodosuccinimide, Dichloroisocyanuric acid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione,Dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione, Diiodoisocyanuric acid and 151,3,5-triiodo-1,3,5-triazinane-2,4,6-trione. 220. The method of paragraph 216 or 217, wherein said oxidant is is N-Chlorosuccinimide. 221. The method of paragraph 216, wherein said stable nitroxyl radical compound is 2,2,6,6-Tetramethyl-1-piperidinyloxy free radical (TEMPO) and said oxidant is N-Chlorosuccinimide(NCS). 20 222. A method of detecting the presence of O-acetyl groups in S. pneumoniae serotype 21glycoconjugate, said method comprising the step of: a) preparing a S. pneumoniae serotype 21glycoconjugate and b) detecting the presence of O-acetyl groups in said glycoconjugate. 223. The method of paragraph 222, wherein the presence of O-acetyl groups is detected by NMR,Mass Spectrometry (MS) or High-performance liquid chromatography (HPLC). 25 224. The method of paragraph 222, wherein the presence of O-acetyl groups is detected by NMR. 225. The method of paragraph 222, wherein the presence of O-acetyl groups is detected by MassSpectrometry (MS). 226. The method of paragraph 222, wherein the presence of O-acetyl groups is detected by High-performance liquid chromatography (HPLC). 30 227. The method of paragraph 222, wherein the presence of O-acetyl groups is detected by High-performance liquid chromatography (HPLC). 161228. A method of measuring the degree of O-acetylation of an isolated S. pneumoniae serotypepolysaccharide, said method comprising the step of: a) isolating an S. pneumoniae serotypepolysaccharide and b) measuring the amount of O-acetyl groups in said polysaccharide. 229. The method of paragraph 228, wherein the amount of O-acetyl groups is measured by NMR,Mass Spectrometry (MS) or High-performance liquid chromatography (HPLC). 5 230. The method of paragraph 228, wherein the amount of O-acetyl groups is measured by NMR. 231. The method of paragraph 228, wherein the amount of O-acetyl groups is measured by MassSpectrometry (MS). 232. The method of paragraph 228, wherein the amount of O-acetyl groups is measured by High-performance liquid chromatography (HPLC). 10 233. A method of measuring the degree of O-acetylation of an isolated S. pneumoniae serotypepolysaccharide, said method comprising the step of: a) isolating an S. pneumoniae serotypepolysaccharide b) treating said polysaccharide with a base and c) measuring the amount ofO-acetyl groups in said polysaccharide. 234. The method of paragraph 233, wherein the amount of O-acetyl groups is measured by NMR, 15Mass Spectrometry (MS) or High-performance liquid chromatography (HPLC). 235. The method of paragraph 233, wherein the amount of O-acetyl groups is measured by NMR. 236. The method of paragraph 233, wherein the amount of O-acetyl groups is measured by MassSpectrometry (MS). 237. The method of paragraph 233, wherein the amount of O-acetyl groups is measured by High- 20performance liquid chromatography (HPLC). 238. A method of measuring the degree of O-acetylation in a reduced serotype 21 polysaccharide,said method comprising the step of: a) reacting an isolated S. pneumoniae serotype 21polysaccharide with a reducing agent and b) measuring the amount of O-acetyl groups in saidreduced polysaccharide. 25 239. The method of paragraph 238, wherein the amount of O-acetyl groups is measured by NMR,Mass Spectrometry (MS) or High-performance liquid chromatography (HPLC). 240. The method of paragraph 238, wherein the amount of O-acetyl groups is measured by NMR. 241. The method of paragraph 238, wherein the amount of O-acetyl groups is measured by MassSpectrometry (MS). 30 242. The method of paragraph 238, wherein the amount of O-acetyl groups is measured by High-performance liquid chromatography (HPLC). 162243. A method of measuring the degree of O-acetylation in S. pneumoniae serotype 21glycoconjugate, said method comprising the step of: a) preparing a S. pneumoniae serotype 21glycoconjugate and b) measuring the amount of O-acetyl groups in said glycoconjugate. 244. The method of paragraph 243, wherein the amount of O-acetyl groups is measured by NMR,Mass Spectrometry (MS) or High-performance liquid chromatography (HPLC). 5 245. The method of paragraph 243, wherein the amount of O-acetyl groups is measured by NMR. 246. The method of paragraph 243, wherein the amount of O-acetyl groups is measured by MassSpectrometry (MS). 247. The method of paragraph 243, wherein the amount of O-acetyl groups is measured by High-performance liquid chromatography (HPLC). 10 248. The glycoconjugate of any one of paragraphs 41-103 for use as an antigen. 249. The glycoconjugate of any one of paragraphs 41-103 for use as a medicament. 250. The glycoconjugate of any one of paragraphs 41-103 for use as a vaccine. 251 The glycoconjugate of any one of paragraphs 41-103 for use in generating an immuneresponse in a subject. 15 252. The glycoconjugate for use of paragraph 251 wherein said subject is a human. 253. The immunogenic composition of any one of paragraphs 104-194 for use as amedicament. 254. The immunogenic composition of any one of paragraphs 104-194 for use in generating animmune response in a subject. 20 255. The immunogenic composition for use of paragraph 254 wherein said subject is a human. 256. The immunogenic composition of any one of paragraphs 104-194 for use is a method ofpreventing, treating or ameliorating a bacterial infection, disease or condition in a subject. 257. The immunogenic composition of any one of paragraphs 104-194 for use is a method ofpreventing, treating or ameliorating a S. pneumoniae serotype 21 infection, disease or condition 25in a subject. 258. The immunogenic composition of any one of paragraphs 104-194 for use is a method ofinducing an immune response to S. pneumoniae serotype 21 in a subject. 259. The immunogenic composition of any one of paragraphs 104-194 for use is a method ofpreventing an infection by S. pneumoniae serotype 21 in a subject. 30 260. The immunogenic composition of any one of paragraphs 104-194 for use is a method ofprotecting a human susceptible to a S. pneumoniae serotype 21 infection. 163261. A method of making a Streptococcus pneumoniae serotype 21 glycoconjugate, using clickchemistry said method comprising the steps of (a) reacting an isolated serotype 21 saccharidewith a carbonic acid derivative and an azido linker in an aprotic solvent to produce an activatedazido saccharide (activation of the saccharide), (b) reacting a carrier protein with an agent bearingan N-Hydroxysuccinimide (NHS) moiety and an alkyne group where the NHS moiety reacts with 5the amino groups to form an amide linkage thereby obtaining an alkyne functionalized carrierprotein (activation of the carrier protein), (c) reacting the activated azido saccharide of step (a)with the activated alkyne-carrier protein of step (b) by Cu+1 mediated azide-alkyne cycloadditionreaction to form a glycoconjugate. 262. The method of paragraph 261 wherein before the activation (a), sizing of the saccharide 10to a target molecular weight (MW) range has been performed. 263. The method of paragraph 261 wherein the isolated serotype 21 saccharide is sized beforeactivation with a carbonic acid derivative and an azido linker. 264. The method of paragraph 263 wherein the isolated serotype 21 capsular polysaccharideis sized to a weight average molecular weight between 50 kDa and 500 kDa. 15 265. The method of paragraph 263 wherein the isolated serotype 21 capsular polysaccharideis sized to a weight average molecular weight between 50 kDa and 400 kDa. 266. The method of paragraph 263 wherein the isolated serotype 21 capsular polysaccharideis sized to a weight average molecular weight between 100 kDa and 500 kDa. 267. The method of paragraph 263 wherein the isolated serotype 21 capsular polysaccharide 20is sized to a weight average molecular weight between about 100 kDa and about 400 kDa. 268. The method of paragraph 263 wherein the isolated serotype 21 capsular polysaccharideis sized to a weight average molecular weight between about 150 kDa and about 300 kDa. 268a. The method of paragraph 263 wherein the isolated serotype 21 capsular polysaccharideis sized to a weight average molecular weight between about 150 kDa and about 400 kDa. 25 269. The method of paragraph 261 wherein the isolated serotype 21 capsular polysaccharideis not sized before activation with a carbonic acid derivative and an azido linker. 270. The method of any one of paragraphs 261 to 269 wherein said carbonic acid derivative isselected from the group consisting of 1,1’-carbonyldiimidazole (CDI), 1,1’-carbonyl-di-(1,2,4-triazole) (CDT), N,N ′-Disuccinimidyl carbonate (DSC) and N-hydroxysuccinimidyl chloroformate. 30 271. The method of any one of paragraphs 261 to 269 wherein said carbonic acid derivative is1,1’-carbonyldiimidazole (CDI). 272. The method of any one of paragraphs 261 to 269 wherein said carbonic acid derivative is1,1'-Carbonyl-di-(1,2,4-triazole) (CDT). 164273. The method of any one of paragraphs 261 to 269 wherein said carbonic acid derivative isN,N ′-Disuccinimidyl carbonate (DSC). 274. The method of any one of paragraphs 261 to 269 wherein said carbonic acid derivative isN-hydroxysuccinimidyl chloroformate. 275. The method of any one of paragraphs 261 to 274 wherein said azido linker is a compound 5of formula (X), (X),wherein X is selected from the group consisting of CH2(CH2) n, (CH 2CH2O)mCH 2CH2, NHCO(CH2)n,NHCO(CH2CH2O)mCH 2CH2, OCH 2(CH2)n and O(CH 2CH2O)mCH2CH2; where n is selected from 1to 10 and m is selected from 1 to 4. 10 276. The method of any one of paragraphs 261 to 274 wherein said azido linker is a compoundof formula (X), wherein X is CH2(CH2)n, and n is selected from 1 to 10. 277. The method of any one of paragraphs 261 to 274 wherein said azido linker is a compoundof formula (X), wherein X is (CH2CH2O)mCH2CH2, wherein m is selected from 1 to 4. 278. The method of any one of paragraphs 261 to 274 wherein said azido linker is a compound 15of formula (X), wherein X is NHCO(CH2)n, and n is selected from 1 to 10. 279. The method of any one of paragraphs 261 to 274 wherein said azido linker is a compoundof formula (X), wherein X is NHCO(CH2CH2O)mCH 2CH2, where m is selected from 1 to 4. 280. The method of any one of paragraphs 261 to 274 wherein said azido linker is a compoundof formula (X), wherein X is OCH2(CH2)n, and n is selected from 1 to 10. 20 281. The method of any one of paragraphs 261 to 274 wherein said azido linker is a compoundof formula (X), wherein X is O(CH2CH2O)mCH2CH2, where m is selected from 1 to 4. 282. The method of any one of paragraphs 261 to 274 wherein said azido linker is a compoundof formula (XI), (XI). 25 283. The method of any one of paragraphs 261 to 274 wherein said azido linker is 3-azido-propylamine. 284. The method of any one of paragraphs 261 to 283 wherein said agent bearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group is an agent bearing an N-Hydroxysuccinimide (NHS) moiety and a terminal alkyne. 30 165285. The method of any one of paragraphs 261 to 283 wherein said agent bearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group is an agent bearing an N-Hydroxysuccinimide (NHS) moiety and a cycloalkyne. 286. The method of any one of paragraphs 261 to 283 wherein said agent bearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group is a compound of formula (XII), 5 (XII),where X is selected from the group consisting of CH2O(CH 2)nCH 2C=O and 10CH2O(CH 2CH2O)m(CH2)nCH2C=O, where n is selected from 0 to 10 and m is selected from 0 to4. 287. The method of any one of paragraphs 261 to 283 wherein said agent bearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group is a compound of formula (XII), whereinX is CH2O(CH 2)nCH2C=O, where n is selected from 0 to 10. 15 288. The method of any one of paragraphs 261 to 283 wherein said agent bearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group is a compound of formula (XII), whereinX is CH2O(CH2CH2O)m(CH2)nCH2C=O, where n is selected from 0 to 10 and m is selectedfrom 0 to 4. 289. The method of any one of paragraphs 261 to 283 wherein said agent bearing an N- 20Hydroxysuccinimide (NHS) moiety and an alkyne group is a compound of formula (XIII): (XIII). 290. The method of any one of paragraphs 261 to 289 wherein, step a) comprises reacting thesaccharide with a carbonic acid derivative followed by reacting the carbonic acid derivative-activated saccharide with an azido linker in an aprotic solvent to produce an activated azido 25saccharide. 291. The method of any one of paragraphs 261 to 289 wherein step a) comprises reacting thesaccharide with an amount of carbonic acid derivative that is between 0.01-10 molar equivalentto the amount of saccharide present in the reaction mixture. 292. The method of any one of paragraphs 261 to 289 wherein at step a) the isolated 30saccharide is reacted with a carbonic acid derivative in an aprotic solvent.
X 166293. The method of any one of paragraphs 261 to 289 wherein the isolated saccharide isreacted with CDI in an aprotic solvent comprising 0.1% to 1% (v/v) water. 294. The method of any one of paragraphs 261 to 293 wherein step a) further comprisesreacting the carbonic acid derivative-activated saccharide with an amount of azido linker that isbetween 0.01-10 molar equivalent to the amount of polysaccharide Repeat Unit of the activated 5saccharide (molar equivalent of RU). 295. The method of any one of paragraphs 261 to 294 wherein the degree of activation of theactivated saccharide following step a) is between 1.0 to 100%. 296 The method of any one of paragraphs 261 to 294 wherein the degree of activation of theactivated saccharide following step a) is between 5 to 70%. 10 297. The method of any one of paragraphs 261 to 294 wherein the degree of activation of theactivated saccharide following step a) is between 15 to 50%. 298. The method of any one of paragraphs 261 to 294 wherein the degree of activation of theactivated saccharide following step a) is between 10 to 40%. 299. The method of any one of paragraphs 261 to 294 wherein the degree of activation of the 15activated saccharide following step a) is about 25%. 300. The method of any one of paragraphs 261 to 299 wherein step b) comprises reacting thecarrier protein with an amount of agent bearing an N-Hydroxysuccinimide (NHS) moiety and analkyne group that is 0.1-10 molar equivalents to the lysines on the carrier. 301. The method of any one of paragraphs 261 to 299 wherein the degree of activation of the 20activated carrier following step b) is between 1 and 50. 302. The method of any one of paragraphs 261 to 299 wherein the degree of activation of theactivated carrier following step b) may be between 5 to 50. 303. The method of any one of paragraphs 261 to 299 wherein the degree of activation of theactivated carrier following step b) is between 10 to 40. 25 304. The method of any one of paragraphs 261 to 299 wherein the degree of activation of theactivated carrier following step b) is between 15 to 25. 305. The method of any one of paragraphs 261 to 304 wherein the conjugation reaction c) iscarried out in aqueous buffer. 306. The method of any one of paragraphs 261 to 304 wherein the conjugation reaction c) is 30carried out in aqueous buffer in the presence of copper (I) as catalyst. 307. The method of any one of paragraphs 261 to 304 wherein the conjugation reaction c) iscarried out in aqueous buffer in the presence an oxidant and of copper (I) as catalyst. 167308. The method of any one of paragraphs 261 to 307 wherein the initial input ratio (weight byweight) of activated azido saccharide to activated alkyne-carrier at step c) is between 0.8 and 1.2. 309. The method of any one of paragraphs 261 to 308 wherein following step c), unreactedazido groups in the conjugates, are capped using a suitable azido group capping agent. 310. The method of any one of paragraphs 261 to 309 wherein following step c) unreacted 5alkyne groups are capped using a suitable alkyne group capping agent. 311. The method of any one of paragraphs 261 to 310 wherein said Streptococcus pneumoniaeserotype 21 glycoconjugate is according to any one of paragraphs 1-40. 312. A method of making a Streptococcus pneumoniae serotype 21 glycoconjugate, usingreductive amination said method comprising the steps of (1) oxidation (activation) of a serotype 10purified saccharide, (2) reduction of the activated saccharide and the carrier protein to form aglycoconjugate. 313. The method of paragraph 312 wherein the isolated serotype 21 polysaccharide is sizedbefore oxidation. 314. A method of making a Streptococcus pneumoniae serotype 21 glycoconjugate, comprising 15the step of: (a) reacting an isolated serotype 21 saccharide with an oxidizing agent; (b)compounding the activated saccharide of step (a) with a carrier protein; and (c) reacting thecompounded activated saccharide and carrier protein with a reducing agent to form aglycoconjugate. 315. The method of paragraph 314 wherein the oxidizing agent is periodate. 20 316. The method of paragraph 315 wherein the degree of oxidation of the activated serotypesaccharide is between 2 and 30. 317. The method of paragraph 315 wherein the degree of oxidation (DO) of the activatedserotype 21 saccharide is between 10 and 21. 318. The method of paragraph 315 wherein the degree of oxidation (DO) of the activated 25serotype 21 saccharide is between 10 and 21 and wherein the initial input ratio (weight by weight)of activated serotype 21 saccharide to carrier protein at step b) is between 1.5:1 and 0.5:1. 319. The method of paragraph 315 wherein the degree of oxidation (DO) of the activatedserotype 21 saccharide is between 10 and 21 and wherein the initial input ratio (weight by weight)of activated serotype 21 saccharide to carrier protein at step b) is between 1.5:1 and 0.5:1, 30wherein the reduction reaction (c) is carried out in an aprotic solvent. 320. The method of paragraph 315 wherein the degree of oxidation (DO) of the activatedserotype 21 saccharide is between 10 and 21 and wherein the initial input ratio (weight by weight)of activated serotype 21 saccharide to carrier protein at step b) is between 1.5:1 and 0.5:1, 168wherein the reduction reaction (c) is carried out in a solution consisting essentially ofdimethylsulphoxide (DMSO). 321. The method of paragraph 315 wherein the degree of oxidation (DO) of the activatedserotype 21 saccharide is between 10 and 21 and wherein the initial input ratio (weight by weight)of activated serotype 21 saccharide to carrier protein at step b) is between 1.5:1 and 0.5:1, 5wherein the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide) solvent. 322. The method of paragraph 315 wherein the degree of oxidation (DO) of the activatedserotype 21 saccharide is between 10 and 21 and wherein the initial input ratio (weight by weight)of activated serotype 21 saccharide to carrier protein at step b) is between 1.5:1 and 0.5:1,wherein the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide) solvent and wherein 10the reducing agent is sodium cyanoborohydride. 323. The method of any one of paragraphs 312 to 322 wherein said Streptococcus pneumoniaeserotype 21 glycoconjugate is according to paragraph 41 or 42. 324. The method of any one of paragraphs 312 to 322 wherein said Streptococcus pneumoniaeserotype 21 glycoconjugate is according to any one of paragraphs 41-103. 15 As used herein, the term "about" means within a statistically meaningful range of a value, suchas a stated concentration range, time frame, molecular weight, temperature or pH. Such a rangecan be within an order of magnitude, typically within 20%, more typically within 10%, and evenmore typically within 5% or within 1% of a given value or range. Sometimes, such a range canbe within the experimental error typical of standard methods used for the measurement and/or 20determination of a given value or range. The allowable variation encompassed by the term"about" will depend upon the particular system under study, and can be readily appreciated byone of ordinary skill in the art. Whenever a range is recited within this application, every numberwithin the range is also contemplated as an embodiment of the disclosure.The terms "comprising", "comprise" and "comprises" herein are intended by the inventors to be 25optionally substitutable with the terms "consisting essentially of", "consist essentially of", "consistsessentially of", "consisting of', "consist of' and "consists of', respectively, in every instance.An "immunogenic amount", an "immunologically effective amount", a "therapeutically effectiveamount", a "prophylactically effective amount", or "dose", each of which is used interchangeablyherein, generally refers to the amount of antigen or immunogenic composition sufficient to elicit 30an immune response, either a cellular (T cell) or humoral (B cell or antibody) response, or both,as measured by standard assays known to one skilled in the art.Any whole number integer within any of the ranges of the present document is contemplated asan embodiment of the disclosure.All references or patent applications cited within this patent specification are incorporated by 35reference herein. 169The invention is illustrated in the accompanying examples. The examples below are carried outusing standard techniques, which are well known and routine to those of skill in the art, exceptwhere otherwise described in detail. The examples are illustrative, but do not limit the invention.
Examples 5 Example 1: Serotype 21 capsular saccharides, samples preparation Streptococcus pneumoniae serotype 21 polysaccharide : 25mg of lyophilized native Streptococcus pneumoniae serotype 21 was weighed and dissolvedin 1000µL of D2O. The sample was bath sonicated for 20 minutes at 50°C. The polysaccharide 10solution was sized using sonication for 2 minutes with 20% amplitude power for 15 second ONand 15 second OFF cycles. Final concentration of the native and sized samples was 25 mg/mL.The sample was transferred into the NMR tube for NMR data collection and analysis.
Deacetylated Streptococcus pneumoniae serotype 21 polysaccharide: 25mg of native serotype 21 polysaccharide was completely deacetylated after incubating with 150.25N NH4OH at room temperature for 24 hours with constant stirring. The sample was thendialyzed against water and lyophilized. The lyophilized polysaccharide was then resuspended in1000µL of D2O. The sample was transferred into the NMR tube for NMR data collection andanalysis.
Example 2: Structural elucidation of Streptococcus pneumoniae serotype 21 20 polysaccharide by NMR experiments Both one-dimensional (1D) and two-dimensional (2D) NMR experiments were conducted. 1DHspectrum was collected to identify the chemical shift fingerprint for each proton in the molecule.2D homo- and hetero-nuclear spectra are collected to identify the chemical bond pattern betweenprotons and carbons in the molecule, to map the backbone of the representative sugars in the 25serotype 21 polymer repeat unit, the inter-sugar glycosidic linkages, and to identify the locationof the different functional groups on the sugar backbones.
All 1D and 2D data was collected at 75°C using Bruker 600 MHz spectrometer equipped withBBO cryoprobe. The NMR data was processed using NvX and analyzed using MestraNova andNMRViewJ (NvJ) software (Methods Mol. Biol. 278, 313, 2004). The proton signals were 30referenced using the TMS signal set to 0 ppm, whereas the carbon signals were indirectlyreferenced against the TMS signal (0 ppm). 1D proton data was collected with 32 scans, with recycle delay of 10s. The following 2D NMRexperiments were recorded:H-H homonuclear COSY (Correlation Spectroscopy, 2048 x 512:total number of point in theH andC dimensions, respectively, with 2 scans, recycle delay 1s), 35 170H-C HSQC (Heteronuclear Single Quantum Coherence, 2048 x 256: total number of point intheH andC dimensions, respectively, with 4 scans, recycle delay 1s),H-C HSQC-TOCSY(Heteronuclear Single Quantum Coherence - Total Correlation Spectroscopy, 2048 x 256: totalnumber of point in theH andC dimensions, respectively, with 48 scans, recycle delay 1s mixingtime of 120 ms),H-C HMBC (Heteronuclear Multiple Bond Correlation, 2048 x 256: total 5number of point in theH andC dimensions, respectively, long range J ~ 5-10 Hz, with 48 scans,recycle delay 1s) andH-C HSQC-COSY (Heteronuclear Single Quantum Coherence –Correlation Spectroscopy, 2048 x 256: total number of point in theH andC dimensions,respectively, with 48 scans, recycle delay 1s),H-C CLIP-HSQC (H decoupled HeteronuclearSingle Quantum Coherence, 2048 x 256: total number of point in theH andC dimensions, 10respectively, with 8 scans, recycle delay 1s). 1DP data was collected with 256 scans, withrecycle delay of 5s.H-P HMBC (Heteronuclear Multiple Bond Correlation, 2048 x 32: totalnumber of points in theH andP dimensions, respectively, long range J ~ 5-10 Hz).
Structural elucidation of the polysaccharides entails assigning all the resonances of the polymerrepeat unit (RU). We achieve this by analyzing both one-dimensional (1D) and two-dimensional 15(2D) NMR experiments. 1DH spectrum was collected to identify the chemical shift fingerprint foreach proton in the molecule. 2D homo- and hetero-nuclear spectra are collected to identify thechemical bond pattern between protons and carbons in the molecule, to map the backbone of therepresentative sugars in the serotype 21 polymer repeat unit, the inter-sugar glycosidic linkages,and to identify the location of the different functional groups on the sugar backbones. 20 The chemical structure of Streptococcus pneumoniae serotype 21 is shown in Figure 1. Theserotype 21 polysaccharide is a hexasaccharide: α-D-galactopyranose (A), β-L-rhamnose (B), β-D-glucose (C), β-D-glucosamine (D), α-D-galactopyranose (E) and O-acetylated β-D-galactofuranose (F). The O-acetylation of β-D-galactofuranose is at 3, 5 and 6 position at differentlevels. The main chain consists of five sugars and one branched sugar ( β-D-galactofuranose) 25linked to 4 position of β-D-glucosamine (D). The backbone repeating unit is linked via phosphategroup at the reducing end of the residue E ( α-D-galactopyranose) and links the 6 position ofresidue A ( α-D-galactopyranose).
Three different populations of serotype 21 repeat unit have been found: ~64% O-acetylated atthe C3 position of β-D-Galf3 0.64OAc; ~30% O-acetylated at β-D-Galf6 0.30OAc and ~6% O- 30acetylated at β-D-Galf5 0.06OAc. 1DH NMR analysis of the serotype 21 polysaccharide The 1DH NMR spectrum of native polysaccharide shown in Figure 2 can be correlated to thepolysaccharide backbone containing the 6 sugar residues. The anomeric protons of the α-D-Galp(Residue A), β-L-Rhap (Residue B), β-D-Glcp (Residue C), β-D-GlcpNAc (Residue D), α-D-Galp 35(Residue E) and β-D-Galf3 0.64,5 0.06,6 0.30OAc (Residue F) are at δ 5.13 ppm, δ 4.86 ppm, δ 4.53ppm, δ 4.80 ppm, δ 5.51 ppm and δ 5.22 ppm ( β-D-Galf3 0.64OAc); δ 5.19 ( β-D-Galf6 0.30OAc), 171respectively. The inset table in Figure 2 shows the excellent agreement between the normalizedarea under the anomeric proton peaks and the expected theoretical area. The area under thesepeaks were deconvoluted using the MestraNova software. The Galf (residue F) of serotype 21polysaccharide is O-acetylated at different carbon position. The level of O-acetylation at position3, 5 and 6 of Galf (residue F) is around 64%, 6% and 30%, respectively. The amount of O- 5acetylation was determined using the F1 anomeric signals and the O-acetylation signals (seeinset showing the O-acetyl resonances). There is good agreement between the level of O-acetylation calculated using different resonance signals. The expanded 1DH spectrum of theanomeric region of serotype 21 polysaccharide is also shown in Figure 2.
The anomers α or β of each sugar units were determined using the three-bondH-H coupling 10constant (J) measured from anomeric proton signals and theH-C coupling constant (JCH) ofthe anomeric carbon and proton. Figure 3 and Table 1 show theJCH andJHH coupling constantsfor the six anomeric resonances for serotype 21, which were used to determine the structure ofserotype 21.
Table 1:JCH andJHH coupling constants for the six anomeric resonances for serotype 21. 15 JCH (Hz) JHH (Hz) α-D-Galp (A) 174 3.7 β-L-Rhap (B) 161 - β-D-Glcp (C) 161 7.9 β-D-GlcpNAc (D) 163 8.3 α-D-Galp (E) 174 3.3 β-D-Galf3,5,6 OAc (F) 175 - 2D NMR analysis of the serotype 21 polysaccharide The complete structural elucidation of sized serotype 21 polysaccharide was achieved by doingthe complete assignment of all the resonances of each sugar unit that are present in the repeatunit. Each of the sugar units were assigned using 2D heteronuclear NMR experiments that useshort rangeH-H (HSQC-COSY), long range (multiple bonds)H-H (HSQC-TOCSY) orC-C 20(HMBC) correlation to map the resonances within the sugar ring.The 2D HSQC experiment provides the correlation between theH andC signals that aredirectly bonded and is very sensitive for analyzing the polysaccharides. 2D HSQC-COSY yieldsaH-H short range and HSQC-TOCSY yields aH-H long range (mixing time ~120 ms) protoncorrelation and is very useful in assigning the resonances within the sugar ring. Similarly, the 25inverse detected 2DH-C HMBC experiment gives rise to cross-peaks between proton andcarbon atoms that are long range scalar coupled through multiple carbon bonds. The intensities 172of these cross peaks are reflected in theJC,H orJC,H values. Generally, three bond correlationsfrom the anomeric carbon to the carbon at 3 and 5 positions are seen. Also quite prominent arethe correlations to the neighbouring carbon through the glycosidic bond, which are helpful insequential assignment of the sugar units and their connectivity.All the sugar backbone resonances were assigned by comparing the resonances from the short 5range (HSQC-COSY) and long range (HSQC-TOCSY),H-C HMBC NMR experiments.
The linkage between the phosphodiester and residue A and residue E was determined comparingtheP-H HMBC andC-H HSQC spectra.
The complete set of the resonances of all sugars of serotype 21 is tabulated in Table 2 for β-D-Galf3 0.64OAc population (left), β -D-Galf6 0.32OAc population (middle), along with resonances of 10deacetylated serotype 21 (right).
Table 2. Chemical shift assignment of serotype 21 for the population -D-Galf30.64OAc (left), forthe population -D-Galf60.32OAc (middle) and de-O-acetylated serotype 21 (right). Acetylated Pn-21 (Galf3OAc) Acetylated Pn-21 (Galf6OAc) O-Deacetylated Pn-21 H (ppm) C (ppm) H (ppm) C (ppm) H (ppm) C (ppm) α-D-Galp (A) A1 5.13 96.3 5.13 96.3 5.13 96.3A2 3.86 68.7 3.86 68.7 3.86 68.7A3 3.95 69.7 3.95 69.7 3.95 69.7A4 4.08 69.3 4.08 69.3 4.07 69.3A5 4.33 70.1 4.33 70.1 4.32 70.1A6-1 4.05 64.7 4.05 64.7 4.04 64.7A6-2 4.02 64.7 4.02 64.7 4.02 64.7 β-L-Rhap (B) B1 4.86 100.8 4.86 100.8 4.86 100.8B2 4.27 67.8 4.27 67.8 4.27 67.8B3 3.68 78.5 3.68 78.5 3.68 78.5B4 3.47 71.0 3.47 71.0 3.45 71.0B5 3.42 72.5 3.42 72.5 3.45 72.5B6 1.33 17.3 1.33 17.3 1.34 17.3 β-D-Glcp (C ) C13OAc 4.53 101.7 4.52 102.2 4.52 102.0C23OAc 3.38 74.1 3.35 74.0 3.36 74.0C3 3.66 76.1 3.66 76.1 3.65 76.0C43OAc 3.52 77.8 3.60 77.4 3.59 77.5C53OAc 3.52 75.4 3.50 75.4 3.49 75.3C63OAc-1 4.00 62.1 3.96 61.4 3.94 61.4C63OAc-2 3.75 62.1 3.81 61.4 3.80 61.4 β-D-GlcpNAc (D) D1 4.80 102.5 4.80 102.5 4.80 102.5D2 3.91 56.1 3.91 56.1 3.91 56.2D33OAc 3.92 74.1 3.87 74.7 3.87 74.5D43OAc 3.86 78.7 3.91 77.0 3.90 76.7 173D5 3.59 75.7 3.59 75.7 3.59 75.7D6-1 3.99 60.4 3.99 60.4 3.96 60.3D6-2 3.88 60.3 3.88 60.3 3.88 60.3D-NAc 2.05 22.7 2.05 22.7 2.05 22.8CO 175.0 175.0 175.1 α-D-Galp (E) E1 5.51 96.0 5.51 96.0 5.51 96.0E2 3.92 67.6 3.92 67.6 3.92 67.6E3 3.94 79.5 3.94 79.5 3.93 79.5E4 4.24 69.3 4.24 69.3 4.23 69.3E5 4.11 71.8 4.11 71.8 4.10 71.8E6 3.73 61.4 3.73 61.4 3.73 61.4 β-Galf3OAc (F) F13OAc 5.22 109.1 5.18 108.0F23OAc 4.15 80.6 4.05 81.7F33OAC 4.98 80.4 4.00 77.9F43OAc 4.46 82.1 4.24 84.1F53OAc 3.86 71.6 3.83 71.7F63OAc-1 3.67 63.4 3.71 63.5F63OAc-2 3.62 63.4 3.66 63.5F-3OAc 2.18 20.7CO 174.4 β-Galf6OAc (F) F16OAc 5.19 108.2F26OAc 4.06 81.8F36OAc 4.02 77.7F46OAc 4.25 83.9F56OAc 4.03 69.0F66OAc-1 4.28 66.5F66OAc-2 4.17 66.5F-6OAc 2.16 20.7CO 173.9 Example 3: Acetyl migration in serotype 21 polysaccharide by NMR experiments Acetylation migration in serotype 21 polysaccharide has been measured at room and elevatedtemperature. The migration of the O-Acetyl group from 3 position to 6 position of β-D-Galf sugarhas been observed after comparing the 1DH spectra of serotype 21 polysaccharide at 0, 9 and 5hours recorded at 75°C. The methyl signal (-COO CH3 ) from 3 position of β-D-Galf decreasedwhereas the methyl signal at 6 position of β-D-Galf increased (Figure 4). This clearly suggeststhat at elevated temperature O-acetyl migration from 3 to 6 position of β-D-Galf (residue F) isobserved. The level of O-acetylation at 6 position doubled after incubation at elevatedtemperature for 9 hrs. No further migration was observed after 9 hours as no increase in the O- 10acetyl signal at the 6 position was observed. The acetylation migration was observed at roomtemperature albeit at slower rate. The level of O-acetylation at the 6 position of β-D-Galf increased 174from 29% to 42% after incubating the polysaccharide for 14 days at room temperature (21°C)(Figure 5, Table 3).
Table 3. Acetyl migration in serotype 21 when incubated at room temperature. Days Normalized Peak Area (E1) Expected Peak Area % Acetylation 0 F-5OAc 0.279F-3OAc 1.82 62F-6OAc 0.86 29 9 F-5OAc 0.2810F-3OAc 1.54 53F-6OAc 1.10 38 14 F-5OAc 0.3111F-3OAc 1.39 47F-6OAc 1.24 42 Example 4: Structural comparison of O-acetylated and de-O-acetylated serotype 21 polysaccharide by NMR experiments The comparison of the anomeric and methyl regions of 1DH NMR spectrum of acetylated(bottom panel) and deacetylated (top panel) serotype 21 polysaccharides is shown at Figure 6. 10All the resonances are annotated. Shaded box denotes the resonances which are observed dueto the acetylation of β-D-Galf residue are absent in the completely deacetylated serotype 21polysaccharide. The structural impact on the polysaccharide upon deacetylation wasdemonstrated by plotting the chemical shift difference between the carbon and proton resonancesof the acetylated and deacetylated serotype 21 polysaccharides using the following equation: 15 ??? = ??+(0.3× ??) , where δH and δC are the chemical shift difference of the protonand carbon resonances (Figure 7; Table 2). Left bottom panel of figure 7 shows the structuralchanges caused by deacetylation at Galf6OAc sugar whereas left top panel shows the structuralchanges caused by deacetylation at Galf3OAc sugar. Most significant shifts are observed aroundthe deacetylation sites, illustrated using filled circles on the structure of serotype 21 20polysaccharide (Figure 7, right bottom and top panel). Deacetylation at the Galf3OAc has greaterimpact on the structural fold of serotype 21 polysaccharide compared to the deacetylation at theGalf6OAc, which can impact the immunogenic response. 175 Example 5: Conjugation of S. pneumoniae Serotype 21 Capsular Polysaccharides by Reductive Amination Mechanical sizing of Serotype 21 Capsular PolysaccharideThe native polysaccharide was subjected to mechanical sizing under 15000 psi pressure toreduce the MW size. The sizing study was performed to identify the number of passes required 5to achieve the target polysaccharide MW of 120-250 kDa.Activating PolysaccharidePolysaccharide oxidation was carried out in 50 mM potassium phosphate buffer (pH 6.0 ± 0.2) bysequential addition of calculated amount of 1 M potassium phosphate buffer (pH 5.7) and waterfor injection (WFI) to give final polysaccharide concentration of 2.0 g/L. If required, the reaction 10pH was adjusted to pH 6.0, approximately. After pH adjustment, the reaction temperature wasadjusted to 5 ± 3 °C. Oxidation was initiated by the addition of approximately 0.10 molarequivalents of sodium periodate. The oxidation reaction was performed at 5 ± 3 °C during 20 hrs,approximately.Concentration and diafiltration of the activated polysaccharide was carried out using 10K MWCO 15ultrafiltration cassettes. Diafiltration was performed against 20-fold diavolumes of WFI. Thepurified activated polysaccharide was then stored at 5 ± 3°C. The purified activated saccharide ischaracterized, inter alia, by (i) saccharide concentration by colorimetric assay; (ii) aldehydeconcentration by colorimetric assay; (iii) degree of oxidation; and (iv) molecular weight by SEC-MALLS. 20The degree of oxidation (DO = moles of sugar repeat unit / moles of aldehyde) of the activatedpolysaccharide was determined as follows:The moles of sugar repeat unit are determined by various colorimetric methods, for example, byusing the Anthrone method. By the Anthrone method, the polysaccharide is first broken down tomonosaccharides by the action of sulfuric acid and heat. The Anthrone reagent reacts with the 25hexoses to form a yellow-green colored complex whose absorbance is readspectrophotometrically at 625nm. Within the range of the assay, the absorbance is directlyproportional to the amount of hexose present.The moles of aldehyde are also determined simultaneously, using the MBTH colorimetric method.The MBTH assay involves the formation of an azine compound by reacting aldehyde groups (from 30a given sample) with a 3-methyl-2-benzothiazolone hydrazone (MBTH assay reagent). Theexcess 3-methyl-2-benzothiazolone hydrazone oxidizes to form a reactive cation. The reactivecation and the azine react to form a blue chromophore. The formed chromophore is then readspectroscopically at 650 nm.Compounding Activated Polysaccharide with Sucrose Excipient, and Lyophilizing 35The activated polysaccharide was compounded with sucrose to a ratio of 25 grams of sucroseper gram of activated polysaccharide. The bottle of compounded mixture was then lyophilized.Following lyophilization, bottles containing lyophilized activated polysaccharide were stored at - 176± 5°C. Calculated amount of CRM 197 protein was shell-frozen and lyophilized separately.Lyophilized CRM 197 was stored at -20 ± 5°C.Reconstituting Lyophilized Activated Polysaccharide and Carrier ProteinLyophilized activated polysaccharide was reconstituted in anhydrous dimethyl sulfoxide (DMSO).Upon complete dissolution of polysaccharide, an equal amount of anhydrous DMSO was added 5to lyophilized CRM 197 for reconstitution.Conjugating and CappingReconstituted activated polysaccharide was combined with reconstituted CRM 197 in the reactionvessel, followed by mixing thoroughly to obtain a clear solution before initiating the conjugationwith sodium cyanoborohydride. The final polysaccharide concentration in reaction solution was 10approximately 1 g/L. Conjugation was initiated by adding 1.0 MEq of sodium cyanoborohydrideto the reaction mixture and incubating at 23 ± 2 °C for 20-28 hrs. The conjugation reaction wasterminated by adding 2 MEq of sodium borohydride (NaBH4) to cap unreacted aldehydes. Thiscapping reaction continued at 23 ± 2°C for 3 ± 1 hrs.Purifying the Conjugate 15The conjugate solution was diluted 1:5 with chilled 5 mM succinate/ saline (pH 6.0) in preparationfor purification by tangential flow filtration using 100K MWCO membranes.The diluted conjugate solution was passed through a 5 µm filter, and diafiltration was performedusing 5 mM succinate / saline (pH 6.0) as the medium. After the diafiltration was completed, theconjugate retentate was transferred through a 0.22 μm filter. The conjugate was diluted further 20with 5 mM succinate / saline (pH 6.0), to a target saccharide concentration of approximately 0.5mg/mL.Table 4 below comprises characterizing data for serotype 21 polysaccharide conjugates obtainedby methods of this invention. Table 4. Pneumo St 21-CRM 197 Conjugates by Reductive Amination Conjugation in DMSO 25 Serotype 21 Conjugates Conjugate # 1 2 3 4 5 6 Sized Poly Mw (kDa) 236 236 236 187 152 128Activation NaIO4 (MEq) 0.1 0.15 0.2 0.15 0.15 0.15 DO 20 14 11 15 16 16 Act poly Mw (kDa) 232 228 224 198 150 127 Act poly yield (%) 90 88 84 91 92 89Conjugation Poly yield (%) 46 63 63 79 98 87 SPR (Output Ratio) 0.9 0.95 0.9 0.94 1.2 1 Free saccharide (%) <5 <5 <5 <5 16 31 Conjugate MW (kDa) 2715 2558 2956 4223 3069 3358 Poly: Polysaccharide; Mw: molecular weight; MEq: Molar Equivalent; DO: Degree of Oxidation;Act Poly: Activated Polysaccharide SPR: Saccharide to protein ratio 177 Example 6: Conjugation of S. pneumoniae Serotype 21 Capsular Polysaccharides using click chemistry 1. Mechanical sizing of Serotype 21 Capsular Polysaccharide (optional)The native polysaccharide was either used without sizing (unsized) or subjected to mechanicalsizing under 15000 psi pressure to reduce the MW size. The sizing study was performed to 5identify the number of passes required to achieve the target polysaccharide MW of 140-200 kDa. 2. Activation of Serotype 21 Capsular Polysaccharide with azido linkerSerotype 21 polysaccharide (either unsized or sized) 400 mg was mixed with 1.2 g imidazole thenfrozen and lyophilized. After lyophilization, the lyophilized polysaccharide was reconstituted withanhydrous DMSO 200 mL. The reaction mixture was then warmed to 35 °C, and then CDI (100 10mg/mL in DMSO, 1.25 mL, 2 MEq) was added. The reaction mixture was stirred at 35 °C for 3hrs. After the reaction mixture was cooled to 23 °C, Water For Injection (WFI) 4 mL (2% v/v) wasadded to quench free CDI and stirred for 30 min at 23 °C.To the reaction mixture, 3-Azido-1-propylamine 76 µL (2 MEq) and 110 µL of triethylamine (2MEq) was added and then stirred at 23 °C for 20 hrs. After the reaction, the mixture was diluted 15with chilled 10 mM SPB in saline (pH 7.0) (5X). The diluted reaction mixture was then purified byUF/DF using 10K MWCO PES membrane against 10 mM SPB in saline (pH 7.0) (30X volume). 3. Activation of SCP to alkyne-SCP with Alkyne NHS esterTo the SCP solution (2 g, 116 mL), 284 mL WFI and 100 mL 0.5 M Sodium Phosphate Buffer(SPB) (pH 8.3) were added to achieve final concentration of 4 mg/mL with 0.1 M ionic strength 20for the reaction. After cooled to 8°C, 3-Propargyloxy-propanoic acid NHS ester (POPS) (20 mg/mLin DMSO) 9.2 mL (0.5 MEq to lysine on SCP) was added to the reaction mixture dropwisemaintaining the reaction temperature at 8 ± 3 °C. After reaction mixture was stirred for 30 min at°C, the reaction mixture was purified by UF/DF using 10K MWCO PES membrane against 10mM SPB in saline (pH 7.0) (30X diavolume). The 418 mL retentate was taken and 62.7 gm 25sucrose (15% w/v) was added and followed by 0.22 um (Millipak 60) filtration. The retentate wasanalyzed using Lowry assay for protein quantification and SEC-MALLS for Mw. 4. Click ConjugationTo the mixture of Serotype 21 azido polysaccharide (as obtained at point 2 above) (62.5 mL) andalkyne-SCP (as obtained at point 3 above) (31.2 mL) or alkyne-CRM197, 1 M SPB (pH 7) 11 mL 30and 5 mL of WFI were added to make a 1-2 g/L reaction mixture with an ionic strength of 100 mMSPB (pH 7). The mixture was stirred at room temperature for 1 hour followed by addition of mixtureof copper sulfate (31 µmoL, 6.2 mL) and Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) (155µmoL, 6.2 mL), aminoguanidine (1240 µmoL, 12.4 mL), and sodium ascorbate (1240 µmoL, 12.4mL). The reaction mixture was stirred for 1.5 hours at room temperature. 35 After 1.5 hours, propargyl alcohol 36 µL (20 MEq per alkyne) was added to the reaction mixtureto cap the unreacted azide on polysaccharide. Additional Click reagents (half amount) were 178subsequently added to enhance the capping reactions; mixture of 5 mM copper sulfate 3.1 mLand 25 mM THPTA 3.1 mL, 100 mM aminoguanidine (same volume as copper mixture solution),and 100 mM ascorbate (same volume as copper mixture solution). The reaction mixture wasstirred for an hour.
Afterwards, 3-azido-propyl alcohol 115 µL (40 MEq per alkyne) was added to cap the unreacted 5alkyne SCP (or CRM197) and stirred for another hour. The reaction mixture was purified by UF/DFusing 100K MWCO RC membrane against 10 mM EDTA + 10 mM SPB in saline (pH 7.0) (30Xdiavolume), followed by 2nd UF/DF against 5 mM succinate in saline (pH 6.0) (20X diavolume).After UF/DF, the retentate was filtered through 0.22 µm filter (Millipak 40), and subsequentlyanalyzed. 10 Table 5 shows attributes of some of the conjugates obtained. Table 5 Serotype 21 Conjugates Conjugate# 7 8 Poly MW (KDa)313(unsized)162 Activated polysaccharide attributes Degree of Activation of Act poly 26% 25% Act Poly Mw (kDa) 391 222 Activated carrier attributes Degree of Activation (DoA) 21 21 Activated carrier MW, kDa 101.4 101.4 Conjugate data Carrier protein SCP SCP Conjugation yield (%) 72 72 SPR (Output Ratio) 0.66 1.04 Free Saccharide (%) <5% 17 Conjugate Mw (kDa) 2312 820Mw: molecular weight; SPR: Saccharide to protein ratio; NA: Not Available; Act Poly: ActivatedPolysaccharide 15 179 Example 7: Additional S. pneumoniae serotype 21 conjugate using Reductive Amination Chemistry in DMSO (RAC-DMSO) Additional serotype 21 conjugate has been generated using RAC-DMSO (see example 5).Table 6 below comprises characterizing data for serotype 21 polysaccharide conjugates obtainedby the methods of this invention. Native (unsized) polysaccharide was used. 5 Table 6 Serotype 21 Conjugates Conjugate# 9 Poly MW (KDa) 361 Chemistry RAC-DMSO DO 18 Act Poly Mw (kDa) 380 Conjugate data Carrier protein CRM197 Conjugation yield (%) 57 SPR (Output Ratio) 0.9 Free Saccharide (%) <5 Conjugate Mw (kDa) 6212Mw: molecular weight; SPR: Saccharide to protein ratio; Act Poly: Activated Polysaccharide.DO: Degree of Oxidation All publications and patent applications mentioned in the specification are indicative of thelevel of those skilled in the art to which this invention pertains. All publications and patentapplications are hereby incorporated by reference to the same extent as if each individualpublication or patent application was specifically and individually indicated to be incorporated byreference. 15Although the foregoing invention has been described in some detail by way of illustrationand example for purposes of clarity of understanding, certain changes and modifications may bepracticed within the scope of the appended claims.
Claims (40)
1. A glycoconjugate comprising an isolated S. pneumoniae serotype 21 saccharide with thefollowing repeating unit: (VIII) where n represents the number of repeating units, wherein the O-acetyl group at position 3 of β-D-Galf is present in about 50% to about 80% of the repeating units, the O-acetyl group at positionof β-D-Galf is present in about 20% to about 40% of the repeating units, wherein the O-acetylgroup at position 5 of β-D-Galf is present in about 1% to about 10% of the repeating units.
2. The glycoconjugate of claim 1, wherein the O-acetyl group at position 3 of β-D-Galf is presentin about 64% of the repeating units, the O-acetyl group at position 6 of β-D-Galf is present inabout 30% of the repeating units, wherein the O-acetyl group at position 5 of β-D-Galf is presentin about 6% of the repeating units.
3. A glycoconjugate comprising an isolated S. pneumoniae serotype 21 saccharide with therepeating unit of formula (VIII), where n represents the number of repeating units, wherein the O-acetyl group at position 3 of β-D-Galf is present in about 25% to about 60% of the repeating units,the O-acetyl group at position 6 of β-D-Galf is present in about 30% to about 65% of the repeatingunits, wherein the O-acetyl group at position 5 of β-D-Galf is present in about 5% to about 15%of the repeating units.
4. The glycoconjugate of any one of claims 1-3, wherein all the repeating unit bears one O-acetylgroup on the β-D-Galf residue.
5. A glycoconjugate comprising an isolated S. pneumoniae serotype 21 saccharide with therepeating unit of formula (VIII), where n represents the number of repeating units, and whereinthe O-acetyl group at position 3, 5 or 6 of β-D-Galf is present in about 0% to about 95% of therepeating units.
6. The serotype 21 glycoconjugate of any one of claims 1-5 wherein said serotype 21glycoconjugate is prepared by direct reductive amination.
7. The serotype 21 glycoconjugate of any one of claims 1-5 wherein said serotype 21glycoconjugate is prepared by click chemistry.
8. A serotype 21 glycoconjugate comprising a serotype 21 saccharide covalently conjugated to acarrier protein (CP) through a spacer and having the general formula (IV): [→ 6)-α-D-Galp-(1 →3)- β-L-Rhap-(1 →4)- β-D-Glcp-(1 →3)- β-D-GlcpNAc-(1→ 3)-α-D- Galp-(1-PO4 →]n↑β-D-Galf 3,5,6OAc 181 (IV),wherein X is selected from the group consisting of CH2(CH2) n’, (CH 2CH 2O)mCH2CH 2,NHCO(CH2)n’, NHCO(CH2CH2O) mCH2CH2, OCH 2(CH2) n’ and O(CH 2CH2O)mCH2CH 2; where n’ isselected from 1 to 10 and m is selected from 1 to 4,wherein X' is selected from the group consisting of CH2O(CH 2) n’’CH 2C=O,CH2O(CH 2CH2O)m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is selected from 0to 4,wherein the structure in square backet represents a repeat unit of the serotype 21 saccharide andwherein n represents the number of repeating units.
9. A serotype 21 glycoconjugate comprising a serotype 21 saccharide covalently conjugated to acarrier protein (CP) through a spacer and having the general formula (IV), wherein X is CH2(CH2) n’,where n’ is 2 and wherein X' is CH2O(CH 2) n’’CH2C=O where n’’ is 1.
10. A serotype 21 glycoconjugate comprising a serotype 21 saccharide covalently conjugated toa carrier protein (CP) through a spacer and having the general formula (V), (V), wherein the structure in square backet represents a repeat unit of the serotype 21 saccharide andwherein n represents the number of repeating units.
11. The glycoconjugate of any one of claims 1 to 10 wherein the weight average molecular weight(Mw) of said S. pneumoniae serotype 21 saccharide before conjugation is between 100 kDa and400 kDa.
12. The glycoconjugate of any one of claims 1 to 10 wherein the weight average molecular weight(Mw) of said S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and400 kDa.
13. The glycoconjugate of any one of claims 1 to 12 wherein said serotype 21 glycoconjugate hasa weight average molecular weight (Mw) of between 500 kDa and 15,000 kDa.
14. The glycoconjugate of any one of claims 1 to 12 wherein said serotype 21 glycoconjugate hasa weight average molecular weight (Mw) of between 750 kDa and 7,500 kDa.
15. The glycoconjugate of any one of claims 7 to 10 wherein the weight average molecular weight(Mw) of said S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and400 kDa and wherein said serotype 21 glycoconjugate has a weight average molecular weight(Mw) of between 800 kDa and 7,000 kDa.
16. The glycoconjugate of claim 6 wherein said serotype 21 glycoconjugate has a weight averagemolecular weight (Mw) of between 2,000 kDa and 10,500 kDa.
17. The glycoconjugate of claim 6 wherein the weight average molecular weight (Mw) of said S.pneumoniae serotype 21 saccharide before conjugation is between 100 kDa and 400 kDa andwherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) of between2000 kDa and 10,500 kDa.
18. The glycoconjugate of any one of claims 1 to 17 wherein the degree of conjugation of saidserotype 21 glycoconjugate is between 2 and 15.
19. The glycoconjugate of any one of claims 7 to 10 wherein the weight average molecular weight(Mw) of said S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and400 kDa and wherein said serotype 21 glycoconjugate has a weight average molecular weight(Mw) of between 800 kDa and 7,000 kDa and wherein the degree of conjugation of said serotypeglycoconjugate is between 2 and 10.
20. The glycoconjugate of claim 6 wherein the weight average molecular weight (Mw) of said S.pneumoniae serotype 21 saccharide before conjugation is between 100 kDa and 400 kDa andwherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) of between2000 kDa and 10,500 kDa and wherein the degree of conjugation of said serotype 21glycoconjugate is between 2 and 10.
21. The glycoconjugate of any one of claims 1 to 20 wherein the ratio of serotype 21 saccharideto carrier protein in the glycoconjugate (w/w) is between 0.5 and 1.5.
22. The glycoconjugate of any one of claims 7 to 10 wherein the weight average molecular weight(Mw) of said S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and400 kDa and wherein said serotype 21 glycoconjugate has a weight average molecular weight(Mw) of between 800 kDa and 7,000 kDa and the ratio of serotype 21 saccharide to carrier proteinin the glycoconjugate (w/w) is between 0.5 and 1.1.
23. The glycoconjugate of claim 6 wherein the weight average molecular weight (Mw) of said S.pneumoniae serotype 21 saccharide before conjugation is between 100 kDa and 400 kDa andwherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) of between 1832000 kDa and 10,500 kDa and the ratio of serotype 21 saccharide to carrier protein in theglycoconjugate (w/w) is between 0.5 and 1.3.
24. The glycoconjugate of any one of claims 1 to 23 wherein said serotype 21 glycoconjugatecomprises less than about 25% of free serotype 21 saccharide compared to the total amount ofserotype 21 saccharide.
25. The glycoconjugate of any one of claims 7 to 10 wherein the weight average molecular weight(Mw) of said S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and400 kDa and wherein said serotype 21 glycoconjugate has a weight average molecular weight(Mw) of between 800 kDa and 7,000 kDa, wherein the ratio of serotype 21 saccharide to carrierprotein in the glycoconjugate (w/w) is between 0.5 and 1.1 and wherein said serotype 21glycoconjugate comprises less than about 25% of free serotype 21 saccharide compared to thetotal amount of serotype 21 saccharide.
26. The glycoconjugate of claim 6 wherein the weight average molecular weight (Mw) of said S.pneumoniae serotype 21 saccharide before conjugation is between 100 kDa and 400 kDa andwherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) of between2000 kDa and 10,500 kDa, wherein the ratio of serotype 21 saccharide to carrier protein in theglycoconjugate (w/w) is between 0.5 and 1.3 and wherein said serotype 21 glycoconjugatecomprises less than about 25% of free serotype 21 saccharide compared to the total amount ofserotype 21 saccharide.
27. The glycoconjugate of any one of claims 7 to 10 wherein the weight average molecular weight(Mw) of said S. pneumoniae serotype 21 saccharide before conjugation is between 150 kDa and400 kDa and wherein said serotype 21 glycoconjugate has a weight average molecular weight(Mw) of between 800 kDa and 7,000 kDa, wherein the ratio of serotype 21 saccharide to carrierprotein in the glycoconjugate (w/w) is between 0.5 and 1.1, wherein said serotype 21glycoconjugate comprises less than about 25% of free serotype 21 saccharide compared to thetotal amount of serotype 21 saccharide and wherein between 65% and 80% of the serotype 21glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.
28. The glycoconjugate of claim 6 wherein the weight average molecular weight (Mw) of said S.pneumoniae serotype 21 saccharide before conjugation is between 100 kDa and 400 kDa andwherein said serotype 21 glycoconjugate has a weight average molecular weight (Mw) of between2000 kDa and 10,500 kDa, wherein the ratio of serotype 21 saccharide to carrier protein in theglycoconjugate (w/w) is between 0.5 and 1.3, wherein said serotype 21 glycoconjugate comprisesless than about 25% of free serotype 21 saccharide compared to the total amount of serotype 21saccharide and wherein between 65% and 80% of the serotype 21 glycoconjugate has a Kd belowor equal to 0.3 in a CL-4B column.
29. The glycoconjugate of any one of claims 1 to 28 wherein the carrier protein of the serotypesaccharide glycoconjugate is selected in the group consisting of: TT, DT, DT mutants and aC5a peptidase from Streptococcus (SCP).
30. The glycoconjugate of any one of claims 1 to 28 wherein the carrier protein of the serotypesaccharide glycoconjugate is rhizavidin [aa 45-179J-GGGGSSS-SP1500- AAA-SP0785](CP1).
31. The glycoconjugate of any one of claims 1 to 28 wherein the carrier protein of the serotypesaccharide glycoconjugate is Rhavi-linker-PdT(G294P)-linker-SP0435 [aa 62-185] fusionprotein (SPP2).
32. The glycoconjugate of any one of claims 1 to 28 wherein the carrier protein of the serotypesaccharide glycoconjugate is CRM 197.
33. The glycoconjugate of any one of claims 1 to 28 wherein the carrier protein of the serotypesaccharide glycoconjugate is SCP.
34. An immunogenic composition comprising a S. pneumoniae serotype 21 saccharide accordingto any one of paragraphs 1-33.
35. The immunogenic composition of claim 34 further comprising glycoconjugates from S.pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F,22F, 23F and 33F.
36. The immunogenic composition of claim 34 further comprising glycoconjugates from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B.
37. The immunogenic composition of claim 34 wherein the S. pneumoniae saccharides fromserotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 24F, 33F, 35B and 38 are conjugated to CRM 197 and the S. pneumoniae saccharide serotypeis conjugated to SCP.
38. The immunogenic composition of any one of claims 34-37 further comprising one adjuvant.
39. The immunogenic composition of any one of claims 34-38 for use as a vaccine.
40. The immunogenic composition of any one of claims 34-38 for use in a method of preventingan infection by S. pneumoniae 21 in a subject said method comprising administering to thesubject an immunologically effective amount of said immunogenic composition. Dr. Gitay Kryger Patent Attorney G.E. Ehrlich (1995) Ltd. 35 HaMasger Street Sky Tower, 13th Floor Tel Aviv 6721407
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363496045P | 2023-04-14 | 2023-04-14 | |
| US202463565616P | 2024-03-15 | 2024-03-15 | |
| PCT/IB2024/053496 WO2024214016A1 (en) | 2023-04-14 | 2024-04-10 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL323911A true IL323911A (en) | 2025-12-01 |
Family
ID=90825683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL323911A IL323911A (en) | 2023-04-14 | 2025-10-12 | Immunogenic compounds containing conjugated capsular sugar antigens and their uses |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240350608A1 (en) |
| EP (1) | EP4694921A1 (en) |
| JP (1) | JP2026513989A (en) |
| KR (1) | KR20250169621A (en) |
| CN (1) | CN121057590A (en) |
| AU (1) | AU2024255922A1 (en) |
| CO (1) | CO2025014261A2 (en) |
| IL (1) | IL323911A (en) |
| MX (1) | MX2025012232A (en) |
| PE (1) | PE20252779A1 (en) |
| TW (1) | TW202504634A (en) |
| WO (1) | WO2024214016A1 (en) |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
| EP0027888B1 (en) | 1979-09-21 | 1986-04-16 | Hitachi, Ltd. | Semiconductor switch |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
| US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
| US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
| GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
| DE3841091A1 (en) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| AU651949B2 (en) | 1989-07-14 | 1994-08-11 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
| IT1237764B (en) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES. |
| SE466259B (en) | 1990-05-31 | 1992-01-20 | Arne Forsgren | PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE |
| ATE128628T1 (en) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | FIBER HEMAGGLUTININ FROM BORDETELLA PERTUSSIS AS A CARRIER FOR CONJUGATE VACCINE. |
| EP0625910B1 (en) | 1992-02-11 | 2003-07-23 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Dual carrier immunogenic construct |
| IT1262896B (en) | 1992-03-06 | 1996-07-22 | CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES. | |
| JP3506431B2 (en) | 1992-05-06 | 2004-03-15 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Diphtheria toxin receptor binding domain |
| DE69313134T2 (en) | 1992-06-25 | 1998-02-26 | Smithkline Beecham Biolog | VACCINE COMPOSITION CONTAINING ADJUVANTIES |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| DK0616034T3 (en) | 1993-03-05 | 2005-02-21 | Wyeth Corp | Plasmid for the preparation of CRM protein and diphtheria toxin |
| KR100310510B1 (en) | 1993-03-23 | 2002-07-04 | 장 스테판느 | Vaccine composition containing 3-0-deacetylated monophosphoryl lipid A |
| EP0720485B1 (en) | 1993-09-22 | 2003-11-19 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
| US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| US5846547A (en) | 1996-01-22 | 1998-12-08 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
| US6355255B1 (en) | 1998-12-07 | 2002-03-12 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
| CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| BR9909915A (en) | 1998-04-09 | 2000-12-26 | Smithkline Beecham Biolog | Adjuvant compositions |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| CN1263510C (en) | 1998-08-19 | 2006-07-12 | 巴克斯特健康护理股份有限公司 | Polysaccharide-protein conjugate or oligosaccharide-protein conjugate, preparation method and application thereof |
| ES2284287T3 (en) | 1998-10-16 | 2007-11-01 | Glaxosmithkline Biologicals S.A. | ADJUSTMENT SYSTEMS AND VACCINES. |
| CA2355364C (en) | 1998-12-21 | 2014-03-18 | Medimmune, Inc. | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
| PL205041B1 (en) | 1998-12-23 | 2010-03-31 | Id Biomedical Corp | Isolated polynucleotide, vector comprising isolated polynucleotide, vector transformed or transfected host cell, method for production of isolated polypeptide coded by isolated polynucleotide, isolated polypeptide, chimeric polypeptide, composition for vaccines and its use in treating streptococcus infection |
| CA2366152A1 (en) | 1999-03-19 | 2000-09-28 | Smithkline Beecham Biologicals S.A. | Streptococcus pneumoniae vaccine |
| WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| DK1187629T3 (en) | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| IL148671A0 (en) | 1999-09-24 | 2002-09-12 | Smithkline Beecham Biolog | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
| HK1049106A1 (en) | 1999-09-24 | 2003-05-02 | Smithkline Beecham Biologicals S.A. | Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| WO2001098334A2 (en) | 2000-06-20 | 2001-12-27 | Shire Biochem Inc. | Streptococcus antigens |
| AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
| US7262024B2 (en) | 2001-12-20 | 2007-08-28 | Id Biomedical Corporation | Streptococcus antigens |
| MXPA05009579A (en) | 2003-03-13 | 2005-11-17 | Glaxosmithkline Biolog Sa | Purification process for bacterial cytolysin. |
| EP1603950A2 (en) | 2003-03-17 | 2005-12-14 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| GB0421083D0 (en) | 2004-09-22 | 2004-10-27 | Glaxosmithkline Biolog Sa | Purification process |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| IL308456A (en) | 2005-04-08 | 2024-01-01 | Wyeth Llc | Multivalent pneumococcal polysacharide-protein conjugate composition |
| PL1866342T3 (en) | 2005-04-08 | 2019-04-30 | Wyeth Llc | Separation of contaminants from streptococcus pneumoniae polysaccharide by ph manipulation |
| CA2665169C (en) | 2006-10-10 | 2017-02-21 | Wyeth | Purification of streptococcus pneumoniae type 3 polysaccharides |
| HUE039169T2 (en) | 2007-03-23 | 2018-12-28 | Wyeth Llc | Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides |
| EA200901578A1 (en) | 2007-06-26 | 2010-08-30 | Глаксосмитклайн Байолоджикалс С.А. | VACCINE CONTAINING CONJUGATES OF CAPSULAR POLYSACCHARIDES STREPTOCOCCUS PNEUMONIAE |
| DK2424562T3 (en) | 2009-04-30 | 2015-12-07 | Coley Pharm Group Inc | Pneumococcal vaccine and uses thereof |
| GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
| GB201103836D0 (en) | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
| RU2632651C2 (en) | 2011-05-11 | 2017-10-06 | Чилдрен'С Медикал Сентер Корпорейшн | Modified biotin-binding protein, fusion proteins based thereon and their application |
| PT2885007T (en) | 2012-08-16 | 2018-12-10 | Pfizer | Glycoconjugation processes and compositions |
| RU2672053C2 (en) | 2012-12-20 | 2018-11-09 | Пфайзер Инк. | Glycoconjugation process |
| CN103495161B (en) | 2013-10-08 | 2019-06-18 | 江苏康泰生物医学技术有限公司 | A kind of mixture and preparation method thereof of polynary pneumococcal capsular polysaccharide-protein conjugate |
| IL312327B2 (en) | 2014-01-21 | 2026-02-01 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| BR112016015835B1 (en) | 2014-01-21 | 2023-12-26 | Pfizer Inc | PROCESS FOR PREPARING CONJUGATES COMPRISING CAPSULAR POLYSACCHARIDES OF STREPTOCOCCUS PNEUMONIAE |
| WO2018144439A1 (en) | 2017-01-31 | 2018-08-09 | Merck Sharp & Dohme Corp. | Methods for making polysaccharide-protein conjugates |
| JP7680185B2 (en) | 2017-02-24 | 2025-05-20 | メルク・シャープ・アンド・ドーム・エルエルシー | Enhanced immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates |
| CN112969474A (en) | 2018-09-12 | 2021-06-15 | 艾芬尼维克斯公司 | Multivalent pneumococcal vaccine |
| JP7239509B6 (en) | 2019-02-22 | 2023-03-28 | ファイザー・インク | Method for purifying bacterial polysaccharides |
| JP7714690B2 (en) * | 2021-05-28 | 2025-07-29 | ファイザー・インク | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CA3221075A1 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| MX2024002779A (en) | 2021-09-09 | 2024-06-11 | Affinivax Inc | Multivalent pneumococcal vaccines. |
| CN115221083B (en) | 2022-09-05 | 2023-01-24 | 浪潮电子信息产业股份有限公司 | PCIe interrupt processing method, device, equipment and medium |
-
2024
- 2024-04-10 PE PE2025002249A patent/PE20252779A1/en unknown
- 2024-04-10 EP EP24720586.7A patent/EP4694921A1/en active Pending
- 2024-04-10 AU AU2024255922A patent/AU2024255922A1/en active Pending
- 2024-04-10 CN CN202480022839.7A patent/CN121057590A/en active Pending
- 2024-04-10 WO PCT/IB2024/053496 patent/WO2024214016A1/en not_active Ceased
- 2024-04-10 KR KR1020257037699A patent/KR20250169621A/en active Pending
- 2024-04-10 JP JP2025559291A patent/JP2026513989A/en active Pending
- 2024-04-11 TW TW113113535A patent/TW202504634A/en unknown
- 2024-04-12 US US18/634,326 patent/US20240350608A1/en active Pending
-
2025
- 2025-10-12 IL IL323911A patent/IL323911A/en unknown
- 2025-10-13 MX MX2025012232A patent/MX2025012232A/en unknown
- 2025-10-14 CO CONC2025/0014261A patent/CO2025014261A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025012232A (en) | 2025-11-03 |
| KR20250169621A (en) | 2025-12-03 |
| PE20252779A1 (en) | 2025-12-22 |
| EP4694921A1 (en) | 2026-02-18 |
| TW202504634A (en) | 2025-02-01 |
| WO2024214016A1 (en) | 2024-10-17 |
| AU2024255922A1 (en) | 2025-10-30 |
| CO2025014261A2 (en) | 2025-10-20 |
| US20240350608A1 (en) | 2024-10-24 |
| CN121057590A (en) | 2025-12-02 |
| JP2026513989A (en) | 2026-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7579900B2 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| AU2011226160B2 (en) | Conjugation process of bacterial polysaccharides to carrier proteins | |
| AU2022281543B2 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| JP7585203B2 (en) | Immunogenic multi-heteroantigenic polysaccharide-protein conjugates and uses thereof | |
| IL303998A (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof | |
| US20240350608A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| TWI910585B (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| TWI887857B (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| WO2024224266A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| TW202600584A (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| WO2025057078A1 (en) | Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof |